Naloxone	I-Entity
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	I-Entity
.	O

In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	I-Entity
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	I-Entity
,	O
5	O
to	O
20	O
micrograms	O
/	O
kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	I-Entity
,	O
0.2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypotensive	I-Entity
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
was	O
also	O
partially	O
reversed	O
by	O
naloxone	I-Entity
.	O

Naloxone	I-Entity
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	I-Entity
rats	O
clonidine	I-Entity
,	O
10(-8	O
)	O
to	O
10(-5	O
)	O

M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	B-Entity
3H]-naloxone	I-Entity
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	I-Entity
,	O
10(-8	O
)	O
to	O
10(-4	O
)	O

M	O
,	O
did	O
not	O
influence	O
clonidine	I-Entity
-	O
suppressible	O
binding	O
of	O
[	B-Entity
3H]-dihydroergocryptine	I-Entity
(	O
1	O
nM	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O

As	O
naloxone	I-Entity
and	O
clonidine	I-Entity
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	I-Entity
or	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	O
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O



Lidocaine	I-Entity
-	O
induced	O
cardiac	B-Entity
asystole	I-Entity
.	O

Intravenous	O
administration	O
of	O
a	O
single	O
50-mg	O
bolus	O
of	O
lidocaine	I-Entity
in	O
a	O
67-year	O
-	O
old	O
man	O
resulted	O
in	O
profound	O
depression	I-Entity
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	I-Entity
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	I-Entity
.	O



Suxamethonium	I-Entity
infusion	O
rate	O
and	O
observed	O
fasciculations	I-Entity
.	O

Suxamethonium	B-Entity
chloride	I-Entity
(	O
Sch	I-Entity
)	O
was	O
administered	O
i.v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O

The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	I-Entity
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	I-Entity
120	O
mg	O
was	O
exceeded	O
.	O

Fasciculations	I-Entity
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	I-Entity
score	O
.	O

The	O
times	O
to	O
first	O
fasciculation	I-Entity
,	O
twitch	I-Entity
suppression	O
and	O
tetanus	I-Entity
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O

Fasciculations	I-Entity
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	I-Entity
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O

Total	O
fasciculation	I-Entity
scores	O
in	O
the	O
30-mg	O
bolus	O
group	O
and	O
the	O
5-mg	O
s-1	O
and	O
20-mg	O
s-1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O



Galanthamine	B-Entity
hydrobromide	I-Entity
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	O
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	I-Entity
(	O
Hyoscine	I-Entity
)	O
.	O

Galanthamine	B-Entity
hydrobromide	I-Entity
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	I-Entity
(	O
hyoscine	I-Entity
)	O

overdosage	I-Entity
.	O

It	O
is	O
longer	O
acting	O
than	O
physostigmine	I-Entity
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non	O
-	O
depolarizing	O
neuromuscular	O
block	O
.	O

However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	I-Entity
intoxication	O
are	O
indicated	O
.	O



Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	I-Entity
-	O
induced	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
in	O
rats	O
.	O

Rats	O
with	O
lithium	I-Entity
-	O
induced	O
nephropathy	I-Entity
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	B-Entity
failure	I-Entity
.	O

Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	I-Entity
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs.	O
19%	O
)	O
,	O
NX	O
or	O
HP+NX	O
for	O
another	O
8	O
weeks	O
.	O

Corresponding	O
non	O
-	O
lithium	I-Entity
pretreated	O
groups	O
were	O
generated	O
.	O

When	O
comparing	O
all	O
lithium	I-Entity
treated	O
versus	O
non	O
-	O
lithium	I-Entity
-	O
treated	O
groups	O
,	O
lithium	I-Entity
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	I-Entity
clearance	O
.	O

Consequently	O
,	O
lithium	I-Entity
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	I-Entity
excretion	O
.	O

Lithium	I-Entity
also	O
caused	O
proteinuria	I-Entity
and	O
systolic	O
hypertension	I-Entity
in	O
absence	O
of	O
glomerulosclerosis	I-Entity
.	O

HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	B-Entity
failure	I-Entity
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	I-Entity
levels	O
in	O
lithium	I-Entity
pretreated	O
rats	O
.	O

NX+HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	I-Entity
-	O
pretreated	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
Li	I-Entity
-	O
induced	O
nephropathy	I-Entity
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	I-Entity
and	O
arterial	O
systolic	O
hypertension	I-Entity
.	O

In	O
this	O
model	O
of	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O



Treatment	O
of	O
Crohn	B-Entity
's	I-Entity
disease	I-Entity
with	O
fusidic	B-Entity
acid	I-Entity
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	I-Entity
.	O

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	I-Entity
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-Entity
's	I-Entity
disease	I-Entity
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Entity
acid	I-Entity
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

Eight	O
Crohn	B-Entity
's	I-Entity
disease	I-Entity
patients	O
were	O
included	O
.	O

Fusidic	B-Entity
acid	I-Entity
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t.d.s	O
.	O

Five	O
of	O
8	O
patients	O
(	O
63%	O
)	O
improved	O
during	O
fusidic	B-Entity
acid	I-Entity
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	I-Entity
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	B-Entity
acid	I-Entity
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	B-Entity
's	I-Entity
disease	I-Entity
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	B-Entity
acid	I-Entity
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	B-Entity
bowel	I-Entity
disease	I-Entity
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O



Electrocardiographic	O
evidence	O
of	O
myocardial	B-Entity
injury	I-Entity
in	O
psychiatrically	O
hospitalized	O
cocaine	I-Entity
abusers	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	I-Entity
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	I-Entity
controls	O
.	O

Eleven	O
of	O
the	O
cocaine	I-Entity
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B-Entity
injury	I-Entity
defined	O
as	O
myocardial	B-Entity
infarction	I-Entity
,	O
ischemia	I-Entity
,	O
and	O
bundle	B-Entity
branch	I-Entity
block	I-Entity
.	O



Sulpiride	I-Entity
-	O
induced	O
tardive	B-Entity
dystonia	I-Entity
.	O

Sulpiride	I-Entity
is	O
a	O
selective	O
D2-receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	I-Entity
properties	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride	I-Entity
-	O
induced	O
tardive	B-Entity
dyskinesia	I-Entity
and	O
parkinsonism	I-Entity
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37-year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	I-Entity
within	O
2	O
months	O
after	O
starting	O
sulpiride	I-Entity
therapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	I-Entity
-	O
induced	O
tardive	B-Entity
dystonia	I-Entity
.	O



Ocular	B-Entity
and	I-Entity
auditory	I-Entity
toxicity	I-Entity
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	I-Entity
.	O

During	O
an	O
18-month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	I-Entity
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW/3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B-Entity
toxicity	I-Entity
.	O

6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	B-Entity
or	I-Entity
auditory	I-Entity
toxicity	I-Entity
.	O

Visual	B-Entity
toxicity	I-Entity
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	I-Entity
,	O
sometimes	O
associated	O
with	O
a	B-Entity
loss	I-Entity
of	I-Entity
visual	I-Entity
acuity	I-Entity
and	O
pigmentary	B-Entity
retinal	I-Entity
deposits	I-Entity
.	O

Auditory	B-Entity
toxicity	I-Entity
was	O
characterized	O
by	O
a	O
mid-	O
to	O
high	O
-	O
frequency	O
neurosensorial	B-Entity
hearing	I-Entity
loss	I-Entity
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O

Desferrioxamine	I-Entity
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B-Entity
loss	I-Entity
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O

This	O
toxicity	I-Entity
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	I-Entity
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	I-Entity
serum	O
levels	O
.	O

The	O
data	O
indicate	O
that	O
audiovisual	B-Entity
toxicity	I-Entity
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	I-Entity
.	O



Myasthenia	B-Entity
gravis	I-Entity
presenting	O
as	O
weakness	O
after	O
magnesium	I-Entity
administration	O
.	O

We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B-Entity
disease	I-Entity
who	O
became	O
virtually	O
quadriplegic	I-Entity
after	O
parenteral	O
magnesium	I-Entity
administration	O
for	O
preeclampsia	I-Entity
.	O

The	O
serum	O
magnesium	I-Entity
concentration	O
was	O
3.0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O

The	O
magnesium	I-Entity
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O

While	O
she	O
was	O
weak	O
,	O
2-Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B-Entity
neuromuscular	I-Entity
blockade	I-Entity
.	O

Her	O
acetylcholine	I-Entity
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O

Although	O
paralysis	I-Entity
after	O
magnesium	I-Entity
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B-Entity
gravis	I-Entity
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	O
.	O

Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	I-Entity
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B-Entity
of	I-Entity
neuromuscular	I-Entity
transmission	I-Entity
.	O



Chloroacetaldehyde	I-Entity
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	I-Entity
or	O
ifosfamide	I-Entity
.	O

Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	I-Entity
(	O
CAA	I-Entity
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	I-Entity
in	O
the	O
development	O
of	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

The	O
data	O
demonstrate	O
that	O
CAA	I-Entity
after	O
i.v	O
.	O

administration	O
does	O
not	O
contribute	O
to	O
bladder	B-Entity
damage	I-Entity
.	O

When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	I-Entity
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	I-Entity
.	O



Source	O
of	O
pain	I-Entity
and	O
primitive	O
dysfunction	O
in	O
migraine	I-Entity
:	O
an	O
identical	O
site	O
?	O

Twenty	O
common	O
migraine	I-Entity
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	I-Entity
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

Early	O
onset	O
migraine	I-Entity
attacks	O
were	O
induced	O
by	O
nitroglycerin	I-Entity
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O

Subsequently	O
20	O
migraine	I-Entity
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	I-Entity
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O

No	O
early	O
onset	O
migraine	I-Entity
was	O
observed	O
.	O

Thus	O
the	O
migraine	I-Entity
-	O
inducing	O
effect	O
of	O
nitroglycerin	I-Entity
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	I-Entity
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	I-Entity
crisis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	I-Entity
attack	O
.	O



Clotiazepam	I-Entity
-	O
induced	O
acute	O
hepatitis	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	I-Entity
with	O
extensive	B-Entity
hepatocellular	I-Entity
necrosis	I-Entity
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	I-Entity
,	O
a	O
thienodiazepine	I-Entity
derivative	O
.	O

Clotiazepam	I-Entity
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O

The	O
administration	O
of	O
several	O
benzodiazepines	I-Entity
,	O
chemically	O
related	O
to	O
clotiazepam	I-Entity
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	I-Entity
.	O

This	O
observation	O
shows	O
that	O
clotiazepam	I-Entity
can	O
induce	O
acute	O
hepatitis	I-Entity
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	I-Entity
between	O
clotiazepam	I-Entity
and	O
several	O
benzodiazepines	I-Entity
.	O



Arterial	O
hypertension	I-Entity
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	I-Entity
treatment	O
.	O

Two	O
of	O
14	O
patients	O
with	O
Cushing	B-Entity
's	I-Entity
syndrome	I-Entity
treated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazole	I-Entity
developed	O
sustained	O
hypertension	I-Entity
.	O

In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	I-Entity
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	I-Entity
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	I-Entity
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O

In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	I-Entity
and	O
11-deoxycortisol	I-Entity
were	O
elevated	O
.	O

In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	I-Entity
and	O
11-deoxycortisol	I-Entity
levels	O
,	O
plasma	O
aldosterone	I-Entity
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O

Our	O
findings	O
show	O
that	O
long	O
-	O
term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	I-Entity
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid	O
-	O
related	O
hypertension	I-Entity
.	O



Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	I-Entity
converting	O
enzyme	O
(	O
Captopril	I-Entity
)	O
on	O
pulmonary	B-Entity
and	I-Entity
renal	I-Entity
insufficiency	I-Entity
due	O
to	O
intravascular	B-Entity
coagulation	I-Entity
in	O
the	O
rat	O
.	O

Induction	O
of	O
intravascular	B-Entity
coagulation	I-Entity
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	B-Entity
acid	I-Entity
(	O
AMCA	I-Entity
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	B-Entity
and	I-Entity
renal	I-Entity
insufficiency	I-Entity
resembling	O
that	O
occurring	O
after	O
trauma	I-Entity
or	O
sepsis	I-Entity
in	O
man	O
.	O

Injection	O
of	O
Captopril	I-Entity
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	I-Entity
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	B-Entity
and	I-Entity
renal	I-Entity
insufficiency	I-Entity
in	O
this	O
rat	O
model	O
.	O

The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	I-Entity
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O

Renal	B-Entity
damage	I-Entity
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	I-Entity
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	I-Entity
.	O

The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	I-Entity
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	I-Entity
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	B-Entity
II	I-Entity
and	O
an	O
increase	O
in	O
prostacyclin	I-Entity
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	I-Entity
)	O
.	O

Captopril	I-Entity
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B-Entity
damage	I-Entity
will	O
be	O
produced	O
.	O



A	O
randomized	O
comparison	O
of	O
labetalol	I-Entity
and	O
nitroprusside	I-Entity
for	O
induced	O
hypotension	I-Entity
.	O

In	O
a	O
randomized	O
study	O
,	O
labetalol	I-Entity
-	O
induced	O
hypotension	I-Entity
and	O
nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O

Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	B-Entity
in	I-Entity
mean	I-Entity
arterial	I-Entity
blood	I-Entity
pressure	I-Entity
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
increase	B-Entity
in	I-Entity
heart	I-Entity
rate	I-Entity
and	I-Entity
cardiac	I-Entity
output	I-Entity
;	O
rebound	O
hypertension	I-Entity
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	I-Entity
.	O

Labetalol	I-Entity
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O

Arterial	O
PO2	I-Entity
decreased	O
in	O
both	O
groups	O
.	O

It	O
was	O
concluded	O
that	O
labetalol	I-Entity
offers	O
advantages	O
over	O
nitroprusside	I-Entity
.	O



Chronic	O
carbamazepine	I-Entity
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	I-Entity
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	I-Entity
concentrations	O
.	O

Folate	I-Entity
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O

Carbamazepine	I-Entity
(	O
CBZ	I-Entity
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	I-Entity
treatment	O
on	O
folate	I-Entity
concentrations	O
in	O
the	O
rat	O
.	O

In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	B-Entity
glycol	I-Entity
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	I-Entity
and	O
inhibited	O
weight	B-Entity
gain	I-Entity
.	O

Seizures	I-Entity
induced	O
by	O
hexafluorodiethyl	B-Entity
ether	I-Entity
(	O
HFDE	I-Entity
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	I-Entity
than	O
seizures	I-Entity
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O

Oral	O
administration	O
of	O
CBZ	I-Entity
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Entity
gain	I-Entity
over	O
8	O
weeks	O
of	O
treatment	O
.	O

The	O
CBZ	I-Entity
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatment	O
with	O
CBZ	I-Entity
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	I-Entity
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	I-Entity
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O



In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	I-Entity
intake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	I-Entity
and	O
epinephrine	I-Entity
during	O
15-minute	O
i.v	O
.	O

6%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	I-Entity
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	I-Entity
release	O
rate	O
(	O
up	O
to	O
0.3	O
microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	I-Entity
induced	O
by	O
hydralazine	I-Entity
or	O
nitroglycerin	I-Entity
.	O

The	O
release	O
rate	O
of	O
epinephrine	I-Entity
(	O
control	O
,	O
6.7	O
+	O
/-	O



Death	I-Entity
from	O
chemotherapy	O
in	O
gestational	B-Entity
trophoblastic	I-Entity
disease	I-Entity
.	O

Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	I-Entity
.	O

The	O
multiple	O
drug	O
schema	O
consisted	O
of	O
:	O
Etoposide	I-Entity
16.213	O
,	O
Methotrexate	I-Entity
,	O
Cyclophosphamide	I-Entity
,	O
Actomycin	B-Entity
-	I-Entity
D	I-Entity
,	O
and	O
Cisplatin	I-Entity
.	O

On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	I-Entity
,	O
Etoposide	I-Entity
and	O
Cyclophosphamide	I-Entity
were	O
administered	O
.	O

Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B-Entity
obstruction	I-Entity
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O

Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	I-Entity
necrosis	I-Entity
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	I-Entity
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	I-Entity
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	I-Entity
emboli	O
.	O

In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	I-Entity
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	I-Entity
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patients	O
with	O
large	O
pelvic	B-Entity
tumor	I-Entity
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	O
resistance	O
.	O



Sexual	B-Entity
dysfunction	I-Entity
among	O
patients	O
with	O
arthritis	I-Entity
.	O

The	O
relationship	O
of	O
arthritis	I-Entity
and	O
sexual	B-Entity
dysfunction	I-Entity
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
,	O
osteoarthritis	I-Entity
and	O
spondyloarthropathy	I-Entity
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O

Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-Entity
mood	I-Entity
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O

Sexual	B-Entity
dysfunctions	I-Entity
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O

Impotence	I-Entity
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	I-Entity
.	O

Depressed	B-Entity
mood	I-Entity
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	I-Entity
.	O

Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	I-Entity
but	O
was	O
associated	O
with	O
sexual	B-Entity
dysfunction	I-Entity
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O



Does	O
paracetamol	I-Entity
cause	O
urothelial	B-Entity
cancer	I-Entity
or	O
renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
?	O

The	O
risk	O
of	O
developing	O
renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
or	O
cancer	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
pelvis	I-Entity
,	I-Entity
ureter	I-Entity
or	I-Entity
bladder	I-Entity
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	I-Entity
or	O
paracetamol	I-Entity
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

The	O
risk	O
of	O
renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
was	O
increased	O
nearly	O
20-fold	O
by	O
consumption	O
of	O
phenacetin	I-Entity
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
pelvis	I-Entity
and	I-Entity
bladder	I-Entity
but	O
not	O
for	O
ureteric	B-Entity
cancer	I-Entity
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	I-Entity
consumption	O
for	O
renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
or	O
any	O
of	O
these	O
cancers	I-Entity
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B-Entity
of	I-Entity
the	I-Entity
ureter	I-Entity
.	O



Dapsone	I-Entity
-	O
associated	O
Heinz	O
body	O
hemolytic	B-Entity
anemia	I-Entity
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O

A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	I-Entity
developed	O
a	O
Heinz	O
body	O
hemolytic	B-Entity
anemia	I-Entity
while	O
taking	O
a	O
dose	O
of	O
dapsone	I-Entity
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	I-Entity
.	O

Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	I-Entity
(	O
GSH	I-Entity
)	O
,	O
and	O
decreased	O
GSH	I-Entity
stability	O
.	O

The	O
pentose	B-Entity
phosphate	I-Entity
shunt	O
activity	O
of	O
the	O
dapsone	I-Entity
-	O
exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	I-Entity
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	I-Entity
content	O
and	O
GSH	I-Entity
stability	O
were	O
normal	O
.	O

The	O
pentose	B-Entity
phosphate	I-Entity
shunt	O
activity	O
of	O
the	O
non	O
-	O
dapsone	I-Entity
-	O
exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	I-Entity
does	O
not	O
cause	O
hemolytic	B-Entity
anemia	I-Entity
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O

Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	I-Entity
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E.	O



Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	I-Entity
,	O
propafenone	I-Entity
,	O
diltiazem	I-Entity
,	O
and	O
sparteine	I-Entity
.	O

A	O
47-year	O
-	O
old	O
patient	O
suffering	O
from	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	I-Entity
with	O
III	O
.	O

AV	B-Entity
block	I-Entity
,	O
severe	O
hypotension	I-Entity
,	O
and	O
impairment	B-Entity
of	I-Entity
ventricular	I-Entity
function	I-Entity
.	O

One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	I-Entity
(	O
100	O
mg	O
t.i.d	O
.	O
and	O
then	O
100	O
mg	O
b.i.d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
days	O
before	O
admission	O
diltiazem	I-Entity
(	O
60	O
mg	O
b.i.d	O
.	O
)	O
was	O
prescribed	O
in	O
addition	O
.	O

Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	I-Entity
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
diltiazem	I-Entity
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	I-Entity
,	O
diltiazem	I-Entity
,	O
propafenone	I-Entity
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	I-Entity
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	I-Entity
/	O
sparteine	I-Entity
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
)	O
.	O

Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	O
of	O
sparteine	I-Entity
/	O
debrisoquine	I-Entity
polymorphism	O
in	O
drug	O
metabolism	O
,	O
which	O
constitutes	O
6.4%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	B-Entity
drug	I-Entity
reactions	I-Entity
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	O
alone	O
.	O



Triazolam	I-Entity
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	I-Entity
in	O
a	O
depressed	I-Entity
patient	O
.	O

Large	O
doses	O
of	O
triazolam	I-Entity
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	I-Entity
in	O
a	O
depressed	I-Entity
elderly	O
woman	O
.	O

Features	O
of	O
organic	B-Entity
mental	I-Entity
disorder	I-Entity
(	O
delirium	I-Entity
)	O
were	O
not	O
present	O
.	O

Manic	I-Entity
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	I-Entity
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazolo	I-Entity
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O



On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Entity
rigidity	I-Entity
produced	O
by	O
morphine	I-Entity
in	O
rats	O
.	O

The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Entity
rigidity	I-Entity
produced	O
by	O
morphine	I-Entity
was	O
studied	O
in	O
rats	O
.	O

Saline	O
-	O
pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	I-Entity
(	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidity	I-Entity
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O

Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	I-Entity
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	I-Entity
after	O
the	O
test	O
dose	O
of	O
morphine	I-Entity
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	I-Entity
(	O
A	O
group	O
)	O
.	O

The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	I-Entity
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and/or	O
gnawing	O
in	O
presence	O
of	O
akinetic	I-Entity
or	O
hyperkinetic	I-Entity
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O

The	O
rigidity	I-Entity
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	I-Entity
(	O
0.2	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	I-Entity
without	O
any	O
dopaminergic	O
interference	O
.	O

Haloperidol	I-Entity
enhanced	O
the	O
rigidity	I-Entity
in	O
the	O
A	O
group	O
.	O

The	O
results	O
suggest	O
that	O
rigidity	I-Entity
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	I-Entity
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum	O
.	O

The	O
rapid	O
alternations	O
of	O
rigidity	I-Entity
and	O
the	O
signs	O
of	O
dopaminergic	O
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS	O
/	O
KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervated	O
structures	O
.	O



Compression	B-Entity
neuropathy	I-Entity
of	I-Entity
the	I-Entity
radial	I-Entity
nerve	I-Entity
due	O
to	O
pentazocine	I-Entity
-	O
induced	O
fibrous	B-Entity
myopathy	I-Entity
.	O

Fibrous	B-Entity
myopathy	I-Entity
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	I-Entity
injection	O
.	O

However	O
,	O
compression	B-Entity
neuropathy	I-Entity
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	I-Entity
-	O
induced	O
myopathy	I-Entity
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37-year	O
-	O
old	O
woman	O
with	O
documented	O
pentazocine	I-Entity
-	O
induced	O
fibrous	B-Entity
myopathy	I-Entity
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three	O
-	O
week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B-Entity
myopathy	I-Entity
.	O



Recurrent	O
reversible	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
from	O
amphotericin	I-Entity
.	O

A	O
patient	O
with	O
cryptogenic	O
cirrhosis	I-Entity
and	O
disseminated	O
sporotrichosis	I-Entity
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	B-Entity
B	I-Entity
on	O
four	O
separate	O
occasions	O
.	O

The	O
abruptness	O
of	O
the	O
renal	B-Entity
failure	I-Entity
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B-Entity
dysfunction	I-Entity
.	O

We	O
propose	O
that	O
amphotericin	I-Entity
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O



Pneumonitis	O
with	O
pleural	B-Entity
and	I-Entity
pericardial	I-Entity
effusion	I-Entity
and	O
neuropathy	I-Entity
during	O
amiodarone	I-Entity
therapy	O
.	O

A	O
patient	O
with	O
sinuatrial	B-Entity
disease	I-Entity
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	I-Entity
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B-Entity
tachyarrhythmias	I-Entity
.	O

He	O
developed	O
pneumonitis	I-Entity
,	O
pleural	B-Entity
and	I-Entity
pericardial	I-Entity
effusions	I-Entity
,	O
and	O
a	O
predominantly	O
proximal	B-Entity
motor	I-Entity
neuropathy	I-Entity
.	O

Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	I-Entity
and	O
treatment	O
with	O
prednisolone	I-Entity
.	O

Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	I-Entity
pneumonitis	I-Entity
,	O
immediate	O
withdrawal	O
of	O
amiodarone	I-Entity
,	O
and	O
prompt	O
but	O
continued	O
steroid	I-Entity
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O



Indomethacin	I-Entity
-	O
induced	O
renal	B-Entity
insufficiency	I-Entity
:	O
recurrence	O
on	O
rechallenge	O
.	O

We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B-Entity
failure	I-Entity
with	O
hyperkalemia	I-Entity
in	O
a	O
patient	O
with	O
cirrhosis	I-Entity
,	O
ascites	I-Entity
,	O
and	O
cor	B-Entity
pulmonale	I-Entity
after	O
indomethacin	I-Entity
therapy	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	I-Entity
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	I-Entity
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	I-Entity
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

Since	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O



administration	O
of	O
flunitrazepam	I-Entity
in	O
volunteers	O
.	O

Flunitrazepam	I-Entity
0.5	O
,	O
1.0	O
or	O
2.0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i.m	O
.	O

Dizziness	I-Entity
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O

There	O
was	O
pain	I-Entity
on	O
i.m	O
.	O

injection	O
of	O
flunitrazepam	I-Entity
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O



Changes	O
in	O
heart	O
size	O
during	O
long	O
-	O
term	O
timolol	I-Entity
treatment	O
after	O
myocardial	B-Entity
infarction	I-Entity
.	O

The	O
effect	O
of	O
long	O
-	O
term	O
timolol	I-Entity
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-Entity
infarction	I-Entity
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	I-Entity
115	O
)	O
.	O

The	O
timolol	I-Entity
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	I-Entity
-	O
induced	O
bradycardia	I-Entity
and	O
a	O
compensatory	O
increase	O
in	O
end	O
-	O
diastolic	O
volume	O
.	O

The	O
timolol	I-Entity
-	O
related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O

In	O
patients	O
with	O
cardiomegaly	I-Entity
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O

After	O
re	O
-	O
infarction	I-Entity
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	I-Entity
group	O
.	O



Vitamin	B-Entity
D3	I-Entity
toxicity	I-Entity
in	O
dairy	O
cows	O
.	O

Large	O
parenteral	O
doses	O
of	O
vitamin	B-Entity
D3	I-Entity
(	O
15	O
to	O
17.5	O
x	O
10(6	O
)	O

IU	O
vitamin	B-Entity
D3	I-Entity
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	I-Entity
,	O
hyperphosphatemia	I-Entity
,	O
and	O
large	O
increases	O
of	O
vitamin	B-Entity
D3	I-Entity
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O

Calcium	I-Entity
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	B-Entity
D3	I-Entity
about	O
32	O
days	O
prepartum	O
(	O
8.8	O
mg/100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5.5	O
mg/100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	B-Entity
D3	I-Entity
showed	O
signs	O
of	O
milk	B-Entity
fever	I-Entity
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B-Entity
fever	I-Entity
during	O
this	O
period	O
.	O

Signs	O
of	O
vitamin	B-Entity
D3	I-Entity
toxicity	I-Entity
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-Entity
D3	I-Entity
toxicity	I-Entity
and	O
10	O
of	O
17	O
cows	O
died	O
.	O

Because	O
of	O
the	O
extreme	O
toxicity	I-Entity
of	O
vitamin	B-Entity
D3	I-Entity
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-Entity
D3	I-Entity
that	O
prevent	O
milk	B-Entity
fever	I-Entity
and	O
doses	O
that	O
induce	O
milk	B-Entity
fever	I-Entity
,	O
we	O
concluded	O
that	O
vitamin	B-Entity
D3	I-Entity
can	O
not	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-Entity
fever	I-Entity
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O



Diseases	B-Entity
of	I-Entity
peripheral	I-Entity
nerves	I-Entity
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O

The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-Entity
nerve	I-Entity
disease	I-Entity
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O

Sensori	B-Entity
-	I-Entity
motor	I-Entity
neuropathy	I-Entity
was	O
the	O
commonest	O
presentation	O
(	O
50%	O
)	O
.	O

Guillain	B-Entity
-	I-Entity
Barr	I-Entity
syndrome	I-Entity
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15.6%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Entity
neuropathy	I-Entity
.	O

Peripheral	B-Entity
neuropathy	I-Entity
due	O
to	O
nutritional	B-Entity
deficiency	I-Entity
of	O
thiamine	I-Entity
and	O
riboflavin	I-Entity
was	O
common	O
(	O
10.1%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori	B-Entity
-	I-Entity
motor	I-Entity
neuropathy	I-Entity
.	O

Diabetes	B-Entity
mellitus	I-Entity
was	O
the	O
major	O
cause	O
of	O
autonomic	B-Entity
neuropathy	I-Entity
.	O

Isoniazid	I-Entity
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	I-Entity
.	O

Migraine	I-Entity
(	O
20%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-Entity
neuropathy	I-Entity
although	O
malignancies	I-Entity
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26%	O
)	O
.	O

In	O
26.5%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	I-Entity
was	O
undetermined	O
.	O

Heredofamilial	O
and	O
connective	B-Entity
tissue	I-Entity
disorders	I-Entity
were	O
rare	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	I-Entity
are	O
briefly	O
discussed	O
.	O



A	O
double	O
-	O
blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-Entity
hydrochloride	I-Entity
in	O
the	O
treatment	O
of	O
major	O
depressive	B-Entity
disorder	I-Entity
.	O

In	O
a	O
6-week	O
double	O
-	O
blind	O
parallel	O
treatment	O
study	O
,	O
dothiepin	I-Entity
and	O
amitriptyline	I-Entity
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	I-Entity
outpatients	O
.	O

Dothiepin	I-Entity
and	O
amitriptyline	I-Entity
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-Entity
illness	I-Entity
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O

The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B-Entity
vision	I-Entity
,	O
dry	B-Entity
mouth	I-Entity
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	I-Entity
than	O
with	O
amitriptyline	I-Entity
.	O

Dothiepin	I-Entity
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

Dothiepin	I-Entity
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	I-Entity
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	I-Entity
in	O
the	O
treatment	O
of	O
depressed	I-Entity
outpatients	O
.	O



Behavioral	O
effects	O
of	O
diazepam	I-Entity
and	O
propranolol	I-Entity
in	O
patients	O
with	O
panic	B-Entity
disorder	I-Entity
and	O
agoraphobia	I-Entity
.	O

The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	I-Entity
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	I-Entity
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B-Entity
disorders	I-Entity
and	O
agoraphobia	I-Entity
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O

Both	O
drugs	O
impaired	B-Entity
immediate	I-Entity
free	I-Entity
recall	I-Entity
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	I-Entity
than	O
propranolol	I-Entity
.	O

Delayed	B-Entity
free	I-Entity
recall	I-Entity
was	I-Entity
also	I-Entity
impaired	I-Entity
but	O
the	O
two	O
drugs	O
did	O
not	O
differ	O
.	O

Patients	O
tapped	O
faster	O
after	O
propranolol	I-Entity
than	O
diazepam	I-Entity
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	I-Entity
than	O
propranolol	I-Entity
.	O

Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-Entity
impairment	I-Entity
.	O



Effect	O
of	O
aspirin	I-Entity
on	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	I-Entity
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
administration	O
of	O
aspirin	I-Entity
with	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	I-Entity
(	O
FANFT	I-Entity
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	I-Entity
-	O
induced	O
bladder	B-Entity
carcinomas	I-Entity
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B-Entity
tumors	I-Entity
.	O

An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F-344	O
rats	O
fed	O
diet	O
containing	O
FANFT	I-Entity
at	O
a	O
level	O
of	O
0.2%	O
and/or	O
aspirin	I-Entity
at	O
a	O
level	O
of	O
0.5%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	I-Entity
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	I-Entity
in	O
the	O
forestomach	O
and	O
bladder	O
.	O

FANFT	I-Entity
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	I-Entity
co	O
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O

In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	I-Entity
did	O
not	O
affect	O
the	O
FANFT	I-Entity
-	O
induced	O
increase	O
in	O
labeling	O
index	O
.	O

The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	I-Entity
carcinogenesis	I-Entity
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	I-Entity
's	O
effect	O
on	O
FANFT	I-Entity
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	I-Entity
.	O



Provocation	O
of	O
postural	O
hypotension	I-Entity
by	O
nitroglycerin	I-Entity
in	O
diabetic	B-Entity
autonomic	I-Entity
neuropathy	I-Entity
?	O

The	O
effect	O
of	O
nitroglycerin	I-Entity
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	I-Entity
subjects	O
without	O
autonomic	B-Entity
neuropathy	I-Entity
,	O
and	O
5	O
diabetic	I-Entity
subjects	O
with	O
autonomic	B-Entity
neuropathy	I-Entity
.	O

The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	I-Entity
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	I-Entity
subjects	O
without	O
autonomic	B-Entity
neuropathy	I-Entity
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	I-Entity
subjects	O
with	O
autonomic	B-Entity
neuropathy	I-Entity
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	I-Entity
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B-Entity
neuropathy	I-Entity
.	O



Characterization	O
of	O
estrogen	I-Entity
-	O
induced	O
adenohypophyseal	B-Entity
tumors	I-Entity
in	O
the	O
Fischer	O
344	O
rat	O
.	O

Pituitary	B-Entity
tumors	I-Entity
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	I-Entity
(	O
DES	I-Entity
,	O
8	O
-	O
10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
days	O
of	O
DES	I-Entity
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES	I-Entity
-	O
treated	O
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	O
-	O
cell	O
preparations	O
.	O

The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and/or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	I-Entity
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O

Total	O
cell	O
yields	O
from	O
DES	I-Entity
-	O
treated	O
pituitaries	O
increased	O
from	O
1.3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58.9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
content	O
ranged	O
from	O
1.9	O
to	O
9.4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	I-Entity
exposure	O
.	O

Beyond	O
8	O
days	O
of	O
DES	I-Entity
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50%	O
of	O
the	O
total	O
population	O
.	O

All	O
these	O
effects	O
of	O
DES	I-Entity
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O

The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	I-Entity
-	O
induced	O
tumor	I-Entity
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O



Triamterene	I-Entity
nephrolithiasis	I-Entity
complicating	O
dyazide	I-Entity
therapy	O
.	O

A	O
case	O
of	O
triamterene	I-Entity
nephrolithiasis	I-Entity
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide	B-Entity
-	I-Entity
triamterene	I-Entity
therapy	O
for	O
hypertension	I-Entity
.	O

The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	I-Entity
metabolite	O
admixed	O
with	O
uric	B-Entity
acid	I-Entity
salts	I-Entity
.	O

Factors	O
affecting	O
triamterene	I-Entity
nephrolithiasis	I-Entity
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O



Metabolic	O
involvement	O
in	O
adriamycin	I-Entity
cardiotoxicity	I-Entity
.	O

The	O
cardiotoxic	I-Entity
effects	O
of	O
adriamycin	I-Entity
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O

Adriamycin	I-Entity
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O

A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	I-Entity
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	I-Entity
-	O
treated	O
cells	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	I-Entity
mole	O
fraction	O
was	O
unchanged	O
.	O

Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	I-Entity
phosphokinase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosine	I-Entity
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	I-Entity
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	I-Entity
pool	O
.	O

In	O
the	O
adriamycin	I-Entity
-	O
treated	O
cells	O
,	O
the	O
addition	O
of	O
adenosine	I-Entity
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O



Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	I-Entity
effects	O
of	O
streptomycin	I-Entity
.	O

Streptomycin	I-Entity
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O

Abnormal	B-Entity
movements	I-Entity
and	O
deafness	I-Entity
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	I-Entity
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	I-Entity
.	O



Crescentic	O
fibrillary	O
glomerulonephritis	I-Entity
associated	O
with	O
intermittent	O
rifampin	I-Entity
therapy	O
for	O
pulmonary	B-Entity
tuberculosis	I-Entity
.	O

This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	I-Entity
in	O
a	O
patient	O
treated	O
with	O
rifampin	I-Entity
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	O
.	O

This	O
patient	O
underwent	O
a	O
10-month	O
regimen	O
of	O
rifampin	I-Entity
and	O
isoniazid	I-Entity
for	O
pulmonary	B-Entity
tuberculosis	I-Entity
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-Entity
failure	I-Entity
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O

Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	I-Entity
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	I-Entity
were	O
investigated	O
and	O
ruled	O
out	O
.	O

This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	I-Entity
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	I-Entity
in	O
a	O
patient	O
treated	O
with	O
rifampin	I-Entity
.	O



Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephropathy	I-Entity
.	O

Reactive	O
oxygen	I-Entity
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN)-induced	I-Entity
nephropathy	I-Entity
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	I-Entity
.	O

The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	I-Entity
was	O
examined	O
in	O
this	O
study	O
.	O

Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
,	O
(	O
PAN	I-Entity
,	O
7.5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3,5,7,10,17,27,41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	O
)	O
.	O

Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-Entity
acid	I-Entity
reactive	O
substances	O
.	O

Proteinuria	I-Entity
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B-Entity
injury	I-Entity
in	O
PAN	I-Entity
nephropathy	I-Entity
.	O



Clomipramine	I-Entity
-	O
induced	O
sleep	B-Entity
disturbance	I-Entity
does	O
not	O
impair	O
its	O
prolactin	O
-	O
releasing	O
action	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B-Entity
disturbance	I-Entity
,	O
induced	O
by	O
clomipramine	I-Entity
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O

Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	I-Entity
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O

During	O
the	O
night	O
clomipramine	I-Entity
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O

10%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-Entity
disturbance	I-Entity
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	O
.	O

The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	I-Entity
ingestion	O
.	O



Angioedema	I-Entity
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	I-Entity
.	O

A	O
72-year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
""""	O
flash	O
""""	O
pulmonary	B-Entity
edema	I-Entity
,	O
preceded	O
by	O
chest	B-Entity
pain	I-Entity
,	O
requiring	O
intubation	O
.	O

Her	O
medical	O
history	O
included	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
with	O
previous	O
myocardial	B-Entity
infarctions	I-Entity
,	O
hypertension	I-Entity
,	O
and	O
diabetes	B-Entity
mellitus	I-Entity
.	O

A	O
history	O
of	O
angioedema	I-Entity
secondary	O
to	O
lisinopril	I-Entity
therapy	O
was	O
elicited	O
.	O

Current	O
medications	O
did	O
not	O
include	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	I-Entity
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	I-Entity
.	O

The	O
angioedema	I-Entity
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	I-Entity
and	O
diphenhydramine	I-Entity
hydrochloride	O
.	O



Effect	O
of	O
coniine	I-Entity
on	O
the	O
developing	O
chick	O
embryo	O
.	O

Coniine	I-Entity
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	I-Entity
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O

However	O
,	O
coniine	I-Entity
has	O
failed	O
to	O
produce	O
arthrogryposis	I-Entity
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	I-Entity
and	O
nicotine	I-Entity
in	O
the	O
developing	O
chick	O
.	O

Concentrations	O
of	O
coniine	I-Entity
and	O
nicotine	I-Entity
sulfate	O
were	O
0.015%	O
,	O
0.03%	O
,	O
0.075%	O
,	O
0.15%	O
,	O
0.75%	O
,	O
1.5%	O
,	O
3%	O
,	O
and	O
6%	O
and	O
1%	O
,	O
5%	O
,	O
and	O
10%	O
,	O
respectively	O
.	O

Both	O
compounds	O
caused	O
deformations	I-Entity
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

All	O
concentrations	O
of	O
nicotine	I-Entity
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	I-Entity
lethality	O
was	O
0.75%	O
.	O

The	O
deformations	I-Entity
caused	O
by	O
both	O
coniine	I-Entity
and	O
nicotine	I-Entity
sulfate	O
were	O
excessive	B-Entity
flexion	I-Entity
or	I-Entity
extension	I-Entity
of	I-Entity
one	I-Entity
or	I-Entity
more	I-Entity
toes	I-Entity
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Entity
hemorrhage	I-Entity
occurred	O
in	O
all	O
nicotine	I-Entity
sulfate	O
-	O
treated	O
chicks	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	I-Entity
and	O
nicotine	I-Entity
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O

Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33.67%	O
of	O
the	O
time	O
,	O
while	O
coniine	I-Entity
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8.95%	O
of	O
a	O
5-min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	I-Entity
sulfate	O
treated	O
chicks	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	I-Entity
-	O
induced	O
arthrogryposis	I-Entity
.	O



Epidural	O
blood	O
flow	O
during	O
prostaglandin	B-Entity
E1	I-Entity
or	O
trimethaphan	I-Entity
induced	O
hypotension	I-Entity
.	O

To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-Entity
E1	I-Entity
(	O
PGE1	I-Entity
)	O
or	O
trimethaphan	I-Entity
(	O
TMP	I-Entity
)	O
induced	O
hypotension	I-Entity
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	I-Entity
anaesthesia	O
.	O

An	O
initial	O
dose	O
of	O
0.1	O
microgram.kg-1.min-1	O
of	O
PGE1	I-Entity
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms.kg-1.min-1	O
of	O
TMP	I-Entity
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypotensive	I-Entity
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O

After	O
starting	O
PGE1	I-Entity
or	O
TMP	I-Entity
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O

(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	I-Entity
due	O
to	O
PGE1	I-Entity
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	I-Entity
infusion	O
whereas	O
in	O
the	O
TMP	I-Entity
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	I-Entity
(	O
preinfusion	O
:	O
45.9	O

These	O
results	O
suggest	O
that	O
PGE1	I-Entity
may	O
be	O
preferable	O
to	O
TMP	I-Entity
for	O
hypotensive	I-Entity
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	I-Entity
decreased	O
EBF	O
.	O



Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-Entity
damage	I-Entity
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O

Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
study	O
axonal	B-Entity
injury	I-Entity
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats	O
.	O

Focal	O
injury	B-Entity
in	I-Entity
the	I-Entity
cortex	I-Entity
was	O
produced	O
by	O
infusion	O
of	O
lactate	I-Entity
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O

Infarcts	B-Entity
in	I-Entity
substantia	I-Entity
nigra	I-Entity
pars	I-Entity
reticulata	I-Entity
were	O
evoked	O
by	O
prolonged	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
.	O

These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-Entity
damage	I-Entity
in	O
various	O
experimental	O
traumatic	I-Entity
or	O
ischemic	O
lesions	O
.	O



Increase	O
of	O
Parkinson	B-Entity
disability	I-Entity
after	O
fluoxetine	I-Entity
medication	O
.	O

Depression	I-Entity
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-Entity
disability	I-Entity
in	O
four	O
patients	O
with	O
idiopathic	B-Entity
Parkinson	I-Entity
's	I-Entity
disease	I-Entity
after	O
exposure	O
to	O
the	O
antidepressant	I-Entity
fluoxetine	I-Entity
.	O

The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	I-Entity
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
patients	O
must	O
be	O
considered	O
.	O



Acetaminophen	I-Entity
-	O
induced	O
hypotension	I-Entity
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	I-Entity
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

The	O
potential	O
for	O
acetaminophen	I-Entity
to	O
produce	O
cardiovascular	B-Entity
toxicities	I-Entity
is	O
very	O
low	O
.	O

However	O
,	O
acetaminophen	I-Entity
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	I-Entity
,	O
including	O
hypotension	I-Entity
,	O
in	O
sensitive	O
individuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B-Entity
ill	I-Entity
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	I-Entity
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	I-Entity
.	O

Other	O
symptoms	O
of	O
allergic	B-Entity
reactions	I-Entity
were	O
not	O
clinically	O
detectable	O
.	O

The	O
hypotensive	I-Entity
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O

The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	I-Entity
in	O
patients	O
with	O
hypotension	I-Entity
of	O
unknown	O
origin	O
.	O



Acute	O
hepatitis	I-Entity
,	O
autoimmune	B-Entity
hemolytic	I-Entity
anemia	I-Entity
,	O
and	O
erythroblastocytopenia	I-Entity
induced	O
by	O
ceftriaxone	I-Entity
.	O

An	O
80-yr	O
-	O
old	O
man	O
developed	O
acute	O
hepatitis	I-Entity
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	I-Entity
.	O

Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	B-Entity
lactam	I-Entity
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	I-Entity
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B-Entity
hemolytic	I-Entity
anemia	I-Entity
and	O
erythroblastocytopenia	I-Entity
.	O

These	O
responded	O
to	O
systemic	O
steroids	I-Entity
and	O
immunoglobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	B-Entity
lactam	I-Entity
antibiotics	O
.	O



Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-Entity
symptoms	I-Entity
(	O
EPS	I-Entity
)	O
,	O
tardive	B-Entity
dyskinesia	I-Entity
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-Entity
hypotension	I-Entity
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B-Entity
dysfunction	I-Entity
,	O
and	O
weight	B-Entity
gain	I-Entity
.	O

The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	I-Entity
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B-Entity
gain	I-Entity
,	O
sexual	B-Entity
dysfunction	I-Entity
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	I-Entity
threshold	O
(	O
primarily	O
clozapine	I-Entity
)	O
,	O
and	O
agranulocytosis	I-Entity
(	O
clozapine	I-Entity
only	O
)	O
.	O



Effects	O
of	O
tetrandrine	I-Entity
and	O
fangchinoline	I-Entity
on	O
experimental	O
thrombosis	I-Entity
in	O
mice	O
and	O
human	O
platelet	B-Entity
aggregation	I-Entity
.	O

Tetrandrine	I-Entity
(	O
TET	I-Entity
)	O
and	O
fangchinoline	I-Entity
(	O
FAN	I-Entity
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	I-Entity
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	I-Entity
and	O
FAN	I-Entity
on	O
the	O
experimental	O
thrombosis	I-Entity
induced	O
by	O
collagen	O
plus	O
epinephrine	I-Entity
(	O
EP	I-Entity
)	O
in	O
mice	O
,	O
and	O
platelet	B-Entity
aggregation	I-Entity
and	O
blood	B-Entity
coagulation	I-Entity
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
of	O
TET	I-Entity
and	O
FAN	I-Entity
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	I-Entity
by	O
55%	O
and	O
35%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Entity
acid	I-Entity
(	O
ASA	I-Entity
,	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30%	O
inhibition	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B-Entity
aggregations	I-Entity
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	I-Entity
and	O
FAN	I-Entity
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	I-Entity
nor	O
FAN	I-Entity
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	I-Entity
and	O
FAN	I-Entity
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O



Gemcitabine	I-Entity
plus	O
vinorelbine	I-Entity
in	O
nonsmall	B-Entity
cell	I-Entity
lung	I-Entity
carcinoma	I-Entity
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
can	O
not	O
receive	O
cisplatin	I-Entity
.	O

Although	O
the	O
prevalence	O
of	O
nonsmall	B-Entity
cell	I-Entity
lung	I-Entity
carcinoma	I-Entity
(	O
NSCLC	I-Entity
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	I-Entity
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	I-Entity
(	O
VNB	I-Entity
)	O
or	O
gemcitabine	I-Entity
(	O
GEM	I-Entity
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	I-Entity
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	I-Entity
of	O
the	O
combination	O
of	O
GEM	I-Entity
and	O
VNB	I-Entity
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	I-Entity
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	I-Entity
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	I-Entity
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/=	O
70	O
years	O
and	O
11	O
were	O
age	O

<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	I-Entity
.	O

All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	I-Entity
.	O

Treatment	O
was	O
comprised	O
of	O
VNB	I-Entity
,	O
25	O
mg	O
/	O
m(2	O
)	O
,	O
plus	O
GEM	I-Entity
,	O
1000	O
mg	O
/	O
m(2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Toxicity	I-Entity
was	O
mild	O
.	O

Six	O
patients	O
(	O
12%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	I-Entity
,	O
2	O
patients	O
(	O
4%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	I-Entity
,	O
and	O
2	O
patients	O
(	O
4%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	I-Entity
.	O

Three	O
patients	O
with	O
severe	O
neutropenia	I-Entity
(	O
6%	O
)	O
died	O
of	O
sepsis	I-Entity
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	I-Entity
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs.	O
72	O
years	O
;	O
P	O
=	O
0.047	O
)	O
.	O

The	O
combination	O
of	O
GEM	I-Entity
and	O
VNB	I-Entity
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	I-Entity
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	I-Entity
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	I-Entity
.	O



Warfarin	I-Entity
-	O
induced	O
artery	B-Entity
calcification	I-Entity
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	B-Entity
D.	I-Entity

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Entity
D	I-Entity
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-Entity
calcification	I-Entity
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	I-Entity
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	I-Entity
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-Entity
calcification	I-Entity
in	O
Warfarin	I-Entity
-	O
treated	O
rats	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	I-Entity
caused	O
massive	O
focal	O
calcification	B-Entity
of	I-Entity
the	I-Entity
artery	I-Entity
media	O
in	O
20-day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	I-Entity
in	O
42-day	O
-	O
old	O
rats	O
.	O

In	O
contrast	O
,	O
no	O
artery	B-Entity
calcification	I-Entity
could	O
be	O
detected	O
in	O
10-month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	I-Entity
treatment	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	I-Entity
-	O
induced	O
artery	B-Entity
calcification	I-Entity
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20-day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6-g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	I-Entity
produced	O
massive	O
focal	O
calcification	B-Entity
of	I-Entity
the	I-Entity
artery	I-Entity
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	B-Entity
calcification	I-Entity
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Entity
calcification	I-Entity
and	O
growth	O
status	O
can	O
not	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	I-Entity
and	O
susceptibility	O
to	O
artery	B-Entity
calcification	I-Entity
,	O
with	O
30%	O
higher	O
levels	O
of	O
serum	O
phosphate	I-Entity
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	I-Entity
-	O
induced	O
artery	B-Entity
calcification	I-Entity
,	O
ie	O
,	O
the	O
10-month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	I-Entity
-	O
induced	O
artery	B-Entity
calcification	I-Entity
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	I-Entity
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-Entity
D	I-Entity
and	O
Warfarin	I-Entity
in	O
artery	B-Entity
calcification	I-Entity
.	O

High	O
doses	O
of	O
vitamin	B-Entity
D	I-Entity
are	O
known	O
to	O
cause	O
calcification	B-Entity
of	I-Entity
the	I-Entity
artery	I-Entity
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
the	O
vitamin	B-Entity
K	I-Entity
antagonist	O
Warfarin	I-Entity
are	O
also	O
known	O
to	O
cause	O
calcification	B-Entity
of	I-Entity
the	I-Entity
artery	I-Entity
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	I-Entity
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	I-Entity
in	O
the	O
media	O
of	O
vitamin	B-Entity
D	I-Entity
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-Entity
D	I-Entity
dose	O
on	O
artery	B-Entity
calcification	I-Entity
and	O
the	O
effect	O
of	O
vitamin	B-Entity
D	I-Entity
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	I-Entity
,	O
which	O
suggests	O
that	O
vitamin	B-Entity
D	I-Entity
may	O
induce	O
artery	B-Entity
calcification	I-Entity
through	O
its	O
effect	O
on	O
serum	O
calcium	I-Entity
.	O

Because	O
Warfarin	I-Entity
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	I-Entity
produced	O
by	O
vitamin	B-Entity
D	I-Entity
,	O
the	O
synergy	O
between	O
Warfarin	I-Entity
and	O
vitamin	B-Entity
D	I-Entity
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	I-Entity
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	I-Entity
inhibitor	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B-Entity
calcification	I-Entity
in	O
rats	O
treated	O
with	O
vitamin	B-Entity
D	I-Entity
plus	O
Warfarin	I-Entity
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-Entity
-	I-Entity
carboxylated	I-Entity
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	B-Entity
-	I-Entity
carboxyglutamate	I-Entity
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	I-Entity
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	I-Entity
sites	O
.	O



Antidepressant	I-Entity
-	O
induced	O
mania	I-Entity
in	O
bipolar	I-Entity
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	I-Entity
associated	O
with	O
antidepressants	I-Entity
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-Entity
depression	I-Entity
.	O

The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B-Entity
disorder	I-Entity
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	I-Entity
or	O
hypomanic	I-Entity
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B-Entity
-	I-Entity
IV	I-Entity
bipolar	I-Entity
I	I-Entity
vs.	O
bipolar	B-Entity
II	I-Entity
)	O
,	O
number	O
of	O
previous	O
manic	I-Entity
episodes	O
,	O
type	O
of	O
antidepressant	I-Entity
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs.	O
antidepressant	I-Entity
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	B-Entity
reuptake	I-Entity
inhibitors	I-Entity
[	O
SSRIs	I-Entity
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	I-Entity
vs.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Switches	O
to	O
hypomania	I-Entity
or	O
mania	I-Entity
occurred	O
in	O
27%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	I-Entity
[	O
8/33	O
]	O
)	O
;	O
16%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	I-Entity
episodes	O
,	O
and	O
11%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	I-Entity
episodes	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-Entity
I	I-Entity
vs.	O
bipolar	B-Entity
II	I-Entity
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	I-Entity
(	O
15%	O
,	O
4/26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	I-Entity
(	O
44%	O
,	O
8/18	O
;	O
p	O
=	O
.04	O
)	O
.	O

The	O
number	O
of	O
previous	O
manic	I-Entity
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.008	O
)	O
.	O

The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	I-Entity
therapy	O
may	O
be	O
reduced	O
by	O
lithium	I-Entity
treatment	O
.	O



Caffeine	I-Entity
-	O
induced	O
cardiac	B-Entity
arrhythmia	I-Entity
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

We	O
describe	O
a	O
25-year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B-Entity
valve	I-Entity
prolapse	I-Entity
who	O
developed	O
intractable	O
ventricular	B-Entity
fibrillation	I-Entity
after	O
consuming	O
a	O
""""	O
natural	O
energy	O
""""	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	I-Entity
.	O



Bladder	O
retention	B-Entity
of	I-Entity
urine	I-Entity
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	I-Entity
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	I-Entity
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	I-Entity
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	I-Entity
administration	O
include	O
chest	B-Entity
wall	I-Entity
rigidity	I-Entity
,	O
hypotension	I-Entity
,	O
respiratory	B-Entity
depression	I-Entity
,	O
and	O
bradycardia	I-Entity
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	B-Entity
bladder	I-Entity
retention	I-Entity
leading	O
to	O
renal	O

pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	I-Entity
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	I-Entity
are	O
reported	O
.	O



Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	I-Entity
and	O
elevates	O
plasma	O
lactate	I-Entity
in	O
transgenic	O
AIDS	I-Entity
mice	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	I-Entity
(	O
CM	I-Entity
)	O
and	O
in	O
elevated	O
plasma	O
lactate	I-Entity
(	O
LA	I-Entity
)	O
in	O
AIDS	I-Entity
through	O
mechanisms	O
of	O
mitochondrial	B-Entity
dysfunction	I-Entity
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8-week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	I-Entity
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O

n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	I-Entity
,	O
lamivudine	I-Entity
,	O
and	O
indinavir	I-Entity
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	I-Entity
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	I-Entity
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	I-Entity
.	O

Biochemically	O
,	O
LA	I-Entity
was	O
elevated	O
(	O
8.5	O
+	O
/-	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	I-Entity
with	O
elevated	O
LA	I-Entity
in	O
AIDS	I-Entity
transgenic	O
mice	O
.	O



Oral	B-Entity
contraceptives	I-Entity
and	O
the	O
risk	O
of	O
myocardial	B-Entity
infarction	I-Entity
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-Entity
contraceptives	I-Entity
and	O
the	O
risk	O
of	O
myocardial	B-Entity
infarction	I-Entity
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	I-Entity
included	O
in	O
third	O
-	O
generation	O
(	O
i.e.	O
,	O
desogestrel	I-Entity
or	O
gestodene	I-Entity
)	O
and	O
second	O
-	O
generation	O
(	O
i.e.	O
,	O
levonorgestrel	I-Entity
)	O
oral	B-Entity
contraceptives	I-Entity

,	O
the	O
dose	O
of	O
estrogen	I-Entity
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-Entity
infarction	I-Entity
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-Entity
infarction	I-Entity
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	O
on	O
oral	B-Entity
-	I-Entity
contraceptive	I-Entity
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B-Entity
infarction	I-Entity
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-Entity
contraceptive	I-Entity
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2.0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
2.8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2.5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
4.1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Entity
contraceptives	I-Entity
and	O
1.3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.7	O
to	O
2.5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-Entity
contraceptives	I-Entity
.	O

Among	O
women	O
who	O
used	O
oral	B-Entity
contraceptives	I-Entity
,	O
the	O
odds	O
ratio	O
was	O
2.1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
3.0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1.9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.6	O
to	O
5.5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-Entity
infarction	I-Entity
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Entity
contraceptives	I-Entity
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	B-Entity
contraceptives	I-Entity
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	B-Entity
contraceptives	I-Entity
.	O

The	O
risk	O
of	O
myocardial	B-Entity
infarction	I-Entity
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Entity
contraceptives	I-Entity
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O



Effects	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	I-Entity
-	O
induced	O
locomotor	B-Entity
hyperactivity	I-Entity
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Entity
hyperactivity	I-Entity
induced	O
by	O
cocaine	I-Entity
in	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	B-Entity
55562	I-Entity
(	O
an	O
antagonist	O
of	O
5-HT1B	O
receptors	O
)	O
or	O
CP	B-Entity
93129	I-Entity
(	O
an	O
agonist	O
of	O
5-HT1B	O
receptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Entity
55562	I-Entity
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Entity
93129	I-Entity
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Systemic	O
cocaine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

GR	B-Entity
55562	I-Entity
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	I-Entity
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-Entity
hyperactivity	I-Entity
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	B-Entity
55562	I-Entity
into	O
the	O
accumbens	O
core	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	I-Entity
,	O
CP	B-Entity
93129	I-Entity
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	I-Entity
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	B-Entity
55562	I-Entity
(	O
1	O
microg	O
/	O
side	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	I-Entity
induced	O
hyperlocomotion	I-Entity
is	O
modified	O
by	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5-HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Entity
55562	I-Entity
)	O
and	O
agonist	O
(	O
CP	B-Entity
93129	I-Entity
)	O
,	O
respectively	O
.	O



Ticlopidine	I-Entity
-	O
induced	O
cholestatic	B-Entity
hepatitis	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	I-Entity
-	O
induced	O
cholestatic	B-Entity
hepatitis	I-Entity
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B-Entity
hepatitis	I-Entity
after	O
receiving	O
ticlopidine	I-Entity
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	I-Entity
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	B-Entity
hepatitis	I-Entity
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	I-Entity
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	O
developed	O
jaundice	I-Entity
following	O
treatment	O
with	O
ticlopidine	I-Entity
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Entity
hepatitis	I-Entity
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Hepatitis	I-Entity
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	I-Entity
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	I-Entity
-	O
induced	O
cholestasis	I-Entity
are	O
unclear	O
.	O

Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	O
's	O
hepatotoxicity	I-Entity
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O

Cholestatic	B-Entity
hepatitis	I-Entity
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	I-Entity
that	O
may	O
be	O
immune	O
mediated	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	I-Entity
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	I-Entity
.	O



Epithelial	O
sodium	I-Entity
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

In	O
experimental	O
nephrotic	B-Entity
syndrome	I-Entity
,	O
urinary	O
sodium	I-Entity
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	I-Entity
transport	O
is	O
the	O
epithelial	O
sodium	I-Entity
channel	O
(	O
ENaC	O
)	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN)-induced	I-Entity
nephrotic	B-Entity
syndrome	I-Entity
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	I-Entity
excretion	O
,	O
plasma	O
aldosterone	I-Entity
concentration	O
and	O
proteinuria	I-Entity
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	I-Entity
or	O
vehicle	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	I-Entity
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	I-Entity
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Sodium	I-Entity
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	I-Entity
injection	O
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	I-Entity
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	I-Entity
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	I-Entity
excretion	O
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	I-Entity
-	O
induced	O
sodium	I-Entity
retention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	I-Entity
after	O
day	O
3	O
.	O



NO	I-Entity
-	O
induced	O
migraine	I-Entity
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	B-Entity
gene	I-Entity
-	I-Entity
related	I-Entity
peptide	I-Entity
(	O
CGRP	I-Entity
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	I-Entity
release	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	B-Entity
gene	I-Entity
-	I-Entity
related	I-Entity
peptide	I-Entity
(	O
CGRP	I-Entity
)	O
concentration	O
and	O
platelet	O
serotonin	I-Entity
(	O
5-hydroxytriptamine	I-Entity
,	O
5-HT	I-Entity
)	O
content	O
during	O
the	O
immediate	O
headache	I-Entity
and	O
the	O
delayed	O
genuine	O
migraine	I-Entity
attack	O
provoked	O
by	O
nitroglycerin	I-Entity
.	O

Fifteen	O
female	O
migraineurs	B-Entity
(	I-Entity
without	I-Entity
aura	I-Entity
)	I-Entity
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O

Sublingual	O
nitroglycerin	I-Entity
(	O
0.5	O
mg	O
)	O
was	O
administered	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	I-Entity
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	I-Entity
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O

In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	I-Entity
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O

Plasma	O
CGRP	I-Entity
concentration	O
increased	O
significantly	O
(	O
P<0.01	O
)	O
during	O
the	O
migraine	I-Entity
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	I-Entity
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	I-Entity
headache	I-Entity
intensity	O
(	O
P<0.001	O
)	O
.	O

However	O
,	O
plasma	O
CGRP	I-Entity
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	I-Entity
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	I-Entity
attack	O
.	O

Basal	O
CGRP	I-Entity
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5-HT	I-Entity
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	I-Entity
attack	O
.	O

Platelet	O
serotonin	I-Entity
content	O
decreased	O
significantly	O
(	O
P<0.01	O
)	O
after	O
nitroglycerin	I-Entity
in	O
subjects	O
with	O
no	O
migraine	I-Entity
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	I-Entity
attack	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	I-Entity
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	I-Entity
headache	I-Entity
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	I-Entity
and	O
migraine	I-Entity
.	O

In	O
contrast	O
,	O
serotonin	I-Entity
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	I-Entity
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	I-Entity
and	O
the	O
concomitant	O
CGRP	I-Entity
release	O
in	O
this	O
model	O
.	O



Coronary	B-Entity
aneurysm	I-Entity
after	O
implantation	O
of	O
a	O
paclitaxel	I-Entity
-	O
eluting	O
stent	O
.	O

Formation	O
of	O
coronary	B-Entity
aneurysm	I-Entity
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	I-Entity
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	I-Entity
or	O
vessel	B-Entity
rupture	I-Entity
.	O

We	O
present	O
a	O
43-year	O
-	O
old	O
man	O
who	O
developed	O
a	O
coronary	B-Entity
aneurysm	I-Entity
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	I-Entity
-	O
eluting	O
stent	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	I-Entity
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15-mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	I-Entity
diameter	O
of	O
6.0	O
mm	O
.	O



Behavioral	O
effects	O
of	O
urotensin	B-Entity
-	I-Entity
II	I-Entity
centrally	O
administered	O
in	O
mice	O
.	O

Urotensin	B-Entity
-	I-Entity
II	I-Entity
(	O
U	B-Entity
-	I-Entity
II	I-Entity
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
injection	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
causes	O
hypertension	I-Entity
and	O
bradycardia	I-Entity
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O

However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	B-Entity
-	I-Entity
II	I-Entity
have	O
received	O
little	O
attention	O
.	O

injections	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O

Administration	O
of	O
graded	O
doses	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
(	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O

Intracerebroventricular	O
injection	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1,000	O
ng	O
/	O
mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10,000	O
ng	O
/	O
mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10,000	O
ng	O
/	O
mouse	O
.	O

Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	I-Entity
-	O
induced	O
penile	B-Entity
erection	I-Entity
and	O
climbing	O
behavior	O
,	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	I-Entity
level	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	B-Entity
-	I-Entity
II	I-Entity
at	O
doses	O
of	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O

These	O
data	O
suggest	O
that	O
U	B-Entity
-	I-Entity
II	I-Entity
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Entity
disorders	I-Entity
.	O



Recurrent	O
dysphonia	I-Entity
and	O
acitretin	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	I-Entity
while	O
she	O
was	O
treated	O
by	O
acitretin	I-Entity
.	O

Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	I-Entity
was	O
reintroduced	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	I-Entity
-	O
induced	O
dysphonia	I-Entity
.	O



Pharmacological	O
modulation	O
of	O
pain	I-Entity
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O

Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	I-Entity
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B-Entity
injury	I-Entity
(	O
secondary	B-Entity
hyperalgesia	I-Entity
)	O
.	O

Secondary	B-Entity
hyperalgesia	I-Entity
shares	O
clinical	O
characteristics	O
with	O
neurogenic	B-Entity
hyperalgesia	I-Entity
in	O
patients	O
with	O
neuropathic	B-Entity
pain	I-Entity
.	O

Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	I-Entity
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	I-Entity
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B-Entity
pain	I-Entity
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O

Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	I-Entity
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	I-Entity
-	O
induced	O
secondary	B-Entity
hyperalgesia	I-Entity
.	O

The	O
dose	O
of	O
gabapentin	I-Entity
was	O
1,800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	I-Entity
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	I-Entity
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	I-Entity
suppressed	O
stimulus	O
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	I-Entity
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	I-Entity
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O



MDMA	I-Entity
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Entity
social	I-Entity
and	I-Entity
emotional	I-Entity
judgement	I-Entity
processes	I-Entity
.	O

In	O
recent	O
years	O
working	O
memory	B-Entity
deficits	I-Entity
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	I-Entity
(	O
3,4-methylenedioxymethamphetamine	I-Entity
,	O
ecstasy	I-Entity
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	I-Entity
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
""""	O
prefrontal	O
""""	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	I-Entity
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	I-Entity
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA	I-Entity
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	I-Entity
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	I-Entity
use	O
.	O



Severe	O
citrate	I-Entity
toxicity	I-Entity
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
citrate	I-Entity
toxicity	I-Entity
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O

Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	I-Entity
,	O
hyperlipidemia	I-Entity
,	O
and	O
depression	I-Entity
.	O

Reported	O
medications	O
included	O
bumetanide	I-Entity
,	O
pravastatin	I-Entity
,	O
and	O
paroxetine	I-Entity
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	I-Entity
.	O

Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-Entity
gluconate	I-Entity
was	O
initiated	O
,	O
and	O
muscle	B-Entity
contractions	I-Entity
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O

The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	I-Entity
chelation	O
by	O
sodium	B-Entity
citrate	I-Entity
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	I-Entity
.	O

Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	I-Entity
is	O
a	O
loop	B-Entity
diuretic	I-Entity
that	O
may	O
cause	O
significant	O
hypocalcemia	I-Entity
.	O

We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	I-Entity
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	I-Entity
toxicity	I-Entity
.	O

Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	I-Entity
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O



Proteinuria	I-Entity
after	O
conversion	O
to	O
sirolimus	I-Entity
in	O
renal	O
transplant	O
recipients	O
.	O

Sirolimus	I-Entity
(	O
SRL	I-Entity
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O

More	O
recently	O
,	O
proteinuria	I-Entity
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	I-Entity
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O

We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	I-Entity
after	O
SRL	I-Entity
conversion	O
.	O

The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	I-Entity
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B-Entity
allograft	I-Entity
nephropathy	I-Entity
(	O
CAN	I-Entity
)	O
(	O
n	O
=	O
15	O
)	O

neoplasia	I-Entity
(	O
n	O
=	O
8)	O
;	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
,	O
Four	O
skin	B-Entity
cancers	I-Entity
,	O
One	O
intestinal	B-Entity
tumors	I-Entity
,	O
One	O
renal	B-Entity
cell	I-Entity
carsinom	I-Entity
)	O
or	O
BK	O
virus	O
nephropathy	I-Entity
(	O
n	O
=	O
2	O
)	O
.	O

SRL	I-Entity
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/-	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	I-Entity
therapy	O
was	O
20	O
+	O
/-	O

Proteinuria	I-Entity
increased	O
from	O
0.445	O
(	O
0	O
to	O
1.5	O
)	O

Before	O
conversion	O
8	O
(	O
32%	O
)	O
patients	O
had	O
no	O
proteinuria	I-Entity
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	I-Entity
.	O

In	O
28%	O
of	O
patients	O
proteinuria	I-Entity
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68%	O
of	O
patients	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	I-Entity
to	O
the	O
nephrotic	I-Entity
range	O
.	O

Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B-Entity
glomerulopathy	I-Entity
and	O
interstitial	B-Entity
nephritis	I-Entity
.	O

Serum	O
creatinine	I-Entity
values	O
did	O
not	O
change	O
significantly	O
:	O
1.98	O
+	O
/-	O

0.8	O
mg	O
/	O
dL	O
before	O
SRL	I-Entity
therapy	O
and	O
2.53	O
+	O
/-	O

Five	O
patients	O
displayed	O
CAN	I-Entity
and	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
.	O

Mean	O
serum	O
creatinine	I-Entity
level	O
before	O
conversion	O
was	O
2.21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4.93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.02	O
)	O
.	O

Heavy	O
proteinuria	I-Entity
was	O
common	O
after	O
the	O
use	O
of	O
SRL	I-Entity
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O

Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	I-Entity
and	O
proteinuria	I-Entity
.	O

glomerular	O
pathology	O
under	O
SRL	I-Entity
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O



In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
in	O
the	O
rat	O
.	O

In	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O

Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	I-Entity
was	O
presently	O
investigated	O
.	O

Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	I-Entity
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O

Generally	O
,	O
atropine	I-Entity
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	B-Entity
,	I-Entity
beta	I-Entity
-	I-Entity
methylene	I-Entity
adenosine-5'-triphosphate	I-Entity
(	O
alpha	B-Entity
,	I-Entity
beta	I-Entity
-	I-Entity
meATP	I-Entity
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscarinic	O
receptor	O
antagonists	O
atropine	I-Entity
,	O
4-diphenylacetoxy	B-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methylpiperidine	I-Entity
(	O
4-DAMP	I-Entity
)	O
(	O
'	O
M(1)/M(3)/M(5)-selective	O
'	O
)	O
,	O
methoctramine	I-Entity
(	O
'	O
M(2)-selective	O
'	O
)	O
and	O
pirenzepine	I-Entity
(	O
'	O
M(1)-selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O

4-DAMP	I-Entity
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	I-Entity
and	O
pirenzepine	I-Entity
.	O

In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	I-Entity
and	O
4-DAMP	I-Entity
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	I-Entity
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

While	O
contractions	O
to	O
carbachol	I-Entity
and	O
ATP	I-Entity
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	I-Entity
response	O
,	O
isoprenaline	I-Entity
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O

Thus	O
,	O
in	O
cystitis	I-Entity
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O



Associations	O
between	O
use	O
of	O
benzodiazepines	I-Entity
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	I-Entity
or	O
related	O
drugs	O
(	O
BZDs	I-Entity
/	O
RDs	O
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	I-Entity
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O

Data	O
on	O
use	O
of	O
BZDs	I-Entity
/	O
RDs	O
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	I-Entity
,	O
temazepam	I-Entity
and	O
zopiclone	I-Entity
were	O
analysed	O
.	O

Two	O
or	O
three	O
BZDs	I-Entity
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O

Long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	I-Entity
.	O

After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs	I-Entity
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDs	I-Entity
/	O
RDs	O
was	O
associated	O
with	O
dizziness	I-Entity
,	O
inability	B-Entity
to	I-Entity
sleep	I-Entity
after	O
awaking	O
at	O
night	O
and	O
tiredness	I-Entity
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-Entity
symptoms	I-Entity
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O

Use	O
of	O
BZDs	I-Entity
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	I-Entity
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O



Acute	O
vocal	B-Entity
fold	I-Entity
palsy	I-Entity
after	O
acute	O
disulfiram	I-Entity
intoxication	O
.	O

Acute	O
peripheral	B-Entity
neuropathy	I-Entity
caused	O
by	O
a	O
disulfiram	I-Entity
overdose	I-Entity
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-Entity
fold	I-Entity
palsy	I-Entity
.	O

A	O
49-year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	I-Entity
,	O
lancinating	O
pain	I-Entity
,	O
sensory	B-Entity
loss	I-Entity
,	O
and	O
paresthesia	I-Entity
of	O
the	O
distal	O
limbs	O
.	O

One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	I-Entity
(	O
130	O
tablets	O
of	O
ALCOHOL	I-Entity
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O

For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	I-Entity
and	O
giddiness	I-Entity
.	O

She	O
noticed	O
hoarseness	I-Entity
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O

A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	I-Entity
.	O

This	O
was	O
a	O
case	O
of	O
acute	O
palsy	I-Entity
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	I-Entity
caused	O
by	O
high	O
-	O
dose	O
disulfiram	I-Entity
intoxication	O
.	O



Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	I-Entity
in	O
patients	O
with	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
.	O

OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two	O
-	O
step	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
(	O
HIT	I-Entity
)	O
antigen	O
assay	O
with	O
thrombosis	I-Entity

;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	I-Entity
concentration	O
.	O

Patients	O
with	O
more	O
than	O
50%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	I-Entity
(	O
<	O
150	O
x	O
10(9)/L	O
)	O
after	O
exposure	O
to	O
heparin	I-Entity
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O

0.4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	I-Entity
]	O
were	O
included	O
in	O
the	O
study	O
.	O

Forty	O
of	O
94	O
HIT	I-Entity
patients	O
had	O
thrombosis	I-Entity
at	O
diagnosis	O
;	O
54/94	O
had	O
isolated	O
-	O
HIT	I-Entity
without	O
thrombosis	I-Entity
.	O

Eight	O
of	O
the	O
isolated	O
-	O
HIT	I-Entity
patients	O
developed	O
thrombosis	I-Entity
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	I-Entity
at	O
day	O
30	O
.	O

At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	I-Entity
patients	O
with	O
thrombosis	I-Entity
and	O
those	O
with	O
isolated	O
-	O
HIT	I-Entity
.	O

However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	I-Entity
(	O
n	O
=	O
48	O
,	O
1.34	O
+	O
/-	O

0.89	O
)	O
,	O
including	O
isolated	O
-	O
HIT	I-Entity
patients	O
who	O
later	O
developed	O
thrombosis	I-Entity
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1.84	O
+	O
/-	O

0.64	O
)	O
as	O
compared	O
to	O
isolated	O
-	O
HIT	I-Entity
patients	O
who	O
did	O
not	O
develop	O
thrombosis	I-Entity
(	O
0.96	O
+	O
/-	O

The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1.27	O
in	O
the	O
isolated	O
-	O
HIT	I-Entity
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	I-Entity
by	O
day	O
30	O
.	O

Multivariate	O
analysis	O
showed	O
a	O
2.8-fold	O
increased	O
risk	O
of	O
thrombosis	I-Entity
in	O
females	O
.	O

Similarly	O
,	O
thrombotic	I-Entity
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O

CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	I-Entity
in	O
patients	O
with	O
isolated	O
-	O
HIT	I-Entity
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O



Central	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
associated	O
with	O
clomiphene	I-Entity
-	O
induced	O
ovulation	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
associated	O
with	O
clomiphene	B-Entity
citrate	I-Entity
(	O
CC	I-Entity
)	O
.	O

PATIENT(S	O
)	O
:	O
A	O
36-year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	I-Entity
clinic	O
for	O
blurred	B-Entity
vision	I-Entity
.	O

INTERVENTION(S	O
)	O
:	O
Ophthalmic	O
examination	O
after	O
CC	I-Entity
therapy	O
.	O

MAIN	O
OUTCOME	O
MEASURE(S	O
)	O
:	O
Central	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
after	O
ovulation	O
induction	O
with	O
CC	I-Entity
.	O

RESULT(S	O
)	O
:	O
A	O
36-year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
after	O
eight	O
courses	O
of	O
CC	I-Entity
.	O

A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	I-Entity
complications	O
of	O
CC	I-Entity
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	B-Entity
disturbance	I-Entity
after	O
CC	I-Entity
intake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION(S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
after	O
treatment	O
with	O
CC	I-Entity
.	O

Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	I-Entity
patients	O
with	O
CC	I-Entity
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O



Nicotine	I-Entity
-	O
induced	O
nystagmus	I-Entity
correlates	O
with	O
midpontine	O
activation	O
.	O

The	O
pathomechanism	O
of	O
nicotine	I-Entity
-	O
induced	O
nystagmus	I-Entity
(	O
NIN	I-Entity
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	I-Entity
generation	O
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	I-Entity
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O

NIN	I-Entity
correlated	O
with	O
blood	O
oxygen	I-Entity
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O

NIN	I-Entity
-	O
induced	O
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O



Protective	O
effect	O
of	O
verapamil	I-Entity
on	O
gastric	B-Entity
hemorrhagic	I-Entity
ulcers	I-Entity
in	O
severe	O
atherosclerotic	I-Entity
rats	O
.	O

Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Entity
hemorrhage	I-Entity
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	I-Entity
rats	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	I-Entity
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Entity
hemorrhage	I-Entity
and	O
ulcer	I-Entity
in	O
rats	O
with	O
atherosclerosis	I-Entity
induced	O
by	O
coadministration	O
of	O
vitamin	B-Entity
D2	I-Entity
and	O
cholesterol	I-Entity
.	O

Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	I-Entity
on	O
this	O
ulcer	I-Entity
model	O
was	O
evaluated	O
.	O

kg	O
of	O
corn	O
oil	O
containing	O
vitamin	B-Entity
D2	I-Entity
and	O
cholesterol	I-Entity
to	O
induce	O
atherosclerosis	I-Entity
.	O

Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	I-Entity
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	I-Entity
hemoglobin	O
content	O
and	O
ulcer	I-Entity
areas	O
were	O
determined	O
.	O

Elevated	O
atherosclerotic	I-Entity
parameters	O
,	O
such	O
as	O
serum	O
calcium	I-Entity
,	O
total	O
cholesterol	I-Entity
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	I-Entity
rats	O
.	O

Severe	O
gastric	O
ulcers	I-Entity
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	I-Entity
release	O
,	O
LPO	O
generation	O
and	O
luminal	I-Entity
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O

Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	I-Entity
to	O
gastric	B-Entity
hemorrhage	I-Entity
and	O
to	O
ulcer	I-Entity
was	O
found	O
in	O
those	O
atherosclerotic	I-Entity
rats	O
.	O

This	O
hemorrhagic	I-Entity
ulcer	I-Entity
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	I-Entity
.	O

Atherosclerosis	I-Entity
could	O
produce	O
gastric	B-Entity
hemorrhagic	I-Entity
ulcer	I-Entity
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	I-Entity
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	I-Entity
in	O
rats	O
.	O



Adriamycin	I-Entity
-	O
induced	O
autophagic	O
cardiomyocyte	O
death	I-Entity
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B-Entity
failure	I-Entity
.	O

The	O
mechanisms	O
underlying	O
heart	B-Entity
failure	I-Entity
induced	O
by	O
adriamycin	I-Entity
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Entity
failure	I-Entity
induced	O
by	O
adriamycin	I-Entity
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B-Entity
failure	I-Entity
.	O

METHODS	O
:	O
3-methyladenine	I-Entity
(	O
3MA	I-Entity
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-Entity
failure	I-Entity
model	O
of	O
rats	O
induced	O
by	O
adriamycin	I-Entity
.	O

Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	I-Entity
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	I-Entity
plus	O
adriamycin	I-Entity
-	O
treated	O
group	O
.	O

We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na+-K+	I-Entity
ATPase	O
activity	O
in	O
vivo	O
.	O

RESULTS	O
:	O
3MA	I-Entity
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O

Furthermore	O
,	O
adriamycin	I-Entity
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	I-Entity
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	I-Entity
-	O
induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O

CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	I-Entity
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-Entity
failure	I-Entity
in	O
rats	O
induced	O
by	O
adriamycin	I-Entity
.	O

Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Entity
failure	I-Entity
caused	O
by	O
adriamycin	I-Entity
via	O
the	O
autophagy	O
pathway	O
.	O



Confusion	I-Entity
,	O
a	O
rather	O
serious	O
adverse	O
drug	O
reaction	O
with	O
valproic	B-Entity
acid	I-Entity
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O

Confusion	I-Entity
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Entity
acid	I-Entity
.	O

Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	I-Entity
reported	O
since	O
1985	O
with	O
valproic	B-Entity
acid	I-Entity
.	O

RESULTS	O
:	O
272	O
cases	O
of	O
confusion	I-Entity
were	O
reported	O
with	O
valproic	B-Entity
acid	I-Entity
:	O
153	O
women	O
and	O
119	O
men	O
.	O

Confusion	I-Entity
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Entity
acid	I-Entity
exposure	O
(	O
39.7%	O
)	O
.	O

This	O
work	O
shows	O
that	O
confusion	I-Entity
with	O
valproic	B-Entity
acid	I-Entity
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	O
drug	O
reaction	O
.	O



Learning	B-Entity
and	I-Entity
memory	I-Entity
deficits	I-Entity
in	O
ecstasy	I-Entity
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	I-Entity
users	O
display	O
impairments	B-Entity
in	I-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	I-Entity
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and/or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	I-Entity
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	I-Entity
use	O
of	O
the	O
ecstasy	I-Entity
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	I-Entity
users	O
(	O
Nestor	O
,	O
L.	O
,	O
Roberts	O
,	O
G.	O
,	O
Garavan	O
,	O
H.	O
,	O
Hester	O
,	O
R.	O
,	O
2008	O
.	O

Deficits	B-Entity
in	I-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
:	O
parahippocampal	O
hyperactivity	I-Entity
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	I-Entity
users	O
.	O

Ecstasy	I-Entity
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	I-Entity
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	I-Entity
-	O
specific	O
hyperactivity	I-Entity
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy	I-Entity
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	I-Entity
and	O
cannabis	I-Entity
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy	I-Entity
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	I-Entity
use	O
.	O

These	O
ecstasy	I-Entity
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	I-Entity
effects	O
of	O
ecstasy	I-Entity
.	O



Prolonged	O
elevation	O
of	O
plasma	O
argatroban	I-Entity
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
with	O
thrombosis	I-Entity
.	O

BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
(	O
HIT	I-Entity
)	O
or	O
HIT	I-Entity
with	O
thrombosis	I-Entity
(	O
HITT	I-Entity
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
report	O
,	O
a	O
65-year	O
-	O
old	O
critically	B-Entity
ill	I-Entity
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	I-Entity
was	O
administered	O
argatroban	I-Entity
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O

The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B-Entity
and	I-Entity
postoperative	I-Entity
bleeding	I-Entity
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	I-Entity
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O

Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	I-Entity
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	I-Entity
half	O
life	O
(	O
t(1/2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t(1/2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	B-Entity
impairment	I-Entity
]	O
)	O
.	O

Correlation	O
of	O
plasma	O
argatroban	I-Entity
concentration	O
versus	O
the	O
patient	O
's	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	I-Entity
may	O
have	O
contributed	O
to	O
the	O
patient	O
's	O
extended	O
coagulopathy	I-Entity
.	O

This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	I-Entity
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	I-Entity
.	O



Antituberculosis	I-Entity
therapy	O
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O

Antituberculosis	I-Entity
therapy	O
(	O
ATT)-associated	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
(	O
ATT	O
-	O
ALF	I-Entity
)	O
is	O
the	O
commonest	O
drug	O
-	O
induced	O
ALF	I-Entity
in	O
South	O
Asia	O
.	O

Prospective	O
studies	O
on	O
ATT	O
-	O
ALF	I-Entity
are	O
lacking	O
.	O

The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	I-Entity
.	O

From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	I-Entity
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5.7%	O
)	O
patients	O
.	O

Another	O
15	O
(	O
1.2%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-Entity
virus	I-Entity
infection	I-Entity
.	O

In	O
44	O
(	O
62.8%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	I-Entity
.	O

ATT	O
-	O
ALF	I-Entity
patients	O
were	O
younger	O
(	O
32.87	O
[	O
+	O
/-15.8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70%	O
)	O
of	O
them	O
were	O
women	O
.	O

Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	I-Entity
encephalopathy	I-Entity
interval	O
was	O
4.5	O
(	O
0	O
-	O
30	O
)	O
days	O
.	O

The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	I-Entity
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O

At	O
presentation	O
,	O
advanced	O
encephalopathy	I-Entity
and	O
cerebral	B-Entity
edema	I-Entity
were	O
present	O
in	O
51	O
(	O
76%	O
)	O
and	O
29	O
(	O
41.4%	O
)	O
patients	O
,	O
respectively	O
.	O

Gastrointestinal	B-Entity
bleed	I-Entity
,	O
seizures	I-Entity
,	O
infection	I-Entity
,	O
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
were	O
documented	O
in	O
seven	O
(	O
10%	O
)	O
,	O
five	O
(	O
7.1%	O
)	O
,	O
26	O
(	O
37.1%	O
)	O
,	O
and	O
seven	O
(	O
10%	O
)	O
patients	O
,	O
respectively	O
.	O

Compared	O
with	O
hepatitis	B-Entity
E	I-Entity
virus	O
(	O
HEV	O
)	O
and	O
non	O
-	O

A	O
non	O
-	O
E	O
-	O
induced	O
ALF	I-Entity
,	O
ATT	O
-	O
ALF	I-Entity
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	I-Entity
was	O
high	O
(	O
67.1%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32.9%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O

In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	I-Entity
(	O
>	O
or=10.8	O
mg	O
/	O
dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or=26	O
seconds	O
)	O
,	O
and	O
grade	O
III	O
/	O
IV	O
encephalopathy	I-Entity
at	O
presentation	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	I-Entity
constituted	O
5.7%	O
of	O
ALF	I-Entity
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O



Central	B-Entity
nervous	I-Entity
system	I-Entity
complications	I-Entity
during	O
treatment	O
of	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
in	O
a	O
single	O
pediatric	O
institution	O
.	O

Central	B-Entity
nervous	I-Entity
system	I-Entity
(	I-Entity
CNS	I-Entity
)	I-Entity
complications	I-Entity
during	O
treatment	O
of	O
childhood	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
(	O
ALL	I-Entity
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O

This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B-Entity
complications	I-Entity
during	O
ALL	I-Entity
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O

Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B-Entity
infiltration	I-Entity
at	O
diagnosis	O
,	O
therapy	O
-	O
related	O
peripheral	B-Entity
neuropathy	I-Entity
,	O
late	O
-	O
onset	O
encephalopathy	I-Entity
,	O
or	O
long	O
-	O
term	O
neurocognitive	B-Entity
defects	I-Entity
.	O

During	O
a	O
9-year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	I-Entity
front	O
-	O
line	O
protocol	O
.	O

CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	I-Entity
syndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroke	I-Entity
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dose	O
methotrexate	I-Entity
toxicity	I-Entity
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	B-Entity
antidiuretic	I-Entity
hormone	I-Entity
secretion	I-Entity
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	I-Entity
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O



Safety	O
of	O
capecitabine	I-Entity
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	I-Entity
,	O
in	O
particular	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	I-Entity
,	O
including	O
colorectal	B-Entity
,	I-Entity
breast	I-Entity
and	I-Entity
head	I-Entity
and	I-Entity
neck	I-Entity
cancers	I-Entity
,	O
for	O
>	O
40	O
years	O
.	O

This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	I-Entity
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	I-Entity
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	B-Entity
and	I-Entity
kidney	I-Entity
disease	I-Entity
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	I-Entity
administration	O
.	O

Capecitabine	I-Entity
is	O
an	O
oral	O
prodrug	O
of	O
5-FU	I-Entity
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Entity
,	I-Entity
breast	I-Entity
,	I-Entity
pancreaticobiliary	I-Entity
,	I-Entity
gastric	I-Entity
,	I-Entity
renal	I-Entity
cell	I-Entity
and	I-Entity
head	I-Entity
and	I-Entity
neck	I-Entity
cancers	I-Entity
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	I-Entity
are	O
diarrhea	I-Entity
,	O
nausea	I-Entity
,	O
vomiting	I-Entity
,	O
stomatitis	I-Entity
and	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
.	O

Capecitabine	I-Entity
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Entity
and	I-Entity
renal	I-Entity
dysfunctions	I-Entity
.	O



Effects	O
of	O
pallidal	O
neurotensin	I-Entity
on	O
haloperidol	I-Entity
-	O
induced	O
parkinsonian	B-Entity
catalepsy	I-Entity
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	I-Entity
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	I-Entity
on	O
haloperidol	I-Entity
-	O
induced	O
parkinsonian	B-Entity
symptoms	I-Entity
.	O

Bilateral	O
infusions	O
of	O
neurotensin	I-Entity
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol	I-Entity
-	O
induced	O
parkinsonian	B-Entity
catalepsy	I-Entity
in	O
rats	O
.	O

Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	I-Entity
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	I-Entity
administration	O
.	O

The	O
neurotensin	B-Entity
type-1	I-Entity
receptor	I-Entity
antagonist	I-Entity
SR48692	I-Entity
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	I-Entity
.	O

CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	I-Entity
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	I-Entity
-	O
induced	O
antiparkinsonian	O
effects	O
.	O



Antihypertensive	O
drugs	O
and	O
depression	I-Entity
:	O
a	O
reappraisal	O
.	O

new	O
referral	O
hypertensive	I-Entity
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	I-Entity
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O

The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	I-Entity
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	I-Entity
group	O
.	O

Hypertensive	I-Entity
patients	O
with	O
psychiatric	I-Entity
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	I-Entity
than	O
the	O
comparison	O
patients	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	I-Entity
occurring	O
in	O
methyl	B-Entity
dopa	I-Entity
treated	O
patients	O
with	O
psychiatric	I-Entity
histories	O
.	O



Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
.	O

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Entity
nitroprusside	I-Entity
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitroprusside	I-Entity
infusion	O
,	O
5	O
cm	O
H2O	I-Entity
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O

cm	O
H2O	I-Entity
CPAP	O
before	O
nitroprusside	I-Entity
infusion	O
produced	O
a	O
further	O
decrease	B-Entity
in	I-Entity
arterial	I-Entity
blood	I-Entity
pressure	I-Entity
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-Entity
cardiac	I-Entity
output	I-Entity
and	O
QS	O
/	O
QT	O
.	O

Nitroprusside	I-Entity
caused	O
significant	O
decreases	B-Entity
in	I-Entity
arterial	I-Entity
blood	I-Entity
pressure	I-Entity
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

H2O	I-Entity
CPAP	O
during	O
nitroprusside	I-Entity
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O

However	O
,	O
10	O
cm	O
H2O	I-Entity
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
data	O
indicate	O
that	O
nitroprusside	I-Entity
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitroprusside	I-Entity
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	I-Entity
)	O
,	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B-Entity
in	I-Entity
arterial	I-Entity
blood	I-Entity
pressure	I-Entity
and	I-Entity
cardiac	I-Entity
output	I-Entity
.	O



Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	I-Entity
by	O
L	B-Entity
-	I-Entity
dopa	I-Entity
via	O
central	O
dopamine	I-Entity
formation	O
in	O
dogs	O
.	O

L	B-Entity
-	I-Entity
Dopa	I-Entity
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK-486	I-Entity
(	O
25	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
in	O

anesthetize	O
MAO	I-Entity
-	O
inhibited	O
dogs	O
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	I-Entity
caused	O
by	O
injected	O
norepinephrine	I-Entity
was	O
significantly	O
enhanced	O
by	O
L	B-Entity
-	I-Entity
dopa	I-Entity
,	O
DL	B-Entity
-	I-Entity
Threo	I-Entity
-	I-Entity
dihydroxyphenylserine	I-Entity
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	I-Entity
.	O

FLA-63	I-Entity
,	O
a	O
dopamine	I-Entity
-	O
beta	O
-	O
oxidase	O
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	I-Entity
,	O
bradycardia	I-Entity
or	O
reflex	O
-	O
enhancing	O
effect	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
.	O

Pimozide	I-Entity
did	O
not	O
affect	O
the	O
actions	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O

Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	I-Entity
.	O

However	O
,	O
L	B-Entity
-	I-Entity
dopa	I-Entity
restored	O
the	O
bradycardia	I-Entity
caused	O
by	O
norepinephrine	I-Entity
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

5-HTP	I-Entity
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O

decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	I-Entity
to	O
norepinephrine	I-Entity
.	O

It	O
is	O
concluded	O
that	O
L	B-Entity
-	I-Entity
dopa	I-Entity
enhances	O
reflex	O
bradycardia	I-Entity
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O

Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	I-Entity
rather	O
than	O
norepinephrine	I-Entity
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O



Cocaine	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O

Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	I-Entity
may	O
result	O
in	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
.	O

In	O
individuals	O
with	O
preexisting	O
,	O
high	O
-	O
grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	I-Entity
demand	O
associated	O
with	O
cocaine	I-Entity
-	O
induced	O
increase	O
in	O
rate	O
-	O
pressure	O
product	O
.	O

In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-Entity
obstruction	I-Entity
,	O
coronary	B-Entity
occlusion	I-Entity
may	O
be	O
due	O
to	O
spasm	I-Entity
,	O
thrombus	I-Entity
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spasm	I-Entity
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	I-Entity
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	I-Entity
involves	O
the	O
epicardial	O
,	O
medium	O
-	O
size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O

Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	I-Entity
.	O

The	O
finding	O
of	O
cocaine	I-Entity
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	I-Entity
effect	O
of	O
cocaine	I-Entity
has	O
not	O
been	O
excluded	O
.	O



Rabbit	B-Entity
syndrome	I-Entity
,	O
antidepressant	I-Entity
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O

The	O
rabbit	B-Entity
syndrome	I-Entity
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O

Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	I-Entity
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	I-Entity
.	O

Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B-Entity
basal	I-Entity
ganglia	I-Entity
perfusion	I-Entity
while	O
the	O
movement	B-Entity
disorder	I-Entity
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-Entity
syndrome	I-Entity
resolved	O
.	O



Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	B-Entity
bromide	I-Entity
and	O
theophylline	I-Entity
in	O
chronic	B-Entity
obstructive	I-Entity
pulmonary	I-Entity
disease	I-Entity
.	O

The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	B-Entity
bromide	I-Entity
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	I-Entity
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-Entity
obstructive	I-Entity
pulmonary	I-Entity
disease	I-Entity
.	O

Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31%	O
and	O
90%	O
,	O
respectively	O
,	O
for	O
ipratropium	I-Entity
and	O
17%	O
and	O
50%	O
,	O
respectively	O
,	O
for	O
theophylline	I-Entity
.	O

The	O
average	O
FEV1	O
increases	O
during	O
the	O
6-hour	O
observation	O
period	O
were	O
18%	O
for	O
ipratropium	I-Entity
and	O
8%	O
for	O
theophylline	I-Entity
.	O

The	O
mean	O
duration	O
of	O
action	O
was	O
3.8	O
hours	O
with	O
ipratropium	I-Entity
and	O
2.4	O
hours	O
with	O
theophylline	I-Entity
.	O

While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	I-Entity
use	O
did	O
involve	O
the	O
cardiovascular	B-Entity
and	I-Entity
gastrointestinal	I-Entity
systems	I-Entity
.	O

These	O
results	O
show	O
that	O
ipratropium	I-Entity
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	I-Entity
in	O
patients	O
with	O
chronic	B-Entity
airflow	I-Entity
obstruction	I-Entity
.	O



Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	I-Entity
in	O
F344	O
rats	O
.	O

Renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
(	O
RPN	I-Entity
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long	O
-	O
term	O
treatment	O
with	O
aspirin	I-Entity
and	O
paracetamol	I-Entity
in	O
female	O
Fischer	O
344	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	I-Entity
.	O



Less	O
frequent	O
lithium	I-Entity
administration	O
and	O
lower	O
urine	O
volume	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	I-Entity
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O

This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	I-Entity
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O

Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	I-Entity
level	O
,	O
creatinine	I-Entity
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O

Multiple	O
daily	O
doses	O
of	O
lithium	I-Entity
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O

The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	I-Entity
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	I-Entity
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	I-Entity
clearance	O
.	O

CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	I-Entity
once	O
daily	O
and/or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O

Lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O



Effect	O
of	O
adriamycin	I-Entity
combined	O
with	O
whole	O
body	O
hyperthermia	I-Entity
on	O
tumor	I-Entity
and	O
normal	O
tissues	O
.	O

Thermal	O
enhancement	O
of	O
Adriamycin	I-Entity
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	I-Entity
by	O
whole	O
body	O
hyperthermia	I-Entity
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	I-Entity
growth	O
delay	O
assay	O
.	O

Acute	O
normal	O
tissue	O
toxicities	I-Entity
(	O
i.e.	O
,	O
leukopenia	I-Entity
and	O
thrombocytopenia	I-Entity
)	O
and	O
late	O
normal	O
tissue	O
toxicities	I-Entity
(	O
i.e.	O
,	O
myocardial	B-Entity
and	I-Entity
kidney	I-Entity
injury	I-Entity
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O

Whole	O
body	O
hyperthermia	I-Entity
(	O
120	O
min	O
at	O
41.5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin	I-Entity
-	O
mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O

Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
""""	O
acute	O
""""	O
hematological	O
changes	O
were	O
1.3	O
,	O
whereas	O
those	O
estimated	O
for	O
""""	O
late	O
""""	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	B-Entity
and	I-Entity
renal	I-Entity
lesions	I-Entity
)	O
varied	O
between	O
2.4	O
and	O
4.3	O
.	O

Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	I-Entity
enhances	O
Adriamycin	I-Entity
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	I-Entity
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O



Prazosin	I-Entity
-	O
induced	O
stress	B-Entity
incontinence	I-Entity
.	O

A	O
case	O
of	O
genuine	O
stress	B-Entity
incontinence	I-Entity
due	O
to	O
prazosin	I-Entity
,	O
a	O
common	O
antihypertensive	O
drug	O
,	O
is	O
presented	O
.	O

Prazosin	I-Entity
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha-1	O
adrenergic	O
receptors	O
.	O

The	O
patient	O
's	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	I-Entity
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	I-Entity
.	O

Her	O
incontinence	I-Entity
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O

Patients	O
who	O
present	O
with	O
stress	B-Entity
incontinence	I-Entity
while	O
taking	O
prazosin	I-Entity
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	I-Entity
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	O
therapy	O
.	O



Myocardial	B-Entity
infarction	I-Entity
following	O
sublingual	O
administration	O
of	O
isosorbide	B-Entity
dinitrate	I-Entity
.	O

A	O
78-year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	I-Entity
suffered	O
a	O
recurrent	O
myocardial	B-Entity
infarction	I-Entity
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	B-Entity
dinitrate	I-Entity
5	O
mg	O
sublingually	O
.	O

After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	I-Entity
and	O
hypotension	I-Entity
-	O
mediated	O
myocardial	B-Entity
ischemia	I-Entity
occurring	O
downstream	O
to	O
significant	O
coronary	B-Entity
arterial	I-Entity
stenosis	I-Entity
in	O
the	O
pathophysiology	O
of	O
acute	B-Entity
coronary	I-Entity
insufficiency	I-Entity
.	O



Fluoxetine	I-Entity
-	O
induced	O
akathisia	I-Entity
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

Five	O
patients	O
receiving	O
fluoxetine	I-Entity
for	O
the	O
treatment	O
of	O
obsessive	B-Entity
compulsive	I-Entity
disorder	I-Entity
or	O
major	B-Entity
depression	I-Entity
developed	O
akathisia	I-Entity
.	O

The	O
typical	O
fluoxetine	I-Entity
-	O
induced	O
symptoms	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	I-Entity
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	O
-	O
induced	O
akathisia	I-Entity
.	O

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	I-Entity
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	I-Entity
-	O
induced	O
akathisia	I-Entity
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

Akathisia	I-Entity
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	I-Entity
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
propranolol	I-Entity
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

The	O
authors	O
suggest	O
that	O
fluoxetine	I-Entity
-	O
induced	O
akathisia	I-Entity
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	I-Entity
-	O
induced	O
akathisia	I-Entity
and	O
tricyclic	O
antidepressant	I-Entity
-	O
induced	O
""""	O
jitteriness	O
""""	O
may	O
be	O
identical	O
.	O



Chronic	B-Entity
active	I-Entity
hepatitis	I-Entity
associated	O
with	O
diclofenac	B-Entity
sodium	I-Entity
therapy	O
.	O

Diclofenac	B-Entity
sodium	I-Entity
(	O
Voltarol	I-Entity
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-Entity
acid	I-Entity
.	O

Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B-Entity
of	I-Entity
liver	I-Entity
function	I-Entity
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	I-Entity
induced	O
by	O
diclofenac	I-Entity
.	O

The	O
patient	O
described	O
developed	O
chronic	B-Entity
active	I-Entity
hepatitis	I-Entity
after	O
six	O
months	O
therapy	O
with	O
diclofenac	B-Entity
sodium	I-Entity
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O



Stroke	I-Entity
associated	O
with	O
cocaine	I-Entity
use	O
.	O

We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	I-Entity
use	O
was	O
related	O
to	O
stroke	I-Entity
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O

Stroke	I-Entity
followed	O
cocaine	I-Entity
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O

Intracranial	B-Entity
aneurysms	I-Entity
or	O
arteriovenous	B-Entity
malformations	I-Entity
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B-Entity
vasculitis	I-Entity
was	O
present	O
in	O
two	O
patients	O
.	O

Cerebral	B-Entity
infarction	I-Entity
occurred	O
in	O
10	O
patients	O
(	O
22%	O
)	O
,	O
intracerebral	B-Entity
hemorrhage	I-Entity
in	O
22	O
(	O
49%	O
)	O
,	O
and	O
subarachnoid	B-Entity
hemorrhage	I-Entity
in	O
13	O
(	O
29%	O
)	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	I-Entity
related	O
to	O
cocaine	I-Entity
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine	I-Entity
-	O
associated	O
stroke	I-Entity
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	I-Entity
may	O
follow	O
any	O
route	O
of	O
cocaine	I-Entity
administration	O
;	O
(	O
4	O
)	O
stroke	I-Entity
after	O
cocaine	I-Entity
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B-Entity
aneurysms	I-Entity
and	O
arteriovenous	B-Entity
malformations	I-Entity
;	O
and	O

(	O
5	O
)	O
in	O
cocaine	I-Entity
-	O
associated	O
stroke	I-Entity
,	O
the	O
frequency	O
of	O
intracranial	B-Entity
hemorrhage	I-Entity
exceeds	O
that	O
of	O
cerebral	B-Entity
infarction	I-Entity
.	O



Glyburide	I-Entity
-	O
induced	O
hepatitis	I-Entity
.	O

Drug	O
-	O
induced	O
hepatotoxicity	I-Entity
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	I-Entity
.	O

For	O
glyburide	I-Entity
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	I-Entity
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	I-Entity
exist	O
.	O

Two	O
patients	O
with	O
type	B-Entity
II	I-Entity
diabetes	I-Entity
mellitus	I-Entity
developed	O
an	O
acute	B-Entity
hepatitis	I-Entity
-	I-Entity
like	I-Entity
syndrome	I-Entity
soon	O
after	O
initiation	O
of	O
glyburide	I-Entity
therapy	O
.	O

There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B-Entity
infection	I-Entity
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug	B-Entity
-	I-Entity
induced	I-Entity
hepatitis	I-Entity
.	O

Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	I-Entity
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
1	O
year	O
.	O

Glyburide	I-Entity
can	O
produce	O
an	O
acute	B-Entity
hepatitis	I-Entity
-	I-Entity
like	I-Entity
illness	I-Entity
in	O
some	O
persons	O
.	O



Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	I-Entity
than	O
during	O
sodium	B-Entity
nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
ventilated	O
dogs	O
.	O

The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive	O
-	O
pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	I-Entity
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	I-Entity
(	O
HEM	I-Entity
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-Entity
nitroprusside	I-Entity
(	O
SNP	I-Entity
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	I-Entity
-	O
induced	O
hypotension	I-Entity
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	I-Entity
group	O
.	O

The	O
SPV	O
during	O
hypotension	I-Entity
was	O
15.7	O
+	O
/-	O

6.7	O
mm	O
Hg	O
in	O
the	O
HEM	I-Entity
group	O
,	O
compared	O
with	O
9.1	O
+	O
/-	O

2.0	O
mm	O
Hg	O
in	O
the	O
SNP	I-Entity
group	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

3.8	O
mm	O
Hg	O
in	O
the	O
HEM	I-Entity
and	O
SNP	I-Entity
groups	O
,	O
respectively	O
,	O
during	O
hypotension	I-Entity
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	I-Entity
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	I-Entity
than	O
during	O
deliberate	O
hypotension	I-Entity
.	O



Drug	O
-	O
induced	O
arterial	O
spasm	I-Entity
relieved	O
by	O
lidocaine	I-Entity
.	O

Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35-year	O
-	O
old	O
man	O
,	O
sodium	B-Entity
pentothal	I-Entity
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B-Entity
ischaemia	I-Entity
.	O

Intense	O
vasospasm	I-Entity
with	O
threatened	O
gangrene	I-Entity
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	I-Entity
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	I-Entity
.	O



Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B-Entity
aneurysms	I-Entity
.	O

Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	I-Entity
were	O
measured	O
during	O
isoflurane	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-Entity
aneurysm	I-Entity
.	O

Flow	O
and	O
metabolism	O
were	O
measured	O
5	O
-	O
13	O
days	O
after	O
the	O
subarachnoid	B-Entity
haemorrhage	I-Entity
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	O
using	O
xenon-133	I-Entity
i.v	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	I-Entity
concentration	O
of	O
0.75%	O
(	O
plus	O
67%	O
nitrous	B-Entity
oxide	I-Entity
in	O
oxygen	I-Entity
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34.3	O
+	O
/-	O

Controlled	O
hypotension	I-Entity
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	I-Entity
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	I-Entity
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2.2	O
+	O
/-	O

After	O
the	O
clipping	O
of	O
the	O
aneurysm	I-Entity
the	O
isoflurane	I-Entity
concentration	O
was	O
reduced	O
to	O
0.75%	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre	O
-	O
hypotensive	I-Entity
values	O
.	O

These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	I-Entity
.	O



Allergic	B-Entity
reaction	I-Entity
to	O
5-fluorouracil	I-Entity
infusion	O
.	O

An	O
allergic	B-Entity
reaction	I-Entity
consisting	O
of	O
angioneurotic	B-Entity
edema	I-Entity
secondary	O
to	O
continuous	O
infusion	O
5-fluorouracil	I-Entity
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
oral	I-Entity
cavity	I-Entity
,	O
cirrhosis	I-Entity
,	O
and	O
cisplatin	I-Entity
-	O
induced	O
impaired	B-Entity
renal	I-Entity
function	I-Entity
.	O

Oral	O
diphenhydramine	I-Entity
and	O
prednisone	I-Entity
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B-Entity
reaction	I-Entity
.	O



Amiodarone	I-Entity
-	O
induced	O
sinoatrial	B-Entity
block	I-Entity
.	O

We	O
observed	O
sinoatrial	B-Entity
block	I-Entity
due	O
to	O
chronic	O
amiodarone	I-Entity
administration	O
in	O
a	O
5-year	O
-	O
old	O
boy	O
with	O
primary	B-Entity
cardiomyopathy	I-Entity
,	O
Wolff	B-Entity
-	I-Entity
Parkinson	I-Entity
-	I-Entity
White	I-Entity
syndrome	I-Entity
and	O
supraventricular	B-Entity
tachycardia	I-Entity
.	O

Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	I-Entity
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-Entity
block	I-Entity
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-Entity
bradycardia	I-Entity
.	O



Possible	O
teratogenicity	O
of	O
sulphasalazine	I-Entity
.	O

Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B-Entity
bowel	I-Entity
disease	I-Entity
who	O
received	O
treatment	O
with	O
sulphasalazine	I-Entity
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-Entity
anomalies	I-Entity
.	O

In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B-Entity
colitis	I-Entity
,	O
and	O
the	O
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B-Entity
of	I-Entity
the	I-Entity
aorta	I-Entity
and	O
a	O
ventricular	B-Entity
septal	I-Entity
defect	I-Entity
.	O

In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B-Entity
's	I-Entity
disease	I-Entity
.	O

The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter	B-Entity
-	I-Entity
type	I-Entity
IIa	I-Entity
polycystic	I-Entity
kidney	I-Entity
and	O
a	O
rudimentary	B-Entity
left	I-Entity
uterine	I-Entity
cornu	I-Entity
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-Entity
's	I-Entity
facies	I-Entity
,	O
hypoplastic	B-Entity
lungs	I-Entity
,	O
absent	B-Entity
kidneys	I-Entity
and	I-Entity
ureters	I-Entity
,	O
and	O
talipes	B-Entity
equinovarus	I-Entity
.	O

Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	I-Entity
may	O
be	O
teratogenic	O
.	O



Veno	B-Entity
-	I-Entity
occlusive	I-Entity
liver	I-Entity
disease	I-Entity
after	O
dacarbazine	I-Entity
therapy	O
(	O
DTIC	I-Entity
)	O
for	O
melanoma	I-Entity
.	O

A	O
case	O
of	O
veno	B-Entity
-	I-Entity
occlusive	I-Entity
disease	I-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
with	O
fatal	O
outcome	O
after	O
dacarbazine	I-Entity
(	O
DTIC	I-Entity
)	O
therapy	O
for	O
melanoma	I-Entity
is	O
reported	O
.	O

There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	I-Entity
.	O

At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-Entity
congestion	I-Entity
.	O

Small-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	I-Entity
.	O



A	O
case	O
of	O
tardive	B-Entity
dyskinesia	I-Entity
caused	O
by	O
metoclopramide	I-Entity
.	O

Abnormal	B-Entity
involuntary	I-Entity
movements	I-Entity
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64-year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	I-Entity
for	O
gastrointestinal	B-Entity
disorder	I-Entity
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O

When	O
the	O
metoclopramide	I-Entity
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-Entity
movements	I-Entity
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O

Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-Entity
dyskinesia	I-Entity
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	O
.	O



Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	I-Entity
therapy	O
.	O

A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra	B-Entity
-	I-Entity
Hisian	I-Entity
block	I-Entity
occurring	O
under	O
amiodarone	I-Entity
treatment	O
for	O
atrial	B-Entity
tachycardia	I-Entity
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B-Entity
conduction	I-Entity
abnormalities	I-Entity
.	O

His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B-Entity
tachycardia	I-Entity
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
days	O
after	O
amiodarone	I-Entity
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B-Entity
flutter	I-Entity
without	O
intra	O
-	O
Hisian	O
or	O
infra	O
-	O
Hisian	O
delay	O
.	O

Amiodarone	I-Entity
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O



Busulfan	I-Entity
-	O
induced	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

A	O
case	O
of	O
a	O
busulfan	I-Entity
-	O
induced	O
hemorrhage	B-Entity
cystitis	I-Entity
is	O
reported	O
.	O

The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	I-Entity
cystitis	I-Entity
and	O
both	O
radiation	O
and	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	I-Entity
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	I-Entity
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long	O
-	O
term	O
therapy	O
.	O



Rebound	O
hypertensive	I-Entity
after	O
sodium	B-Entity
nitroprusside	I-Entity
prevented	O
by	O
saralasin	I-Entity
in	O
rats	O
.	O

The	O
role	O
of	O
the	O
renin	O
--	O
angiotensin	I-Entity
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	I-Entity
anesthesia	O
and	O
sodium	B-Entity
nitroprusside	I-Entity
(	O
SNP)-induced	I-Entity
hypotension	I-Entity
was	O
evaluated	O
.	O

Control	O
rats	O
received	O
halothane	I-Entity
anesthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	I-Entity
infusion	O
,	O
40	O
microgram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30-min	O
recovery	O
period	O
.	O

A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	I-Entity
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-Entity
II	I-Entity
)	O
throughout	O
the	O
experimental	O
period	O
.	O

In	O
each	O
group	O
,	O
SNP	I-Entity
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O

During	O
the	O
SNP	I-Entity
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	I-Entity
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuation	O
of	O
SNP	I-Entity
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	I-Entity
-	O
treated	O
rats	O
.	O

This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	I-Entity
anesthesia	O
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	I-Entity
infusion	O
and	O
the	O
post	O
-	O
SNP	I-Entity
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	I-Entity
.	O

This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
--	O
angiotensin	I-Entity
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	I-Entity
effects	O
of	O
halothane	I-Entity
and	O
SNP	I-Entity
.	O



Toxic	B-Entity
hepatitis	I-Entity
induced	O
by	O
antithyroid	O
drugs	O
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	I-Entity
and	O
benzylthiouracil	I-Entity
.	O

This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	B-Entity
adverse	I-Entity
effects	I-Entity
encountered	O
with	O
antithyroid	O
drugs	O
.	O

Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	I-Entity
admitted	O
in	O
our	O
department	O
(	O
in-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

Four	O
patients	O
(	O
1.7%	O
)	O
were	O
identified	O
with	O
toxic	B-Entity
hepatitis	I-Entity
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O

Two	O
patients	O
had	O
a	O
cholestatic	B-Entity
hepatitis	I-Entity
induced	O
by	O
carbimazole	I-Entity
(	O
N	B-Entity
omercazole	I-Entity
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	I-Entity
and	O
cytolytic	O
)	O
hepatitis	I-Entity
following	O
carbimazole	I-Entity
.	O

One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	I-Entity
which	O
appeared	O
after	O
Benzylthiouracil	I-Entity
(	O
Basd	B-Entity
ne	I-Entity
)	O
had	O
replaced	O
carbimazole	I-Entity
.	O

Biological	O
features	O
of	O
hepatitis	I-Entity
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O

Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	I-Entity
.	O

CONCLUSION	O
:	O
Toxic	B-Entity
hepatitis	I-Entity
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O

Moreover	O
,	O
hepatotoxicity	I-Entity
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	O
agents	O
.	O



Study	O
of	O
the	O
role	O
of	O
vitamin	B-Entity
B12	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	I-Entity
of	O
zidovudine	I-Entity
.	O

A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-Entity
B12	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
supplementation	O
in	O
preventing	O
zidovudine	I-Entity
(	O
ZDV)-induced	I-Entity
bone	B-Entity
marrow	I-Entity
suppression	I-Entity
.	O

Seventy	O
-	O
five	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
(	I-Entity
HIV)-infected	I-Entity
patients	O
with	O
CD4	O
+	O
cell	O
counts	O

<	O
500/mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	I-Entity
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	B-Entity
acid	I-Entity
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	B-Entity
B12	I-Entity
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	I-Entity
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O

During	O
the	O
study	O
,	O
vitamin	B-Entity
B12	I-Entity
and	O
folate	I-Entity
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O

Severe	O
hematologic	O
toxicity	I-Entity
(	O
neutrophil	O
count	O
<	O
1000/mm3	O
and/or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

There	O
was	O
no	O
correlation	O
between	O
vitamin	B-Entity
B12	I-Entity
or	O
folate	I-Entity
levels	O
and	O
development	O
of	O
myelosuppression	I-Entity
.	O

Vitamin	B-Entity
B12	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
supplementation	O
of	O
ZDV	I-Entity
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	I-Entity
-	O
induced	O
myelotoxicity	I-Entity
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
can	O
not	O
be	O
excluded	O
.	O



Acute	O
confusion	I-Entity
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5-fluorouracil	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
.	O

A	O
61-year	O
-	O
old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	I-Entity
,	O
etoposide	I-Entity
,	O
high	O
-	O
dose	O
5-fluorouracil	I-Entity
(	O
2,250	O
mg	O
/	O
m2/24	O
hours	O
)	O
and	O
folinic	B-Entity
acid	I-Entity
for	O
an	O
inoperable	O
gastric	B-Entity
adenocarcinoma	I-Entity
.	O

He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	I-Entity
,	O
disorientation	I-Entity
and	O
irritability	I-Entity
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	I-Entity
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5-fluorouracil	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
infusion	O
.	O

This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5-fluorouracil	I-Entity
and	O
folinic	B-Entity
acid	I-Entity
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given	O
.	O

Because	O
folinic	B-Entity
acid	I-Entity
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	I-Entity
due	O
to	O
high	O
-	O
dose	O
5-fluorouracil	I-Entity
was	O
highly	O
suspected	O
.	O

The	O
pathogenesis	O
of	O
5-fluorouracil	I-Entity
neurotoxicity	I-Entity
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	I-Entity
and	O
fluorocitrate	I-Entity
,	O
thiamine	I-Entity
deficiency	O
,	O
or	O
dihydrouracil	I-Entity
dehydrogenase	O
deficiency	O
.	O

High	O
-	O
dose	O
5-fluorouracil	I-Entity
/	O
folinic	B-Entity
acid	I-Entity
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	I-Entity
.	O



Effect	O
of	O
switching	O
carbamazepine	I-Entity
to	O
oxcarbazepine	I-Entity
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O

Carbamazepine	I-Entity
was	O
switched	O
to	O
its	O
10-keto	O
analogue	O
oxcarbazepine	I-Entity
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	I-Entity
or	O
organic	B-Entity
psychotic	I-Entity
patients	O
using	O
concomitantly	O
haloperidol	I-Entity
,	O
chlorpromazine	I-Entity
or	O
clozapine	I-Entity
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B-Entity
symptoms	I-Entity
.	O

The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	I-Entity
oxcarbazepine	I-Entity
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	O
drugs	O
.	O



Erythema	B-Entity
multiforme	I-Entity
and	O
hypersensitivity	B-Entity
myocarditis	I-Entity
caused	O
by	O
ampicillin	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-Entity
multiforme	I-Entity
and	O
hypersensitivity	B-Entity
myocarditis	I-Entity
caused	O
by	O
ampicillin	I-Entity
.	O

A	O
13-year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
ampicillin	I-Entity
and	O
gentamicin	I-Entity
because	O
of	O
suspected	O
septicemia	I-Entity
.	O

Medications	O
were	O
discontinued	O
when	O
erythema	B-Entity
multiforme	I-Entity
and	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
caused	O
by	O
myocarditis	I-Entity
occurred	O
.	O

The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	I-Entity
and	O
gradually	O
improved	O
.	O

Macrophage	O
-	O
migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	I-Entity
was	O
positive	O
.	O

After	O
most	O
infections	I-Entity
causing	O
erythema	B-Entity
multiforme	I-Entity
and	O
myocarditis	I-Entity
were	O
ruled	O
out	O
,	O
a	O
drug	B-Entity
-	I-Entity
induced	I-Entity
allergic	I-Entity
reaction	I-Entity
was	O
suspected	O
.	O

Positive	O
MIF	O
test	O
for	O
ampicillin	I-Entity
showed	O
sensitization	O
of	O
the	O
patient	O
's	O
lymphocytes	O
to	O
ampicillin	I-Entity
.	O

Hypersensitivity	B-Entity
myocarditis	I-Entity
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	I-Entity
to	O
penicillins	I-Entity
.	O



Immediate	O
allergic	B-Entity
reactions	I-Entity
to	O
amoxicillin	I-Entity
.	O

A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-Entity
reactions	I-Entity
to	O
beta	B-Entity
-	I-Entity
lactam	I-Entity
antibiotics	O
was	O
evaluated	O
.	O

A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	I-Entity
to	O
beta	B-Entity
-	I-Entity
lactam	I-Entity
antibiotics	O
had	O
selective	O
immediate	O
allergic	I-Entity
responses	O
to	O
amoxicillin	I-Entity
(	O
AX	I-Entity
)	O
or	O
were	O
cross	O
-	O
reacting	O
with	O
other	O
penicillin	I-Entity
derivatives	O
.	O

Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl	B-Entity
-	I-Entity
poly	I-Entity
-	I-Entity
L	I-Entity
-	I-Entity
lysine	I-Entity
(	O
BPO	B-Entity
-	I-Entity
PLL	I-Entity
)	O
,	O
benzylpenicilloate	I-Entity
,	O
benzylpenicillin	I-Entity

(	O
PG	I-Entity
)	O
,	O
ampicillin	I-Entity
(	O
AMP	I-Entity
)	O
,	O
and	O
AX	I-Entity
.	O

RAST	O
for	O
BPO	B-Entity
-	I-Entity
PLL	I-Entity
and	O
AX	I-Entity
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	I-Entity
were	O
negative	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	I-Entity
or	O
sensitivity	O
to	O
AX	I-Entity
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	I-Entity
to	O
beta	B-Entity
-	I-Entity
lactam	I-Entity
antibiotics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30.5%	O
)	O
cases	O
of	O
immediate	O
AX	I-Entity
allergy	I-Entity
with	O
good	O
tolerance	O
of	O
PG	I-Entity
.	O

Anaphylaxis	I-Entity
was	O
seen	O
in	O
37	O
patients	O
(	O
69%	O
)	O
,	O
the	O
other	O
17	O
(	O
31%	O
)	O
having	O
urticaria	I-Entity
and/or	O
angioedema	I-Entity
.	O

All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	I-Entity
;	O
49	O
of	O
51	O
(	O
96%	O
)	O
were	O
also	O
negative	O
to	O
MDM	I-Entity
,	O
and	O
44	O
of	O
46	O
(	O
96%	O
)	O
to	O
PG	I-Entity
.	O

Skin	O
tests	O
with	O
AX	I-Entity
were	O
positive	O
in	O
34	O
(	O
63%	O
)	O
patients	O
.	O

RAST	O
was	O
positive	O
for	O
AX	I-Entity
in	O
22	O
patients	O
(	O
41%	O
)	O
and	O
to	O
BPO	I-Entity
in	O
just	O
5	O
(	O
9%	O
)	O
.	O

None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	I-Entity
were	O
positive	O
to	O
BPO	I-Entity
.	O

Challenge	O
tests	O
with	O
AX	I-Entity
were	O
performed	O
in	O
23	O
subjects	O
(	O
43%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-Entity
reaction	I-Entity
to	O
AX	I-Entity
,	O
and	O
in	O
15	O
cases	O
(	O
28%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	I-Entity
were	O
negative	O
.	O

PG	I-Entity
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O

We	O
describe	O
the	O
largest	O
group	O
of	O
AX	I-Entity
-	O
allergic	I-Entity
patients	O
who	O
have	O
tolerated	O
PG	I-Entity
reported	O
so	O
far	O
.	O

Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	I-Entity
-	O
related	O
reagents	O
are	O
employed	O
.	O



Persistent	O
paralysis	I-Entity
after	O
prolonged	O
use	O
of	O
atracurium	I-Entity
in	O
the	O
absence	O
of	O
corticosteroids	O
.	O

Reports	O
of	O
persistent	O
paralysis	I-Entity
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	B-Entity
bromide	I-Entity
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O

Atracurium	B-Entity
besylate	I-Entity
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolinium	I-Entity
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	I-Entity
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	O
.	O

We	O
report	O
a	O
case	O
of	O
atracurium	I-Entity
-	O
related	O
paralysis	I-Entity
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O



Habitual	O
use	O
of	O
acetaminophen	I-Entity
as	O
a	O
risk	O
factor	O
for	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
:	O
a	O
comparison	O
with	O
phenacetin	I-Entity
.	O

Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	I-Entity
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
and	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
(	O
ESRD	I-Entity
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	I-Entity
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O

However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	I-Entity
is	O
also	O
associated	O
with	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
and	O
ESRD	I-Entity
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	I-Entity
and	O
acetaminophen	I-Entity
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	I-Entity
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	I-Entity
potential	O
of	O
the	O
drugs	O
themselves	O
.	O

A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	I-Entity
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O

Thus	O
,	O
acetaminophen	I-Entity
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	I-Entity
was	O
available	O
only	O
in	O
combinations	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	I-Entity
alone	O
increases	O
the	O
risk	O
of	O
ESRD	I-Entity
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
can	O
not	O
be	O
dismissed	O
.	O



Reduction	O
of	O
heparan	B-Entity
sulphate	I-Entity
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

Heparan	B-Entity
sulphate	I-Entity
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	I-Entity
by	O
streptozotocin	I-Entity
and	O
in	O
age-	O
adn	O
sex	O
-	O
matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	B-Entity
blue	I-Entity
.	O

The	O
heparan	B-Entity
sulphate	I-Entity
specificity	O
of	O
the	O
cuprolinic	B-Entity
blue	I-Entity
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	I-Entity
-	O
degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O

The	O
majority	O
of	O
anionic	O
sites	O
(	O
74%	O
in	O
diabetic	I-Entity
and	O
81%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p<0.001	O
and	O
p<0.01	O
for	O
diabetic	I-Entity
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O

Diabetic	I-Entity
rats	O
progressively	O
developed	O
albuminuria	I-Entity
reaching	O
40.3	O
(	O
32.2	O
-	O
62.0	O
)	O

At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	B-Entity
sulphate	I-Entity
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19%	O
(	O
p<0.021	O
)	O
and	O
by	O
26%	O
(	O
p<0.02	O
)	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
in	O
streptozotocin	I-Entity
-	O
diabetic	I-Entity
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	B-Entity
sulphate	I-Entity
charge	O
barrier	O
/	O
density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O



Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B-Entity
toxicity	I-Entity
.	O

The	O
nephrotoxic	I-Entity
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	I-Entity
(	O
NG	I-Entity
)	O
,	O
methotrexate	I-Entity
(	O
MTX	I-Entity
)	O
,	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
and	O
cyclophosphamide	I-Entity
(	O

CY	I-Entity
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	I-Entity
+	O
5-FU	I-Entity
+	O
CY	I-Entity
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O

After	O
drug	O
administration	O
,	O
creatinine	I-Entity
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	I-Entity
clearance	O
.	O

After	O
MTX	I-Entity
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0.0228	O
)	O
in	O
the	O
plasma	O
creatinine	I-Entity
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0.0001	O
)	O
decrease	O
in	O
creatinine	I-Entity
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O

After	O
the	O
administration	O
of	O
NG	I-Entity
,	O
5-FU	I-Entity
and	O
CY	I-Entity
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	I-Entity
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	I-Entity
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O

Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen	O
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0.0343	O
)	O
in	O
creatinine	I-Entity
clearance	O
was	O
found	O
,	O
but	O
creatinine	I-Entity
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O

CY	I-Entity
caused	O
hemorrhagic	B-Entity
cystitis	I-Entity
in	O
40%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5-FU	I-Entity
and	O
MTX	I-Entity
.	O

Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	I-Entity
,	O
CY	I-Entity
and	O
NG	I-Entity
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5-FU	I-Entity
and	O
joint	O
administration	O
of	O
MTX	I-Entity
+	O
5-FU	I-Entity

+	O
CY	I-Entity
compared	O
to	O
controls	O
.	O

Our	O
studies	O
indicate	O
that	O
nephrotoxicity	I-Entity
of	O
MTX	I-Entity
+	O
5-FU	I-Entity
+	O
CY	I-Entity
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O



Lithium	I-Entity
-	O
associated	O
cognitive	B-Entity
and	I-Entity
functional	I-Entity
deficits	I-Entity
reduced	O
by	O
a	O
switch	O
to	O
divalproex	B-Entity
sodium	I-Entity
:	O
a	O
case	O
series	O
.	O

Lithium	I-Entity
remains	O
a	O
first	O
-	O
line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B-Entity
disorder	I-Entity
.	O

Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	I-Entity
,	O
such	O
as	O
polyuria	I-Entity
and	O
tremor	I-Entity
,	O
more	O
subtle	O
lithium	I-Entity
side	O
effects	O
such	O
as	O
cognitive	B-Entity
deficits	I-Entity
,	O
loss	B-Entity
of	I-Entity
creativity	I-Entity
,	O
and	O
functional	B-Entity
impairments	I-Entity
remain	O
understudied	O
.	O

This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	I-Entity
patients	O
from	O
lithium	I-Entity
to	O
divalproex	B-Entity
sodium	I-Entity
to	O
alleviate	O
such	O
cognitive	B-Entity
and	I-Entity
functional	I-Entity
impairments	I-Entity
.	O

We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	I-Entity
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Entity
sodium	I-Entity
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Entity
,	I-Entity
motivational	I-Entity
,	I-Entity
or	I-Entity
creative	I-Entity
deficits	I-Entity
attributed	O
to	O
lithium	I-Entity
in	O
our	O
bipolar	I-Entity
patients	O
.	O

In	O
this	O
preliminary	O
report	O
,	O
divalproex	B-Entity
sodium	I-Entity
was	O
a	O
superior	O
alternative	O
to	O
lithium	I-Entity
in	O
bipolar	I-Entity
patients	O
experiencing	O
cognitive	B-Entity
deficits	I-Entity
,	O
loss	B-Entity
of	I-Entity
creativity	I-Entity
,	O
and	O
functional	B-Entity
impairments	I-Entity
.	O



Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-Entity
cancer	I-Entity
by	O
mitoxantrone	I-Entity
and	O
48-hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5-FU	I-Entity
and	O
leucovorin	I-Entity
(	O
MFL	I-Entity
)	O
:	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	I-Entity
.	O

For	O
previously	O
treated	O
advanced	O
breast	B-Entity
cancer	I-Entity
,	O
there	O
is	O
no	O
standard	O
second	O
-	O
line	O
therapy	O
.	O

Combination	O
chemotherapy	O
with	O
mitoxantrone	I-Entity
,	O
high	O
-	O
dose	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
and	O
leucovorin	I-Entity
(	O
MFL	B-Entity
regimen	I-Entity
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O

From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy	O
-	O
treated	O
metastatic	O
breast	B-Entity
cancer	I-Entity
by	O
mitoxantrone	I-Entity
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5-FU	I-Entity
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovorin	I-Entity
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	I-Entity
.	O

Median	O
number	O
of	O
courses	O
of	O
MFL	B-Entity
regimen	I-Entity
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	I-Entity
was	O
68.35	O
mg	O
/	O
m2	O
.	O

Major	O
toxicities	I-Entity
were	O
cardiotoxicity	I-Entity
and	O
leukopenia	I-Entity
.	O

Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	O
-	O
related	O
toxicity	I-Entity
.	O

The	O
MFL	B-Entity
regimen	I-Entity
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	I-Entity
at	O
a	O
fairly	O
high	O
rate	O
.	O

Administration	O
of	O
this	O
regimen	O
to	O
breast	B-Entity
cancer	I-Entity
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-Entity
heart	I-Entity
function	I-Entity
requires	O
careful	O
attention	O
.	O



Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	I-Entity
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	I-Entity
-	O
induced	O
diabetes	B-Entity
insipidus	I-Entity
rat	O
.	O

The	O
expression	O
of	O
arginine	B-Entity
vasopressin	I-Entity
(	O
AVP	I-Entity
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	I-Entity
(	O
Li)-induced	I-Entity
polyuria	I-Entity
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O

The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	I-Entity
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	I-Entity
.	O

The	O
Li	I-Entity
-	O
treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O

Plasma	O
sodium	I-Entity
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	I-Entity
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O

Plasma	O
concentration	O
of	O
AVP	I-Entity
and	O
transcripts	O
of	O
AVP	I-Entity
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	I-Entity
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
dehydration	I-Entity
and/or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	I-Entity
and	O
the	O
upregulation	O
of	O
AVP	I-Entity
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	I-Entity
-	O
induced	O
diabetes	B-Entity
insipidus	I-Entity
rat	O
.	O



Suxamethonium	I-Entity
-	O
induced	O
cardiac	B-Entity
arrest	I-Entity
and	O
death	I-Entity
following	O
5	O
days	O
of	O
immobilization	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B-Entity
arrest	I-Entity
and	O
subsequent	O
death	I-Entity
as	O
a	O
result	O
of	O
hyperkalaemia	I-Entity
following	O
the	O
use	O
of	O
suxamethonium	I-Entity
in	O
a	O
23-year	O
-	O
old	O
Malawian	O
woman	O
.	O

Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	I-Entity
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O

Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	I-Entity
,	O
bradycardia	I-Entity
and	O
cardiac	B-Entity
arrest	I-Entity
occurred	O
.	O

The	O
serum	O
level	O
of	O
potassium	I-Entity
was	O
observed	O
to	O
be	O
8.4	O
mequiv	O

Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	I-Entity
following	O
the	O
administration	O
of	O
suxamethonium	I-Entity
.	O

It	O
is	O
postulated	O
that	O
her	O
death	I-Entity
was	O
caused	O
by	O
hypersensitivity	I-Entity
to	O
suxamethonium	I-Entity
,	O
associated	O
with	O
her	O
5-day	O
immobilization	O
.	O



An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	I-Entity
with	O
adrenaline	I-Entity
.	O

An	O
increase	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
,	O
accompanied	O
by	O
atrial	B-Entity
fibrillation	I-Entity
,	O
agitation	I-Entity
,	O
incomprehensible	B-Entity
shouts	I-Entity
and	O
loss	B-Entity
of	I-Entity
consciousness	I-Entity
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	O
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	I-Entity
850	O
mg	O
containing	O
adrenaline	I-Entity
0.225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	B-Entity
's	I-Entity
contracture	I-Entity
.	O

After	O
intravenous	O
administration	O
of	O
labetalol	I-Entity
,	O
metoprolol	I-Entity
and	O
midazolam	I-Entity
the	O
patient	O
's	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B-Entity
fibrillation	I-Entity
.	O

Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	I-Entity
with	O
adrenaline	I-Entity
and/or	O
interaction	O
of	O
these	O
drugs	O
with	O
the	O
patient	O
's	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	O
.	O



Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	I-Entity
(	O
FK506	I-Entity
)	O
for	O
at	O
least	O
one	O
year	O
.	O

We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	I-Entity
(	O
FK506	I-Entity
)	O
for	O
more	O
than	O
1	O
year	O
.	O

The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n=5	O
)	O
,	O
AR+CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B-Entity
nephropathy	I-Entity
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	I-Entity
nephropathy	I-Entity
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	I-Entity
nephropathy	I-Entity
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal	O
-	O
type	O
and	O
mild	O
-	O
type	O
chronic	O
FK506	I-Entity
nephropathy	I-Entity
,	O
respectively	O
.	O

Chronic	O
FK506	I-Entity
nephropathy	I-Entity
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	B-Entity
segmental	I-Entity
glomerulosclerosis	I-Entity
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	B-Entity
fibrosis	I-Entity
(	O
11	O
biopsies	O
)	O
.	O

The	O
serum	O
creatinine	I-Entity
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	I-Entity
nephropathy	I-Entity
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506-nephropathy	I-Entity
group	O
(	O
P	O

This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	I-Entity
nephropathy	I-Entity
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild	O
-	O
type	O
chronic	O
FK506	I-Entity
nephropathy	I-Entity
is	O
a	O
condition	O
which	O
may	O
lead	O
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O



Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	I-Entity
releaser	O
PG-9	I-Entity
.	O

The	O
effects	O
of	O
PG-9	I-Entity
(	O
3alpha	B-Entity
-	I-Entity
tropyl	I-Entity
2-(p	I-Entity
-	I-Entity
bromophenyl)propionate	I-Entity
)	O
,	O
the	O
acetylcholine	I-Entity
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O

In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG-9	I-Entity
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	I-Entity
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	I-Entity
and	O
the	O
M1-selective	O
antagonist	O
S-(-)-ET-126	I-Entity
.	O

In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG-9	I-Entity
(	O
5	O
-	O
20	O
microg	O
per	O
mouse	O
,	O
i.c.v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	I-Entity
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O

At	O
the	O
highest	O
effective	O
doses	O
,	O
PG-9	I-Entity
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O
PG-9	I-Entity

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG-9	I-Entity
were	O
17.6-fold	O
of	O
the	O
control	O
value	O
.	O

During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG-9	I-Entity
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG-9	I-Entity
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O

Therefore	O
,	O
PG-9	I-Entity
could	O
represent	O
a	O
potential	O
useful	O
drug	O
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O



Angioedema	I-Entity
due	O
to	O
ACE	B-Entity
inhibitors	I-Entity
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O

The	O
estimated	O
incidence	O
of	O
angioedema	I-Entity
during	O
angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
(	I-Entity
ACE	I-Entity
)	I-Entity
inhibitor	I-Entity
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O



Accumulation	O
of	O
atracurium	I-Entity
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	O
respiratory	B-Entity
arrest	I-Entity
with	O
severe	O
desaturation	I-Entity
and	O
bradycardia	I-Entity
occurred	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B-Entity
blockade	I-Entity
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O



Recurrent	O
use	O
of	O
newer	O
oral	B-Entity
contraceptives	I-Entity
and	O
the	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
(	O
VTE	I-Entity
)	O
associated	O
with	O
newer	O
oral	B-Entity
contraceptives	I-Entity
(	O
OC	I-Entity
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	I-Entity
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	I-Entity
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	I-Entity
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	I-Entity
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	I-Entity
was	O
0.6	O
(	O
95%	O
CI:0.3	O
-	O
1.2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1.3	O
(	O
95%	O
CI:0.7	O
-	O
2.4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	I-Entity
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	I-Entity
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O



Development	O
of	O
apomorphine	I-Entity
-	O
induced	O
aggressive	B-Entity
behavior	I-Entity
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	O
development	O
of	O
apomorphine	I-Entity
-	O
induced	O
(	O
1.0	O
mg	O
/	O
kg	O
s.c	O
.	O

once	O
daily	O
)	O
aggressive	B-Entity
behavior	I-Entity
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	I-Entity
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B-Entity
behavior	I-Entity
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	I-Entity
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	I-Entity
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	I-Entity
-	O
induced	O
aggressive	B-Entity
behavior	I-Entity
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O



Serotonergic	B-Entity
antidepressants	I-Entity
and	O
urinary	B-Entity
incontinence	I-Entity
.	O

Many	O
new	O
serotonergic	B-Entity
antidepressants	I-Entity
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinary	B-Entity
incontinence	I-Entity
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	I-Entity
while	O
taking	O
venlafaxine	I-Entity
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	I-Entity
secondary	O
to	O
the	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitors	O
paroxetine	I-Entity
and	O
sertraline	I-Entity
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	I-Entity
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-Entity
carbonate	I-Entity
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	I-Entity
.	O

Animal	O
studies	O
suggest	O
that	O
incontinence	I-Entity
secondary	O
to	O
serotonergic	B-Entity
antidepressants	I-Entity
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O



Hypotension	I-Entity
following	O
the	O
initiation	O
of	O
tizanidine	I-Entity
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	I-Entity
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	I-Entity
.	O

Centrally	O
acting	O
alpha-2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	I-Entity
related	O
to	O
disorders	B-Entity
of	I-Entity
the	I-Entity
central	I-Entity
nervous	I-Entity
system	I-Entity
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	I-Entity
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	I-Entity
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	I-Entity
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

The	O
authors	O
present	O
a	O
10-year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	I-Entity
,	O
an	O
angiotensin	I-Entity
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	I-Entity
who	O
developed	O
hypotension	I-Entity
following	O
the	O
addition	O
of	O
tizanidine	I-Entity
,	O
an	O
alpha-2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	I-Entity
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	I-Entity
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	I-Entity
or	O
spasticity	I-Entity
in	O
such	O
patients	O
.	O



Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B-Entity
disease	I-Entity
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Entity
glomerulopathy	I-Entity
(	O
TG	I-Entity
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	I-Entity
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	I-Entity
,	O
chronic	B-Entity
allograft	I-Entity
nephropathy	I-Entity
and	O
stable	O
grafts	O
(	O
""""	O
protocol	O
biopsies	O
""""	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	I-Entity
as	O
well	O
as	O
cases	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
,	O
malignant	B-Entity
hypertension	I-Entity
,	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
,	O
and	O
acute	B-Entity
tubular	I-Entity
necrosis	I-Entity
.	O

We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	I-Entity
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	I-Entity
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	B-Entity
hypertension	I-Entity
,	O
thrombotic	B-Entity
microangiopathy	I-Entity
,	O
lupus	B-Entity
nephritis	I-Entity
,	O
Henoch	B-Entity
-	I-Entity
Schonlein	I-Entity
nephritis	I-Entity
,	O
crescentic	O
glomerulonephritis	I-Entity
,	O
and	O
cocaine	I-Entity
-	O
related	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	I-Entity
did	O
not	O
predict	O
renal	B-Entity
failure	I-Entity
or	O
significant	O
proteinuria	I-Entity
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	I-Entity
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	I-Entity
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-Entity
diseases	I-Entity
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	I-Entity
.	O

We	O
suggest	O
that	O
repeated	O
endothelial	B-Entity
injury	I-Entity
,	O
including	O
immunologic	B-Entity
injury	I-Entity
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O



Conformationally	O
restricted	O
analogs	O
of	O
BD1008	I-Entity
and	O
an	O
antisense	O
oligodeoxynucleotide	I-Entity
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	I-Entity
effects	O
in	O
mice	O
.	O

Cocaine	I-Entity
's	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	I-Entity
(	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	I-Entity
)	O
,	O
BD1063	I-Entity
(	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	I-Entity
)	O
,	O
and	O
LR132	I-Entity
(	O
1R,2S-(+)-cis	O
-	O
N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine	O
)	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	I-Entity
,	O
opioid	O
,	O
GABA(A	I-Entity
)	O
and	O
NMDA	I-Entity
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	I-Entity
,	O
BD1063	I-Entity
,	O
or	O
LR132	I-Entity
significantly	O
attenuated	O
cocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
and	O
lethality	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	I-Entity
prevented	O
cocaine	I-Entity
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Entity
-	I-Entity
o	I-Entity
-	I-Entity
tolylguanidine	I-Entity
(	O
DTG	I-Entity
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	I-Entity
(	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	I-Entity
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	I-Entity
of	O
cocaine	I-Entity
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	I-Entity
,	O
BD1063	I-Entity
and	O
LR132	I-Entity
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	I-Entity
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	I-Entity
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	I-Entity
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	I-Entity
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	I-Entity
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	I-Entity
-	O
induced	O
behaviors	O
.	O



Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	I-Entity
,	O
cisapride	I-Entity
,	O
terfenadine	I-Entity
and	O
terodiline	I-Entity
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O

Torsades	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TDP	I-Entity
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	B-Entity
tachycardia	I-Entity
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

TDP	I-Entity
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e.g.	O
terfenadine	I-Entity
and	O
terodiline	I-Entity
)	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	I-Entity
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	I-Entity
were	O
investigated	O
:	O
terfenadine	I-Entity
,	O
terodiline	I-Entity
,	O
cisapride	I-Entity
and	O
E4031	I-Entity
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	I-Entity
(	O
1.9	O
nM	O
)	O
,	O
terodiline	I-Entity
(	O
76	O
nM	O
)	O
,	O
cisapride	I-Entity
(	O
11	O
nM	O
)	O
and	O
E4031	I-Entity
(	O
1.9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	I-Entity
in	O
the	O
clinic	O
(	O
terfenadine	I-Entity
,	O
terodiline	I-Entity
,	O
cisapride	I-Entity
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10-fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	I-Entity
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O



Fatal	O
myeloencephalopathy	I-Entity
due	O
to	O
accidental	O
intrathecal	O
vincristin	I-Entity
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	I-Entity
instillation	O
in	O
a	O
5-year	O
old	O
girl	O
with	O
recurrent	O
acute	B-Entity
lymphoblastic	I-Entity
leucemia	I-Entity
and	O
a	O
57-year	O
old	O
man	O
with	O
lymphoblastic	B-Entity
lymphoma	I-Entity
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	I-Entity
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B-Entity
,	I-Entity
sensory	I-Entity
and	I-Entity
motor	I-Entity
dysfunction	I-Entity
and	O
ascending	O
paralysis	I-Entity
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD-68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B-Entity
of	I-Entity
myelin	I-Entity
and	I-Entity
axons	I-Entity
as	O
well	O
as	O
pseudocystic	B-Entity
transformation	I-Entity
in	O
areas	O
exposed	O
to	O
vincristine	I-Entity
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	I-Entity
and	O



Intravenous	O
administration	O
of	O
prochlorperazine	I-Entity
by	O
15-minute	O
infusion	O
versus	O
2-minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	I-Entity
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	I-Entity
after	O
administration	O
of	O
intravenous	O
prochlorperazine	I-Entity
as	O
a	O
2-minute	O
bolus	O
or	O
15-minute	O
infusion	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	I-Entity
for	O
headache	I-Entity
,	O
nausea	I-Entity
,	O
or	O
vomiting	I-Entity
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	I-Entity
administered	O
intravenously	O
by	O
means	O
of	O
2-minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15-minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	I-Entity
within	O
60	O
minutes	O
of	O
administration	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	I-Entity
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	I-Entity
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	I-Entity
rating	O
scale	O
.	O

The	O
intensity	O
of	O
headache	I-Entity
and	O
nausea	I-Entity
was	O
measured	O
with	O
a	O
100-mm	O
visual	O
analog	O
scale	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73/99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	I-Entity
and	O
70%	O
(	O
70/99	O
)	O
for	O
nausea	I-Entity
.	O

In	O
the	O
bolus	O
group	O
,	O
26.0%	O
(	O
13/50	O
)	O
had	O
akathisia	I-Entity
compared	O
with	O
32.7%	O
(	O
16/49	O
)	O
in	O
the	O
infusion	O
group	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50%	O
reduction	O
in	O
their	O
headache	I-Entity
intensity	O
within	O
30	O
minutes	O
was	O
11.8%	O
(	O
95%	O
CI	O
-9.6%	O
to	O
33.3%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50%	O
reduction	O
in	O
their	O
nausea	I-Entity
was	O
12.6%	O
(	O
95%	O
CI	O
-4.6%	O
to	O
29.8%	O
)	O
.	O

A	O
50%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	I-Entity
when	O
prochlorperazine	I-Entity
was	O
administered	O
by	O
means	O
of	O
15-minute	O
intravenous	O
infusion	O
versus	O
a	O
2-minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	I-Entity
in	O
the	O
treatment	O
of	O
headache	I-Entity
and	O
nausea	I-Entity
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O



Antithymocyte	B-Entity
globulin	I-Entity
in	O
the	O
treatment	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
.	O

A	O
patient	O
who	O
received	O
antithymocyte	B-Entity
globulin	I-Entity
therapy	O
for	O
aplastic	B-Entity
anemia	I-Entity
due	O
to	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
therapy	O
is	O
described	O
.	O

Use	O
of	O
antithymocyte	B-Entity
globulin	I-Entity
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
.	O



The	O
relationship	O
between	O
hippocampal	O
acetylcholine	I-Entity
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	I-Entity
-	O
prone	O
and	O
withdrawal	O
seizure	I-Entity
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O

The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	I-Entity
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	I-Entity
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	I-Entity
withdrawal	O
severity	O
.	O

Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	I-Entity
-	O
na	O
ve	O

Withdrawal	O
Seizure	I-Entity
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

Animals	O
were	O
administered	O
nicotine	I-Entity
,	O
carbachol	I-Entity
,	O
or	O
neostigmine	I-Entity
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	I-Entity
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	I-Entity
-	O
stimulated	O
acetylcholine	I-Entity
(	O
ACh	I-Entity
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	I-Entity
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	I-Entity
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	I-Entity
.	O

Sensitivity	O
to	O
several	O
convulsion	I-Entity
endpoints	O
induced	O
by	O
nicotine	I-Entity
,	O
carbachol	I-Entity
,	O
and	O
neostigmine	I-Entity
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	I-Entity
,	O
and	O
50	O
mM	O
KCl	I-Entity
increased	O
ACh	I-Entity
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	I-Entity
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	I-Entity
was	O
2-fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	I-Entity
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	I-Entity
,	O
extracellular	O
ACh	I-Entity
was	O
significantly	O
elevated	O
(	O
192%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59%	O
)	O
in	O
WSR	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	I-Entity
may	O
be	O
associated	O
with	O
ethanol	I-Entity
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	I-Entity
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	I-Entity
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O



Prenatal	O
dexamethasone	I-Entity
programs	O
hypertension	I-Entity
and	O
renal	B-Entity
injury	I-Entity
in	O
the	O
rat	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	I-Entity
programmed	O
a	O
progressive	O
increase	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
and	O
renal	B-Entity
injury	I-Entity
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	I-Entity
(	O
0.2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	I-Entity
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20%	O
reduction	B-Entity
in	I-Entity
glomerular	I-Entity
number	I-Entity
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527+/-509	O
versus	O
28	O
050+/-561	O
,	O
P<0.05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six-	O
to	O
9-month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	I-Entity
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380+/-587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P<0.05	O
)	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	I-Entity
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B-Entity
blood	I-Entity
pressures	I-Entity
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B-Entity
in	I-Entity
glomerular	I-Entity
number	I-Entity
.	O

Adult	O
rats	O
given	O
dexamethasone	I-Entity
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	I-Entity
than	O
control	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	I-Entity
in	O
rats	O
results	O
in	O
a	O
reduction	B-Entity
in	I-Entity
glomerular	I-Entity
number	I-Entity
,	O
glomerulosclerosis	I-Entity
,	O
and	O
hypertension	I-Entity
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	I-Entity
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B-Entity
in	I-Entity
glomerular	I-Entity
number	I-Entity
,	O
suggesting	O
that	O
a	O
reduction	B-Entity
in	I-Entity
glomerular	I-Entity
number	I-Entity
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	I-Entity
.	O



The	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
in	O
women	O
prescribed	O
cyproterone	B-Entity
acetate	I-Entity
in	O
combination	O
with	O
ethinyl	B-Entity
estradiol	I-Entity
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

Cyproterone	B-Entity
acetate	I-Entity
combined	O
with	O
ethinyl	B-Entity
estradiol	I-Entity
(	O
CPA	I-Entity
/	O
EE	I-Entity
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	I-Entity
and	O
hirsutism	I-Entity
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	B-Entity
ovary	I-Entity
syndrome	I-Entity
(	O
PCOS	I-Entity
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
(	O
VTE	I-Entity
)	O
associated	O
with	O
CPA	I-Entity
/	O
EE	I-Entity
compared	O
with	O
conventional	O
combined	O
oral	B-Entity
contraceptives	I-Entity
(	O
COCs	O
)	O
.	O

Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	I-Entity
,	O
hirsutism	I-Entity
or	O
PCOS	I-Entity
to	O
estimate	O
the	O
risk	O
of	O
VTE	I-Entity
associated	O
with	O
CPA	I-Entity
/	O
EE	I-Entity
.	O

The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	I-Entity
/	O
EE	I-Entity
versus	O
conventional	O
COCs	O
was	O
2.20	O
[	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.35	O
-	O
3.58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR(adj	O
)	O
)	O
of	O
7.44	O
(	O
95%	O
CI	O
3.67	O
-	O
15.08	O
)	O
for	O
CPA	I-Entity
/	O
EE	I-Entity
use	O
compared	O
with	O
an	O
OR(adj	O
)	O
of	O
2.58	O
(	O
95%	O
CI	O
1.60	O
-	O
4.18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	I-Entity
associated	O
with	O
the	O
use	O
of	O
CPA	I-Entity
/	O
EE	I-Entity
in	O
women	O
with	O
acne	I-Entity
,	O
hirsutism	I-Entity
or	O
PCOS	I-Entity
although	O
residual	O
confounding	O
by	O
indication	O
can	O
not	O
be	O
excluded	O
.	O



Pseudoacromegaly	I-Entity
induced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	I-Entity
.	O

Acromegaly	I-Entity
is	O
an	O
endocrine	B-Entity
disorder	I-Entity
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	I-Entity
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-Entity
verticis	I-Entity
gyrata	I-Entity
.	O

Pseudoacromegaly	I-Entity
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	I-Entity
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	I-Entity
at	O
an	O
unusually	O
high	O
dose	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	I-Entity
as	O
a	O
side	O
effect	O
of	O
minoxidil	I-Entity
use	O
.	O



Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	I-Entity
in	O
prostate	B-Entity
cancer	I-Entity
patients	O
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB)-induced	O
anemia	I-Entity
in	O
prostate	B-Entity
cancer	I-Entity
patients	O
without	O
bone	O
involvement	O
.	O

Forty	O
-	O
two	O
patients	O
with	O
biopsy	O
-	O
proven	O
prostatic	B-Entity
adenocarcinoma	I-Entity
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	B-Entity
acetate	I-Entity
(	O
LHRH	B-Entity
-	I-Entity
A	I-Entity
)	O
3.75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	I-Entity
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	I-Entity
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterone	I-Entity
measurements	O
were	O
recorded	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	I-Entity
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14.3%	O
)	O
.	O

This	O
CAB	O
-	O
induced	O
anemia	I-Entity
was	O
normochromic	O
and	O
normocytic	O
.	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	I-Entity
had	O
a	O
Hb	O
mean	O
value	O
of	O
10.2	O
+	O
/-	O

SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	I-Entity
with	O
Hb	O
mean	O
value	O
of	O
13.2	O
+	O
/-	O

The	O
development	O
of	O
severe	O
anemia	I-Entity
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2.5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0.01	O
)	O
.	O

The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	I-Entity
in	O
prostate	B-Entity
cancer	I-Entity
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O

Severe	O
and	O
clinically	O
evident	O
anemia	I-Entity
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	I-Entity
occurs	O
in	O
14.3%	O
of	O
prostate	B-Entity
cancer	I-Entity
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O



Reversible	O
dilated	B-Entity
cardiomyopathy	I-Entity
related	O
to	O
amphotericin	B-Entity
B	I-Entity
therapy	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	B-Entity
cardiomyopathy	I-Entity
and	O
clinical	O
congestive	O
heart	B-Entity
failure	I-Entity
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	B-Entity
B	I-Entity
(	O
AmB	I-Entity
)	O
for	O
disseminated	O
coccidioidomycosis	I-Entity
.	O

His	O
echocardiographic	O
abnormalities	O
and	O
heart	B-Entity
failure	I-Entity
resolved	O
after	O
posaconazole	I-Entity
was	O
substituted	O
for	O
AmB.	I-Entity
It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	I-Entity
of	O
AmB.	I-Entity



Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	I-Entity
.	O

Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	B-Entity
leg	I-Entity
cramps	I-Entity
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	I-Entity
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	I-Entity
may	O
produce	O
neurological	B-Entity
complications	I-Entity
,	O
including	O
confusion	I-Entity
,	O
altered	O
mental	O
status	O
,	O
seizures	I-Entity
,	O
and	O
coma	I-Entity
,	O
particularly	O
in	O
older	O
women	O
.	O

Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	I-Entity
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O



Organophosphate	I-Entity
-	O
induced	O
convulsions	I-Entity
and	O
prevention	O
of	O
neuropathological	B-Entity
damages	I-Entity
.	O

Such	O
organophosphorus	I-Entity
(	O
OP	I-Entity
)	O
compounds	O
as	O
diisopropylfluorophosphate	I-Entity
(	O
DFP	I-Entity
)	O
,	O
sarin	I-Entity
and	O
soman	I-Entity
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

The	O
acute	O
toxicity	I-Entity
of	O
OPs	I-Entity
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	I-Entity
(	O
ACh	I-Entity
)	O
levels	O
.	O

The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	I-Entity
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10-weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime-2-chloride	I-Entity
(	O
2PAM	I-Entity
)	O
(	O
30.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	I-Entity
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A(1)-adenosine	I-Entity
receptor	O
agonist	O

N(6)-cyclopentyl	B-Entity
adenosine	I-Entity
(	O
CPA	I-Entity
)	O
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	I-Entity
-	O
receptor	O
antagonist	O
dizocilpine	B-Entity
maleate	I-Entity
(	O
+	O
-MK801	O
hydrogen	O
maleate	O
)	O
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	B-Entity
sulfate	I-Entity
(	O
50.0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	I-Entity
.	O

The	O
control	O
rats	O
received	O
atropine	B-Entity
sulfate	I-Entity
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	I-Entity
,	O
respectively	O
.	O

All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	I-Entity
injection	O
.	O

The	O
rats	O
treated	O
with	O
DFP	I-Entity
-	O
atropine	I-Entity
showed	O
severe	O
typical	O
OP	I-Entity
-	O
induced	O
toxicity	I-Entity
signs	O
.	O

When	O
CPA	I-Entity
,	O
diazepam	I-Entity
or	O
2PAM	I-Entity
was	O
given	O
immediately	O
after	O
DFP	I-Entity
-	O
atropine	I-Entity
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	I-Entity
.	O

Atropine	I-Entity
-	O
MK801	I-Entity
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	I-Entity
toxicity	I-Entity
.	O

In	O
conclusion	O
,	O
CPA	I-Entity
,	O
diazepam	I-Entity
and	O
2PAM	I-Entity
in	O
combination	O
with	O
atropine	I-Entity
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	I-Entity
and	O
thus	O
reduced	O
the	O
toxicity	I-Entity
of	O
DFP	I-Entity
in	O
rat	O
.	O



Differential	O
modulation	O
by	O
estrogen	I-Entity
of	O
alpha2-adrenergic	O
and	O
I1-imidazoline	I-Entity
receptor	O
-	O
mediated	O
hypotension	I-Entity
in	O
female	O
rats	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	I-Entity
negatively	O
modulates	O
the	O
hypotensive	I-Entity
effect	O
of	O
clonidine	I-Entity
(	O
mixed	O
alpha2-/I1-receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	I-Entity
involves	O
interaction	O
with	O
alpha2-	O
and/or	O
I1-receptors	O
.	O

Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	I-Entity
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1-	O
and	O
alpha2-receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O

Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12-wk	O
estrogen	I-Entity
replacement	O
.	O

In	O
sham	O
-	O
operated	O
rats	O
,	O
rilmenidine	I-Entity
or	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
elicited	O
similar	O
hypotension	I-Entity
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

SDRR	O
was	O
reduced	O
only	O
by	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
.	O

Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	I-Entity
response	O
to	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	I-Entity
hypotension	I-Entity
.	O

The	O
enhanced	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
hypotension	I-Entity
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-Entity
reduced	I-Entity
locomotor	I-Entity
activity	I-Entity
.	O

Estrogen	O
replacement	O
(	O
17beta	B-Entity
-	I-Entity
estradiol	I-Entity
subcutaneous	O
pellet	O
,	O
14.2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
to	O
sham	O
-	O
operated	O
levels	O
.	O

These	O
findings	O
suggest	O
that	O
estrogen	I-Entity
downregulates	O
alpha2-	O
but	O
not	O
I1-receptor	O
-	O
mediated	O
hypotension	I-Entity
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	B-Entity
-	I-Entity
methyldopa	I-Entity
-	O
estrogen	I-Entity
interaction	O
.	O



Cardioprotective	O
effect	O
of	O
tincture	B-Entity
of	I-Entity
Crataegus	I-Entity
on	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

Tincture	B-Entity
of	I-Entity
Crataegus	I-Entity
(	O
TCR	I-Entity
)	O
,	O
an	O
alcoholic	B-Entity
extract	I-Entity
of	I-Entity
the	I-Entity
berries	I-Entity
of	I-Entity
hawthorn	I-Entity
(	O
Crataegus	B-Entity
oxycantha	I-Entity
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	I-Entity
on	O
experimentally	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

Pretreatment	O
of	O
TCR	I-Entity
,	O
at	O
a	O
dose	O
of	O
0.5	O
mL/100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	I-Entity
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg(-1	O
)	O
s.	O
c.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	I-Entity
prevented	O
the	O
isoproterenol	I-Entity
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	I-Entity
-	O
stimulated	O
oxygen	I-Entity
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	I-Entity
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	I-Entity
in	O
rat	O
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	I-Entity
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	I-Entity
in	O
rat	O
heart	O
.	O



Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	I-Entity
:	O
multiple	O
outcomes	O
of	O
raloxifene	I-Entity
evaluation	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	I-Entity
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	I-Entity
therapy	O
or	O
tamoxifen	I-Entity
.	O

The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	I-Entity
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
enrolled	O
7,705	O
postmenopausal	O
women	O
with	O
osteoporosis	I-Entity
.	O

Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	I-Entity
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placebo	O
.	O

Outcomes	O
included	O
venous	B-Entity
thromboembolism	I-Entity
,	O
cataracts	I-Entity
,	O
gallbladder	B-Entity
disease	I-Entity
,	O
and	O
endometrial	B-Entity
hyperplasia	I-Entity
or	I-Entity
cancer	I-Entity
.	O

During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3.3	O
years	O
,	O
raloxifene	I-Entity
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-Entity
thromboembolism	I-Entity
(	O
relative	O
risk	O
[	O
RR	O
]	O
2.1	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.2	O
-	O
3.8	O
)	O
.	O

Risk	O
in	O
the	O
raloxifene	I-Entity
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O

Raloxifene	I-Entity
did	O
not	O
increase	O
risk	O
for	O
cataracts	I-Entity
(	O
RR	O
0.9	O
;	O
95%	O
CI	O
0.8	O
-	O
1.1	O
)	O
,	O
gallbladder	B-Entity
disease	I-Entity
(	O
RR	O
1.0	O
;	O
95%	O
CI	O
0.7	O
-	O
1.3	O
)	O
,	O
endometrial	B-Entity
hyperplasia	I-Entity
(	O
RR	O
1.3	O
;	O
95%	O
CI	O
0.4	O
-	O
5.1	O
)	O
,	O
or	O
endometrial	B-Entity
cancer	I-Entity
(	O
RR	O
0.9	O
;	O
95%	O
CI	O
0.3	O
-	O
2.7	O
)	O
.	O

Raloxifene	I-Entity
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-Entity
thromboembolism	I-Entity
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	I-Entity
,	O
gallbladder	B-Entity
disease	I-Entity
,	O
endometrial	B-Entity
hyperplasia	I-Entity
,	O
or	O
endometrial	B-Entity
cancer	I-Entity
.	O



Ceftriaxone	I-Entity
-	O
associated	O
biliary	B-Entity
pseudolithiasis	I-Entity
in	O
paediatric	O
surgical	O
patients	O
.	O

It	O
is	O
well	O
known	O
that	O
ceftriaxone	I-Entity
leads	O
to	O
pseudolithiasis	I-Entity
in	O
some	O
patients	O
.	O

Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	B-Entity
dysfunction	I-Entity
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	I-Entity
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	I-Entity
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O

Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	I-Entity
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms	O
.	O

Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	I-Entity
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables	O
.	O

After	O
cessation	O
of	O
the	O
treatment	O
,	O
pseudolithiasis	I-Entity
resolved	O
spontaneously	O
within	O
a	O
short	O
period	O
.	O

The	O
incidence	O
of	O
pseudolithiasis	I-Entity
is	O
not	O
affected	O
by	O
fasting	O
.	O



Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	I-Entity
as	O
an	O
immunotherapy	O
for	O
cocaine	B-Entity
overdose	I-Entity
.	O

The	O
illicit	O
use	O
of	O
cocaine	I-Entity
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B-Entity
overdose	I-Entity
remains	O
elusive	O
.	O

The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	I-Entity
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-Entity
overdose	I-Entity
.	O

Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocaine	I-Entity
and	O
GNC92H2	I-Entity
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC92H2	I-Entity
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	I-Entity
treatment	O
.	O

Significant	O
blockade	O
of	O
cocaine	I-Entity
toxicity	I-Entity
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	I-Entity
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40%	O
,	O
seizures	I-Entity
up	O
to	O
77%	O
and	O
death	I-Entity
by	O
72%	O
.	O

Importantly	O
,	O
GNC92H2	I-Entity
prevented	O
death	I-Entity
even	O
post	O
-	O
cocaine	I-Entity
injection	O
.	O

The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	I-Entity
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-Entity
overdose	I-Entity
.	O



The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	I-Entity
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
.	O

inhibitor-1	O
(	O
PAI-1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	I-Entity
administration	O
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	I-Entity
or	O
osteoporosis	I-Entity
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	B-Entity
hydrochloride	I-Entity
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	I-Entity
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	I-Entity
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	I-Entity
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16%	O
change	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25%	O
change	O
,	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	I-Entity
(	O
P	O
<	O
0.05	O
;	O
r	O
=	O
0.33	O
)	O
.	O

:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
due	O
to	O
raloxifene	I-Entity
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O



Ketoconazole	I-Entity
induced	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drug	O
.	O

Ketoconazole	I-Entity
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drugs	O
.	O

We	O
report	O
a	O
woman	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
who	O
developed	O
a	O
markedly	O
prolonged	B-Entity
QT	I-Entity
interval	I-Entity
and	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TdP	I-Entity
)	O
after	O
taking	O
ketoconazole	I-Entity
for	O
treatment	O
of	O
fungal	B-Entity
infection	I-Entity
.	O

Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	I-Entity
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	I-Entity
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP.	I-Entity

This	O
calls	O
for	O
attention	O
when	O
ketoconazole	I-Entity
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B-Entity
QT	I-Entity
syndrome	I-Entity
.	O



Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B-Entity
dysfunctions	I-Entity
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	I-Entity
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O

The	O
ethanolic	O
extract	B-Entity
of	I-Entity
Daucus	I-Entity
carota	I-Entity
seeds	I-Entity
(	O
DCE	I-Entity
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O

Diazepam-	I-Entity
,	O
scopolamine-	I-Entity
and	O
ageing	O
-	O
induced	O
amnesia	I-Entity
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O

DCE	I-Entity
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	I-Entity
was	O
23%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O

Furthermore	O
,	O
DCE	I-Entity
reversed	O
the	O
amnesia	I-Entity
induced	O
by	O
scopolamine	I-Entity
(	O
0.4	O
mg	O
/	O

kg	O
,	O
i.p	O
.	O
)	O
and	O
diazepam	I-Entity
(	O
1	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

Daucus	B-Entity
carota	I-Entity
extract	I-Entity
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O

reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	I-Entity
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	I-Entity
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22%	O
in	O
young	O
and	O
19%	O
in	O
aged	O
mice	O
.	O

There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	I-Entity
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23%	O
in	O
young	O
and	O
21%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	I-Entity
.	O

Therefore	O
,	O
DCE	I-Entity
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Entity
dysfunctions	I-Entity
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	I-Entity
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O



Cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
after	O
epidural	O
steroid	I-Entity
injection	O
:	O
a	O
case	O
report	O
.	O

Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	I-Entity
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	I-Entity
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O

Cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O

The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	I-Entity
and	O
bupivacaine	I-Entity
.	O

A	O
50-year	O
-	O
old	O
woman	O
with	O
low	B-Entity
back	I-Entity
and	I-Entity
right	I-Entity
leg	I-Entity
pain	I-Entity
was	O
scheduled	O
for	O
epidural	O
steroid	I-Entity
injection	O
.	O

After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	I-Entity
and	O
triamcinolone	B-Entity
diacetate	I-Entity
were	O
injected	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	I-Entity
and	O
lower	B-Entity
extremity	I-Entity
weakness	I-Entity
.	O

The	O
neurologic	O
evaluation	O
revealed	O
loss	B-Entity
of	I-Entity
sensation	I-Entity
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O

Complications	O
associated	O
with	O
epidural	O
steroid	I-Entity
injections	O
are	O
rare	O
.	O

Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B-Entity
deterioration	I-Entity
after	O
epidural	O
steroid	I-Entity
injections	O
is	O
important	O
.	O



High	O
-	O
dose	O
testosterone	I-Entity
is	O
associated	O
with	O
atherosclerosis	I-Entity
in	O
postmenopausal	O
women	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
long	O
-	O
term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	I-Entity
in	O
postmenopausal	O
women	O
.	O

In	O
a	O
population	O
-	O
based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54	O
-	O
67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self	O
-	O
reported	O
intramuscularly	O
administered	O
high	O
-	O
dose	O
estrogen	I-Entity
-	O
testosterone	I-Entity
therapy	O
(	O
estradiol-	B-Entity
and	I-Entity
testosterone	I-Entity
esters	I-Entity
)	O
and	O
aortic	O
atherosclerosis	I-Entity
.	O

Aortic	O
atherosclerosis	I-Entity
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	I-Entity
.	O

In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	I-Entity
of	O
the	O
aorta	O
was	O
present	O
(	O
n=11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	I-Entity
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20%	O
(	O
OR	O
3.1	O
;	O
95%	O
CI	O
,	O
1.1	O
-	O
8.5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	O
,	O
smoking	O
,	O
and	O
body	O
mass	O
index	O
)	O
.	O

The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	I-Entity
,	O
cholesterol	I-Entity
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	I-Entity
use	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	I-Entity
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	I-Entity
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O



Sirolimus	I-Entity
-	O
associated	O
proteinuria	I-Entity
and	O
renal	B-Entity
dysfunction	I-Entity
.	O

Sirolimus	I-Entity
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	I-Entity
protein	O
kinase	O
.	O

Sirolimus	I-Entity
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	I-Entity
.	O

Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	I-Entity
,	O
autoimmunity	I-Entity
,	O
cystic	B-Entity
renal	I-Entity
diseases	I-Entity
and	O
renal	B-Entity
cancer	I-Entity
is	O
under	O
investigation	O
.	O

Because	O
sirolimus	I-Entity
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	I-Entity
drug	O
'	O
.	O

However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	I-Entity
is	O
associated	O
with	O
proteinuria	I-Entity
and	O
acute	B-Entity
renal	I-Entity
dysfunction	I-Entity
.	O

A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre	O
-	O
existing	O
chronic	B-Entity
renal	I-Entity
damage	I-Entity
.	O

The	O
mechanisms	O
of	O
sirolimus	I-Entity
-	O
associated	O
proteinuria	I-Entity
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	I-Entity
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
acute	B-Entity
renal	I-Entity
dysfunction	I-Entity
associated	O
with	O
sirolimus	I-Entity
(	O
such	O
as	O
in	O
delayed	O
graft	O
function	O
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival	O
/	O
repair	O
processes	O
.	O

Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	I-Entity
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	I-Entity
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	I-Entity
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B-Entity
II	I-Entity
receptor	O
blockers	O
if	O
proteinuria	I-Entity
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	I-Entity
as	O
de	O
novo	O



Progressive	O
myopathy	I-Entity
with	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	I-Entity
therapy	O
.	O

Statins	I-Entity
can	O
cause	O
a	O
necrotizing	O
myopathy	I-Entity
and	O
hyperCKaemia	I-Entity
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	I-Entity
may	O
induce	O
a	O
myopathy	I-Entity
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O

All	O
had	O
myofibre	O
necrosis	I-Entity
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O

In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
necrotic	I-Entity
fibres	O
.	O

Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	I-Entity
and	O
methotrexate	I-Entity
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O

These	O
observations	O
suggest	O
that	O
statins	I-Entity
may	O
initiate	O
an	O
immune	O
-	O
mediated	O
myopathy	I-Entity
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	I-Entity
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	I-Entity
of	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
with	O
associated	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O



Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Entity
nucleotide	I-Entity
-	O
gated	O
pacemaker	O
channels	O
by	O
clonidine	I-Entity
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B-Entity
disease	I-Entity
,	O
including	O
arrhythmia	I-Entity
,	O
coronary	B-Entity
heart	I-Entity
disease	I-Entity
,	O
and	O
chronic	O
heart	B-Entity
failure	I-Entity
.	O

Activation	O
of	O
presynaptic	O
alpha2-adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	I-Entity
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	I-Entity
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	I-Entity
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2-adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2-adrenoceptor	O
subtypes	O
(	O
alpha2ABC-/-	O
)	O
.	O

Alpha2ABC-/-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	I-Entity
;	O
however	O
,	O
clonidine	I-Entity
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC-/-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clonidine	I-Entity
-	O
induced	O
bradycardia	I-Entity
in	O
conscious	O
alpha2ABC-/-	O
mice	O
was	O
32.3%	O
(	O
10	O
microg	O
/	O
kg	O
)	O
and	O
26.6%	O
(	O
100	O
microg	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wild	O
-	O
type	O
mice	O
.	O

A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	I-Entity
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Clonidine	I-Entity
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I(f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I(f)-generating	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Entity
nucleotide	I-Entity
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O

As	O
a	O
consequence	O
of	O
blocking	O
I(f	O
)	O
,	O
clonidine	I-Entity
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild	O
-	O
type	O
and	O
alpha2ABC	O
-	O
knockout	O
mice	O
.	O

Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	I-Entity
gene	O
-	O
targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine	I-Entity
-	O
like	O
drugs	O
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O



Influence	O
of	O
smoking	I-Entity
on	O
developing	O
cochlea	O
.	O

Does	O
smoking	I-Entity
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O

Maternal	O
tobacco	O
smoking	I-Entity
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O

The	O
influence	O
of	O
smoking	I-Entity
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	I-Entity
has	O
been	O
positively	O
associated	O
with	O
hearing	B-Entity
loss	I-Entity
in	O
adults	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	I-Entity
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O

This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	B-Entity
impairment	I-Entity
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O

Newborns	O
whose	O
mothers	O
reported	O
smoking	I-Entity
during	O
pregnancy	O
(	O
n=200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(	O
n=200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non	O
-	O
smokers	O
.	O

However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B-Entity
of	I-Entity
TEOAEs	I-Entity
amplitudes	I-Entity
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O

In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	I-Entity
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O

Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	I-Entity
on	O
the	O
neonate	O
's	O
hearing	O
acuity	O
.	O



Neuroinflammation	I-Entity
and	O
behavioral	B-Entity
abnormalities	I-Entity
after	O
neonatal	O
terbutaline	I-Entity
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	I-Entity
.	O

Autism	I-Entity
is	O
a	O
neurodevelopmental	B-Entity
disorder	I-Entity
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B-Entity
in	I-Entity
communication	I-Entity
and	I-Entity
social	I-Entity
skills	I-Entity
and	O
repetitive	B-Entity
behaviors	I-Entity
.	O

In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	I-Entity
.	O

Terbutaline	I-Entity
,	O
a	O
beta2-adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Entity
labor	I-Entity
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	I-Entity
in	O
dizygotic	O
twins	O
.	O

We	O
studied	O
the	O
effects	O
of	O
terbutaline	I-Entity
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O

Newborn	O
rats	O
were	O
given	O
terbutaline	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	I-Entity
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O

None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	I-Entity
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	I-Entity
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O

Our	O
findings	O
indicate	O
that	O
beta2-adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B-Entity
abnormalities	I-Entity
,	O
similar	O
to	O
those	O
described	O
in	O
autism	I-Entity
.	O

This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B-Entity
spectrum	I-Entity
disorders	I-Entity
.	O



Acute	O
myocarditis	I-Entity
associated	O
with	O
clozapine	I-Entity
.	O

A	O
case	O
of	O
acute	O
myocarditis	I-Entity
associated	O
with	O
the	O
commencement	O
of	O
clozapine	I-Entity
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	I-Entity
use	O
.	O

A	O
20-year	O
-	O
old	O
male	O
with	O
schizophrenia	I-Entity
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	I-Entity
after	O
commencement	O
of	O
clozapine	I-Entity
.	O

The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	I-Entity
in	O
an	O
inpatient	O
setting	O
.	O

Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	I-Entity
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O

Myocarditis	I-Entity
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	I-Entity
.	O

Considering	O
that	O
clozapine	I-Entity
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	I-Entity
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	I-Entity
.	O



Encephalopathy	I-Entity
induced	O
by	O
levetiracetam	I-Entity
added	O
to	O
valproate	I-Entity
.	O

BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	I-Entity
(	O
LEV)-induced	I-Entity
encephalopathy	I-Entity
.	O

A	O
28-year	O
-	O
old	O
man	O
suffering	O
from	O
idiopathic	B-Entity
epilepsy	I-Entity
with	O
generalized	O
seizures	I-Entity
was	O
treated	O
with	O
LEV	I-Entity
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	I-Entity
(	O
VPA	I-Entity
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequency	O
of	O
generalized	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizures	I-Entity
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O

Neuropsychological	O
testing	O
showed	O
impaired	B-Entity
word	I-Entity
fluency	I-Entity
,	I-Entity
psychomotor	I-Entity
speed	I-Entity
and	I-Entity
working	I-Entity
memory	I-Entity
.	O

Following	O
discontinuation	O
of	O
LEV	I-Entity
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	I-Entity
frequency	O
decreased	O
.	O



Norepinephrine	I-Entity
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	I-Entity
-	O
induced	O
anxiety	I-Entity
.	O

Cocaine	I-Entity
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

While	O
the	O
mechanisms	O
underlying	O
cocaine	I-Entity
's	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	I-Entity
,	O
such	O
as	O
anxiety	I-Entity
.	O

:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	I-Entity
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-/-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	I-Entity
(	O
NE	I-Entity
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	I-Entity
-	O
induced	O
anxiety	I-Entity
.	O

We	O
found	O
that	O
cocaine	I-Entity
dose	O
-	O
dependently	O
increased	O
anxiety	I-Entity
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+	O
/-	O

mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	I-Entity
.	O

Cocaine	I-Entity
-	O
induced	O
anxiety	I-Entity
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/-	O

mice	O
following	O
administration	O
of	O
disulfiram	I-Entity
,	O
a	O
dopamine	I-Entity
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O

In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists	O
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	I-Entity
blocked	O
cocaine	I-Entity
-	O
induced	O
anxiety	I-Entity
-	O
like	O
behavior	O
in	O
Dbh	O
+	O
/-	O

and	O
wild	O
-	O
type	O
C57BL6/J	O
mice	O
,	O
while	O
the	O
alpha(1	O
)	O
antagonist	O
prazosin	I-Entity
and	O
the	O
alpha(2	O
)	O
antagonist	O
yohimbine	I-Entity
had	O
no	O
effect	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	I-Entity
-	O
induced	O
anxiety	I-Entity
in	O
mice	O
.	O



Clonidine	I-Entity
for	O
attention	B-Entity
-	I-Entity
deficit	I-Entity
/	I-Entity
hyperactivity	I-Entity
disorder	I-Entity
:	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	I-Entity
used	O
alone	O
or	O
with	O
methylphenidate	I-Entity
in	O
children	O
with	O
attention	B-Entity
-	I-Entity
deficit	I-Entity
/	I-Entity
hyperactivity	I-Entity
disorder	I-Entity
(	O
ADHD	I-Entity
)	O
.	O

In	O
a	O
16-week	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	I-Entity
were	O
randomly	O
assigned	O
to	O
clonidine	I-Entity
(	O
n	O
=	O
31	O
)	O
,	O

methylphenidate	I-Entity
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	I-Entity
and	O
methylphenidate	I-Entity
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O

Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg	O
/	O
day	O
for	O
clonidine	I-Entity
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	I-Entity
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O

There	O
were	O
more	O
incidents	O
of	O
bradycardia	I-Entity
in	O
subjects	O
treated	O
with	O
clonidine	I-Entity
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	I-Entity
(	O
17.5%	O
versus	O
3.4%	O
;	O
p	O
=	O
.02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O

There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	I-Entity
and	O
methylphenidate	I-Entity
regarding	O
cardiovascular	O
outcomes	O
.	O

Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	I-Entity
(	O
79.4%	O
versus	O
49.2%	O
;	O
p	O
=	O
.0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O

Drowsiness	I-Entity
was	O
common	O
on	O
clonidine	I-Entity
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O

CONCLUSIONS	O
:	O
Clonidine	I-Entity
,	O
used	O
alone	O
or	O
with	O
methylphenidate	I-Entity
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	I-Entity
.	O

Physicians	O
prescribing	O
clonidine	I-Entity
should	O
monitor	O
for	O
bradycardia	I-Entity
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	I-Entity
.	O



Thalidomide	I-Entity
has	O
limited	O
single	O
-	O
agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non	B-Entity
-	I-Entity
Hodgkin	I-Entity
lymphomas	I-Entity
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	I-Entity
and	O
Leukemia	I-Entity
Group	O
B.	O
Thalidomide	I-Entity
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B-Entity
myeloma	I-Entity
,	O
mantle	B-Entity
cell	I-Entity
lymphoma	I-Entity
and	O
lymphoplasmacytic	B-Entity
lymphoma	I-Entity
.	O

Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	I-Entity
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed	O
/	O
refractory	O
indolent	O
lymphomas	I-Entity
received	O
thalidomide	I-Entity
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1	O
-	O
2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O

included	O
myelosuppression	I-Entity
,	O
fatigue	I-Entity
,	O
somnolence	I-Entity
/	O
depressed	B-Entity
mood	I-Entity
,	O
neuropathy	I-Entity
and	O
dyspnea	I-Entity
.	O

Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	I-Entity
events	O
.	O

Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	I-Entity
in	O
indolent	O
lymphomas	I-Entity
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	I-Entity
.	O



Intracavernous	O
epinephrine	I-Entity
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	I-Entity
in	O
the	O
emergency	O
department	O
.	O

Priapism	I-Entity
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O

A	O
45-year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	I-Entity
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	I-Entity
after	O
cocaine	I-Entity
use	O
.	O

The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	I-Entity
instillation	O
,	O
are	O
discussed	O
.	O



Effect	O
of	O
green	B-Entity
tea	I-Entity
and	O
vitamin	B-Entity
E	I-Entity
combination	O
in	O
isoproterenol	I-Entity
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Entity
tea	I-Entity
and	O
vitamin	B-Entity
E	I-Entity
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	I-Entity
(	O
ISO)-induced	I-Entity
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	I-Entity
(	O
200	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P<0.05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca+2	I-Entity
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P<0.05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na+/	I-Entity
K+	I-Entity
ATPase	O
and	O
Mg+2	I-Entity
ATPase	O
levels	O
.	O

Administration	O
of	O
green	B-Entity
tea	I-Entity
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
and	O
vitamin	B-Entity
E	I-Entity
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O

together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	I-Entity
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P<0.05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca+2	I-Entity
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na+/K+	I-Entity
ATPase	O
and	O
Mg+2	I-Entity
ATPase	O
when	O
compared	O
with	O
ISO	I-Entity
treated	O
group	O
and	O
green	B-Entity
tea	I-Entity
or	O
vitamin	B-Entity
E	I-Entity
alone	O
treated	O
groups	O
.	O

These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-Entity
tea	I-Entity
and	O
vitamin	B-Entity
E	I-Entity
during	O
ISO	I-Entity
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O



Development	O
of	O
ocular	B-Entity
myasthenia	I-Entity
during	O
pegylated	B-Entity
interferon	I-Entity
and	O
ribavirin	I-Entity
treatment	O
for	O
chronic	B-Entity
hepatitis	I-Entity
C.	I-Entity

A	O
63-year	O
-	O
old	O
male	O
experienced	O
sudden	O
diplopia	I-Entity
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	B-Entity
interferon	I-Entity
(	I-Entity
IFN	I-Entity
)	I-Entity
alpha-2b	I-Entity
and	O
ribavirin	I-Entity
for	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
(	O
CHC	I-Entity
)	O
.	O

Ophthalmologic	O
examinations	O
showed	O
ptosis	B-Entity
on	I-Entity
the	I-Entity
right	I-Entity
upper	I-Entity
lid	I-Entity
and	O
restricted	B-Entity
right	I-Entity
eye	I-Entity
movement	I-Entity
without	O
any	O
other	O
neurological	O
signs	O
.	O

The	O
acetylcholine	I-Entity
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal	O
.	O

The	O
patient	O
's	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	B-Entity
IFN	I-Entity
alpha-2b	I-Entity
and	O
ribavirin	I-Entity
.	O

The	O
ocular	B-Entity
myasthenia	I-Entity
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	B-Entity
IFN	I-Entity
alpha-2b	I-Entity
and	O
ribavirin	I-Entity
for	O
CHC	I-Entity
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	I-Entity
therapy	O
.	O



The	O
glycine	I-Entity
transporter-1	O
inhibitor	O
SSR103800	I-Entity
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O

Schizophrenia	I-Entity
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	I-Entity
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	I-Entity
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptor	O
produce	O
schizophrenic	I-Entity
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	I-Entity
receptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	I-Entity
receptor	O
.	O

Among	O
them	O
are	O
glycine	I-Entity
transporter-1	O
(	O
GlyT1	O
)	O

inhibitors	O
such	O
as	O
SSR103800	I-Entity
,	O
which	O
indirectly	O
enhance	O
NMDA	I-Entity
receptor	O
function	O
by	O
increasing	O
the	O
glycine	I-Entity
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	I-Entity
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	I-Entity
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	I-Entity
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	I-Entity
and	O
MK-801	I-Entity
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	I-Entity
Nr1(neo-/-	O
)	O
and	O
DAT(-/-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	I-Entity
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O

blocked	O
hyperactivity	I-Entity
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	I-Entity
receptor	O
antagonist	O
,	O
MK-801	I-Entity
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	I-Entity
of	O
NMDA	I-Entity
Nr1(neo-/-	O
)	O
mice	O
.	O

In	O
contrast	O
,	O
SSR103800	I-Entity
failed	O
to	O
affect	O
hyperactivity	I-Entity
induced	O
by	O
amphetamine	I-Entity
or	O
naturally	O
observed	O
in	O
dopamine	I-Entity
transporter	O
(	O
DAT(-/-	O
)	O
)	O
knockout	O
mice	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	I-Entity
)	O
and	O
atypical	O
(	O
olanzapine	I-Entity
,	O
clozapine	I-Entity
and	O
aripiprazole	I-Entity
)	O

antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	I-Entity
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	I-Entity
did	O
not	O
produce	O
catalepsy	I-Entity
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	I-Entity
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O



Phenylephrine	I-Entity
but	O
not	O
ephedrine	I-Entity
reduces	B-Entity
frontal	I-Entity
lobe	I-Entity
oxygenation	I-Entity
following	O
anesthesia	O
-	O
induced	O
hypotension	I-Entity
.	O

Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	I-Entity
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	I-Entity
and	O
ephedrine	I-Entity
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	I-Entity
.	O

Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	I-Entity
(	O
0.15	O
mg	O
kg(-1	O
)	O
)	O
and	O
propofol	I-Entity
(	O
2.0	O
mg	O
kg(-1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	I-Entity
(	O
0.1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	I-Entity
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

MAP	O
,	O
stroke	I-Entity
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
were	O
registered	O
.	O

Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	B-Entity
decrease	I-Entity
in	I-Entity
MAP	I-Entity
,	I-Entity
HR	I-Entity
,	I-Entity
SV	I-Entity
,	I-Entity
and	I-Entity
CO	I-Entity
concomitant	O
with	O
an	O
elevation	O
in	O
S(c)O(2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	I-Entity
,	O
MAP	O
increased	O
(	O
51	O
+	O
/-	O

The	O
administration	O
of	O
ephedrine	I-Entity
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/-	O

The	O
utilization	O
of	O
phenylephrine	I-Entity
to	O
correct	O
hypotension	I-Entity
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S(c)O(2	O
)	O
while	O
ephedrine	I-Entity
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O



A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive	B-Entity
-	I-Entity
compulsive	I-Entity
-	I-Entity
like	I-Entity
behaviors	I-Entity
in	O
animals	O
.	O

Current	O
animal	O
models	O
of	O
obsessive	B-Entity
-	I-Entity
compulsive	I-Entity
disorder	I-Entity
(	O
OCD	I-Entity
)	O
typically	O
involve	O
acute	O
,	O
drug	O
-	O
induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	I-Entity
.	O

None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	I-Entity
-	O
like	O
behaviors	O
.	O

Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	I-Entity
clomipramine	I-Entity
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O

RESULTS	O
:	O
Clomipramine	I-Entity
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	I-Entity
(	O
elevated	O
plus	O
maze	O
and	O
marble	O
burying	O
)	O
,	O
behavioral	B-Entity
inflexibility	I-Entity
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B-Entity
impairment	I-Entity
(	O
e.g.	O
,	O
win	O
-	O
shift	O
paradigm	O
)	O
,	O
hoarding	I-Entity
,	O
and	O
corticostriatal	B-Entity
dysfunction	I-Entity
.	O

Dopamine	I-Entity
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	I-Entity
2C	O
,	O
but	O
not	O
serotonin	I-Entity
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	I-Entity
-	O
like	O
profile	O
in	O
animals	O
.	O

Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	I-Entity
.	O

This	O
novel	O
model	O
of	O
OCD	I-Entity
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	O
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-Entity
disorders	I-Entity
.	O



Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
.	O

A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
(	O
HUS	I-Entity
)	O
in	O
a	O
woman	O
taking	O
oral	B-Entity
contraceptives	I-Entity
.	O

She	O
was	O
treated	O
with	O
heparin	I-Entity
,	O
dipyridamole	I-Entity
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	I-Entity
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O

This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	I-Entity
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	I-Entity
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	I-Entity
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	I-Entity
and	O
microangiopathic	B-Entity
hemolytic	I-Entity
anemia	I-Entity
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O



Effects	O
of	O
acetylsalicylic	B-Entity
acid	I-Entity
,	O
dipyridamole	I-Entity
,	O
and	O
hydrocortisone	I-Entity
on	O
epinephrine	I-Entity
-	O
induced	O
myocardial	B-Entity
injury	I-Entity
in	O
dogs	O
.	O

A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B-Entity
injury	I-Entity
(	O
epinephrine	I-Entity
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	B-Entity
infarction	I-Entity
.	O

Infusions	O
of	O
epinephrine	I-Entity
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	I-Entity
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline	O
-	O
infused	O
control	O
animals	O
(	O
4,957	O
vs.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	I-Entity
also	O
increased	O
significantly	O
(	O
12.0	O
vs.	O
5.0	O
mg.per	O
100	O
Gm	O
.	O

Infusions	O
of	O
calcium	B-Entity
chloride	I-Entity
sufficient	O
to	O
raise	O
serum	O
calcium	I-Entity
concentrations	O
2	O
mEq	O
.	O

per	O
liter	O
failed	O
to	O
increase	O
calcium	I-Entity
influx	O
into	O
the	O
myocardial	O
cell	O
.	O

Mitochondrial	O
radiocalcium	I-Entity
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	B-Entity
acid	I-Entity
or	O
dipyridamole	I-Entity
or	O
when	O
hydrocortisone	I-Entity
was	O
added	O
to	O
the	O
epinephrine	I-Entity
infusion	O
(	O
2,682,2,803	O
,	O
and	O
3,424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O

Myocardial	O
calcium	I-Entity
concentrations	O
also	O
were	O
decreased	O
(	O
11.2	O
,	O
8.3	O
,	O
and	O
8.9	O
mg	O
.	O

Acetylsalicylic	B-Entity
acid	I-Entity
,	O
dipyridamole	I-Entity
,	O
and	O
hydrocortisone	I-Entity
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O



Changes	O
in	O
depressive	I-Entity
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O

Depression	I-Entity
and	O
sexual	B-Entity
dysfunction	I-Entity
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta	O
-	O
blockers	O
.	O

We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta	O
-	O
blocker	O
(	O
timolol	I-Entity
)	O
and	O
a	O
selective	O
beta	O
-	O
blocker	O
(	O
betaxolol	I-Entity
)	O
regarding	O
CNS	O
side	O
effects	O
.	O

Eight	O
glaucomatous	I-Entity
patients	O
chronically	O
treated	O
with	O
timolol	I-Entity
0.5%/12h	O
,	O
suffering	O
from	O
depression	I-Entity
diagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

During	O
the	O
six	O
-	O
month	O
follow	O
up	O
,	O
depression	I-Entity
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	O
.	O

In	O
a	O
double	O
blind	O
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	I-Entity
treatment	O
presented	O
higher	O
depression	I-Entity
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O

These	O
results	O
suggest	O
that	O
betaxolol	I-Entity
could	O
be	O
less	O
of	O
a	O
depression	I-Entity
-	O
inducer	O
than	O
timolol	I-Entity
in	O
predisposed	O
patients	O
.	O



Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	I-Entity
renal	B-Entity
toxicity	I-Entity
in	O
children	O
treated	O
for	O
malignant	B-Entity
mesenchymal	I-Entity
tumors	I-Entity
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O

The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	B-Entity
mesenchymal	I-Entity
tumors	I-Entity
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	I-Entity
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B-Entity
Mesenchymal	I-Entity
Tumor	I-Entity
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O

Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	I-Entity
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	B-Entity
,	I-Entity
vincristine	I-Entity
,	I-Entity
and	I-Entity
dactinomycin	I-Entity
[	O
IVA	I-Entity
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cisplatin	I-Entity
chemotherapy	O
.	O

The	O
most	O
common	O
primary	O
tumor	I-Entity
site	O
was	O
the	O
head	O
and	O
neck	O
.	O

Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	I-Entity
,	O
proteinuria	I-Entity
,	O
aminoaciduria	I-Entity
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	I-Entity
clearance	O
,	O
phosphate	I-Entity
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O

Fifty	O
-	O
eight	O
patients	O
(	O
78%	O
)	O
had	O
normal	O
renal	O
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22%	O
)	O
had	O
renal	B-Entity
abnormalities	I-Entity
.	O

the	O
first	O
included	O
four	O
patients	O
(	O
5%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	I-Entity
resulting	O
in	O
Fanconi	B-Entity
's	I-Entity
syndrome	I-Entity
(	O
TDFS	I-Entity
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	I-Entity
reabsorption	O
.	O

Severe	O
toxicity	I-Entity
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	I-Entity
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1/2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	I-Entity
involvement	O
.	O

This	O
low	O
percentage	O
(	O
5%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	I-Entity
in	O
the	O
treatment	O
of	O
mesenchymal	B-Entity
tumors	I-Entity
in	O
children	O
.	O



Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	I-Entity
receptors	O
in	O
mediating	O
nicotine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
in	O
rats	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	I-Entity
-	O
induced	O
locomotor	O
stimulation	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	I-Entity
in	O
rats	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	I-Entity
receptors	O
in	O
mediating	O
nicotine	I-Entity
-	O
induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	I-Entity
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	I-Entity
.	O

Nicotine	I-Entity
(	O
1.0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
increase	B-Entity
in	I-Entity
locomotor	I-Entity
activity	I-Entity
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O

The	O
stimulant	O
action	O
of	O
nicotine	I-Entity
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	I-Entity
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	I-Entity
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O

Nicotine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	B-Entity
23390	I-Entity
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	I-Entity
and	O
the	O
D1/D2	O
antagonist	O
fluphenazine	I-Entity
.	O

Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	I-Entity
enhanced	O
nicotine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	B-Entity
38393	I-Entity
had	O
no	O
effect	O
.	O

The	O
results	O
indicate	O
that	O
acute	O
nicotine	I-Entity
injection	O
induces	O
a	O
pronounced	O
hyperactivity	I-Entity
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O

The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	I-Entity
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	I-Entity
receptors	O
.	O



Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	I-Entity
.	O

This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	I-Entity
.	O

Reactions	O
consisted	O
mainly	O
of	O
seizures	I-Entity
,	O
acute	O
psychoses	I-Entity
,	O
anxiety	B-Entity
neurosis	I-Entity
,	O
and	O
major	O
disturbances	B-Entity
of	I-Entity
sleep	I-Entity
-	I-Entity
wake	I-Entity
rhythm	I-Entity
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8,000	O
mefloquine	I-Entity
users	O
suffers	O
from	O
such	O
reactions	O
.	O

The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13,000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	I-Entity
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O

Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	I-Entity
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	I-Entity
are	O
recommended	O
.	O



Reduction	O
in	O
injection	O
pain	I-Entity
using	O
buffered	O
lidocaine	I-Entity
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	I-Entity
associated	O
with	O
the	O
injection	O
of	O
lidocaine	I-Entity
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	I-Entity
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	I-Entity
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O

Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	I-Entity
after	O
receiving	O
standard	O
lidocaine	I-Entity
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	I-Entity
in	O
the	O
opposite	O
femoral	O
area	O
.	O

The	O
mean	O
pain	I-Entity
score	O
for	O
buffered	O
lidocaine	I-Entity
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	I-Entity
(	O
2.7	O
+	O
/-	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	I-Entity
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	I-Entity
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O



Randomized	O
,	O
double	O
-	O
blind	O
trial	O
of	O
mazindol	I-Entity
in	O
Duchenne	B-Entity
dystrophy	I-Entity
.	O

There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	I-Entity
in	O
Duchenne	B-Entity
dystrophy	I-Entity
.	O

We	O
conducted	O
a	O
12-month	O
controlled	O
trial	O
of	O
mazindol	I-Entity
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	B-Entity
dystrophy	I-Entity
.	O

Muscle	O
strength	O
,	O
contractures	O
,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	I-Entity
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placebo	O
.	O

The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0.90	O
to	O
detect	O
a	O
slowing	O
to	O
25%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	I-Entity
at	O
P	O
less	O
than	O
0.05	O
.	O

Mazindol	I-Entity
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O

Side	O
effects	O
attributable	O
to	O
mazindol	I-Entity
included	O
decreased	B-Entity
appetite	I-Entity
(	O
36%	O
)	O
,	O
dry	B-Entity
mouth	I-Entity
(	O
10%	O
)	O
,	O
behavioral	O
change	O
(	O
22%	O
)	O
,	O
and	O
gastrointestinal	B-Entity
symptoms	I-Entity
(	O
18%	O
)	O
;	O
mazindol	I-Entity
dosage	O
was	O
reduced	O
in	O
43%	O
of	O
patients	O
.	O

The	O
effect	O
of	O
mazindol	I-Entity
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF	O
-	O
I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	I-Entity
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O

Although	O
mazindol	I-Entity
-	O
treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo	O
-	O
treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF	O
-	O
I	O
levels	O
was	O
observed	O
.	O

Mazindol	I-Entity
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	I-Entity
in	O
Duchenne	B-Entity
dystrophy	I-Entity
.	O



Pentoxifylline	I-Entity
(	O
Trental	I-Entity
)	O
does	O
not	O
inhibit	O
dipyridamole	I-Entity
-	O
induced	O
coronary	O
hyperemia	I-Entity
:	O
implications	O
for	O
dipyridamole	I-Entity
-	O
thallium-201	I-Entity
myocardial	O
imaging	O
.	O

Dipyridamole	I-Entity
-	O
thallium-201	I-Entity
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	B-Entity
vascular	I-Entity
disease	I-Entity
.	O

Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	I-Entity
(	O
Trental	I-Entity
)	O
,	O
a	O
methylxanthine	I-Entity
derivative	O
which	O
may	O
improve	O
intermittent	B-Entity
claudication	I-Entity
.	O

Whether	O
pentoxifylline	I-Entity
inhibits	O
dipyridamole	I-Entity
-	O
induced	O
coronary	O
hyperemia	I-Entity
like	O
other	O
methylxanthines	I-Entity
such	O
as	O
theophylline	I-Entity
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	I-Entity
-	O
thallium-201	I-Entity
imaging	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	I-Entity
in	O
seven	O
open	O
-	O
chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	I-Entity
(	O
0	O
,	O

7.5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
or	O
theophylline	I-Entity
(	O
3	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
.	O

Dipyridamole	I-Entity
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7.5	O
or	O
15	O
mm	O
/	O
kg	O
i.v	O
.	O

pentoxifylline	I-Entity
(	O
p	O
less	O
than	O
0.002	O
)	O
.	O

Neither	O
dose	O
of	O
pentoxifylline	I-Entity
significantly	O
decreased	O
the	O
dipyridamole	I-Entity
-	O
induced	O
hyperemia	I-Entity
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	I-Entity
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyifylline	I-Entity
does	O
not	O
inhibit	O
dipyridamole	I-Entity
-	O
induced	O
coronary	O
hyperemia	I-Entity
even	O
at	O
high	O
doses	O
.	O



Cause	O
of	O
death	I-Entity
among	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B-Entity
haemorrhage	I-Entity
.	O

Causes	O
of	O
death	I-Entity
,	O
with	O
special	O
reference	O
to	O
cerebral	B-Entity
haemorrhage	I-Entity
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
death	I-Entity
were	O
pneumonia	I-Entity
and	O
bronchitis	I-Entity
(	O
44.1%	O
)	O
,	O
malignant	O
neoplasms	I-Entity
(	O
11.6%	O
)	O
,	O
heart	B-Entity
diseases	I-Entity
(	O
4.1%	O
)	O
,	O
cerebral	B-Entity
infarction	I-Entity
(	O
3.7%	O
)	O
and	O
septicaemia	I-Entity
(	O
3.3%	O
)	O
.	O

Cerebral	B-Entity
haemorrhage	I-Entity
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	I-Entity
,	O
accounting	O
for	O
only	O
0.8%	O
of	O
deaths	I-Entity
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	I-Entity
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O

The	O
low	O
incidence	O
of	O
cerebral	B-Entity
haemorrhage	I-Entity
as	O
a	O
cause	O
of	O
death	I-Entity
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
may	O
reflect	O
the	O
hypotensive	I-Entity
effect	O
of	O
levodopa	I-Entity
and	O
a	O
hypotensive	I-Entity
mechanism	O
due	O
to	O
reduced	O
noradrenaline	I-Entity
levels	O
in	O
the	O
parkinsonian	I-Entity
brain	O
.	O



Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	I-Entity
in	O
patients	O
with	O
Argentine	B-Entity
hemorrhagic	I-Entity
fever	I-Entity
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	I-Entity
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	B-Entity
hemorrhagic	I-Entity
fever	I-Entity
(	O
AHF	I-Entity
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O

Administration	O
of	O
ribavirin	I-Entity
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	I-Entity
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O

The	O
average	O
time	O
of	O
death	I-Entity
was	O
delayed	O
.	O

A	O
reversible	O
anemia	I-Entity
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	I-Entity
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	I-Entity
,	O
and	O
that	O
anemia	I-Entity
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	I-Entity
during	O
the	O
initial	O
days	O
of	O
AHF	I-Entity
is	O
discussed	O
.	O



Dipyridamole	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
.	O

Angina	I-Entity
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	I-Entity
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	I-Entity
therapy	O
,	O
although	O
dipyridamole	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O

Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
""""	O
steal	O
""""	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	I-Entity
-	O
induced	O
ischemia	I-Entity
observed	O
.	O



Nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Entity
vasopressin	I-Entity
nor	O
oxytocin	I-Entity
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2-h	O
systemic	O
corticosterone	I-Entity
infusion	O
in	O
urethane	I-Entity
-	O
anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	B-Entity
vasopressin	I-Entity
and	O
oxytocin	I-Entity
at	O
any	O
corticosterone	I-Entity
feedback	O
dose	O
tested	O
.	O

Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	I-Entity
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	I-Entity
levels	O
of	O
40	O
micrograms	O
/	O
dl	O
.	O

Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	I-Entity
level	O
between	O
8	O
-	O
12	O
micrograms	O
/	O
dl	O
.	O



Noradrenergic	O
involvement	O
in	O
catalepsy	I-Entity
induced	O
by	O
delta	B-Entity
9-tetrahydrocannabinol	I-Entity
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	B-Entity
9-tetrahydrocannabinol	I-Entity
(	O
THC	I-Entity
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6-hydroxydopamine	I-Entity
(	O
6-OHDA	I-Entity
)	O
or	O
with	O
desipramine	I-Entity
and	O
6-OHDA	I-Entity
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
THC	I-Entity
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6-OHDA	I-Entity
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	I-Entity
and	O
6-OHDA	I-Entity
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	I-Entity
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	I-Entity
and	O
6-OHDA	I-Entity
but	O
not	O
in	O
rats	O
treated	O
with	O
6-OHDA	I-Entity
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	I-Entity
induced	O
by	O
THC	I-Entity
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	I-Entity
induced	O
by	O
haloperidol	I-Entity
.	O



Intracranial	O
pressure	O
increases	O
during	O
alfentanil	I-Entity
-	O
induced	O
rigidity	I-Entity
.	O

Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil	I-Entity
-	O
induced	O
rigidity	I-Entity
in	O
rats	O
.	O

Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	I-Entity
anesthesia	O
.	O

Following	O
instrumentation	O
,	O
halothane	I-Entity
was	O
discontinued	O
and	O
alfentanil	I-Entity
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	I-Entity
anesthesia	O
.	O

In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	B-Entity
rigidity	I-Entity
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7.5	O
+	O
/-	O

These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	I-Entity
was	O
abolished	O
with	O
metocurine	I-Entity
.	O

In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	I-Entity
.	O

These	O
observations	O
suggest	O
that	O
rigidity	I-Entity
should	O
be	O
prevented	O
when	O
alfentanil	I-Entity
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	O
,	O
are	O
used	O
in	O
the	O
anesthetic	O
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O



Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis	B-Entity
-	I-Entity
platin	I-Entity
and	O
5-fluorouracil	I-Entity
.	O

Survival	O
for	O
patients	O
with	O
advanced	O
head	B-Entity
and	I-Entity
neck	I-Entity
carcinoma	I-Entity
and	O
esophageal	B-Entity
carcinoma	I-Entity
is	O
poor	O
with	O
radiotherapy	O
and/or	O
surgery	O
.	O

In	O
the	O
present	O
study	O
,	O
cis	B-Entity
-	I-Entity
platin	I-Entity
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5-FU	I-Entity
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O

In	O
the	O
pre	O
-	O
treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B-Entity
disease	I-Entity
were	O
found	O
in	O
33	O
patients	O
(	O
43%	O
)	O
.	O

The	O
incidence	O
of	O
cardiotoxicity	I-Entity
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-Entity
disease	I-Entity
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O

The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	I-Entity
were	O
chest	B-Entity
pain	I-Entity
,	O
ST	O
-	O
T	O
wave	O
changes	O
and	O
atrial	B-Entity
fibrillation	I-Entity
.	O

This	O
was	O
followed	O
by	O
ventricular	B-Entity
fibrillation	I-Entity
in	O
one	O
patient	O
and	O
sudden	B-Entity
death	I-Entity
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patients	O
on	O
5-FU	I-Entity
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-Entity
pain	I-Entity
or	O
tachyarrhythmia	I-Entity
is	O
observed	O
.	O



Verapamil	I-Entity
-	O
induced	O
carbamazepine	I-Entity
neurotoxicity	I-Entity
.	O

Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	I-Entity
neurotoxicity	I-Entity
after	O
combined	O
treatment	O
with	O
verapamil	I-Entity
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	I-Entity
entry	O
blocker	O
.	O

Use	O
of	O
verapamil	I-Entity
in	O
combination	O
with	O
carbamazepine	I-Entity
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	I-Entity
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	I-Entity
dose	O
by	O
one	O
half	O
)	O
.	O



Serial	O
studies	O
of	O
auditory	B-Entity
neurotoxicity	I-Entity
in	O
patients	O
receiving	O
deferoxamine	I-Entity
therapy	O
.	O

Visual	B-Entity
and	I-Entity
auditory	I-Entity
neurotoxicity	I-Entity
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion	O
-	O
dependent	O
anemia	I-Entity
who	O
were	O
receiving	O
iron	I-Entity
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	I-Entity
.	O

Twenty	O
-	O
two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	B-Entity
audiograms	I-Entity
with	I-Entity
deficits	I-Entity
mostly	I-Entity
in	I-Entity
the	I-Entity
high	I-Entity
frequency	I-Entity
range	I-Entity
of	I-Entity
4,000	I-Entity
to	I-Entity
8,000	I-Entity
Hz	I-Entity
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O

When	O
deferoxamine	I-Entity
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O

Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	B-Entity
disability	I-Entity
.	O

Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	I-Entity
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	B-Entity
abnormality	I-Entity
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	I-Entity
was	O
demonstrated	O
.	O

Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	I-Entity
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relation	O
between	O
deferoxamine	I-Entity
administration	O
and	O
ototoxicity	I-Entity
.	O

Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	I-Entity
.	O

With	O
mild	O
toxicity	I-Entity
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	I-Entity
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

In	O
those	O
with	O
symptoms	O
of	O
hearing	B-Entity
loss	I-Entity
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
.	O

Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B-Entity
dysfunction	I-Entity
.	O



Flurbiprofen	I-Entity
in	O
the	O
treatment	O
of	O
juvenile	B-Entity
rheumatoid	I-Entity
arthritis	I-Entity
.	O

Thirty	O
-	O
four	O
patients	O
with	O
juvenile	B-Entity
rheumatoid	I-Entity
arthritis	I-Entity
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	I-Entity
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	I-Entity
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	B-Entity
joints	I-Entity
,	O
the	O
severity	O
of	O
swelling	I-Entity
and	O
tenderness	I-Entity
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	B-Entity
stiffness	I-Entity
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B-Entity
occult	I-Entity
blood	I-Entity
(	O
25%	O
of	O
patients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	B-Entity
(	I-Entity
GI	I-Entity
)	I-Entity
bleeding	I-Entity
in	O
these	O
patients	O
.	O

One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	I-Entity
and	O
abdominal	B-Entity
pain	I-Entity
.	O



The	O
correlation	O
between	O
neurotoxic	I-Entity
esterase	O
inhibition	O
and	O
mipafox	I-Entity
-	O
induced	O
neuropathic	B-Entity
damage	I-Entity
in	O
rats	O
.	O

The	O
correlation	O
between	O
neuropathic	B-Entity
damage	I-Entity
and	O
inhibition	O
of	O
neurotoxic	I-Entity
esterase	O
or	O
neuropathy	I-Entity
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	I-Entity
(	O
N	B-Entity
,	I-Entity
N'-diisopropylphosphorodiamidofluoridate	I-Entity
)	O
,	O
a	O
neurotoxic	I-Entity
organophosphate	I-Entity
.	O

Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long	O
-	O
Evans	O
male	O
rats	O
1	O
hr	O
post	O
-	O
exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	I-Entity
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B-Entity
damage	I-Entity
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14	O
-	O
21	O
days	O
post	O
-	O
exposure	O
.	O

In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	I-Entity
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60%	O
produced	O
this	O
degree	O
of	O
cord	B-Entity
damage	I-Entity
in	O
only	O
9%	O
of	O
the	O
animals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	I-Entity
exposure	O
can	O
predict	O
neuropathic	B-Entity
damage	I-Entity
in	O
rats	O
several	O
weeks	O
later	O
.	O



Cerebral	B-Entity
infarction	I-Entity
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	I-Entity
.	O

Phenylpropanolamine	I-Entity
(	O
PPA	I-Entity
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	I-Entity
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O

Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	I-Entity
,	O
intracerebral	B-Entity
hemorrhage	I-Entity
,	O
neuropsychiatric	B-Entity
symptoms	I-Entity
,	O
and	O
nonhemorrhagic	O
cerebral	B-Entity
infarction	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B-Entity
infarction	I-Entity
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	I-Entity
.	O



Treatment	O
of	O
psoriasis	I-Entity
with	O
azathioprine	I-Entity
.	O

Azathioprine	I-Entity
treatment	O
benefited	O
19	O
(	O
66%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	I-Entity
.	O

Minimal	O
cholestasis	I-Entity
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	I-Entity
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O

Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	I-Entity
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B-Entity
damage	I-Entity
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O



Maternal	O
lithium	I-Entity
and	O
neonatal	O

Ebstein	B-Entity
's	I-Entity
anomaly	I-Entity
:	O
evaluation	O
with	O
cross	O
-	O
sectional	O
echocardiography	O
.	O

Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	I-Entity
during	O
pregnancy	O
.	O

In	O
one	O
infant	O
,	O
Ebstein	B-Entity
's	I-Entity
anomaly	I-Entity
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O

In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-Entity
's	I-Entity
anomaly	I-Entity
.	O

Cross	O
-	O
sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	I-Entity
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	I-Entity
-	O
induced	O
cardiac	B-Entity
malformations	I-Entity
.	O



Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B-Entity
infarction	I-Entity
in	O
aging	O
rats	O
.	O

The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20,40,60	O
and	O
80	O
weeks	O
of	O
age	O
.	O

The	O
occurrence	O
of	O
infarcts	I-Entity
were	O
confirmed	O
by	O
histological	O
methods	O
.	O

Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary	O
-	O
isoproterenols	I-Entity
and	O
minimum	O
in	O
the	O
exercise	O
-	O
controls	O
.	O

Studies	O
dealing	O
with	O
myocardial	B-Entity
infarction	I-Entity
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O



Effect	O
of	O
polyethylene	B-Entity
glycol	I-Entity
400	I-Entity
on	O
adriamycin	I-Entity
toxicity	I-Entity
in	O
mice	O
.	O

The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	B-Entity
glycol	I-Entity
400	I-Entity
(	O
PEG	B-Entity
400	I-Entity
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	I-Entity
(	O
ADR	I-Entity
)	O
was	O
evaluated	O
in	O
mice	O
.	O

PEG	B-Entity
400	I-Entity
impressively	O
decreased	O
both	O
acute	O
high	O
-	O
dose	O
and	O
chronic	O
low	O
-	O
dose	O
-	O
ADR	I-Entity
-	O
associated	O
lethality	O
.	O

Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	I-Entity
-	O
induced	O
cardiac	B-Entity
morphological	I-Entity
alterations	I-Entity
.	O

Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	I-Entity
antitumor	O
activity	O
in	O
L1210	B-Entity
leukemia	I-Entity
and	O
in	O
Ehrlich	B-Entity
ascites	I-Entity
tumor	I-Entity
.	O



Intra	O
-	O
arterial	O
BCNU	I-Entity
chemotherapy	O
for	O
treatment	O
of	O
malignant	B-Entity
gliomas	I-Entity
of	O
the	O
central	O
nervous	O
system	O
.	O

Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	I-Entity
(	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	I-Entity
)	O
,	O
intra	O
-	O
arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	B-Entity
gliomas	I-Entity
.	O

Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	I-Entity
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O

Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	I-Entity
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	I-Entity
without	O
prior	O
radiation	O
therapy	O
.	O

After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	I-Entity
size	O
and	O
surrounding	O
edema	I-Entity
on	O
contrast	O
-	O
enhanced	O
computerized	O
tomography	O
scans	O
.	O

Twenty	O
-	O
four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	I-Entity
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra	O
-	O
arterial	O
BCNU	I-Entity
therapy	O
.	O

The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	I-Entity
.	O

A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	B-Entity
of	I-Entity
vision	I-Entity
secondary	O
to	O
a	O
retinal	B-Entity
vasculitis	I-Entity
.	O

The	O
frequency	O
of	O
visual	B-Entity
loss	I-Entity
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	I-Entity
diluent	O
was	O
lowered	O
.	O



Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	I-Entity
infusion	O
in	O
conscious	O
rats	O
.	O

Sodium	B-Entity
chloride	I-Entity
solution	O
(	O
0.9%	O
)	O
or	O

noradrenaline	I-Entity
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O

Intrarenal	O
infusion	O
of	O
noradrenaline	I-Entity
caused	O
hypertension	I-Entity
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O

Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	I-Entity
caused	O
higher	O
plasma	O
noradrenaline	I-Entity
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	I-Entity
concentration	O
-	O
blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	I-Entity
levels	O
.	O

These	O
results	O
suggest	O
that	O
hypertension	I-Entity
after	O
chronic	O
intrarenal	O
noradrenaline	I-Entity
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	I-Entity
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O



Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	I-Entity
.	O

In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	I-Entity
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	I-Entity
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	I-Entity
.	O

Cimetidine	I-Entity
clearance	O
decreased	O
with	O
age	O
.	O

The	O
extrapolated	O
6-hr	O
serum	O
concentration	O
of	O
cimetidine	I-Entity
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	I-Entity
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O

The	O
ratio	O
of	O
cimetidine	I-Entity
clearance	O
to	O
creatinine	I-Entity
clearance	O
(	O
Rc	O
)	O
averaged	O
4.8	O
+	O
/-	O

2.0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	I-Entity
.	O

Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	I-Entity
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	I-Entity
is	O
a	O
saturable	O
process	O
.	O

There	O
was	O
only	O
one	O
case	O
of	O
dementia	I-Entity
possibly	O
due	O
to	O
cimetidine	I-Entity
(	O
with	O
a	O
drug	O
level	O
of	O
1.9	O
microgram	O
/	O
ml	O
6	O

hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	B-Entity
or	I-Entity
kidney	I-Entity
disease	I-Entity
who	O
had	O
cimetidine	I-Entity
levels	O
above	O
1.25	O
microgram	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimetidine	I-Entity
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	I-Entity
.	O



Development	O
of	O
clear	B-Entity
cell	I-Entity
adenocarcinoma	I-Entity
in	O
DES	I-Entity
-	O
exposed	O
offspring	O
under	O
observation	O
.	O

Two	O
cases	O
of	O
clear	B-Entity
cell	I-Entity
adenocarcinoma	I-Entity
of	I-Entity
the	I-Entity
vagina	I-Entity
detected	O
at	O
follow	O
-	O
up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	I-Entity
are	O
reported	O
.	O

One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	I-Entity
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O

In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	I-Entity
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O



Phenobarbitone	I-Entity
-	O
induced	O
enlargement	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	B-Entity
tetrachloride	I-Entity
-	O
induced	O
cirrhosis	I-Entity
.	O

The	O
yield	O
of	O
severe	O
cirrhosis	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	I-Entity
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2.2	O
g	O
/	O
dl	O
,	O
splenomegaly	I-Entity
2	O
-	O
3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	I-Entity
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	B-Entity
tetrachloride	I-Entity
given	O
intragastrically	O
in	O
the	O
phenobarbitone	I-Entity
-	O
primed	O
rat	O
was	O
increased	O
from	O
25%	O
to	O
56%	O
by	O
giving	O
the	O
initial	O
""""	O
calibrating	O
""""	O
dose	O
of	O
carbon	B-Entity
tetrachloride	I-Entity
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	I-Entity
-	O
induced	O
enlargement	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450/CCl4	I-Entity
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O

The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	I-Entity
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight	O
.	O

The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	B-Entity
tetrachloride	I-Entity
was	O
after	O
14	O
days	O
on	O
phenobarbitone	I-Entity
.	O



Attenuation	O
of	O
the	O
lithium	I-Entity
-	O
induced	O
diabetes	B-Entity
-	I-Entity
insipidus	I-Entity
-	I-Entity
like	I-Entity
syndrome	I-Entity
by	O
amiloride	I-Entity
in	O
rats	O
.	O

The	O
effect	O
of	O
amiloride	I-Entity
on	O
lithium	I-Entity
-	O
induced	O
polydipsia	I-Entity
and	O
polyuria	I-Entity
and	O
on	O
the	O
lithium	I-Entity
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	I-Entity
.	O

Amiloride	I-Entity
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O

6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	I-Entity
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	I-Entity
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	I-Entity
levels	O
.	O

After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	I-Entity
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O

In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	I-Entity
-	O
induced	O
diabetes	B-Entity
-	I-Entity
insipidus	I-Entity
-	I-Entity
like	I-Entity
syndrome	I-Entity
by	O
amiloride	I-Entity
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	I-Entity
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	I-Entity
level	O
.	O

It	O
is	O
concluded	O
that	O
acute	O
amiloride	I-Entity
administration	O
to	O
lithium	I-Entity
-	O
treated	O
patients	O
suffering	O
from	O
polydipsia	I-Entity
and	O
polyuria	I-Entity
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	I-Entity
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	I-Entity
levels	O
and	O
might	O
be	O
hazardous	O
.	O



Safety	O
and	O
side	O
-	O
effects	O
of	O
alprazolam	I-Entity
.	O

Controlled	O
study	O
in	O
agoraphobia	I-Entity
with	O
panic	B-Entity
disorder	I-Entity
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	I-Entity
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O

The	O
efficacy	O
of	O
alprazolam	I-Entity
and	O
placebo	O
in	O
panic	B-Entity
disorder	I-Entity
with	O
agoraphobia	I-Entity
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured	O
.	O

In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B-Entity
disorder	I-Entity
with	O
agoraphobia	I-Entity
were	O
randomised	O
to	O
alprazolam	I-Entity
or	O
placebo	O
.	O

Mean	O
alprazolam	I-Entity
dose	O
was	O
5	O
mg	O
daily	O
.	O

Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	I-Entity
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21%	O
v.	O
0%	O
)	O
of	O
depression	I-Entity
,	O
enuresis	I-Entity
,	O
disinhibition	O
and	O
aggression	I-Entity
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	O
,	O
irritability	I-Entity
,	O
impaired	B-Entity
memory	I-Entity
,	O
weight	B-Entity
loss	I-Entity
and	O
ataxia	I-Entity
.	O

Alprazolam	I-Entity
caused	O
side	O
-	O
effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O



Dup	B-Entity
753	I-Entity
prevents	O
the	O
development	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrosis	I-Entity
.	O

The	O
appearance	O
of	O
nephrotic	B-Entity
syndromes	I-Entity
such	O
as	O
proteinuria	I-Entity
,	O
hypoalbuminemia	I-Entity
,	O
hypercholesterolemia	I-Entity
and	O
increase	O
in	O
blood	B-Entity
nitrogen	I-Entity
urea	I-Entity
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	B-Entity
753	I-Entity
(	O
losartan	I-Entity
)	O
,	O
a	O
novel	O
angiotensin	B-Entity
II	I-Entity
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O

The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin	O
-	O
angiotensin	I-Entity
system	O
in	O
the	O
development	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrosis	I-Entity
.	O



Sodium	B-Entity
bicarbonate	I-Entity
alleviates	O
penile	B-Entity
pain	I-Entity
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B-Entity
dysfunction	I-Entity
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B-Entity
pain	I-Entity
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B-Entity
pain	I-Entity
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	B-Entity
bicarbonate	I-Entity
to	O
the	O
intracorporeal	O
medications	O
.	O

A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	I-Entity
received	O
0.2	O
ml	O
.	O
of	O
a	O
combination	O
of	O
3	O
drugs	O
:	O
6	O
mg	O
.	O

papaverine	I-Entity
,	O
100	O
micrograms	O
.	O

phentolamine	I-Entity
and	O
10	O
micrograms	O
.	O

prostaglandin	B-Entity
E1	I-Entity
with	O
(	O
pH	O
7.05	O
)	O
or	O
without	O
(	O
pH	O
4.17	O
)	O
the	O
addition	O
of	O
sodium	B-Entity
bicarbonate	I-Entity
(	O
0.03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patients	O
without	O
sodium	B-Entity
bicarbonate	I-Entity
added	O
to	O
the	O
medication	O
11	O
(	O
58%	O
)	O
complained	O
of	O
penile	B-Entity
pain	I-Entity
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5%	O
)	O
who	O
received	O
sodium	B-Entity
bicarbonate	I-Entity
complained	O
of	O
penile	B-Entity
pain	I-Entity
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B-Entity
pain	I-Entity
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O



Prospective	O
study	O
of	O
the	O
long	O
-	O
term	O
effects	O
of	O
somatostatin	O
analog	O
(	O
octreotide	I-Entity
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	I-Entity
formation	O
in	O
Chinese	O
acromegalic	I-Entity
patients	O
.	O

This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	I-Entity
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	O
analog	O
octreotide	I-Entity
in	O
dosages	O
of	O
300	O
-	O
1500	O
micrograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24.2	O
+	O
/-	O

During	O
treatment	O
with	O
octreotide	I-Entity
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	I-Entity
,	O
and	O
1	O
developed	O
acute	B-Entity
cholecystitis	I-Entity
requiring	O
surgery	O
.	O

In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	I-Entity
throughout	O
therapy	O
.	O

After	O
withdrawal	O
of	O
octreotide	I-Entity
in	O
10	O
patients	O
without	O
gallstones	I-Entity
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	I-Entity
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	I-Entity
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	I-Entity
,	O
and	O
cholecystitis	I-Entity
during	O
octreotide	I-Entity
therapy	O
in	O
Chinese	O
acromegalic	I-Entity
patients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long	O
-	O
term	O
octreotide	I-Entity
therapy	O
of	O
acromegalic	I-Entity
patients	O
.	O



Improvement	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
by	O
propranolol	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Seven	O
patients	O
suffering	O
from	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
with	O
severely	O
disabling	O
dyskinesia	I-Entity
received	O
low	O
-	O
dose	O
propranolol	I-Entity
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
40%	O
improvement	O
in	O
the	O
dyskinesia	I-Entity
score	O
without	O
increase	O
of	O
parkinsonian	I-Entity
motor	B-Entity
disability	I-Entity
.	O

Ballistic	O
and	O
choreic	O
dyskinesia	I-Entity
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	I-Entity
was	O
not	O
.	O

This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta	O
-	O
blockers	O
may	O
improve	O
levodopa	I-Entity
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	I-Entity
in	O
PD	I-Entity
.	O



Morphological	O
features	O
of	O
encephalopathy	I-Entity
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	I-Entity
to	O
rats	O
.	O

Long	O
-	O
term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	B-Entity
valproate	I-Entity
(	O
Vupral	O
""""	O
Polfa	O
""""	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
b.	O
w.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	B-Entity
disorders	I-Entity
indicating	O
cerebellum	B-Entity
damage	I-Entity
(	O
""""	O
valproate	I-Entity
encephalopathy	I-Entity
""""	O
)	O
.	O

Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	I-Entity
of	O
endothelial	O
cells	O
.	O

Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	I-Entity
protrusions	O
and	O
swollen	O
microvilli	O
.	O

Fragments	O
of	O
necrotic	I-Entity
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O

In	O
electron	O
micrographs	O
both	O
luminal	I-Entity
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O

The	O
possible	O
influence	O
of	O
the	O
hepatic	B-Entity
damage	I-Entity
,	O
mainly	O
hyperammonemia	I-Entity
,	O
upon	O
the	O
development	O
of	O
valproate	I-Entity
encephalopathy	I-Entity
is	O
discussed	O
.	O



Macula	O
toxicity	I-Entity
after	O
intravitreal	O
amikacin	I-Entity
.	O

Although	O
intravitreal	O
aminoglycosides	I-Entity
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	I-Entity
,	O
macular	O
infarction	I-Entity
may	O
impair	O
full	O
visual	O
recovery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	I-Entity
retinal	B-Entity
toxicity	I-Entity
following	O
treatment	O
with	O
amikacin	I-Entity
and	O
vancomycin	I-Entity
for	O
alpha	O
-	O
haemolytic	O
streptococcal	B-Entity
endophthalmitis	I-Entity
.	O

Endophthalmitis	I-Entity
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6/24	O
at	O
three	O
months	O
.	O

Fundus	O
fluorescein	I-Entity
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	I-Entity
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	B-Entity
toxicity	I-Entity
and	O
macular	O
ischaemia	I-Entity
.	O

Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	B-Entity
toxicity	I-Entity
are	O
discussed	O
.	O



Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-Entity
reentrant	I-Entity
tachycardia	I-Entity
after	O
verapamil	I-Entity
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B-Entity
-	I-Entity
Parkinson	I-Entity
-	I-Entity
White	I-Entity
syndrome	I-Entity
and	O
idiopathic	B-Entity
dilated	I-Entity
cardiomyopathy	I-Entity
.	O

In	O
a	O
patient	O
with	O
WPW	B-Entity
syndrome	I-Entity
and	O
idiopathic	B-Entity
dilated	I-Entity
cardiomyopathy	I-Entity
,	O
intractable	O
atrioventricular	B-Entity
reentrant	I-Entity
tachycardia	I-Entity
(	O
AVRT	I-Entity
)	O
was	O
iatrogenically	O
induced	O
.	O

QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	I-Entity
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	I-Entity
attack	O
.	O



Epidemic	O
of	O
liver	B-Entity
disease	I-Entity
caused	O
by	O
hydrochlorofluorocarbons	I-Entity
used	O
as	O
ozone	I-Entity
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	I-Entity
.	O

BACKGROUND	O
:	O
Hydrochlorofluorocarbons	I-Entity
(	O
HCFCs	I-Entity
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	I-Entity
-	O
depleting	O
chlorofluorocarbons	I-Entity
(	O
CFCs	I-Entity
)	O
.	O

Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	I-Entity
of	O
some	O
of	O
these	O
compounds	O
.	O

We	O
investigated	O
an	O
epidemic	O
of	O
liver	B-Entity
disease	I-Entity
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1,1-dichloro-2,2,2-trifluoroethane	I-Entity
(	O
HCFC	B-Entity
123	I-Entity
)	O
and	O
1-chloro-1,2,2,2-tetrafluoroethane	I-Entity

(	O
HCFC	B-Entity
124	I-Entity
)	O
.	O

Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1-bromo-1-chloro-2,2,2-trifluoroethane	I-Entity
(	O
halothane	I-Entity
)	O
to	O
form	O
reactive	O
trifluoroacetyl	I-Entity
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	I-Entity
of	O
halothane	I-Entity
.	O

We	O
aimed	O
to	O
test	O
whether	O
HCFCs	B-Entity
123	I-Entity
and	I-Entity
124	I-Entity
can	O
result	O
in	O
serious	O
liver	B-Entity
disease	I-Entity
.	O

METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	I-Entity
protein	O
adducts	O
were	O
done	O
.	O

The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	I-Entity
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	I-Entity
)	O
.	O

Trifluoroacetyl	I-Entity
-	O
adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O

Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B-Entity
hepatitis	I-Entity
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O

INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	B-Entity
123	I-Entity
and	I-Entity
124	I-Entity
can	O
result	O
in	O
serious	O
liver	B-Entity
injury	I-Entity
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O

Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	I-Entity
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	I-Entity
-	O
altered	O
liver	O
proteins	O
are	O
involved	O
.	O



The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B-Entity
loss	I-Entity
following	O
spinal	O
anaesthesia	O
.	O

The	O
cause	O
of	O
hearing	B-Entity
loss	I-Entity
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B-Entity
loss	I-Entity
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B-Entity
loss	I-Entity
.	O

prilocaine	I-Entity
2%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	I-Entity
0.5%	O
.	O

Patients	O
given	O
prilocaine	I-Entity
were	O
more	O
likely	O
to	O
develop	O
hearing	B-Entity
loss	I-Entity
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	I-Entity
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
average	O
hearing	B-Entity
loss	I-Entity
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	I-Entity
and	O
15	O
dB	O
after	O
bupivacaine	I-Entity
.	O

None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B-Entity
loss	I-Entity
.	O



A	O
transient	O
neurological	B-Entity
deficit	I-Entity
following	O
intrathecal	O
injection	O
of	O
1%	O
hyperbaric	O
bupivacaine	I-Entity
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O

We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	B-Entity
deficit	I-Entity
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1%	O
hyperbaric	O
bupivacaine	I-Entity
slowly	O
injected	O
through	O
a	O
25-gauge	O
pencil	O
-	O
point	O
spinal	O
needle	O
.	O

The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3-L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B-Entity
of	I-Entity
pinprick	I-Entity
sensation	I-Entity
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil	O
-	O
point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	B-Entity
deficit	I-Entity
.	O



Pethidine	I-Entity
-	O
associated	O
seizure	I-Entity
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	I-Entity
for	O
postoperative	B-Entity
pain	I-Entity
control	O
.	O

A	O
healthy	O
17-year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	I-Entity
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Entity
pain	I-Entity
control	O
.	O

postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	I-Entity
.	O

Both	O
plasma	O
pethidine	I-Entity
and	O
norpethidine	I-Entity
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	I-Entity
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	I-Entity
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	I-Entity
and	O
norpethidine	I-Entity
.	O

The	O
routine	O
use	O
of	O
pethidine	I-Entity
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	O
should	O
be	O
reconsidered	O
.	O



Drug	O
-	O
associated	O
acute	O
-	O
onset	O
vanishing	B-Entity
bile	I-Entity
duct	I-Entity
and	O
Stevens	B-Entity
-	I-Entity
Johnson	I-Entity
syndromes	I-Entity
in	O
a	O
child	O
.	O

Acute	O
vanishing	B-Entity
bile	I-Entity
duct	I-Entity
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	I-Entity
in	O
adults	O
,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O

Stevens	B-Entity
-	I-Entity
Johnson	I-Entity
syndrome	I-Entity
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	I-Entity
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	I-Entity
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O

A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	B-Entity
bile	I-Entity
duct	I-Entity
syndrome	I-Entity
shortly	O
after	O
Stevens	B-Entity
-	I-Entity
Johnson	I-Entity
syndrome	I-Entity
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	I-Entity
use	O
.	O

Despite	O
therapy	O
with	O
ursodeoxycholic	B-Entity
acid	I-Entity
,	O
prednisone	I-Entity
,	O
and	O
then	O
tacrolimus	I-Entity
,	O
her	O
cholestatic	B-Entity
disease	I-Entity
was	O
unrelenting	O
,	O
with	O
cirrhosis	I-Entity
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O

This	O
case	O
documents	O
acute	O
drug	O
-	O
related	O
vanishing	B-Entity
bile	I-Entity
duct	I-Entity
syndrome	I-Entity
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens	B-Entity
-	I-Entity
Johnson	I-Entity
syndrome	I-Entity
and	O
vanishing	B-Entity
bile	I-Entity
duct	I-Entity
syndrome	I-Entity
.	O



High	O
incidence	O
of	O
primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
associated	O
with	O
appetite	B-Entity
suppressants	I-Entity
in	O
Belgium	O
.	O

Primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	B-Entity
suppressant	I-Entity
drugs	O
.	O

The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	B-Entity
suppressants	I-Entity
.	O

Thirty	O
-	O
five	O
patients	O
with	O
primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O

Exposure	O
to	O
appetite	B-Entity
-	I-Entity
suppressants	I-Entity
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	B-Entity
suppressants	I-Entity
,	O
mainly	O
fenfluramines	I-Entity
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6%	O
,	O

Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-Entity
suppressants	I-Entity
.	O

In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	B-Entity
suppressants	I-Entity
.	O

The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	B-Entity
suppressants	I-Entity
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O

A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	B-Entity
suppressants	I-Entity
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
.	O

Intake	O
of	O
appetite	B-Entity
suppressants	I-Entity
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	O
.	O



Choreoathetoid	B-Entity
movements	I-Entity
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	I-Entity
.	O

Choreatiform	B-Entity
hyperkinesias	I-Entity
are	O
known	O
to	O
be	O
occasional	O
movement	B-Entity
abnormalities	I-Entity
during	O
intoxications	O
with	O
cocaine	I-Entity
but	O
not	O
opiates	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	B-Entity
movements	I-Entity
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu	O
-	O
opioid	O
receptor	O
agonist	O
methadone	I-Entity
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	I-Entity
and	O
cocaine	I-Entity
.	O



Cocaine	I-Entity
-	O
induced	O
mood	B-Entity
disorder	I-Entity
:	O
prevalence	O
rates	O
and	O
psychiatric	I-Entity
symptoms	O
in	O
an	O
outpatient	O
cocaine	I-Entity
-	O
dependent	O
sample	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance	O
-	O
induced	O
and	O
other	O
mood	B-Entity
disorders	I-Entity
.	O

243	O
cocaine	I-Entity
-	O
dependent	O
outpatients	O
with	O
cocaine	I-Entity
-	O
induced	O
mood	B-Entity
disorder	I-Entity
(	O
CIMD	I-Entity
)	O
,	O
other	O
mood	B-Entity
disorders	I-Entity
,	O
or	O
no	O
mood	B-Entity
disorder	I-Entity
were	O
compared	O
on	O
measures	O
of	O
psychiatric	I-Entity
symptoms	O
.	O

The	O
prevalence	O
rate	O
for	O
CIMD	I-Entity
was	O
12%	O
at	O
baseline	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	I-Entity
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B-Entity
disorders	I-Entity
.	O

Patients	O
with	O
CIMD	I-Entity
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	B-Entity
disorder	I-Entity
.	O

These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	I-Entity
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O



Hemolysis	I-Entity
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	I-Entity
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	I-Entity
(	O
TAM	I-Entity
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B-Entity
cancer	I-Entity
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Entity
anemia	I-Entity
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	I-Entity
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	I-Entity
induces	O
hemolysis	I-Entity
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O

The	O
extension	O
of	O
hemolysis	I-Entity
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12.5	O
microM	O
TAM	I-Entity
induces	O
total	O
hemolysis	I-Entity
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	I-Entity
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O

The	O
hemolytic	I-Entity
effect	O
of	O
TAM	I-Entity
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	B-Entity
-	I-Entity
tocopherol	I-Entity
(	O
alpha	B-Entity
-	I-Entity
T	I-Entity
)	O
and	O
alpha	B-Entity
-	I-Entity
tocopherol	I-Entity
acetate	I-Entity
(	O
alpha	B-Entity
-	I-Entity
TAc	I-Entity
)	O
(	O
inactivated	O
functional	O
hydroxyl	I-Entity
)	O
indicating	O
that	O
TAM	I-Entity
-	O
induced	O
hemolysis	I-Entity
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	I-Entity
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	I-Entity
-	O
induced	O
hemolysis	I-Entity
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	I-Entity
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	I-Entity
,	O
thus	O
ruling	O
out	O
TAM	I-Entity
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Hemolysis	I-Entity
caused	O
by	O
TAM	I-Entity
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K(+	I-Entity
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	I-Entity
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

However	O
,	O
TAM	I-Entity
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha	B-Entity
-	I-Entity
T	I-Entity
or	O
alpha	B-Entity
-	I-Entity
TAc	I-Entity
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	I-Entity
partition	O
into	O
model	O
membranes	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	I-Entity
by	O
tocopherols	I-Entity
is	O
related	O
to	O
a	O
decreased	O
TAM	I-Entity
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	I-Entity
-	O
induced	O
hemolysis	I-Entity
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	I-Entity
,	O
resulting	O
in	O
hemolytic	B-Entity
anemia	I-Entity
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	I-Entity
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O



Changes	O
of	O
sodium	I-Entity
and	O
ATP	I-Entity
affinities	O
of	O
the	O
cardiac	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
during	O
and	O
after	O
nitric	B-Entity
oxide	I-Entity
deficient	O
hypertension	I-Entity
.	O

In	O
the	O
cardiovascular	O
system	O
,	O
NO	I-Entity
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	O
of	O
NO	I-Entity
synthesis	O
induces	O
sustained	O
hypertension	I-Entity
.	O

In	O
several	O
models	O
of	O
hypertension	I-Entity
,	O
elevation	O
of	O
intracellular	O
sodium	I-Entity
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na+	I-Entity
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
to	O
NO	I-Entity
-	O
deficient	O
hypertension	I-Entity
induced	O
in	O
rats	O
by	O
NO	I-Entity
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O

N(G)-nitro	B-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
methyl	I-Entity
ester	I-Entity
(	O
L	B-Entity
-	I-Entity
NAME	I-Entity
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4-week	O
administration	O
of	O
L	B-Entity
-	I-Entity
NAME	I-Entity
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36%	O
.	O

When	O
activating	O
the	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
with	O
its	O
substrate	O
ATP	I-Entity
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	I-Entity
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na+	I-Entity
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K(Na	I-Entity
)	O
increased	O
by	O
50%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na+-binding	I-Entity
site	O
in	O
NO	I-Entity
-	O
deficient	O
rats	O
.	O

After	O
recovery	O
from	O
hypertension	I-Entity
,	O
the	O
activity	O
of	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	I-Entity
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	I-Entity
.	O

The	O
K(Na	I-Entity
)	O
value	O
for	O
Na+	I-Entity
returned	O
to	O
control	O
value	O
.	O

Inhibition	O
of	O
NO	I-Entity
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	I-Entity
accompanied	O
by	O
depressed	I-Entity
Na+-extrusion	I-Entity
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na+-binding	I-Entity
properties	O
of	O
the	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na+	I-Entity
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	I-Entity
,	O
K)-ATPase	I-Entity
activity	O
.	O



Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	I-Entity
on	O
bromocriptine	I-Entity
-	O
induced	O
tachycardia	I-Entity
in	O
conscious	O
rats	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	I-Entity
-	O
induced	O
tachycardia	I-Entity
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	I-Entity
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5-day	O
isoproterenol	I-Entity
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	I-Entity
could	O
abolish	O
bromocriptine	I-Entity
-	O
induced	O
tachycardia	I-Entity
in	O
conscious	O
rats	O
.	O

Isoproterenol	I-Entity
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B-Entity
hypertrophy	I-Entity
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	I-Entity
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	I-Entity
and	O
tachycardia	I-Entity
.	O

Bromocriptine	I-Entity
-	O
induced	O
hypotension	I-Entity
was	O
unaffected	O
by	O
isoproterenol	I-Entity
pretreatment	O
,	O
while	O
tachycardia	I-Entity
was	O
reversed	O
to	O
significant	O
bradycardia	I-Entity
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i.v	O
.	O

domperidone	I-Entity
(	O
0.5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	I-Entity
pretreatment	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	I-Entity
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	I-Entity
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	I-Entity
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22-fold	O
)	O
.	O

These	O
results	O
show	O
that	O
15-day	O
isoproterenol	I-Entity
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	I-Entity
-	O
induced	O
tachycardia	I-Entity
to	O
bradycardia	I-Entity
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	I-Entity
of	O
bromocriptine	I-Entity
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	I-Entity
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	I-Entity
D2	O
receptors	O
.	O



A	O
developmental	O
analysis	O
of	O
clonidine	I-Entity
's	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O

adrenoceptor	O
agonist	O
,	O
clonidine	I-Entity
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	I-Entity
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	I-Entity
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	I-Entity
,	O
we	O
hypothesized	O
that	O
clonidine	I-Entity
's	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	I-Entity
administration	O
(	O
0.5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2-	O
,	O
8-	O
,	O
15-	O
,	O
and	O
20-day	O
-	O
old	O
rats	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	I-Entity
-	O
induced	O
bradycardia	I-Entity
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	I-Entity
's	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O



Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	I-Entity
and	O
lidocaine	I-Entity
on	O
dynamic	O
and	O
static	O
hyperalgesia	I-Entity
induced	O
by	O
intradermal	O
capsaicin	I-Entity
in	O
humans	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	I-Entity
and	O
lidocaine	I-Entity
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	I-Entity
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O

hyperalgesia	I-Entity
induced	O
by	O
capsaicin	I-Entity
.	O

Capsaicin	I-Entity
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i.v	O
.	O

infusion	O
of	O
ketamine	I-Entity
(	O
bolus	O
0.1	O
mg	O
kg-1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg-1	O

min-1	O
)	O
,	O
lidocaine	I-Entity
5	O
mg	O
kg-1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	I-Entity
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	I-Entity
,	O
pain	I-Entity
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	I-Entity
.	O

Ketamine	I-Entity
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O

hyperalgesia	I-Entity
significantly	O

and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	I-Entity
.	O

Lidocaine	I-Entity
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	I-Entity
significantly	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	I-Entity
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	I-Entity
.	O

The	O
differential	O
effects	O
of	O
ketamine	I-Entity
and	O
lidocaine	I-Entity
on	O
static	O
and	O
dynamic	O
hyperalgesia	I-Entity
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	I-Entity
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O



Cyclosporine	I-Entity
and	O
tacrolimus	I-Entity
-	O
associated	O
thrombotic	B-Entity
microangiopathy	I-Entity
.	O

The	O
development	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
(	O
TMA	I-Entity
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	I-Entity
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	I-Entity
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	I-Entity
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	I-Entity
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	I-Entity
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	I-Entity
-	O
induced	O
TMA	I-Entity
.	O

With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	I-Entity
in	O
organ	O
transplantation	O
,	O
tacrolimus	I-Entity
-	O
associated	O
TMA	I-Entity
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	I-Entity
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	I-Entity
and	O
tacrolimus	I-Entity
is	O
limited	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	I-Entity
-	O
induced	O
TMA	I-Entity
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	I-Entity
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	O
of	O
tacrolimus	I-Entity
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	I-Entity
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	I-Entity
to	O
tacrolimus	I-Entity
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	I-Entity
.	O



Repeated	O
transient	O
anuria	I-Entity
following	O
losartan	I-Entity
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70-year	O
-	O
old	O
hypertensive	I-Entity
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	B-Entity
renal	I-Entity
insufficiency	I-Entity
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	I-Entity
after	O
losartan	I-Entity
administration	O
.	O

He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B-Entity
infarction	I-Entity
with	O
pulmonary	B-Entity
edema	I-Entity
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

Due	O
to	O
severe	O
systolic	B-Entity
dysfunction	I-Entity
losartan	I-Entity
was	O
prescribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	I-Entity
resulted	O
in	O
a	O
sudden	O
anuria	I-Entity
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	I-Entity
and	O
amine	I-Entity
infusion	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	I-Entity
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	I-Entity
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	I-Entity
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80%	O
renal	B-Entity
artery	I-Entity
stenosis	I-Entity
.	O

In	O
this	O
patient	O
,	O
renal	B-Entity
artery	I-Entity
stenosis	I-Entity
combined	O
with	O
heart	B-Entity
failure	I-Entity
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	I-Entity
system	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	B-Entity
II	I-Entity
receptor	O
blockade	O
by	O
losartan	I-Entity
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Entity
II	I-Entity
receptor	O
antagonist	O
losartan	I-Entity
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B-Entity
disease	I-Entity
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O



In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	I-Entity
cell	O
deaths	O
during	O
acetaminophen	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
,	O
amiodarone	I-Entity
-	O
induced	O
lung	B-Entity
toxicity	I-Entity
and	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
by	O
a	O
novel	O
IH636	B-Entity
grape	I-Entity
seed	I-Entity
proanthocyanidin	I-Entity
extract	I-Entity
.	O

Grape	B-Entity
seed	I-Entity
extract	I-Entity
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	I-Entity
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	B-Entity
grape	I-Entity
seed	I-Entity
proanthocyanidin	I-Entity
extract	I-Entity
(	O
GSPE	I-Entity
)	O
to	O
prevent	O
acetaminophen	I-Entity
(	O
AAP)-induced	I-Entity
nephrotoxicity	I-Entity
,	O
amiodarone	I-Entity
(	O
AMI)-induced	I-Entity
lung	B-Entity
toxicity	I-Entity
,	O
and	O
doxorubicin	I-Entity

(	O
DOX)-induced	I-Entity
cardiotoxicity	I-Entity
in	O
mice	O
.	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	I-Entity
alone	O
,	O
drug	O
alone	O
and	O
GSPE+drug	I-Entity
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	I-Entity
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i.p	O
.	O

injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	I-Entity
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	I-Entity
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O

DOX	I-Entity
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Results	O
indicate	O
that	O
GSPE	I-Entity
preexposure	O
prior	O
to	O
AAP	I-Entity
,	O
AMI	I-Entity
and	O
DOX	I-Entity
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	B-Entity
damage	I-Entity
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	I-Entity
preexposure	O
than	O
in	O
its	O
presence	O
.	O

GSPE+drug	I-Entity
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	I-Entity
,	O
AMI	I-Entity
and	O
DOX	I-Entity
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	I-Entity
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	I-Entity
.	O

Since	O
AAP	I-Entity
,	O
AMI	I-Entity
and	O
DOX	I-Entity
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	I-Entity
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and/or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	I-Entity
-	O
induced	O
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	I-Entity
's	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O



Palpebral	B-Entity
twitching	I-Entity
in	O
a	O
depressed	I-Entity
adolescent	O
on	O
citalopram	I-Entity
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0.4%	O
and	O
8.3%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-Entity
depression	I-Entity
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	I-Entity
by	O
a	O
15-year	O
-	O
old	O
boy	O
with	O
major	B-Entity
depression	I-Entity
who	O
exhibited	O
palpebral	B-Entity
twitching	I-Entity
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	I-Entity
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O



Metamizol	I-Entity
potentiates	O
morphine	I-Entity
antinociception	O
but	O
not	O
constipation	I-Entity
after	O
chronic	O
treatment	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	I-Entity
effects	O
of	O
the	O
combination	O
of	O
3.2	O
mg	O
/	O
kg	O
s.c	O
.	O

morphine	I-Entity
with	O
177.8	O
mg	O

metamizol	I-Entity
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	I-Entity
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	I-Entity
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	O
administration	O
of	O
morphine	I-Entity
with	O
metamizol	I-Entity
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298+/-7	O
vs.	O
139+/-36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P<0.001	O
)	O
and	O
repeated	O
administration	O
(	O
280+/-17	O
vs.	O
131+/-22	O

Antinociceptive	O
effect	O
of	O
morphine	I-Entity
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39+/-10	O
vs.	O
18+/-5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298+/-7	O
vs.	O
280+/-17	O
au	O
)	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3.2	O
mg	O
/	O
kg	O
naloxone	I-Entity
s.c	O
.	O

In	O
independent	O
groups	O
,	O
morphine	I-Entity
inhibited	O
the	O
intestinal	O
transit	O
in	O
48+/-4%	O
and	O
38+/-4%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	I-Entity
effects	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	I-Entity
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	I-Entity
did	O
not	O
potentiate	O
morphine	I-Entity
-	O
induced	O
constipation	I-Entity
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	I-Entity
and	O
metamizol	I-Entity
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B-Entity
pain	I-Entity
.	O



Ifosfamide	I-Entity
encephalopathy	I-Entity
presenting	O
with	O
asterixis	I-Entity
.	O

CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	I-Entity
(	O
IFX	I-Entity
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51-year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	I-Entity
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	I-Entity
for	O
plasmacytoma	I-Entity
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	B-Entity
lesions	I-Entity
of	I-Entity
the	I-Entity
brain	I-Entity
and	O
metabolic	B-Entity
abnormalities	I-Entity
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	I-Entity
.	O

The	O
administration	O
of	O
ifosfamide	I-Entity
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	I-Entity
resolved	O
completely	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	I-Entity
during	O
infusion	O
of	O
ifosfamide	I-Entity
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	I-Entity
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	I-Entity
.	O



Sub	O
-	O
chronic	O
low	O
dose	O
gamma	B-Entity
-	I-Entity
vinyl	I-Entity
GABA	I-Entity
(	O
vigabatrin	I-Entity
)	O
inhibits	O
cocaine	I-Entity
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	I-Entity
.	O

RATIONALE	O
:	O
gamma	B-Entity
-	I-Entity
Vinyl	I-Entity
GABA	I-Entity
(	O
GVG	I-Entity
)	O
irreversibly	O
inhibits	O
GABA	I-Entity
-	O
transaminase	O
.	O

This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	I-Entity
catabolism	O
.	O

Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	B-Entity
abuse	I-Entity
and	O
the	O
increased	O
risk	O
of	O
visual	B-Entity
field	I-Entity
defects	I-Entity
(	O
VFD	I-Entity
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	I-Entity
on	O
cocaine	I-Entity
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
.	O

Sub	O
-	O
chronic	O
GVG	I-Entity
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	I-Entity
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	I-Entity
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	I-Entity
-	O
induced	O
increases	O
in	O
dopamine	I-Entity
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O



Amount	O
of	O
bleeding	I-Entity
and	O
hematoma	I-Entity
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	B-Entity
hemorrhage	I-Entity
rat	O
model	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	B-Entity
hemorrhage	I-Entity
(	O
ICH	I-Entity
)	O
with	O
drugs	O
used	O
for	O
stroke	I-Entity
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	I-Entity
model	O
for	O
detection	O
of	O
ICH	I-Entity
deterioration	O
.	O

In	O
ICH	I-Entity
intrastriatally	O
induced	O
by	O
0.014-unit	O
,	O
0.070-unit	O
,	O
and	O
0.350-unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	I-Entity
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	I-Entity
volume	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	I-Entity
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	I-Entity
induced	O
by	O
0.014-unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	I-Entity
deterioration	O
.	O

In	O
ICH	I-Entity
induction	O
using	O
0.014-unit	O
collagenase	O
,	O
heparin	I-Entity
enhanced	O
the	O
hematoma	I-Entity
volume	O
3.4-fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	I-Entity
animals	O
and	O
the	O
bleeding	I-Entity
7.6-fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	I-Entity
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	I-Entity
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	I-Entity
.	O



Estradiol	I-Entity
reduces	O
seizure	I-Entity
-	O
induced	O
hippocampal	B-Entity
injury	I-Entity
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	B-Entity
injury	I-Entity
induced	O
by	O
kainic	B-Entity
acid	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
(	O
SE	I-Entity
)	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	B-Entity
-	I-Entity
estradiol	I-Entity
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	I-Entity
-	O
pilocarpine	I-Entity
-	O
induced	O
SE	I-Entity
.	O

Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta	B-Entity
-	I-Entity
estradiol	I-Entity
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O

SE	I-Entity
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silver	I-Entity
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	I-Entity
.	O

17beta	B-Entity
-	I-Entity
Estradiol	I-Entity
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O

17beta	B-Entity
-	I-Entity
Estradiol	I-Entity
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3-C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O

In	O
males	O
,	O
estradiol	I-Entity
increased	O
the	O
total	O
damage	O
score	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	I-Entity
on	O
seizure	I-Entity
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O



Delirium	I-Entity
during	O
clozapine	I-Entity
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O

Incidence	O
and	O
risk	O
factors	O
for	O
delirium	I-Entity
during	O
clozapine	I-Entity
treatment	O
require	O
further	O
clarification	O
.	O

We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	I-Entity
inpatients	O
treated	O
with	O
clozapine	I-Entity
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	I-Entity
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

23.3	O
days	O
,	O
and	O
given	O
clozapine	I-Entity
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/-	O

Delirium	I-Entity
was	O
diagnosed	O
in	O
14	O
(	O
10.1	O
%	O
incidence	O
,	O
or	O
1.48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71.4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17.5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	I-Entity
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

Delirium	I-Entity
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	I-Entity
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

Delirium	I-Entity
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O



Ketoconazole	I-Entity
-	O
induced	O
neurologic	B-Entity
sequelae	I-Entity
.	O

A	O
77-y	O
-	O
old	O
patient	O
developed	O
weakness	B-Entity
of	I-Entity
extremities	I-Entity
,	O
legs	B-Entity
paralysis	I-Entity
,	O
dysarthria	I-Entity
and	O
tremor	I-Entity
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	I-Entity
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

All	O
complaints	O
faded	O
away	O
within	O
24	O
h.	O
Few	O
days	O
later	O
,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	I-Entity
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O

This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	B-Entity
drug	I-Entity
reactions	I-Entity
,	O
particularly	O
in	O
the	O
elderly	O
.	O



Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
--	O
an	O
experimental	O
model	O
for	O
vascular	B-Entity
dysfunctions	I-Entity
in	O
cluster	B-Entity
headache	I-Entity
.	O

Cluster	B-Entity
headache	I-Entity
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	B-Entity
vascular	I-Entity
disturbances	I-Entity
.	O

Capsaicin	I-Entity
(	O
0.01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	B-Entity
in	I-Entity
dural	I-Entity
and	I-Entity
cortical	I-Entity
blood	I-Entity
flow	I-Entity
and	O
provoked	O
lacrimation	O
.	O

These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre	O
-	O
administration	O
of	O
hexamethonium	B-Entity
chloride	I-Entity
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
evoked	O
increases	B-Entity
in	I-Entity
dural	I-Entity
blood	I-Entity
flow	I-Entity
were	O
also	O
abolished	O
by	O
topical	O
pre	O
-	O
administration	O
of	O
atropine	I-Entity
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2,5	O
,	O
Arg3,4	O
,	O
Tyr6]-VIP	O
(	O
0.1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O

The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	I-Entity
and	O
VIP	O
within	O
the	O
meninges	O
.	O

Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	B-Entity
headache	I-Entity
.	O



Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O

Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	I-Entity
injection	O
causes	O
status	B-Entity
epilepticus	I-Entity
(	O
SE	I-Entity
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	I-Entity
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL/6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	I-Entity
-	O
treated	O
and	O
untreated	O
mice	O
.	O

In	O
Mg(2+)-free	I-Entity
bathing	O
medium	O
containing	O
bicuculline	I-Entity
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	I-Entity
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	I-Entity
.	O

In	O
SE	I-Entity
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	I-Entity
receptor	O
antagonists	O
.	O

Focal	O
glutamate	I-Entity
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	I-Entity
survivors	O
but	O
not	O
other	O
groups	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	I-Entity
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	I-Entity
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O



The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	I-Entity
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
hypolocomotion	I-Entity
in	O
mice	O
.	O

Binding	O
of	O
nicotine	I-Entity
to	O
nicotinic	O
acetylcholine	I-Entity
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	I-Entity
,	O
to	O
seizures	I-Entity
and	O
death	I-Entity
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
hypolocomotion	I-Entity
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-/-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/-	O

mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	I-Entity
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

mice	O
were	O
partially	O
resistant	O
to	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
when	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
hypolocomotion	I-Entity
.	O



Recurrent	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
induced	O
by	O
azithromycin	I-Entity
.	O

A	O
14-year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	I-Entity
-	O
induced	O
,	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
.	O

Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B-Entity
injury	I-Entity
.	O



Valproate	I-Entity
-	O
induced	O
encephalopathy	I-Entity
.	O

Valproate	I-Entity
-	O
induced	O
encephalopathy	I-Entity
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	I-Entity
individuals	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	I-Entity
.	O

A	O
case	O
of	O
valproate	I-Entity
-	O
induced	O
encephalopathy	I-Entity
is	O
presented	O
.	O



Nitro	B-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
methyl	I-Entity
ester	I-Entity
:	O
a	O
potential	O
protector	O
against	O
gentamicin	I-Entity
ototoxicity	I-Entity
.	O

The	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
inhibitor	O
nitro	B-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
methyl	I-Entity
ester	I-Entity
(	O
L	B-Entity
-	I-Entity
NAME	I-Entity
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high	B-Entity
-	I-Entity
frequency	I-Entity
hearing	I-Entity
loss	I-Entity
caused	O
by	O
gentamicin	I-Entity
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O

Aminoglycoside	I-Entity
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O

Their	O
ototoxicity	I-Entity
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	I-Entity
mechanism	O
involves	O
the	O
production	O
of	O
NO	I-Entity
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	I-Entity
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	I-Entity
-	O
induced	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
.	O

In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	I-Entity
instilled	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoprotectant	O
L	B-Entity
-	I-Entity
NAME	I-Entity
was	O
administered	O
topically	O
to	O
12/27	O
animals	O
.	O

Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B-Entity
loss	I-Entity
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O

L	B-Entity
-	I-Entity
NAME	I-Entity
reduced	O
gentamicin	I-Entity
-	O
induced	O
hearing	B-Entity
loss	I-Entity
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O



Cerebral	B-Entity
vasculitis	I-Entity
following	O
oral	O
methylphenidate	I-Entity
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O

Methylphenidate	I-Entity
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	I-Entity
.	O

Cerebral	B-Entity
vasculitis	I-Entity
associated	O
with	O
amphetamine	B-Entity
abuse	I-Entity
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	B-Entity
stroke	I-Entity
has	O
been	O
reported	O
after	O
methylphenidate	I-Entity
intake	O
in	O
children	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
63-year	O
-	O
old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	I-Entity
due	O
to	O
hyperactivity	I-Entity
and	O
suffered	O
from	O
multiple	O
ischaemic	B-Entity
strokes	I-Entity
.	O

We	O
consider	O
drug	O
-	O
induced	O
cerebral	B-Entity
vasculitis	I-Entity
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	B-Entity
strokes	I-Entity
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylphenidate	I-Entity
mediated	O
vasculitis	I-Entity
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	I-Entity
therapy	O
.	O

This	O
potential	O
side	O
-	O
effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	I-Entity
.	O



Cerebral	B-Entity
haemorrhage	I-Entity
induced	O
by	O
warfarin	I-Entity
-	O
the	O
influence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin	I-Entity
-	O
induced	O
cerebral	B-Entity
haemorrhages	I-Entity
due	O
to	O
warfarin	I-Entity
and	O
warfarin	I-Entity
-	O
drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
tland	O
,	O
Sweden	O
.	O

All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B-Entity
haemorrhage	I-Entity
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000	O
-	O
2002	O
were	O
identified	O
.	O

Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	I-Entity
and	O
warfarin	I-Entity
-	O
drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B-Entity
haemorrhage	I-Entity
.	O

Among	O
593	O
patients	O
with	O
cerebral	B-Entity
haemorrhage	I-Entity
,	O
59	O
(	O
10%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	I-Entity
treatment	O
.	O

Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25%	O
)	O
among	O
the	O
non	O
-	O
warfarin	I-Entity
patients	O
(	O
p	O
<	O
0.01	O
)	O
.	O

A	O
warfarin	I-Entity
-	O
drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	I-Entity
in	O
24	O
(	O
41%	O
)	O
of	O
the	O
warfarin	I-Entity
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12%	O
)	O
the	O
bleeding	I-Entity
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

Warfarin	I-Entity
-	O
induced	O
cerebral	B-Entity
haemorrhages	I-Entity
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	I-Entity
-	O
drug	O
interaction	O
.	O

A	O
significant	O
proportion	O
of	O
warfarin	I-Entity
-	O
related	O
cerebral	B-Entity
haemorrhages	I-Entity
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	I-Entity
.	O



Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	I-Entity
and	O
gentamicin	I-Entity
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
.	O

To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	I-Entity
and	O
gentamicin	I-Entity
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	I-Entity
surgery	O
.	O

A	O
double	O
-	O
blind	O
double	O
-	O
armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub	O
-	O
Tenon	O
's	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	I-Entity
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg/0.5	O
mL	O
of	O
methylprednisolone	I-Entity
and	O
10	O
mg/0.5	O
mL	O
of	O
gentamicin	I-Entity
injected	O
into	O
the	O
posterior	O
sub	O

Postoperatively	O
,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B-Entity
,	I-Entity
vomiting	I-Entity
,	O
and	O
headache	I-Entity
.	O

Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	B-Entity
emetic	I-Entity
symptoms	I-Entity
,	O
headache	I-Entity
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O

The	O
administration	O
of	O
methylprednisolone	I-Entity
and	O
gentamicin	I-Entity
in	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B-Entity
,	I-Entity
vomiting	I-Entity
,	O
and	O
headache	I-Entity
.	O



Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	I-Entity
in	O
patients	O
with	O
chronic	B-Entity
kidney	I-Entity
disease	I-Entity
.	O

No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	B-Entity
medium	I-Entity
iopamidol	I-Entity
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	B-Entity
medium	I-Entity
iodixanol	I-Entity
in	O
high	O
-	O
risk	O
patients	O
.	O

The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
comparison	O
of	O
iopamidol	I-Entity
and	O
iodixanol	I-Entity
in	O
patients	O
with	O
chronic	B-Entity
kidney	I-Entity
disease	I-Entity
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O

Serum	O
creatinine	I-Entity
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Entity
mellitus	I-Entity
,	O
use	O
of	O
N	B-Entity
-	I-Entity
acetylcysteine	I-Entity
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

>	O
or	O
=	O
0.5	O
mg	O
/	O
dL	O
occurred	O
in	O
4.4%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	I-Entity
and	O
6.7%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	I-Entity
(	O
P=0.39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25%	O
were	O
9.8%	O
and	O
12.4%	O
,	O
respectively	O
(	O
P=0.44	O
)	O
.	O

In	O
patients	O
with	O
diabetes	I-Entity
,	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg	O
/	O
dL	O
were	O
5.1%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	I-Entity
and	O
13.0%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	I-Entity
(	O
P=0.11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25%	O
were	O
10.3%	O
and	O
15.2%	O
,	O
respectively	O
(	O
P=0.37	O
)	O
.	O

Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	I-Entity
(	O
all	O
patients	O
:	O
0.07	O
versus	O
0.12	O
mg	O
/	O
dL	O
,	O
6.2	O
versus	O
10.6	O
micromol	O
/	O
L	O
,	O
P=0.03	O
;	O
patients	O
with	O
diabetes	I-Entity
:	O
0.07	O
versus	O
0.16	O
mg	O
/	O
dL	O
,	O
6.2	O
versus	O
14.1	O
micromol	O
/	O
L	O
,	O
P=0.01	O
)	O
.	O

The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	I-Entity
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	I-Entity
or	O
iodixanol	I-Entity
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-Entity
mellitus	I-Entity
.	O



A	O
novel	O
compound	O
,	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
,	O
attenuates	O
cognitive	B-Entity
deficits	I-Entity
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	I-Entity
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
by	O
the	O
esterification	O
of	O
maltol	I-Entity
and	O
p	B-Entity
-	I-Entity
coumaric	I-Entity
acid	I-Entity
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
could	O
improve	O
cognitive	B-Entity
decline	I-Entity
in	O
scopolamine	I-Entity
-	O
injected	O
rats	O
and	O
in	O
amyloid	B-Entity
beta	I-Entity
peptide(1	I-Entity
-	I-Entity
42)-infused	I-Entity
rats	O
.	O

Maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
was	O
found	O
to	O
attenuate	O
cognitive	B-Entity
deficits	I-Entity
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-Entity
beta	I-Entity
peptide(1	I-Entity
-	I-Entity
42)-infused	I-Entity
rats	O
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
,	O
before	O
exposed	O
to	O
amyloid	B-Entity
beta	I-Entity
peptide(1	I-Entity
-	I-Entity
42	I-Entity
)	I-Entity
,	O
glutamate	I-Entity
or	O
H2O2	I-Entity
.	O

We	O
found	O
that	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	O
3	O
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-Entity
p	I-Entity
-	I-Entity
coumarate	I-Entity
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Entity
death	I-Entity
and	O
progressive	O
decline	B-Entity
of	I-Entity
cognitive	I-Entity
function	I-Entity
.	O



Interaction	O
between	O
warfarin	I-Entity
and	O
levofloxacin	I-Entity
:	O
case	O
series	O
.	O

Warfarin	I-Entity
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

Levofloxacin	I-Entity
,	O
a	O
fluoroquinolone	I-Entity
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	O
.	O

While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	I-Entity
and	O
levofloxacin	I-Entity
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	I-Entity
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	I-Entity
.	O

We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	I-Entity
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	I-Entity
and	O
levofloxacin	I-Entity
.	O

Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	I-Entity
to	O
patients	O
taking	O
warfarin	I-Entity
.	O



Mutations	O
associated	O
with	O
lamivudine	I-Entity
-	O
resistance	O
in	O
therapy	O
-	O
na	I-Entity
ve	O
hepatitis	B-Entity
B	I-Entity
virus	I-Entity
(	I-Entity
HBV	I-Entity
)	I-Entity
infected	I-Entity
patients	O
with	O
and	O
without	O
HIV	B-Entity
co	I-Entity
-	I-Entity
infection	I-Entity
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Entity
and	I-Entity
HIV	I-Entity
co	I-Entity
-	I-Entity
infected	I-Entity
South	O
African	O
patients	O
.	O

This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	I-Entity
-	O
resistant	O
hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	I-Entity
-	O
na	I-Entity
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
(	I-Entity
HIV	I-Entity
)	I-Entity
co	I-Entity
-	I-Entity
infection	I-Entity
in	O
South	O
African	O
patients	O
.	O

Thirty	O
-	O
five	O
lamivudine	I-Entity
-	O
na	I-Entity

ve	O
HBV	B-Entity
infected	I-Entity
patients	O
with	O
or	O
without	O
HIV	B-Entity
co	I-Entity
-	I-Entity
infection	I-Entity
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-Entity
mono	I-Entity
-	I-Entity
infected	I-Entity
patients	O
and	O
20	O
HBV	B-Entity
-	I-Entity
HIV	I-Entity
co	I-Entity
-	I-Entity
infected	I-Entity
patients	O
.	O

The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	I-Entity
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg-	I-Entity
positive	O
)	O
patients	O
.	O

HBsAg	I-Entity
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	O
1/2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	I-Entity
-	O
methionine	I-Entity
-	O
aspartate	I-Entity
-	O
aspartate	I-Entity
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O

HBV	O
lamivudine	I-Entity
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-Entity
B	I-Entity
patients	O
and	O
10	O
of	O
20	O
HBV	B-Entity
-	I-Entity
HIV	I-Entity
co	I-Entity
-	I-Entity
infected	I-Entity
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	I-Entity
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	I-Entity
ve	O
HBV	B-Entity
-	I-Entity
HIV	I-Entity
co	I-Entity
-	I-Entity
infected	I-Entity
patients	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	I-Entity
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-Entity
-	I-Entity
HIV	I-Entity
co	I-Entity
-	I-Entity
infected	I-Entity
patients	O
.	O



Sex	O
differences	O
in	O
NMDA	I-Entity
antagonist	O
enhancement	O
of	O
morphine	I-Entity
antihyperalgesia	O
in	O
a	O
capsaicin	I-Entity
model	O
of	O
persistent	O
pain	I-Entity
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-Entity
pain	I-Entity
.	O

In	O
acute	B-Entity
pain	I-Entity
models	O
,	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	I-Entity
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	I-Entity
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B-Entity
pain	I-Entity
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O

To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	I-Entity
was	O
induced	O
by	O
administration	O
of	O
capsaicin	I-Entity
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail	O
-	O
withdrawal	O
latencies	O
measured	O
.	O

For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B-Entity
pain	I-Entity
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail	O
-	O
withdrawal	O
procedures	O
.	O

In	O
males	O
,	O
the	O
non	O
-	O
competitive	O
NMDA	I-Entity
antagonist	O
dextromethorphan	I-Entity
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	I-Entity
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Enhancement	O
of	O
morphine	I-Entity
antinociception	O
by	O
dextromethorphan	I-Entity
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B-Entity
pain	I-Entity
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O

These	O
findings	O
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	O
between	O
NMDA	I-Entity
antagonists	O
and	O
morphine	I-Entity
in	O
a	O
persistent	O
pain	I-Entity
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-Entity
pain	I-Entity
models	O
.	O



Development	O
of	O
proteinuria	I-Entity
after	O
switch	O
to	O
sirolimus	I-Entity
-	O
based	O
immunosuppression	O
in	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
.	O

Calcineurin	O
-	O
inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	B-Entity
dysfunction	I-Entity
in	O
heart	O
transplantation	O
patients	O
.	O

The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	O
sirolmus	I-Entity
(	O
Srl	I-Entity
)	O
lacks	O
nephrotoxic	I-Entity
effects	O
;	O
however	O
,	O
proteinuria	I-Entity
associated	O
with	O
Srl	I-Entity
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O

In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	I-Entity
associated	O
with	O
Srl	I-Entity
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	I-Entity
to	O
Srl	I-Entity
-	O
based	O
IS	O
.	O

Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	B-Entity
mofetil	I-Entity

steroids	I-Entity
.	O

Before	O
the	O
switch	O
,	O
11.5%	O
of	O
patients	O
had	O
high	O
-	O
grade	O
proteinuria	I-Entity
(	O
>	O
1.0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	O
to	O
22.9%	O
postswitch	O
(	O
p	O
=	O
0.006	O
)	O
.	O

ACE	B-Entity
inhibitor	I-Entity
and	O
angiotensin	B-Entity
-	I-Entity
releasing	I-Entity
blocker	I-Entity
(	O
ARB	I-Entity
)	O
therapy	O
reduced	O
proteinuria	I-Entity
development	O
.	O

Patients	O
without	O
proteinuria	I-Entity
had	O
increased	O
renal	O
function	O
(	O
median	O
42.5	O
vs.	O
64.1	O
,	O
p	O
=	O
0.25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high	O
-	O
grade	O
proteinuria	I-Entity
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
median	O
39.6	O
vs.	O
29.2	O
,	O
p	O
=	O
0.125	O
)	O
.	O

Thus	O
,	O
proteinuria	I-Entity
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	I-Entity
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O

Srl	I-Entity
should	O
be	O
used	O
with	O
ACEi	I-Entity
/	O
ARB	I-Entity
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	I-Entity
and	O
increased	O
renal	B-Entity
dysfunction	I-Entity
.	O



Synthesis	O
of	O
N	B-Entity
-	I-Entity
pyrimidinyl-2-phenoxyacetamides	I-Entity
as	O
adenosine	I-Entity
A2A	O
receptor	O
antagonists	O
.	O

A	O
series	O
of	O
N	B-Entity
-	I-Entity
pyrimidinyl-2-phenoxyacetamide	I-Entity
adenosine	I-Entity
A(2A	O
)	O
antagonists	O
is	O
described	O
.	O

>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
model	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O



Methamphetamine	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O

Methamphetamine	I-Entity
(	O
METH	I-Entity
)	O
damages	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	I-Entity
-	O
induced	O
neurodegeneration	I-Entity
of	O
DA	I-Entity
neurons	O
.	O

Because	O
the	O
CNS	B-Entity
damage	I-Entity
caused	O
by	O
METH	I-Entity
and	O
MPTP	I-Entity
is	O
highly	O
selective	O
for	O
the	O
DA	I-Entity
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	I-Entity
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
and	O
microglial	O
activation	O
.	O

Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	I-Entity
and	O
examined	O
for	O
striatal	O
neurotoxicity	I-Entity
.	O

METH	I-Entity
depleted	O
DA	I-Entity
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O

The	O
effects	O
of	O
METH	I-Entity
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O

Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	I-Entity
that	O
are	O
characteristic	O
of	O
activation	O
.	O

This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	I-Entity
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	I-Entity
neurotoxicity	I-Entity
or	O
microglial	O
activation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	I-Entity
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O



Recovery	O
of	O
tacrolimus	I-Entity
-	O
associated	O
brachial	B-Entity
neuritis	I-Entity
after	O
conversion	O
to	O
everolimus	I-Entity
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
--	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	I-Entity
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	I-Entity
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	I-Entity
,	O
headaches	I-Entity
,	O
seizures	I-Entity
,	O
or	O
neurological	B-Entity
deficits	I-Entity
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	I-Entity
and	O
right	O
brachial	B-Entity
plexitis	I-Entity
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	I-Entity
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	I-Entity
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	I-Entity
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	I-Entity
.	O



Valvular	B-Entity
heart	I-Entity
disease	I-Entity
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
treated	O
with	O
pergolide	I-Entity
.	O

Valvular	B-Entity
heart	I-Entity
abnormalities	I-Entity
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
treated	O
with	O
pergolide	I-Entity
.	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B-Entity
heart	I-Entity
abnormality	I-Entity
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
PD	I-Entity
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	I-Entity
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O

Thirty	O
PD	I-Entity
patients	O
participated	O
in	O
the	O
study	O
.	O

A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	I-Entity
withdrawal	O
(	O
n=10	O
patients	O
)	O
.	O

Controls	O
were	O
age-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	I-Entity
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O

Compared	O
to	O
controls	O
,	O
aortic	B-Entity
regurgitation	I-Entity
(	O
OR	O
:	O
3.1	O
;	O
95%	O
IC	O
:	O
1.1	O
-	O
8.8	O
)	O
and	O
mitral	B-Entity
regurgitation	I-Entity
(	O
OR	O
:	O
10.7	O
;	O
95%	O
IC	O
:	O
2.1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	I-Entity
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affected	O
valves	O
(	O
n=2.4+/-0.7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n=2.8+/-1.09	O
)	O
were	O
higher	O
(	O
p=0.008	O
and	O
p=0.006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	I-Entity
group	O
.	O

Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	I-Entity
cumulative	O
dose	O
.	O

A	O
restrictive	O
pattern	O
of	O
valvular	B-Entity
regurgitation	I-Entity
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	I-Entity
,	O
was	O
observed	O
in	O
12/30	O
(	O
40%	O
)	O
patients	O
including	O
two	O
with	O
heart	B-Entity
failure	I-Entity
.	O

Pergolide	I-Entity
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p=0.01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-Entity
failure	I-Entity
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O

This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	B-Entity
regurgitation	I-Entity
in	O
PD	I-Entity
patients	O
treated	O
with	O
pergolide	I-Entity
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non	O
-	O
ergot	O
dopamine	I-Entity
agonists	O
.	O



Adverse	O
effects	O
of	O
topical	O
papaverine	I-Entity
on	O
auditory	O
nerve	O
function	O
.	O

Papaverine	B-Entity
hydrochloride	I-Entity
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	I-Entity
during	O
various	O
neurosurgical	O
operations	O
.	O

Transient	O
cranial	B-Entity
nerve	I-Entity
dysfunction	I-Entity
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	I-Entity
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	I-Entity
for	O
vasospasm	I-Entity
.	O

Topical	O
papaverine	I-Entity
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	I-Entity
in	O
a	O
total	O
of	O
11	O
patients	O
.	O

The	O
timing	O
of	O
papaverine	I-Entity
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O

A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	I-Entity
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O

The	O
average	O
temporal	O
delay	O
between	O
papaverine	I-Entity
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	I-Entity
.	O

One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
.	O

The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	I-Entity
baseline	O
values	O
was	O
39	O
min	O
.	O

Topical	O
papaverine	I-Entity
for	O
the	O
treatment	O
of	O
vasospasm	I-Entity
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B-Entity
effect	I-Entity
on	I-Entity
the	I-Entity
proximal	I-Entity
eighth	I-Entity
nerve	I-Entity
.	O

Recommendations	O
to	O
avoid	O
potential	O
cranial	B-Entity
nerve	I-Entity
deficits	I-Entity
from	O
papaverine	I-Entity
are	O
provided	O
.	O



Massive	O
proteinuria	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
after	O
oral	O
bisphosphonate	I-Entity
(	O
alendronate	I-Entity
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B-Entity
segmental	I-Entity
glomerulosclerosis	I-Entity
.	O

A	O
61-year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B-Entity
syndrome	I-Entity
due	O
to	O
focal	B-Entity
segmental	I-Entity
glomerulosclerosis	I-Entity
was	O
initially	O
responding	O
well	O
to	O
steroid	I-Entity
therapy	O
.	O

Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	I-Entity
(	O
alendronate	B-Entity
sodium	I-Entity
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

After	O
discontinuing	O
the	O
oral	O
alendronate	I-Entity
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O

Urinary	O
volume	O
and	O
serum	O
creatinine	I-Entity
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O

This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	I-Entity
can	O
aggravate	O
proteinuria	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O



Serum-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

Doxorubicin	I-Entity
-	O
induced	O
nephropathy	I-Entity
leads	O
to	O
epithelial	O
sodium	I-Entity
channel	O
(	O
ENaC)-dependent	O
volume	B-Entity
retention	I-Entity
and	O
renal	O
fibrosis	I-Entity
.	O

The	O
aldosterone	I-Entity
-	O
sensitive	O
serum-	O
and	O
glucocorticoid	O

-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	I-Entity
following	O
mineralocorticoid	O
and	O
salt	O
excess	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B-Entity
retention	I-Entity
and	O
fibrosis	I-Entity
during	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

To	O
this	O
end	O
,	O
doxorubicin	I-Entity
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1(-/-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1(+/+	O
)	O
)	O
.	O

Doxorubicin	I-Entity
treatment	O
resulted	O
in	O
heavy	O
proteinuria	I-Entity
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	O
)	O
in	O
15/44	O
of	O
sgk1(+/+	O
)	O
and	O
15/44	O
of	O
sgk1(-/-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-Entity
syndrome	I-Entity
with	O
ascites	I-Entity
,	O
lipidemia	I-Entity
,	O
and	O
hypoalbuminemia	I-Entity
in	O
both	O
genotypes	O
.	O

Plasma	O
aldosterone	I-Entity
levels	O
increased	O
in	O
nephrotic	I-Entity
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1(+/+	O
)	O
mice	O
.	O

Urinary	O
sodium	I-Entity
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1(+/+	O
)	O
mice	O
(	O
15	O
+	O
/-	O

5	O
mumol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Entity
gain	I-Entity
in	O
sgk1(+/+	O
)	O
compared	O
with	O
sgk1(-/-	O
)	O
mice	O
(	O
+	O
6.6	O
+	O
/-	O

During	O
the	O
course	O
of	O
nephrotic	B-Entity
syndrome	I-Entity
,	O
serum	O
urea	I-Entity
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1(-/-	O
)	O
mice	O
than	O
in	O
sgk1(+/+	O
)	O

mice	O
leading	O
to	O
uremia	I-Entity
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1(-/-	O
)	O
mice	O
(	O
29	O
vs.	O
40	O
days	O
in	O
sgk1(+/+	O
)	O
mice	O
)	O
.	O

In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B-Entity
retention	I-Entity
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	I-Entity
during	O
experimental	O
nephrotic	B-Entity
syndrome	I-Entity
.	O



Severe	O
and	O
long	O
lasting	O
cholestasis	I-Entity
after	O
high	O
-	O
dose	O
co	B-Entity
-	I-Entity
trimoxazole	I-Entity
treatment	O
for	O
Pneumocystis	B-Entity
pneumonia	I-Entity
in	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
patients	O
--	O
a	O
report	O
of	O
two	O
cases	O
.	O

Pneumocystis	B-Entity
pneumonia	I-Entity
(	O
PCP	I-Entity
)	O
,	O
a	O
common	O
opportunistic	B-Entity
infection	I-Entity
in	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co	B-Entity
-	I-Entity
trimoxazole	I-Entity
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
patients	O
who	O
developed	O
severe	O
intrahepatic	B-Entity
cholestasis	I-Entity
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-Entity
abscess	I-Entity
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-Entity
-	I-Entity
trimoxazole	I-Entity
treatment	O
for	O
PCP	I-Entity
.	O

Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co	B-Entity
-	I-Entity
trimoxazole	I-Entity
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O



Clinically	O
significant	O
proteinuria	I-Entity
following	O
the	O
administration	O
of	O
sirolimus	I-Entity
to	O
renal	O
transplant	O
recipients	O
.	O

Sirolimus	I-Entity
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	I-Entity
than	O
calcineurin	O
inhibitor	O
(	O
CNI)-based	O
regimens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	I-Entity
linked	O
with	O
the	O
use	O
of	O
sirolimus	I-Entity
.	O

We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	I-Entity
associated	O
with	O
sirolimus	I-Entity
use	O
.	O

In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	I-Entity
therapy	O
and	O
proteinuria	I-Entity
implicated	O
sirolimus	I-Entity
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	I-Entity
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	I-Entity
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O

In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	I-Entity
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	I-Entity
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	I-Entity
/	O
day	O
.	O

Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	I-Entity
use	O
.	O

Twenty	O
-	O
eight	O
patients	O
(	O
24%	O
)	O
developed	O
increased	O
proteinuria	I-Entity
from	O
baseline	O
during	O
their	O
post	O
-	O
transplantation	O
course	O
.	O

In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	I-Entity
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	I-Entity
and	O
the	O
development	O
of	O
nephrotic	I-Entity
-	O
range	O
proteinuria	I-Entity
.	O

Proteinuria	I-Entity
correlated	O
most	O
strongly	O
with	O
sirolimus	I-Entity
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	I-Entity
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	I-Entity
.	O

Sirolimus	I-Entity
induces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuria	I-Entity
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O

Proteinuria	I-Entity
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	I-Entity
is	O
withdrawn	O
.	O



Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate	O
-	O
release	O
oxycodone	I-Entity
in	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10-mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	I-Entity
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	I-Entity
.	O

Seventy	O
-	O
one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10-mg	O
oxycodone	I-Entity
)	O
.	O

Plasma	O
oxycodone	I-Entity
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
and	O
pupil	O
size	O
,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
.	O

Significant	O
declines	B-Entity
in	I-Entity
simple	I-Entity
and	I-Entity
sustained	I-Entity
attention	I-Entity
,	I-Entity
working	I-Entity
memory	I-Entity
,	I-Entity
and	I-Entity
verbal	I-Entity
memory	I-Entity
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O

This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	B-Entity
pain	I-Entity
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10-mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	I-Entity
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aged	O
adults	O
.	O

Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	I-Entity
are	O
similar	O
for	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O



Normalizing	O
effects	O
of	O
modafinil	I-Entity
on	O
sleep	O
in	O
chronic	O
cocaine	I-Entity
users	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	I-Entity
on	O
sleep	O
and	O
daytime	B-Entity
sleepiness	I-Entity
in	O
chronic	O
cocaine	I-Entity
users	O
.	O

Twenty	O
cocaine	I-Entity
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	I-Entity
,	O
400	O
mg	O
(	O
N=10	O
)	O
,	O
or	O
placebo	O
(	O
N=10	O
)	O
every	O
morning	O
at	O
7:30	O
a.m.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O

Progressive	O
abstinence	O
from	O
cocaine	I-Entity
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O

Compared	O
with	O
placebo	O
,	O
modafinil	I-Entity
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	I-Entity
-	O
dependent	O
participants	O
.	O

The	O
effect	O
of	O
modafinil	I-Entity
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O

Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	I-Entity
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	I-Entity
in	O
cocaine	I-Entity
-	O
dependent	O
participants	O
.	O

Modafinil	I-Entity
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Entity
sleepiness	I-Entity
.	O

Morning	O
-	O
dosed	O
modafinil	I-Entity
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-Entity
sleepiness	I-Entity
in	O
abstinent	O
cocaine	I-Entity
users	O
.	O

These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	I-Entity
dependence	O
.	O



Efficacy	O
and	O
safety	O
of	O
asenapine	I-Entity
in	O
a	O
placebo-	O
and	O
haloperidol	I-Entity
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	I-Entity
.	O

Asenapine	I-Entity
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	I-Entity
or	O
of	O
manic	I-Entity
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Entity
I	I-Entity
disorder	I-Entity
with	O
or	O
without	O
psychotic	I-Entity
features	O
.	O

In	O
a	O
double	O
-	O
blind	O
6-week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	I-Entity
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	I-Entity
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	I-Entity
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	I-Entity
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O

With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	I-Entity
at	O
5	O
mg	O
BID	O
(	O
-16.2	O
)	O
and	O
haloperidol	I-Entity
(	O
-15.4	O
)	O
than	O
placebo	O
(	O
-10.7	O
;	O
both	O
P	O
<	O
0.05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	I-Entity
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-21.3	O
and	O
-19.4	O
,	O
respectively	O
)	O
and	O
haloperidol	I-Entity
(	O
-20.0	O
)	O
than	O
placebo	O
(	O
-14.6	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O

On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	I-Entity
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44%	O
and	O
52%	O
,	O
57%	O
,	O
and	O
41%	O
of	O
the	O
asenapine	I-Entity
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	I-Entity
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Extrapyramidal	B-Entity
symptoms	I-Entity
reported	O
as	O
AEs	O
occurred	O
in	O
15%	O
and	O
18%	O
,	O
34%	O
,	O
and	O
10%	O
of	O
the	O
asenapine	I-Entity
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	I-Entity
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	I-Entity
and	O
haloperidol	I-Entity
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-Entity
symptoms	I-Entity
.	O



Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Entity
aminonucleoside	I-Entity
nephrosis	I-Entity
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	I-Entity
starts	O
.	O

Using	O
puromycin	B-Entity
aminonucleoside	I-Entity
nephrosis	I-Entity
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	I-Entity
,	O
appeared	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	I-Entity
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	I-Entity
.	O



Twin	O
preterm	O
neonates	O
with	O
cardiac	B-Entity
toxicity	I-Entity
related	O
to	O
lopinavir	B-Entity
/	I-Entity
ritonavir	I-Entity
therapy	O
.	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
infection	I-Entity
.	O

One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-Entity
block	I-Entity
and	O
dilated	B-Entity
cardiomyopathy	I-Entity
related	O
to	O
lopinavir	B-Entity
/	I-Entity
ritonavir	I-Entity
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	I-Entity
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir	B-Entity
/	I-Entity
ritonavir	I-Entity
in	O
the	O
immediate	O
neonatal	O
period	O
.	O



Learning	O
of	O
rats	O
under	O
amnesia	I-Entity
caused	O
by	O
pentobarbital	I-Entity
.	O

Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	I-Entity
produced	O
by	O
pentobarbital	I-Entity
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	I-Entity
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O

It	O
was	O
shown	O
that	O
memory	B-Entity
dissociation	I-Entity
occurred	O
in	O
both	O
groups	O
.	O

Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	I-Entity
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O

These	O
findings	O
show	O
that	O
the	O
brain	O
-	O
dissociated	O
state	O
induced	O
by	O
pentobarbital	I-Entity
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O



Angiosarcoma	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
associated	O
with	O
diethylstilbestrol	I-Entity
.	O

Angiosarcoma	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
occurred	O
in	O
a	O
76-year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
with	O
diethylstilbestrol	I-Entity
for	O
13	O
years	O
.	O

Angiosarcoma	I-Entity
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O

The	O
possibility	O
that	O
the	O
intraarterial	B-Entity
lesions	I-Entity
might	O
represent	O
independent	O
primary	O
tumors	I-Entity
is	O
considered	O
.	O



Role	O
of	O
xanthine	I-Entity
oxidase	O
in	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
rats	O
.	O
1	O
.	O

Glucocorticoid	O
-	O
induced	O
hypertension	I-Entity
(	O
GC	O
-	O
HT	I-Entity
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	B-Entity
oxide	I-Entity
-	O
redox	O
imbalance	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthine	I-Entity
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
(	O
dex	I-Entity
-	O
HT	I-Entity
)	O
.	O

Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	I-Entity
(	O
dex	I-Entity
)	O
,	O
allopurinol	I-Entity
plus	O
saline	O
,	O
and	O
allopurinol	I-Entity
plus	O
dex	I-Entity
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	I-Entity
to	O
assess	O
XO	O
inhibition	O
.	O

Dex	I-Entity
increased	B-Entity
SBP	I-Entity
(	O
110	O
+	O
/-	O

3	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
and	O
decreased	B-Entity
thymus	I-Entity
(	I-Entity
P	I-Entity
<	I-Entity
0.001	I-Entity
)	I-Entity
and	I-Entity
bodyweights	I-Entity
(	O
P	O
""""	O
<	O
0.01	O
)	O
.	O

Allopurinol	I-Entity
decreased	O
serum	O
urate	I-Entity
from	O
76	O
+	O
/-	O

/	O
L	O
in	O
dex	I-Entity
-	O
treated	O
(	O
P	O
<	O
0.01	O
)	O
groups	O
.	O

Allopurinol	I-Entity
did	O
not	O
prevent	O
dex	I-Entity
-	O
HT	I-Entity
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	I-Entity
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	I-Entity
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	O
-	O
HT	I-Entity
in	O
the	O
rat	O
.	O



Extrapyramidal	O
side	O
effects	O
with	O
risperidone	I-Entity
and	O
haloperidol	I-Entity
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O

Risperidone	I-Entity
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	I-Entity
D2	O
and	O
serotonin	B-Entity
5-HT2	I-Entity
receptors	O
.	O

Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	I-Entity
's	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B-Entity
symptoms	I-Entity
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	O
'	O
neuroleptics	O
.	O

To	O
determine	O
if	O
routine	O
risperidone	I-Entity
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I]IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	I-Entity
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	I-Entity
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risperidone	I-Entity
and	O
haloperidol	I-Entity
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90%	O
at	O
standard	O
clinical	O
doses	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	I-Entity
or	O
risperidone	I-Entity
.	O

Drug	B-Entity
-	I-Entity
induced	I-Entity
parkinsonism	I-Entity
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	I-Entity
(	O
42%	O
)	O
and	O
haloperidol	I-Entity
(	O
29%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60%	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5-HT2	O
blockade	O
obtained	O
with	O
risperidone	I-Entity
at	O
D2	O
occupancy	O
rates	O
of	O
60%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O



Simvastatin	B-Entity
-	I-Entity
ezetimibe	I-Entity
-	O
induced	O
hepatic	B-Entity
failure	I-Entity
necessitating	O
liver	O
transplantation	O
.	O

A	O
reductase	O
inhibitor	O
(	O
statin	I-Entity
)	O
therapy	O
.	O

However	O
,	O
hepatotoxic	I-Entity
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	I-Entity
or	O
the	O
combination	O
agent	O
simvastatin	B-Entity
-	I-Entity
ezetimibe	I-Entity
.	O

We	O
describe	O
a	O
70-year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	I-Entity
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-Entity
10	I-Entity
mg	I-Entity
-	I-Entity
ezetimibe	I-Entity
40	I-Entity
mg	I-Entity
/	O
day	O
.	O

The	O
patient	O
's	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	I-Entity
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	I-Entity
.	O

Simvastatinezetimibe	I-Entity
and	O
escitalopram	I-Entity
(	O
which	O
she	O
was	O
taking	O
for	O
depression	I-Entity
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	I-Entity
were	O
excluded	O
.	O

A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-Entity
toxicity	I-Entity
.	O

Ezetimibe	I-Entity
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Entity
diphosphate	I-Entity
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Entity
hydroxy	I-Entity
acid	I-Entity
,	O
resulting	O
in	O
increased	O
simvastatin	I-Entity
exposure	O
and	O
subsequent	O
hepatotoxicity	I-Entity
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Entity
-	I-Entity
ezetimibe	I-Entity
-	O
induced	O
liver	B-Entity
failure	I-Entity
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O

We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	I-Entity
-	O
induced	O
hepatotoxicity	I-Entity
is	O
the	O
increased	O
simvastatin	I-Entity
exposure	O
by	O
ezetimibe	I-Entity
inhibition	O
of	O
UGT	O
enzymes	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	I-Entity
with	O
simvastatin	B-Entity
-	I-Entity
ezetimibe	I-Entity
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O



Oral	O
manifestations	O
of	O
""""	O
meth	B-Entity
mouth	I-Entity
""""	O
:	O
a	O
case	O
report	O
.	O

The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
""""	O
meth	B-Entity
mouth	I-Entity
""""	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

Methamphetamine	I-Entity
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B-Entity
dysrhythmias	I-Entity
,	O
hypertension	I-Entity
,	O
hallucinations	I-Entity
,	O
and	O
violent	B-Entity
behavior	I-Entity
.	O

Dental	O
patients	O
abusing	O
methamphetamine	I-Entity
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	I-Entity
,	O
rampant	O
caries	I-Entity
(	O
""""	O
meth	B-Entity
mouth	I-Entity
""""	O
)	O
,	O
and	O
excessive	O
tooth	B-Entity
wear	I-Entity
.	O

Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	I-Entity
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30-year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	I-Entity
,	O
bad	B-Entity
breath	I-Entity
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O

A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B-Entity
lesions	I-Entity
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O

She	O
reported	O
her	O
use	O
of	O
methamphetamine	I-Entity
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B-Entity
episodes	I-Entity
before	O
she	O
started	O
using	O
the	O
drug	O
.	O

The	O
patient	O
's	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
""""	O
meth	B-Entity
mouth	I-Entity
.	O

This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	B-Entity
mouth	I-Entity
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	I-Entity
.	O



Thyroxine	I-Entity
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	I-Entity
in	O
pregnancy	O
.	O

Eating	B-Entity
disorders	I-Entity
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B-Entity
abuse	I-Entity
are	O
uncommon	O
in	O
pregnancy	O
.	O

This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B-Entity
disorders	I-Entity
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	O
abuse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B-Entity
disorders	I-Entity
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	I-Entity
remains	O
obscure	O
,	O
thyroxine	I-Entity
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O



Attenuation	O
of	O
methamphetamine	I-Entity
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	I-Entity
in	O
mice	O
by	O
lipopolysaccharide	I-Entity
pretreatment	O
.	O

Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	I-Entity
-	O
induced	O
dopaminergic	B-Entity
terminal	I-Entity
damage	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	I-Entity
,	O
a	O
pro	O
-	O
inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	I-Entity
-	O
induced	O
nigrostriatal	O
dopamine	I-Entity
neurotoxicity	I-Entity
.	O

Lipopolysaccharide	I-Entity
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	I-Entity
-	O
elicited	O
hyperthermia	I-Entity
three	O
days	O
later	O
.	O

Such	O
systemic	O
lipopolysaccharide	I-Entity
treatment	O
mitigated	O
methamphetamine	I-Entity
-	O
induced	O
striatal	O
dopamine	I-Entity
and	O
3,4-dihydroxyphenylacetic	B-Entity
acid	I-Entity
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	I-Entity
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	I-Entity
dosing	O
regimen	O
,	O
methamphetamine	I-Entity
-	O
induced	O
striatal	O
dopamine	I-Entity
and	O
3,4-dihydroxyphenylacetic	B-Entity
acid	I-Entity
depletions	O
remained	O
unaltered	O
.	O

Moreover	O
,	O
systemic	O
lipopolysaccharide	I-Entity
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	I-Entity
infusion	O
-	O
produced	O
dopamine	I-Entity
and	O
3,4-dihydroxyphenylacetic	B-Entity
acid	I-Entity
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	I-Entity
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	I-Entity
.	O

We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	I-Entity
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	I-Entity
-	O
induced	O
nigrostriatal	O
dopamine	I-Entity
neurotoxicity	I-Entity
.	O



Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	I-Entity
-	O
induced	O
nephropathy	I-Entity
.	O

The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	I-Entity
was	O
assessed	O
in	O
Munich	O
-	O
Wistar	O
rats	O
with	O
established	O
adriamycin	I-Entity
nephrosis	I-Entity
.	O

Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	I-Entity
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	I-Entity
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O

Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	I-Entity
.	O

These	O
short	O
-	O
term	O
studies	O
showed	O
that	O
enalapril	I-Entity
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+	O
/-	O

2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0.05	O
)	O
without	O
reducing	O
albuminuria	I-Entity
(	O
617	O
+	O
/-	O
50	O
vs.	O
570	O
+	O
/-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1.03	O
+	O
/-	O

Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	I-Entity
on	O
progression	O
of	O
renal	B-Entity
injury	I-Entity
in	O
adriamycin	I-Entity
nephrosis	I-Entity
.	O

Chronic	O
enalapril	I-Entity
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	I-Entity
in	O
group	O
4	O
.	O

Enalapril	I-Entity
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0.86	O
+	O
/-	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B-Entity
sclerosis	I-Entity
in	O
both	O
treated	O
and	O
untreated	O
rats.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	I-Entity
after	O
succinylcholine	I-Entity
for	O
electroconvulsive	O
therapy	O
.	O

patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	I-Entity
as	O
part	O
of	O
the	O
anesthetic	O
procedure	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	I-Entity
after	O
ECT	O
.	O

We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	I-Entity
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O

The	O
duration	O
of	O
apnea	I-Entity
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O

The	O
duration	O
of	O
apnea	I-Entity
was	O
5	O
-	O
15	O
min	O
compared	O
with	O
3	O
-	O
5.3	O
min	O
from	O
the	O
literature	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	I-Entity
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	I-Entity
.	O



Ketamine	I-Entity
sedation	O
for	O
the	O
reduction	O
of	O
children	O
's	O
fractures	I-Entity
in	O
the	O
emergency	O
department	O
.	O

There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	I-Entity
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	I-Entity
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
's	O
fractures	I-Entity
in	O
the	O
emergency	O
department	O
.	O

One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5.3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	I-Entity
or	O
dislocation	I-Entity
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	I-Entity
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	B-Entity
hydrochloride	I-Entity
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

Any	O
pain	I-Entity
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	I-Entity
Scale	O
(	O
CHEOPS	O
)	O
.	O

The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	I-Entity
to	O
manipulation	O
of	O
the	O
fracture	I-Entity
or	O
dislocation	I-Entity
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	I-Entity
Scale	O
was	O
6.4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	I-Entity
during	O
fracture	I-Entity
reduction	O
.	O

Adequate	O
fracture	I-Entity
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	I-Entity
(	O
thirteen	O
patients	O
)	O
,	O
emesis	I-Entity
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	I-Entity
)	O
,	O
clumsiness	I-Entity
(	O
evident	O
as	O
ataxic	B-Entity
movements	I-Entity
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Entity
reaction	I-Entity
(	O
one	O
patient	O
)	O
.	O

No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	I-Entity
or	O
nightmares	O
.	O

Ketamine	I-Entity
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
's	O
fractures	I-Entity
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

Ketamine	I-Entity
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O



Prophylactic	O
use	O
of	O
lamivudine	I-Entity
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	B-Entity
disorders	I-Entity
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	I-Entity
in	O
hepatitis	B-Entity
B	I-Entity
virus	I-Entity
surface	I-Entity
antigen	I-Entity
(	O
HBs	B-Entity
Ag	I-Entity
)	O
positive	O
patients	O
with	O
rheumatologic	B-Entity
disease	I-Entity
.	O

From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	B-Entity
Ag	I-Entity
positive	O
patients	O
with	O
rheumatologic	B-Entity
diseases	I-Entity
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	I-Entity
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O

Liver	O
function	O
tests	O
,	O
hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O

Lamivudine	I-Entity
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O

Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	B-Entity
liver	I-Entity
function	I-Entity
tests	O
.	O

Lamivudine	I-Entity
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O

Prophylactic	O
administration	O
of	O
lamivudine	I-Entity
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O



OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	I-Entity
(	O
MZ	I-Entity
)	O
and	O
Flumazenil	I-Entity
(	O
FL	I-Entity
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O

METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	I-Entity
associated	O
to	O
moderate	O
sedation	O
.	O

We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia	O
,	O
with	O
MZ	I-Entity
use	O
and	O
with	O
the	O
procedure	O
.	O

Uni-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	I-Entity
,	O
myocardiopathy	I-Entity
(	O
MP	I-Entity
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-Entity
regurgitation	I-Entity
(	O
MR	I-Entity
)	O
and	O
the	O
MZ	I-Entity
dose	O
.	O

The	O
mean	O
doses	O
of	O
MZ	I-Entity
and	O
FL	I-Entity
were	O
4.3+/-1.9	O
mg	O
and	O
0.28+/-0.2	O
mg	O
,	O
respectively	O
.	O

Mild	O
hypoxia	I-Entity
(	O
SO2<90%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2%	O
)	O
presented	O
transient	O
hypoxia	I-Entity
due	O
to	O
upper	O
airway	B-Entity
obstruction	I-Entity
by	O
probe	O
introduction	O
and	O
8	O
(	O
5.8%	O
)	O
due	O
to	O
hypoxia	I-Entity
caused	O
by	O
MZ	I-Entity
use	O
.	O

Transient	O
hypotension	I-Entity
(	O
SAP<90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0.7%	O
)	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	I-Entity
,	O
MP	I-Entity
(	O
EF<45%	O
)	O
and	O
high	O
doses	O
of	O
MZ	I-Entity
(	O
>	O
5	O
mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p<0.001	O
)	O
.	O

The	O
EF	O
was	O
40%	O
,	O
in	O
the	O
group	O
with	O
MP	I-Entity
and	O
44%	O
in	O
the	O
group	O
with	O
severe	O
MR	I-Entity
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O



Effects	O
of	O
calcium	I-Entity
channel	O
blockers	O
on	O
bupivacaine	I-Entity
-	O
induced	O
toxicity	I-Entity
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	I-Entity
channel	O
blockers	O
on	O
bupivacaine	I-Entity
-	O
induced	O
acute	O
toxicity	I-Entity
.	O

For	O
each	O
of	O
the	O
three	O
tested	O
calcium	I-Entity
channel	O
blockers	O
(	O
diltiazem	I-Entity
,	O
verapamil	I-Entity
and	O
bepridil	I-Entity
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i.e.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i.p	O
.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i.p	O
.	O

dose	O
of	O
bupivacaine	I-Entity
.	O

The	O
local	O
anesthetic	O
-	O
induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	I-Entity
channel	O
blockers	O
.	O

The	O
convulsant	O
activity	O
of	O
bupivacaine	I-Entity
was	O
not	O
significantly	O
modified	O
but	O
calcium	I-Entity
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	I-Entity
-	O
induced	O
convulsions	I-Entity
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	I-Entity
.	O



Selegiline	I-Entity
-	O
induced	O
postural	B-Entity
hypotension	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

The	O
United	O
Kingdom	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	I-Entity
per	O
day	O
and	O
L	B-Entity
-	I-Entity
dopa	I-Entity
compared	O
with	O
those	O
taking	O
L	B-Entity
-	I-Entity
dopa	I-Entity
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	I-Entity
and	O
L	B-Entity
-	I-Entity
dopa	I-Entity
was	O
associated	O
with	O
selective	O
systolic	B-Entity
orthostatic	I-Entity
hypotension	I-Entity
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	I-Entity
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	I-Entity
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B-Entity
hypotension	I-Entity
.	O

The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	I-Entity
patients	O
receiving	O
selegiline	I-Entity
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

Head	O
-	O
up	O
tilt	O
caused	O
systolic	B-Entity
orthostatic	I-Entity
hypotension	I-Entity
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	I-Entity
patients	O
on	O
selegiline	I-Entity
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	O
of	O
orthostatic	B-Entity
hypotension	I-Entity
occurred	O
with	O
standing	O
.	O

Orthostatic	B-Entity
hypotension	I-Entity
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	I-Entity
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Stopping	O
selegiline	I-Entity
also	O
significantly	O
reduced	B-Entity
the	I-Entity
supine	I-Entity
systolic	I-Entity
and	I-Entity
diastolic	I-Entity
blood	I-Entity
pressures	I-Entity
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	I-Entity
in	O
combination	O
with	O
L	B-Entity
-	I-Entity
dopa	I-Entity
is	O
associated	O
with	O
selective	O
orthostatic	B-Entity
hypotension	I-Entity
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	I-Entity
and	O
metamphetamine	I-Entity
are	O
discussed	O
.	O



Explicit	O
episodic	O
memory	O
for	O
sensory	O
-	O
discriminative	O
components	O
of	O
capsaicin	I-Entity
-	O
induced	O
pain	I-Entity
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O

Pain	I-Entity
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	I-Entity
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	I-Entity
conditions	O
.	O

Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	I-Entity
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
pain	I-Entity
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	I-Entity
(	O
0.05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O

Pain	I-Entity
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1/s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O

Subjects	O
also	O
recalled	O
their	O
pains	I-Entity
one	O
week	O
later	O
.	O

Capsaicin	I-Entity
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p<0.001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

The	O
strong	O
burning	O
pain	I-Entity
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O

Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	I-Entity
magnitude	O
and	O
duration	O
across	O
capsaicin	I-Entity
doses	O
(	O
both	O
p<0.001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pain	I-Entity
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	I-Entity
.	O



Reversibility	O
of	O
captopril	I-Entity
-	O
induced	O
renal	B-Entity
insufficiency	I-Entity
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	B-Entity
hypertension	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	I-Entity
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	O
kidney	O
,	O
who	O
developed	O
sudden	B-Entity
deterioration	I-Entity
of	I-Entity
renal	I-Entity
function	I-Entity
following	O
treatment	O
with	O
captopril	I-Entity
.	O

His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	I-Entity
but	O
returned	O
to	O
pre	O
-	O
treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	O
.	O

This	O
indicates	O
reversibility	O
in	O
captopril	I-Entity
-	O
induced	O
renal	B-Entity
failure	I-Entity
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O



Liver	B-Entity
disease	I-Entity
caused	O
by	O
propylthiouracil	I-Entity
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-Entity
active	I-Entity
(	I-Entity
aggressive	I-Entity
)	I-Entity
hepatitis	I-Entity
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	I-Entity
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B-Entity
disease	I-Entity
.	O



Capsaicin	I-Entity
-	O
induced	O
muscle	B-Entity
pain	I-Entity
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	B-Entity
disorders	I-Entity
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B-Entity
pain	I-Entity
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	B-Entity
muscle	I-Entity
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O

Capsaicin	I-Entity
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	I-Entity
in	O
11	O
healthy	O
volunteers	O
.	O

Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	I-Entity
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	I-Entity
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	B-Entity
muscle	I-Entity
.	O

Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	B-Entity
pain	I-Entity
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O



Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
""""	O
real	O
""""	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
""""	O
sham	O
""""	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	I-Entity
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
.	O

Ten	O
patients	O
with	O
PD	I-Entity
and	O
prominent	O
dyskinesias	I-Entity
had	O
rTMS	O
(	O
1,800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	I-Entity
severity	O
.	O

However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	I-Entity
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystonia	I-Entity
subscore	O
.	O

Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	I-Entity
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	I-Entity
symptoms	O
were	O
noted	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	I-Entity
in	O
PD	I-Entity
.	O



Disulfiram	I-Entity
-	O
like	O
syndrome	O
after	O
hydrogen	B-Entity
cyanamide	I-Entity
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O

Hydrogen	B-Entity
cyanamide	I-Entity
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O

Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	I-Entity
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	I-Entity
syndrome	O
in	O
case	O
of	O
alcohol	I-Entity
use	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	I-Entity
-	O
like	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	B-Entity
cyanamide	I-Entity
.	O

The	O
first	O
case	O
involved	O
a	O
59-year	O
-	O
old	O
man	O
who	O
used	O
Dormex	I-Entity
,	O
which	O
contains	O
hydrogen	B-Entity
cyanamide	I-Entity
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	I-Entity
during	O
a	O
meal	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	I-Entity
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-Entity
of	I-Entity
the	I-Entity
face	I-Entity
,	O
tachycardia	I-Entity
,	O
and	O
dyspnea	I-Entity
.	O

The	O
second	O
case	O
occurred	O
in	O
a	O
55-year	O
-	O
old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	I-Entity
.	O

Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram	I-Entity
-	O
like	O
syndrome	O
with	O
flushing	I-Entity
,	O
tachycardia	I-Entity
,	O
and	O
arterial	B-Entity
hypotension	I-Entity
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O

These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	I-Entity
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	I-Entity
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O



Repeated	O
trimipramine	I-Entity
induces	O
dopamine	I-Entity
D2/D3	O
and	O
alpha1-adrenergic	O
up	O
-	O
regulation	O
.	O

Trimipramine	I-Entity
(	O
TRI	I-Entity
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	I-Entity
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	I-Entity
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	I-Entity
and	O
5-hydroxytryptamine	I-Entity
,	O
nor	O
does	O
it	O
induce	O
beta	O
-	O
adrenergic	O
down	O
-	O
regulation	O
.	O

The	O
mechanism	O
of	O
its	O
antidepressant	I-Entity
activity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	I-Entity
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1-adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	I-Entity
.	O

TRI	I-Entity
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O

In	O
the	O
acute	O
experiment	O
TRI	I-Entity
(	O
given	O
i.p	O
.	O
)	O

does	O
not	O
antagonize	O
the	O
reserpine	I-Entity
hypothermia	I-Entity
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5-hydroxytryptophan	I-Entity
head	O
twitches	O
in	O
rats	O
.	O

TRI	I-Entity
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	I-Entity
induced	O
by	O
d	B-Entity
-	I-Entity
amphetamine	I-Entity
,	O
quinpirole	I-Entity
and	O
(	O
+	O
)	O
-7-hydroxy	O
-	O
dipropyloaminotetralin	O
(	O

dopamine	I-Entity
D2	O
and	O
D3	O
effects	O
)	O
.	O

The	O
stereotypies	O
induced	O
by	O
d	B-Entity
-	I-Entity
amphetamine	I-Entity
or	O
apomorphine	I-Entity
are	O
not	O
potentiated	O
by	O
TRI	I-Entity
.	O

It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	I-Entity
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	I-Entity
evoked	O
by	O
clonidine	I-Entity
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1-adrenergic	O
receptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	I-Entity
studied	O
previously	O
,	O
TRI	I-Entity
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	I-Entity
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1-adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	I-Entity
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	I-Entity
activity	O
.	O



Ranitidine	I-Entity
-	O
induced	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	I-Entity
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O

This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
in	O
native	O
kidneys	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	I-Entity
-	O
induced	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O



Late	O
,	O
late	O
doxorubicin	I-Entity
cardiotoxicity	I-Entity
.	O

Cardiac	B-Entity
toxicity	I-Entity
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	I-Entity
as	O
a	O
chemotherapeutic	O
agent	O
.	O

Cardiomyopathy	I-Entity
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	I-Entity
two	O
and	O
one	O
-	O
half	O
years	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	I-Entity
.	O



Acetazolamide	I-Entity
-	O
induced	O
nephrolithiasis	I-Entity
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	B-Entity
disorders	I-Entity
.	O

Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	I-Entity
.	O

We	O
studied	O
20	O
patients	O
receiving	O
long	O
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	I-Entity
and	O
myotonia	I-Entity
.	O

Three	O
patients	O
on	O
acetazolamide	I-Entity
(	O
15%	O
)	O
developed	O
renal	B-Entity
calculi	I-Entity
.	O

Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B-Entity
calculus	I-Entity
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	I-Entity
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O

Nephrolithiasis	I-Entity
is	O
a	O
complication	O
of	O
acetazolamide	I-Entity
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O



Is	O
the	O
treatment	O
of	O
scabies	I-Entity
hazardous	O
?	O

Treatment	O
for	O
scabies	I-Entity
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	I-Entity
(	O
gamma	B-Entity
benzene	I-Entity
hexachloride	I-Entity
)	O
the	O
treatment	O
of	O
choice	O
.	O

Lindane	I-Entity
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O

Evidence	O
is	O
accumulating	O
that	O
lindane	I-Entity
can	O
be	O
toxic	B-Entity
to	I-Entity
the	I-Entity
central	I-Entity
nervous	I-Entity
system	I-Entity
and	O
may	O
be	O
associated	O
with	O
aplastic	B-Entity
anaemia	I-Entity
.	O

Preparations	O
containing	O
lindane	I-Entity
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O

This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at	O
-	O
risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	I-Entity
.	O



Anaesthetists	O
'	O
nightmare	O
:	O
masseter	B-Entity
spasm	I-Entity
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Entity
congenita	I-Entity
.	O

We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Entity
congenita	I-Entity
in	O
a	O
24-year	O
-	O
old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	B-Entity
spasm	I-Entity
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	I-Entity
for	O
induction	O
of	O
anaesthesia	O
.	O



Toxicity	I-Entity
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8-aminoquinoline	I-Entity

8-[(4-amino	B-Entity
-	I-Entity
l	I-Entity
-	I-Entity
methylbutyl)amino]-	I-Entity
5-(l	I-Entity
-	I-Entity
hexyloxy)-6-methoxy-4-methylquinoline	I-Entity
(	O
WR242511	I-Entity
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	I-Entity
.	O

Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	I-Entity
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8-aminoquinoline	I-Entity
WR242511	I-Entity
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	I-Entity
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3.5	O
and/or	O
7.0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	I-Entity
orally	O
(	O
PO	O
)	O
at	O
7.0	O
mg	O
/	O
kg	O
.	O

The	O
selected	O
doses	O
of	O
WR242511	I-Entity
,	O
which	O
produced	O
significant	O
methemoglobinemia	I-Entity
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2.0%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O

Furthermore	O
,	O
transient	O
hemoglobinuria	I-Entity
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	I-Entity
(	O
3.5	O
or	O
7.0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7.0	O
mg	O
/	O
kg	O
dose	O
.	O

Myoglobinuria	I-Entity
was	O
also	O
observed	O
following	O
the	O
7.0	O
mg	O
/	O
kg	O
dose	O
.	O

Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B-Entity
and	I-Entity
kidney	I-Entity
toxicity	I-Entity
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O

These	O
data	O
demonstrate	O
direct	O
and/or	O
indirect	O
drug	O
-	O
induced	O
toxicity	I-Entity
.	O

It	O
is	O
concluded	O
that	O
WR242511	I-Entity
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	I-Entity
unless	O
the	O
anti	O
-	O
CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	I-Entity
.	O



Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B-Entity
loss	I-Entity
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B-Entity
loss	I-Entity
.	O

Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	I-Entity
and	O
furosemide	I-Entity
.	O

The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-Entity
loss	I-Entity
.	O



The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	I-Entity
.	O

Atypical	B-Entity
sensations	I-Entity
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	I-Entity
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
with	O
tingling	B-Entity
or	I-Entity
burning	I-Entity
sensations	I-Entity
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	I-Entity
.	O



Tremor	I-Entity
side	O
effects	O
of	O
salbutamol	I-Entity
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
tremor	I-Entity
side	O
effects	O
of	O
salbutamol	I-Entity
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O

METHODS	O
:	O
Tremor	I-Entity
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique	O
.	O

To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	I-Entity
in	O
44	O
patients	O
with	O
obstructive	B-Entity
lung	I-Entity
disease	I-Entity
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	I-Entity
.	O

In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	I-Entity
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a.m.	O
,	O
4	O
p.m.	O
and	O
9	O
a.m.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Postural	O
tremor	I-Entity
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	I-Entity
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	I-Entity
was	O
measured	O
after	O
holding	O
a	O
2-kg	O
weight	O
until	O
exhaustion	O
.	O

Tremor	I-Entity
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers	O
.	O

Salbutamol	I-Entity
significantly	O
increased	O
tremor	I-Entity
severity	O
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	I-Entity
severity	O
(	O
r	O
=	O
0.093	O
;	O
P	O
=	O
0.53	O
)	O
.	O

Postural	O
tremor	I-Entity
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0.07	O
)	O
.	O

Support	O
of	O
the	O
arm	O
decreased	O
tremor	I-Entity
severity	O
,	O
exhaustion	O
increased	O
tremor	I-Entity
severity	O
significantly	O
.	O

DISCUSSION	O
:	O
Quantifying	O
tremor	I-Entity
by	O
using	O
an	O
inexpensive	O
laser	O
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O



Increased	O
frequency	O
of	O
venous	B-Entity
thromboembolism	I-Entity
with	O
the	O
combination	O
of	O
docetaxel	I-Entity
and	O
thalidomide	I-Entity
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Entity
thromboembolism	I-Entity
(	O
VTE	I-Entity
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
who	O
were	O
treated	O
with	O
docetaxel	I-Entity
alone	O
or	O
in	O
combination	O
with	O
thalidomide	I-Entity
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
.	O

Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	I-Entity
30	O
mg	O
/	O
m2/week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	I-Entity
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	I-Entity
regimen	O
.	O

This	O
4-week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	I-Entity
or	O
disease	O
progression	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	I-Entity
alone	O
developed	O
VTE	I-Entity
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19%	O
)	O
who	O
received	O
docetaxel	I-Entity
plus	O
thalidomide	I-Entity
developed	O
VTE	I-Entity
(	O
p=0.025	O
)	O
.	O

The	O
addition	O
of	O
thalidomide	I-Entity
to	O
docetaxel	I-Entity
in	O
the	O
treatment	O
of	O
prostate	B-Entity
cancer	I-Entity
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	I-Entity
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	I-Entity
to	O
chemotherapeutic	O
regimens	O
.	O



Sublingual	O
absorption	O
of	O
the	O
quaternary	B-Entity
ammonium	I-Entity
antiarrhythmic	O
agent	O
,	O
UM-272	I-Entity
.	O

UM-272	I-Entity
(	O
N	B-Entity
,	I-Entity
N	I-Entity
-	I-Entity
dimethylpropranolol	I-Entity
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	I-Entity
-	O
induced	O
ventricular	B-Entity
tachycardias	I-Entity
.	O

Sublingual	O
UM-272	I-Entity
converted	O
ventricular	B-Entity
tachycardia	I-Entity
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O



Severe	O
thrombocytopenia	I-Entity
and	O
haemolytic	B-Entity
anaemia	I-Entity
associated	O
with	O
ciprofloxacin	I-Entity
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O

Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	I-Entity
.	O

A	O
30-year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B-Entity
pain	I-Entity
and	O
jaundice	I-Entity
after	O
3-day	O
administration	O
of	O
oral	O
ciprofloxacin	I-Entity
for	O
a	O
suspect	O
of	O
urinary	B-Entity
tract	I-Entity
infection	I-Entity
.	O

Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	I-Entity
and	O
haemolysis	I-Entity
.	O

The	O
patient	O
progressively	O
developed	O
petechiae	I-Entity
and	O
purpura	I-Entity
on	O
thorax	O
and	O
lower	O
limbs	O
.	O

An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	I-Entity
.	O

No	O
signs	O
of	O
bone	B-Entity
marrow	I-Entity
depression	I-Entity
were	O
found	O
.	O

No	O
thrombi	I-Entity
or	O
signs	O
of	O
microangiopathies	I-Entity
were	O
observed	O
in	O
arterial	O
vessels	O
.	O

This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	I-Entity
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	I-Entity
and	O
haemolytic	B-Entity
anaemia	I-Entity
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O



Simvastatin	I-Entity
-	O
induced	O
bilateral	O
leg	O
compartment	B-Entity
syndrome	I-Entity
and	O
myonecrosis	I-Entity
associated	O
with	O
hypothyroidism	I-Entity
.	O

A	O
54-year	O
-	O
old	O
hypothyroid	I-Entity
male	O
taking	O
thyroxine	I-Entity
and	O
simvastatin	I-Entity
presented	O
with	O
bilateral	O
leg	O
compartment	B-Entity
syndrome	I-Entity
and	O
myonecrosis	I-Entity
.	O

Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	I-Entity
.	O

It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	I-Entity
patients	O
.	O



Bile	B-Entity
duct	I-Entity
hamartoma	I-Entity
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
bile	B-Entity
duct	I-Entity
hamartoma	I-Entity
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazol	I-Entity
treatment	O
.	O

If	O
the	O
patient	O
develops	O
a	O
liver	B-Entity
mass	I-Entity
,	O
because	O
of	O
non	O
-	O
specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O



Granulomatous	B-Entity
hepatitis	I-Entity
due	O
to	O
combination	B-Entity
of	I-Entity
amoxicillin	I-Entity
and	I-Entity
clavulanic	I-Entity
acid	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin	B-Entity
-	I-Entity
clavulanic	I-Entity
acid	I-Entity
-	O
induced	O
hepatitis	I-Entity
with	O
histologic	O
multiple	O
granulomas	I-Entity
.	O

This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B-Entity
injury	I-Entity
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B-Entity
syndrome	I-Entity
.	O

The	O
association	O
of	O
granulomas	I-Entity
and	O
eosinophilia	I-Entity
favor	O
an	O
immunoallergic	O
mechanism	O
.	O

As	O
penicillin	I-Entity
derivatives	O
and	O
amoxicillin	I-Entity
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	I-Entity
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	B-Entity
acid	I-Entity
,	O
might	O
have	O
a	O
major	O
role	O
.	O



Intracranial	B-Entity
aneurysms	I-Entity
and	O
cocaine	B-Entity
abuse	I-Entity
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

The	O
outcome	O
of	O
subarachnoid	B-Entity
hemorrhage	I-Entity
associated	O
with	O
cocaine	B-Entity
abuse	I-Entity
is	O
reportedly	O
poor	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6-year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	I-Entity
-	O
related	O
aneurysms	I-Entity
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-Entity
aneurysms	I-Entity
and	O
no	O
history	O
of	O
cocaine	B-Entity
abuse	I-Entity
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B-Entity
hemorrhage	I-Entity
,	O
size	O
of	O
the	O
aneurysm	I-Entity
,	O
location	O
of	O
the	O
aneurysm	I-Entity
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	I-Entity
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	I-Entity
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/-	O

0.007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	I-Entity
-	O
related	O
aneurysms	I-Entity
.	O

CONCLUSION	O
:	O
Cocaine	I-Entity
use	O
predisposed	O
aneurysmal	B-Entity
rupture	I-Entity
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	I-Entity
.	O



Anti	O
-	O
epileptic	I-Entity
drugs	O
-	O
induced	O
de	O
novo	O
absence	B-Entity
seizures	I-Entity
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-Entity
epilepsy	I-Entity
after	O
administration	O
of	O
carbamazepine	I-Entity
and	O
vigabatrin	I-Entity
.	O

Despite	O
the	O
underlying	O
diseases	O
,	O
the	O
prognosis	O
for	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Entity
seizure	I-Entity
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O

The	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B-Entity
epilepsy	I-Entity
.	O

Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Entity
seizure	I-Entity
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	B-Entity
seizure	I-Entity
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	I-Entity
frequency	O
and/or	O
new	O
seizure	I-Entity
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	B-Entity
epilepsy	I-Entity
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	I-Entity
and	O
prevent	O
drug	O
-	O
induced	O
absence	B-Entity
seizures	I-Entity
.	O



Procainamide	I-Entity
-	O
induced	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

Seven	O
cases	O
of	O
procainamide	I-Entity
-	O
induced	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
are	O
presented	O
.	O

In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	I-Entity
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	I-Entity
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	B-Entity
ventricular	I-Entity
contractions	I-Entity
or	O
atrial	B-Entity
flutter	I-Entity
.	O

These	O
patients	O
had	O
Q	B-Entity
-	I-Entity
T	I-Entity
prolongation	I-Entity
and	O
recurrent	O
syncope	I-Entity
due	O
to	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

In	O
four	O
patients	O
,	O
the	O
arrhythmia	I-Entity
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	I-Entity
.	O

In	O
two	O
patients	O
,	O
the	O
arrhythmia	I-Entity
degenerated	O
into	O
irreversible	O
ventricular	B-Entity
fibrillation	I-Entity
and	O
both	O
patients	O
died	O
.	O

In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	I-Entity
therapy	O
,	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
did	O
not	O
reoccur	O
.	O

These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	I-Entity
can	O
produce	O
an	O
acquired	O
prolonged	B-Entity
Q	I-Entity
-	I-Entity
T	I-Entity
syndrome	I-Entity
with	O
polymorphous	O
ventricular	B-Entity
tachycardia	I-Entity
.	O



Role	O
of	O
activation	O
of	O
bradykinin	I-Entity
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	I-Entity
.	O

Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	I-Entity
are	O
not	O
clear	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis	O
/	O
release	O
of	O
bradykinin	I-Entity
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	I-Entity
.	O

Permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent	O
-	O
labeled	O
dextran	I-Entity
before	O
and	O
during	O
phenylephrine	I-Entity
-	O
induced	O
acute	O
hypertension	I-Entity
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe-140	I-Entity
(	O
0.1	O
microM	O
)	O
.	O

Phenylephrine	I-Entity
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	I-Entity
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O

These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	I-Entity
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	I-Entity
to	O
activate	O
B2	O
receptors	O
.	O



5-azacytidine	I-Entity
potentiates	O
initiation	B-Entity
induced	I-Entity
by	I-Entity
carcinogens	I-Entity
in	O
rat	O
liver	O
.	O

To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	B-Entity
of	I-Entity
carcinogenic	I-Entity
process	I-Entity
,	O
5-azacytidine	I-Entity
(	O
5-AzC	I-Entity
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo[a]-pyrene	I-Entity
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
N	I-Entity
-	I-Entity
nitrosourea	I-Entity
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1,2-dimethylhydrazine	I-Entity
(	O
1,2-DMH	I-Entity
)	O

The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma	O
-	O
glutamyltransferase	O
(	O
gamma	O
-	O
GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2-week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0.02%	O
2-acetylaminofluorene	I-Entity
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	I-Entity
.	O

The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5-AzC	I-Entity
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
foci	O
/	O
cm2	O
in	O
5-AzC	I-Entity
and	O
carcinogen	O
-	O
treated	O
rats	O
compared	O
with	O
3	O
-	O
5	O
foci	O
/	O
cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O

Administration	O
of	O
[	B-Entity
3H]-5-azadeoxycytidine	I-Entity
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1,2-DMH	I-Entity
further	O
showed	O
that	O
0.019	O
mol	O
%	O
of	O
cytosine	I-Entity
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5-AzC	I-Entity
occurs	O
during	O
repair	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5-AzC	I-Entity
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma	O
-	O
GT	O
positive	O
foci	O
.	O



Withdrawal	B-Entity
-	I-Entity
emergent	I-Entity
rabbit	I-Entity
syndrome	I-Entity
during	O
dose	O
reduction	O
of	O
risperidone	I-Entity
.	O

Rabbit	B-Entity
syndrome	I-Entity
(	O
RS	I-Entity
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	B-Entity
-	I-Entity
emergent	I-Entity
RS	I-Entity
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patient	O
developed	O
RS	I-Entity
during	O
dose	O
reduction	O
of	O
risperidone	I-Entity
.	O

The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	I-Entity
anticholinergic	O
therapy	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	B-Entity
-	I-Entity
emergent	I-Entity
RS	I-Entity
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	I-Entity
,	O
a	O
serotonin	I-Entity
-	O
dopamine	I-Entity
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	I-Entity
system	O
in	O
the	O
development	O
of	O
RS	I-Entity
.	O



Verapamil	I-Entity
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-Entity
infarction	I-Entity
in	O
a	O
hypertensive	I-Entity
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O

Verapamil	I-Entity
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertensive	O
drug	O
.	O

Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	I-Entity
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B-Entity
infarction	I-Entity
coincided	O
with	O
the	O
introduction	O
of	O
captopril	I-Entity
and	O
the	O
withdrawal	O
of	O
verapamil	I-Entity
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	I-Entity
.	O

Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	I-Entity
-	O
related	O
increase	O
in	O
platelet	O
and/or	O
vascular	O
alpha	O
2-adrenoreceptor	O
affinity	O
for	O
catecholamines	I-Entity
are	O
discussed	O
.	O



Remission	O
induction	O
of	O
meningeal	B-Entity
leukemia	I-Entity
with	O
high	O
-	O
dose	O
intravenous	O
methotrexate	I-Entity
.	O

Twenty	O
children	O
with	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
who	O
developed	O
meningeal	B-Entity
disease	I-Entity
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
intravenous	O
methotrexate	I-Entity
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	I-Entity
concentrations	O
of	O
10(-5	O
)	O

The	O
methotrexate	I-Entity
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6,000	O
mg	O
/	O
m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1,200	O
mg	O
/	O
m2/h	O
for	O
23	O
hours	O
.	O

Leucovorin	I-Entity
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	I-Entity
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10(-7	O
)	O
mol	O
/	O
L.	O

The	O
mean	O
steady	O
-	O
state	O
plasma	O
and	O
CSF	O
methotrexate	I-Entity
concentrations	O
achieved	O
were	O
1.1	O
X	O
10(-3	O
)	O

The	O
most	O
common	O
toxicities	I-Entity
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	I-Entity
elevations	O
,	O
neutropenia	I-Entity
,	O
and	O
mucositis	I-Entity
.	O

One	O
patient	O
had	O
focal	O
seizures	I-Entity
and	O
transient	B-Entity
hemiparesis	I-Entity
but	O
recovered	O
completely	O
.	O

High	O
-	O
dose	O
intravenous	O
methotrexate	I-Entity
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
.	O



Hypersensitivity	I-Entity
to	O
carbamazepine	I-Entity
presenting	O
with	O
a	O
leukemoid	B-Entity
reaction	I-Entity
,	O
eosinophilia	I-Entity
,	O
erythroderma	I-Entity
,	O
and	O
renal	B-Entity
failure	I-Entity
.	O

We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	I-Entity
to	O
carbamazepine	I-Entity
presented	O
with	O
generalized	O
erythroderma	I-Entity
,	O
a	O
severe	O
leukemoid	B-Entity
reaction	I-Entity
,	O
eosinophilia	I-Entity
,	O
hyponatremia	I-Entity
,	O
and	O
renal	B-Entity
failure	I-Entity
.	O

This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	I-Entity
.	O



The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	I-Entity
's	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O

Partial	O
lesions	O
were	O
made	O
with	O
kainic	B-Entity
acid	I-Entity
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O

Compared	O
with	O
sham	O
-	O
operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0.25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomotor	B-Entity
hypoactivity	I-Entity
caused	O
by	O
nicotine	I-Entity
(	O
0.5	O
mg	O
kg(-1	O
)	O
,	O
i.m	O
.	O
)	O
,	O
enhanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicotine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O

Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	I-Entity
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0.025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	I-Entity
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O

We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	I-Entity
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O



Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
.	O

Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
.	O

To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12-lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
,	O
using	O
Tc99m	B-Entity
-	I-Entity
Sestamibi	I-Entity
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	I-Entity
.	O

:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	I-Entity
-	O
SPECT	O
/	O
dobutamine	I-Entity
stress	O
test	O
.	O

dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	I-Entity
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	I-Entity
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	I-Entity
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-Entity
ischemia	I-Entity
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O



Acute	B-Entity
liver	I-Entity
failure	I-Entity
in	O
two	O
patients	O
with	O
regular	O
alcohol	I-Entity
consumption	O
ingesting	O
paracetamol	I-Entity
at	O
therapeutic	O
dosage	O
.	O

The	O
possible	O
role	O
of	O
alcohol	I-Entity
in	O
the	O
development	O
of	O
hepatotoxicity	I-Entity
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	I-Entity
(	O
acetaminophen	I-Entity
)	O
is	O
currently	O
debated	O
.	O

We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	I-Entity
and	O
who	O
developed	O
liver	B-Entity
failure	I-Entity
within	O
3	O
-	O
5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	I-Entity
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	I-Entity
/	O
day	O
.	O

A	O
paracetamol	I-Entity
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O

Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	I-Entity
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	I-Entity
are	O
discussed	O
.	O

In	O
patients	O
with	O
risk	O
factors	O
,	O
e.g.	O
regular	O
consumption	O
of	O
alcohol	I-Entity
,	O
liver	B-Entity
failure	I-Entity
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O

We	O
propose	O
that	O
the	O
paracetamol	I-Entity
dose	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	I-Entity
.	O



Cocaine	I-Entity
related	O
chest	B-Entity
pain	I-Entity
:	O

The	O
recreational	O
use	O
of	O
cocaine	I-Entity
is	O
on	O
the	O
increase	O
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	I-Entity
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	I-Entity
to	O
produce	O
chest	B-Entity
pain	I-Entity
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B-Entity
pain	I-Entity
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

The	O
mechanism	O
of	O
chest	B-Entity
pain	I-Entity
related	O
to	O
cocaine	I-Entity
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	I-Entity
users	O
will	O
be	O
addressed	O
.	O



Severe	O
rhabdomyolysis	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	I-Entity
,	O
amiodarone	I-Entity
,	O
and	O
atazanavir	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	I-Entity
,	O
amiodarone	I-Entity
,	O
and	O
atazanavir	I-Entity
resulting	O
in	O
rhabdomyolysis	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

A	O
72-year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
,	O
atrial	B-Entity
fibrillation	I-Entity
,	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
and	O
hyperlipidemia	I-Entity
presented	O
with	O
generalized	O
pain	I-Entity
,	O
fatigue	I-Entity
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O

The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	I-Entity
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	I-Entity
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	I-Entity
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O

Laboratory	O
evaluation	O
revealed	O
66,680	O
U	O
/	O
L	O
creatine	I-Entity
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
,	O
4.6	O
mg	O
/	O
dL	O
creatinine	I-Entity
,	O
1579	O
U	O
/	O
L	O
aspartate	I-Entity
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	I-Entity
aminotransferase	O
.	O

Simvastatin	I-Entity
,	O
amiodarone	I-Entity
,	O
and	O
the	O
patient	O
's	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O

Nine	O
days	O
later	O
the	O
patient	O
's	O
creatine	I-Entity
kinase	O
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	I-Entity
was	O
3.3	O
mg	O
/	O
dL.	O
The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O

The	O
risk	O
of	O
rhabdomyolysis	I-Entity
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	I-Entity
metabolism	O
.	O

Simvastatin	I-Entity
is	O
metabolized	O
by	O
CYP3A4	O
.	O

Amiodarone	I-Entity
and	O
atazanavir	I-Entity
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O

CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	I-Entity
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O

In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	I-Entity
and	O
CYP3A4	O
inhibitors	O
,	O
pravastatin	I-Entity
,	O
fluvastatin	I-Entity
,	O
and	O
rosuvastatin	I-Entity
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	I-Entity
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	I-Entity
and	O
lovastatin	I-Entity
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	O
inhibitors	O
.	O



Phase	O
II	O
trial	O
of	O
vinorelbine	I-Entity
in	O
metastatic	O
squamous	B-Entity
cell	I-Entity
esophageal	I-Entity
carcinoma	I-Entity
.	O

European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	I-Entity
Gastrointestinal	O
Treat	O
Cancer	I-Entity
Cooperative	O
Group	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	I-Entity
(	O
VNB	I-Entity
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B-Entity
cell	I-Entity
esophageal	I-Entity
carcinoma	I-Entity
.	O

Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	I-Entity
-	O
based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	I-Entity
and	O
response	O
.	O

VNB	I-Entity
was	O
administered	O
weekly	O
as	O
a	O
25-mg	O
/	O
m2	O
short	O
intravenous	O
(	O
i.v	O
.	O
)	O

VNB	I-Entity
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	I-Entity
occurred	O
.	O

At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	I-Entity
was	O
seen	O
in	O
59%	O
of	O
patients	O
.	O

A	O
grade	O
2	O
or	O
3	O
infection	I-Entity
occurred	O
in	O
16%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	I-Entity
occurred	O
.	O

Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	B-Entity
neurotoxicity	I-Entity
has	O
been	O
minor	O
(	O
26%	O
grade	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	I-Entity
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B-Entity
squamous	I-Entity
cell	I-Entity
carcinoma	I-Entity
.	O

Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	I-Entity
,	O
further	O
evaluation	O
of	O
VNB	I-Entity
in	O
combination	O
therapy	O
is	O
warranted	O
.	O



Paclitaxel	I-Entity
,	O
cisplatin	I-Entity
,	O
and	O
gemcitabine	I-Entity
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	B-Entity
cell	I-Entity
lung	I-Entity
carcinoma	I-Entity
.	O

Cisplatin	I-Entity
-	O
based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B-Entity
cell	I-Entity
lung	I-Entity
carcinoma	I-Entity
(	O
NSCLC	I-Entity
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	I-Entity
of	O
a	O
paclitaxel	I-Entity
,	O
cisplatin	I-Entity
,	O
and	O
gemcitabine	I-Entity
combination	O
to	O
treat	O
metastatic	O
NSCLC	I-Entity
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	I-Entity
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	I-Entity
(	O
135	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	I-Entity
(	O
120	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	I-Entity
(	O
800	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	I-Entity
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	I-Entity
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m(2	O
)	O
for	O
paclitaxel	I-Entity
(	O
97.3%	O
)	O
,	O
117	O
mg	O
/	O
m(2	O
)	O
for	O
cisplatin	I-Entity
(	O
97.3%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m(2	O
)	O
for	O
gemcitabine	I-Entity
(	O
86.2%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	I-Entity
and	O
thrombocytopenia	I-Entity
occurred	O
in	O
39.9%	O
and	O
11.4%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
one	O
treatment	O
-	O
related	O
death	I-Entity
.	O

Nonhematologic	O
toxicities	I-Entity
were	O
mild	O
.	O

The	O
combination	O
of	O
paclitaxel	I-Entity
,	O
cisplatin	I-Entity
,	O
and	O
gemcitabine	I-Entity
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	I-Entity
.	O

This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	I-Entity
-	O
based	O
regimens	O
.	O



Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	B-Entity
hydrochloride	I-Entity
ophthalmic	O
solution	O
.	O

We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	I-Entity
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1%	O
apraclonidine	I-Entity
in	O
their	O
right	O
eyes	O
.	O

The	O
ocular	B-Entity
hypotensive	I-Entity
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	I-Entity
-	O
treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1%	O
apraclonidine	I-Entity
.	O

Decreases	B-Entity
in	I-Entity
systolic	I-Entity
blood	I-Entity
pressure	I-Entity
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O

Conjunctival	B-Entity
blanching	I-Entity
and	O
mydriasis	I-Entity
were	O
commonly	O
found	O
.	O

While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	I-Entity
and	O
marked	O
corneal	B-Entity
abrasion	I-Entity
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O



Carmofur	I-Entity
-	O
induced	O
organic	B-Entity
mental	I-Entity
disorders	I-Entity
.	O

Organic	B-Entity
mental	I-Entity
disorder	I-Entity
was	O
observed	O
in	O
a	O
29-year	O
-	O
old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	I-Entity
-	O
induced	O
leukoencephalopathy	I-Entity
.	O

Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	B-Entity
personality	I-Entity
syndrome	I-Entity
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R.	O
It	O
is	O
referred	O
to	O
as	O
a	O
frontal	B-Entity
lobe	I-Entity
syndrome	I-Entity
.	O

Consequently	O
,	O
carmofur	I-Entity
-	O
induced	O
leukoencephalopathy	I-Entity
may	O
uncommonly	O
result	O
in	O
organic	B-Entity
personality	I-Entity
syndrome	I-Entity
in	O
the	O
residual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
structural	B-Entity
damage	I-Entity
to	I-Entity
the	I-Entity
frontal	I-Entity
lobe	I-Entity
.	O



International	O
mexiletine	I-Entity
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I.	O
Report	O
on	O
arrhythmia	I-Entity
and	O
other	O
findings	O
.	O

The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	I-Entity
(	O
Mexitil	B-Entity
-	I-Entity
Perlongets	I-Entity
)	O
were	O
evaluated	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B-Entity
infarction	I-Entity
.	O

Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	I-Entity
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O

These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	I-Entity
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	O
.	O

There	O
were	O
more	O
deaths	I-Entity
in	O
the	O
mexiletine	I-Entity
group	O
(	O
7.6%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4.8%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	I-Entity
and	O
gastrointestinal	B-Entity
problems	I-Entity
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	I-Entity
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O



Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
by	O
intracerebral	O
calcitonin	I-Entity
injections	O
.	O

Calcitonin	I-Entity
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	I-Entity
can	O
produce	O
behavioral	O
effects	O
.	O

Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	I-Entity
-	O
induced	O
locomotor	O
activity	O
.	O

In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	I-Entity
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O

In	O
the	O
present	O
experiment	O
calcitonin	I-Entity
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O

The	O
areas	O
where	O
calcitonin	I-Entity
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	I-Entity
in	O
inhibiting	O
amphetamine	I-Entity
-	O
induced	O
locomotor	O
activity	O
.	O



Fatal	O
intracranial	B-Entity
bleeding	I-Entity
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	I-Entity
.	O

We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B-Entity
reaction	I-Entity
in	O
a	O
case	O
of	O
pulmonary	B-Entity
edema	I-Entity
with	O
wheezing	I-Entity
.	O

The	O
sudden	O
onset	O
of	O
respiratory	B-Entity
distress	I-Entity
,	O
rash	I-Entity
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	I-Entity
.	O

Subsequently	O
,	O
acute	O
cardiac	B-Entity
arrest	I-Entity
and	O
fatal	O
subarachnoid	B-Entity
hemorrhage	I-Entity
occurred	O
.	O

Epinephrine	I-Entity
has	O
a	O
proven	O
role	O
in	O
cardiac	B-Entity
arrest	I-Entity
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-Entity
reaction	I-Entity
and	O
severe	O
hypertension	I-Entity
should	O
be	O
viewed	O
with	O
caution	O
.	O



A	O
case	O
of	O
massive	O
rhabdomyolysis	I-Entity
following	O
molindone	I-Entity
administration	O
.	O

Rhabdomyolysis	I-Entity
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	I-Entity
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O

The	O
clinical	O
signs	O
and	O
symptoms	O
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	O
of	O
rhabdomyolysis	I-Entity
are	O
presented	O
.	O

The	O
case	O
of	O
a	O
schizophrenic	I-Entity
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	I-Entity
and	O
subsequent	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
molindone	I-Entity
administration	O
.	O

Physicians	O
who	O
prescribe	O
molindone	I-Entity
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O



Cardiovascular	B-Entity
alterations	I-Entity
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	I-Entity
channel	O
blockers	O
.	O

Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	I-Entity
channel	O
blocker	O
,	O
Ro	B-Entity
40	I-Entity
-	I-Entity
5967	I-Entity
,	O
induced	O
cardiovascular	B-Entity
alterations	I-Entity
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	I-Entity
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	B-Entity
malformations	I-Entity
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O

We	O
studied	O
three	O
calcium	I-Entity
channel	O
blockers	O
of	O
different	O
structure	O
,	O
nifedipine	I-Entity
,	O
diltiazem	I-Entity
,	O
and	O
verapamil	I-Entity
,	O
along	O
with	O
the	O
new	O
agent	O
.	O

Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	I-Entity
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B-Entity
malformations	I-Entity
.	O

A	O
low	O
incidence	O
of	O
cardiovascular	B-Entity
malformations	I-Entity
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	I-Entity
channel	O
blockers	O
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	I-Entity
and	O
nifedipine	I-Entity
.	O

All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	B-Entity
40	I-Entity
-	I-Entity
5967	I-Entity
and	O
verapamil	I-Entity
.	O



Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120	O
T	O
on	O
the	O
replication	O
of	O
lamivudine	I-Entity
-	O
resistant	O
hepatitis	B-Entity
B	I-Entity
virus	I-Entity
e	I-Entity
antigen	I-Entity
-	O
positive	O
and	O
-negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120	O
T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	I-Entity
(	O
LAM	I-Entity
)	O
and/or	O
HBeAg	I-Entity
negativity	O
.	O

Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120	O
T	O
and	O
LAM	I-Entity
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O

/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	I-Entity
-	O
positive	O
and	O
an	O
HBeAg	I-Entity
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	I-Entity
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	I-Entity
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120	O
T	O
substitution	O
also	O
impaired	O
HBsAg	I-Entity
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	I-Entity
-	O
resistant	O
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	I-Entity
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120	O
T	O
,	O
and	O
LAM	I-Entity
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	I-Entity
resistance	O
mutations	O
,	O
the	O
nucleotide	I-Entity
analogues	O
adefovir	I-Entity
and	O
tenofovir	I-Entity
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O



The	O
effects	O
of	O
sevoflurane	I-Entity
on	O
lidocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O

The	O
influence	O
of	O
sevoflurane	I-Entity
on	O
lidocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
was	O
studied	O
in	O
cats	O
.	O

The	O
convulsive	I-Entity
threshold	O
(	O
mean	O
+	O
/-	O

l(-1	O
)	O
with	O
lidocaine	I-Entity
infusion	O
(	O
6	O
mg.kg(-1).min(-1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66.6	O
+	O
/-	O

l(-1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	I-Entity
was	O
0.8%	O
.	O

l(-1	O
)	O
)	O
during	O
1.6%	O
sevoflurane	I-Entity
was	O
not	O
significant	O
from	O
that	O
during	O
0.8%	O
sevoflurane	I-Entity
,	O
indicating	O
a	O
celling	O
effect	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	I-Entity
threshold	O
between	O
sevoflurane	I-Entity
and	O
enflurane	I-Entity
.	O

The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	I-Entity
or	O
enflurane	I-Entity
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	I-Entity
decreased	O
significantly	O
in	O
1.6%	O
sevoflurane	I-Entity
,	O
and	O
in	O
0.8%	O
and	O
1.6%	O
enflurane	I-Entity
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	I-Entity
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

Apamin	I-Entity
,	O
a	O
selective	O
blocker	O
of	O
calcium	I-Entity
-	O
dependent	O
potassium	I-Entity
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0.8%	O
sevoflurane	I-Entity
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O

Apamin	I-Entity
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	I-Entity
threshold	O
(	O
21.6	O
+	O
/-	O

It	O
is	O
suggested	O
that	O
sevoflurane	I-Entity
reduces	O
the	O
convulsive	I-Entity
effect	O
of	O
lidocaine	I-Entity
toxicity	I-Entity
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	I-Entity
.	O



Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	I-Entity
in	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
the	O
rat	O
.	O
1	O
.	O

Dexamethasone	I-Entity

(	O
Dex)-induced	I-Entity
hypertension	I-Entity
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
deficiency	O
and	O
increased	O
superoxide	I-Entity
(	O
O2-	I-Entity
)	O
production	O
.	O

Atorvastatin	I-Entity
(	O
Ato	I-Entity
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	I-Entity
and	O
reduced	O
O2-	I-Entity
production	O
in	O
various	O
forms	O
of	O
hypertension	I-Entity
.	O

,	O
Ato	I-Entity
could	O
prevent	O
endothelial	O

NO	I-Entity
synthase	O
(	O
eNOS	O
)	O

downregulation	O
and	O
the	O
increase	O
in	O
O2-	I-Entity
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O

were	O
treated	O
with	O
Ato	I-Entity
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dexamethasone	I-Entity
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s.c	O
.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	I-Entity
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O

Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	I-Entity
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	I-Entity
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O

In	O
rats	O
treated	O
with	O
Dex	I-Entity
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/-	O

In	O
the	O
Ato	I-Entity
+	O
Dex	I-Entity
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/-	O

<	O
0.001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	I-Entity
alone	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	I-Entity
+	O
Ato	I-Entity
group	O
than	O
in	O
the	O
Dex	I-Entity
only	O
group	O
(	O
P	O
<	O
0.05	O
and	O
P	O

Aortic	O
superoxide	I-Entity
production	O
was	O
lower	O
in	O
the	O
Dex	I-Entity
+	O
Ato	I-Entity
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	I-Entity
alone	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Treatment	O
with	O
Ato	I-Entity
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	I-Entity
production	O
and	O
reduced	O
SBP	O
in	O
Dex	I-Entity
-	O
treated	O
SD	O
rats	O
.	O



99mTc	B-Entity
-	I-Entity
glucarate	I-Entity
for	O
detection	O
of	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

Infarct	I-Entity
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Entity
infarction	I-Entity
.	O

The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	I-Entity
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	I-Entity
.	O

A	O
new	O
infarct	I-Entity
-	O
avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	B-Entity
acid	I-Entity
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	B-Entity
-	I-Entity
glucarate	I-Entity
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	I-Entity
-	O
induced	O
acute	O
myocardial	B-Entity
infarction	I-Entity
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	I-Entity
18	O
h	O
after	O
isoproterenol	I-Entity
administration	O
.	O

Thirty	O
minutes	O
after	O
99mTc	B-Entity
-	I-Entity
glucarate	I-Entity
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S(h)UV	O
was	O
4.7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B-Entity
infarction	I-Entity
.	O



A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
dose	O
-	O
comparison	O
trial	O
of	O
haloperidol	I-Entity
for	O
psychosis	I-Entity
and	O
disruptive	B-Entity
behaviors	I-Entity
in	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	I-Entity
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	I-Entity
and	O
disruptive	B-Entity
behaviors	I-Entity
in	O
patients	O
with	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O

In	O
a	O
6-week	O
random	O
-	O
assignment	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	I-Entity
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	I-Entity
,	O
0.50	O
-	O
0.75	O
mg	O
/	O
day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O

For	O
the	O
subsequent	O
6-week	O
double	O
-	O
blind	O
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard-	O
or	O
low	O
-	O
dose	O
haloperidol	I-Entity
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard-	O
or	O
low	O
-	O
dose	O
haloperidol	I-Entity
.	O

For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard	O
-	O
dose	O
haloperidol	I-Entity
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dose	O
haloperidol	I-Entity
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	I-Entity
factor	O
and	O
on	O
psychomotor	B-Entity
agitation	I-Entity
.	O

In	O
phase	O
A	O
,	O
extrapyramidal	B-Entity
signs	I-Entity
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O

Low	O
-	O
dose	O
haloperidol	I-Entity
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O

The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	I-Entity
in	O
doses	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B-Entity
signs	I-Entity
.	O

The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	I-Entity
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
patients	O
with	O
psychosis	I-Entity
and	O
disruptive	B-Entity
behaviors	I-Entity
.	O



Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	I-Entity
-	O
induced	O
renal	B-Entity
damage	I-Entity
.	O

In	O
man	O
,	O
differences	O
in	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	O
prognosis	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	B-Entity
damage	I-Entity
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	I-Entity
in	O
rats	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip	B-Entity
-	I-Entity
His	I-Entity
-	I-Entity
Leu	I-Entity
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O

After	O
1	O
week	O
of	O
recovery	O
,	O
proteinuria	I-Entity
was	O
induced	O
by	O
adriamycin	I-Entity
[	O
1.5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i.v	O
.	O
)	O

Proteinuria	I-Entity
was	O
measured	O
every	O
2	O
weeks	O
.	O

As	O
anticipated	O
,	O
adriamycin	I-Entity
elicited	O
nephrotic	I-Entity
range	O
proteinuria	I-Entity
,	O
renal	B-Entity
interstitial	I-Entity
damage	I-Entity
and	O
mild	O
focal	B-Entity
glomerulosclerosis	I-Entity
.	O

Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	I-Entity
after	O
adriamycin	I-Entity
(	O
r	O
=	O
0.62	O
,	O
P<0.01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.49	O
,	O
P<0.05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0.56	O
,	O
P<0.05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0.53	O
,	O
P<0.05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.74	O
,	O
P<0.01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0.48	O
,	O
P<0.05	O
)	O
.	O

ACE	O
did	O
not	O
correlate	O
with	O
focal	B-Entity
glomerulosclerosis	I-Entity
(	O
r	O
=	O
0.22	O
,	O
NS	O
)	O
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	I-Entity
-	O
induced	O
renal	B-Entity
damage	I-Entity
in	O
this	O
outbred	O
rat	O
strain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B-Entity
damage	I-Entity
.	O



Clinical	O
nephrotoxicity	I-Entity
of	O
tobramycin	I-Entity
and	O
gentamicin	I-Entity
.	O

Nearly	O
3.2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	I-Entity
antibiotics	O
annually	O
.	O

Gentamicin	B-Entity
sulfate	I-Entity
and	O
tobramycin	B-Entity
sulfate	I-Entity
continue	O
to	O
demonstrate	O
ototoxicity	I-Entity
and	O
nephrotoxicity	I-Entity
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamicin	B-Entity
sulfate	I-Entity
or	O
tobramycin	B-Entity
sulfate	I-Entity
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	I-Entity
-	O
related	O
renal	B-Entity
failure	I-Entity
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	O
function	O
.	O

In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B-Entity
failure	I-Entity
could	O
be	O
identified	O
.	O

Five	O
of	O
33	O
(	O
15%	O
)	O
of	O
the	O
tobramycin	I-Entity
-	O
treated	O
patients	O
and	O
16	O
of	O
29	O
(	O
55.2%	O
)	O
of	O
the	O
gentamicin	I-Entity
-	O
treated	O
patients	O
had	O
renal	B-Entity
failure	I-Entity
.	O

Thus	O
,	O
gentamicin	I-Entity
was	O
associated	O
with	O
renal	B-Entity
failure	I-Entity
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	I-Entity
.	O



Neuroprotective	O
action	O
of	O
MPEP	I-Entity
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	I-Entity
-	O
induced	O
dopaminergic	O
neurotoxicity	I-Entity
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	I-Entity
outflow	O
and	O
inhibition	O
of	O
hyperthermia	I-Entity
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	I-Entity
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	I-Entity
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

Methamphetamine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	I-Entity
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2-methyl-6-(phenylethynyl)pyridine	I-Entity
(	O
MPEP	I-Entity
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	I-Entity
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	I-Entity
effects	O
.	O

A	O
single	O
MPEP	I-Entity
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	I-Entity
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	I-Entity
release	O
stimulated	O
either	O
by	O
methamphetamine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	I-Entity
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
sc)-induced	O
hyperthermia	I-Entity
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

MPEP	I-Entity
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	I-Entity
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	I-Entity
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	I-Entity
-	O
induced	O
toxicity	I-Entity
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	I-Entity
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	I-Entity
-	O
induced	O
dopamine	I-Entity
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	I-Entity
.	O



Pharmacokinetics	O
of	O
desipramine	B-Entity
HCl	I-Entity
when	O
administered	O
with	O
cinacalcet	B-Entity
HCl	I-Entity
.	O

In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	I-Entity
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	I-Entity
on	O
CYP2D6	O
activity	O
,	O
using	O
desipramine	I-Entity
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O

Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	I-Entity
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	I-Entity
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O

Relative	O
to	O
desipramine	I-Entity
alone	O
,	O
mean	O
AUC	O
and	O
C(max	O
)	O
of	O
desipramine	I-Entity
increased	O
3.6-	O
and	O
1.8-fold	O
when	O
coadministered	O
with	O
cinacalcet	I-Entity
.	O

The	O
t	O
(	O
1/2,z	O
)	O
of	O
desipramine	I-Entity
was	O
longer	O
when	O
desipramine	I-Entity
was	O
coadministered	O
with	O
cinacalcet	I-Entity
(	O
21.0	O
versus	O
43.3	O
hs	O
)	O
.	O

Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	I-Entity
alone	O
than	O
when	O
receiving	O
desipramine	I-Entity
with	O
cinacalcet	I-Entity
(	O
33	O
versus	O
86%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	I-Entity
and	O
headache	I-Entity
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	I-Entity
or	O
cinacalcet	I-Entity
.	O

This	O
study	O
demonstrates	O
that	O
cinacalcet	I-Entity
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O

These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	I-Entity
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O



Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
-	O
induced	O
dyskinesia	I-Entity
.	O

L	B-Entity
-	I-Entity
DOPA	I-Entity
-	O
induced	O
dyskinesia	I-Entity
(	O
LID	I-Entity
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
.	O

To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	I-Entity
[	O
Neurobiol	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6-hydroxydopamine	I-Entity
-	O
lesion	O
rat	O
model	O
of	O
PD	I-Entity
treated	O
with	O
saline	O
,	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
or	O
bromocriptine	I-Entity
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

Rats	O
treated	O
with	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	I-Entity
.	O

Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	I-Entity
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	O
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha-2	O
subunit	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	I-Entity
.	O



Pseudo	O
-	O
allergic	B-Entity
reactions	I-Entity
to	O
corticosteroids	I-Entity
:	O
diagnosis	O
and	O
alternatives	O
.	O

Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	I-Entity
(	O
Triniol	O
)	O
and	O
dexamethasone	I-Entity
(	O
Sedionbel	O
)	O
are	O
described	O
.	O

A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	O
,	O
they	O
presented	O
urticaria	I-Entity
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	I-Entity
(	O
patient	O
1	O
)	O
.	O

Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	I-Entity
and	O
ELISA	O
tests	O
were	O
performed	O
.	O

In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	I-Entity
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	O
.	O

We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	I-Entity
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O

These	O
results	O
suggest	O
that	O
paramethasone	I-Entity
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O

Corticosteroids	O
different	O
from	O
paramethasone	I-Entity
also	O
produced	O
hypersensitivity	I-Entity
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo	O
-	O
allergy	I-Entity
caused	O
by	O
paramethasone	I-Entity
.	O



Valproic	B-Entity
acid	I-Entity
induced	O
encephalopathy--19	I-Entity
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-a	O
side	O
effect	O
associated	O
to	O
VPA	I-Entity
-	O
therapy	O
not	O
only	O
in	O
young	O
children	O
.	O

Valproic	B-Entity
acid	I-Entity
(	O
VPA	I-Entity
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	I-Entity
,	O
bone	B-Entity
marrow	I-Entity
suppression	I-Entity
,	O
VPA	I-Entity
-	O
induced	O
hepatotoxicity	I-Entity
and	O
VPA	I-Entity
-	O
induced	O
encephalopathy	I-Entity
.	O

The	O
typical	O
signs	O
of	O
VPA	I-Entity
-	O
induced	O
encephalopathy	I-Entity
are	O
impaired	B-Entity
consciousness	I-Entity
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	I-Entity
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	I-Entity
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	I-Entity
in	O
patients	O
with	O
encephalopathy	I-Entity
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
report	O
19	O
patients	O
with	O
VPA	I-Entity
-	O
associated	O
encephalopathy	I-Entity
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O



Haemolytic	B-Entity
-	I-Entity
uraemic	I-Entity
syndrome	I-Entity
after	O
treatment	O
with	O
metronidazole	I-Entity
.	O

This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic	B-Entity
-	I-Entity
uraemic	I-Entity
syndrome	I-Entity
after	O
treatment	O
with	O
metronidazole	I-Entity
.	O

While	O
the	O
involvement	O
of	O
metronidazole	I-Entity
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	B-Entity
-	I-Entity
uraemic	I-Entity
syndrome	I-Entity
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	B-Entity
-	I-Entity
uraemic	I-Entity
syndrome	I-Entity
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	I-Entity
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	B-Entity
-	I-Entity
uraemic	I-Entity
syndrome	I-Entity
.	O



Risk	O
factors	O
of	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
in	O
preterm	O
infants	O
.	O

Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1.46%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
.	O

Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B-Entity
loss	I-Entity
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications	O
.	O

Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B-Entity
loss	I-Entity
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	O
.	O

Ototoxicity	I-Entity
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	I-Entity
drugs	O
,	O
particularly	O
aminoglycosides	I-Entity
and	O
furosemide	I-Entity
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-Entity
loss	I-Entity
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O



Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	I-Entity
-	O
associated	O
mental	O
confusion	I-Entity
.	O

15	O
cases	O
of	O
cimetidine	I-Entity
-	O
associated	O
mental	O
confusion	I-Entity
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M.S.	O
)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M.S.	O
change	O
on	O
cimetidine	I-Entity
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O

These	O
6	O
patients	O
had	O
both	O
renal	B-Entity
and	I-Entity
liver	I-Entity
dysfunction	I-Entity
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	I-Entity
trough	O
-	O
concentrations	O
of	O
more	O
than	O
1.25	O
microgram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	I-Entity
concentrations	O
was	O
0.24:1	O
and	O
indicates	O
that	O
cimetidine	I-Entity
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M.S.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	I-Entity
H2-receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentrations	O
and	O
mental	O
confusion	I-Entity
are	O
those	O
with	O
both	O
severe	O
renal	B-Entity
and	I-Entity
hepatic	I-Entity
dysfunction	I-Entity
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	I-Entity
.	O



Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	B-Entity
and	I-Entity
extrahepatic	I-Entity
cholestasis	I-Entity
.	O

Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	I-Entity
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O

We	O
used	O
rat	O
models	O
of	O
intrahepatic	B-Entity
cholestasis	I-Entity
by	O
ethinyl	B-Entity
estradiol	I-Entity
(	O
EE	I-Entity
)	O
treatment	O
and	O
extrahepatic	B-Entity
cholestasis	I-Entity
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O

After	O
EE	I-Entity
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	I-Entity
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O



Long	O
term	O
audiological	O
evaluation	O
of	O
beta	B-Entity
-	I-Entity
thalassemic	I-Entity
patients	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	B-Entity
loss	I-Entity
in	O
children	O
and	O
young	O
adults	O
with	O
beta	B-Entity
-	I-Entity
thalassemia	I-Entity
major	O
.	O

Subjects	O
were	O
receiving	O
desferrioxamine	I-Entity
(	O
DFO	I-Entity
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O

Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20.2%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B-Entity
hearing	I-Entity
loss	I-Entity
(	O
SNHL	I-Entity
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O

No	O
ototoxic	I-Entity
factor	O
,	O
other	O
than	O
DFO	I-Entity
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
SNHL	I-Entity
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O

Subjects	O
with	O
SNHL	I-Entity
were	O
submitted	O
to	O
DFO	I-Entity
reduction	O
or	O
temporary	O
withdrawal	O
.	O

CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	I-Entity
's	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	B-Entity
impairment	I-Entity
.	O

Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	I-Entity
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	B-Entity
impairment	I-Entity
.	O



Design	O
and	O
analysis	O
of	O
the	O
HYPREN	O
-	O
trial	O
:	O
safety	O
of	O
enalapril	I-Entity
and	O
prazosin	I-Entity
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
.	O

Since	O
the	O
introduction	O
of	O
angiotensin	B-Entity
converting	I-Entity
enzyme	I-Entity
(	I-Entity
ACE	I-Entity
)	I-Entity
inhibitors	I-Entity
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
,	O
cases	O
of	O
severe	O
hypotension	I-Entity
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	B-Entity
inhibitor	I-Entity
enalapril	I-Entity
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin	I-Entity
-	O
controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	I-Entity
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O

Trial	O
medication	O
was	O
2.5	O
mg	O
enalapril	I-Entity
or	O
0.5	O
prazosin	I-Entity
.	O

Patients	O
who	O
received	O
enalapril	I-Entity
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	I-Entity
(	O
5.2%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	I-Entity
(	O
12.9%	O
)	O
.	O

It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	I-Entity
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	I-Entity
to	O
inpatients	O
.	O



Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	I-Entity
-	O
induced	O
anemia	I-Entity
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Azidothymidine	I-Entity
(	O
AZT)-induced	I-Entity
anemia	I-Entity
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL-3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL-3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL-3	O
and	O
EPO	O
in	O
AZT	I-Entity
-	O
treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL-3	O
or	O
EPO	O
alone	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	I-Entity
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL-3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL-3	O
significantly	O
reduced	O
thymidine	I-Entity
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O



Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na]o	I-Entity
and	O
[	O
Ca]o	I-Entity
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O

The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	I-Entity
and	O
Ca	I-Entity
(	O
[	O
Na]o	I-Entity
and	O
[	O
Ca]o	I-Entity
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	I-Entity
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O

in	O
control	O
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	O
Na	I-Entity
and	O
1.35	O
mM	O
Ca	I-Entity
(	O
N	O
)	O
.	O

3%	O
by	O
lowering	O
[	O
Na]o	I-Entity
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O

[	O
Na]o	I-Entity
to	O
78	O
mM	O
and	O
[	O
Ca]o	I-Entity
to	O
0.675	O
mM	O
(	O
LNa+LCa	O
)	O
and	O
31	O
+	O
/-	O

5%	O
by	O
lowering	O
[	O
Na]o	I-Entity
to	O
78	O

mM	O
plus	O
increasing	O
[	O
Ca]o	I-Entity
to	O
3.6	O
mM	O
(	O
LNa+HCa	O
)	O
.	O

At	O
normal	O
[	O
Na]o	I-Entity
,	O
decrease	O
(	O
0.675	O
mM	O
)	O
or	O
increase	O
(	O
3.6	O
mM	O
)	O
of	O
[	O
Ca]o	I-Entity
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0.135	O
mM	O
of	O
normal	O
[	O
Ca]o	I-Entity
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+	O
/-	O

Dose	O
-	O
dependent	O
bradycardia	I-Entity
induced	O
by	O
verapamil	I-Entity
was	O
potentiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	I-Entity
and	O
Ca	I-Entity
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil]o	I-Entity
needed	O
to	O
reduce	O
BF	O
by	O
30%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O

The	O
[	O
verapamil]o	I-Entity
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O

The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na]o	I-Entity
than	O
on	O
[	O
Ca]o	I-Entity
in	O
a	O
range	O
of	O
+	O
/-	O

Also	O
the	O
enhancement	O
of	O
verapamil	I-Entity
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Sodium	I-Entity
status	O
influences	O
chronic	O
amphotericin	B-Entity
B	I-Entity
nephrotoxicity	I-Entity
in	O
rats	O
.	O

The	O
nephrotoxic	I-Entity
potential	O
of	O
amphotericin	B-Entity
B	I-Entity
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
.	O

In	O
salt	O
-	O
depleted	O
rats	O
,	O
amphotericin	B-Entity
B	I-Entity
decreased	O
creatinine	I-Entity
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85%	O
reduction	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	O
rats	O
creatinine	I-Entity
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	O
-	O
loaded	O
rats	O
creatinine	I-Entity
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43%	O
at	O
week	O
3	O
.	O

All	O
rats	O
in	O
the	O
sodium	I-Entity
-	O
depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	O
or	O
salt	O
-	O
loaded	O
rat	O
.	O

Concentrations	O
of	O
amphotericin	B-Entity
B	I-Entity
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	B-Entity
B	I-Entity
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt	O
-	O
depleted	O
and	O
normal	O
-	O
salt	O
rats	O
than	O
those	O
in	O
salt	O
-	O
loaded	O
rats	O
,	O
with	O
plasma	O
/	O
kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	I-Entity
clearance	O
and	O
renal	O
amphotericin	B-Entity
B	I-Entity
accumulation	O
after	O
chronic	O
amphotericin	B-Entity
B	I-Entity
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	I-Entity
loading	O
in	O
rats	O
.	O



Reversible	O
inferior	B-Entity
colliculus	I-Entity
lesion	I-Entity
in	O
metronidazole	I-Entity
-	O
induced	O
encephalopathy	I-Entity
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Entity
colliculus	I-Entity
lesions	I-Entity
in	O
metronidazole	I-Entity
-	O
induced	O
encephalopathy	I-Entity
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O

From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	I-Entity
-	O
induced	O
encephalopathy	I-Entity
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazole	I-Entity
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	I-Entity
in	O
various	O
organs	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	I-Entity
administration	O
.	O

All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B-Entity
lesion	I-Entity
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Entity
colliculus	I-Entity
lesions	I-Entity
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	I-Entity
-	O
induced	O
encephalopathy	I-Entity
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O



infusions	O
of	O
morphine	I-Entity
and	O
regional	O
analgesia	O
by	O
extradural	O
block	O
.	O

The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	I-Entity
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i.v	O
.	O

infusion	O
of	O
morphine	I-Entity
(	O
mean	O
73.6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0.25%	O
bupivacaine	I-Entity
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24-h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O

Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	B-Entity
dioxide	I-Entity
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O

Both	O
obstructive	B-Entity
(	I-Entity
P	I-Entity
less	I-Entity
than	I-Entity
0.05	I-Entity
)	I-Entity
and	I-Entity
central	I-Entity
apnoea	I-Entity
(	O
P	O
less	O
than	O
0.05	O
)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	I-Entity
infusion	O
.	O

There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	I-Entity
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
ventricular	B-Entity
ectopic	I-Entity
beats	I-Entity
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
the	O
morphine	I-Entity
infusion	O
group	O
.	O



Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	I-Entity
patients	O
after	O
phenytoin	I-Entity
overdosages	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	I-Entity
medication	O
and	O
cerebellar	B-Entity
atrophy	I-Entity
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O

Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	I-Entity
duration	O
,	O
elevation	O
of	O
phenytoin	I-Entity
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O

However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	I-Entity
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O

We	O
conclude	O
that	O
phenytoin	I-Entity
overdosage	I-Entity
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-Entity
atrophy	I-Entity
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	I-Entity
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-Entity
atrophy	I-Entity
in	O
the	O
remaining	O
patients	O
.	O

Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B-Entity
disorders	I-Entity
.	O



Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B-Entity
damage	I-Entity
in	O
doxorubicin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	B-Entity
cell	I-Entity
injury	I-Entity
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Entity
damage	I-Entity
in	O
a	O
rat	O
model	O
of	O
doxorubicin	I-Entity
(	O
DOX)-induced	I-Entity
cardiomyopathy	I-Entity
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B-Entity
disorders	I-Entity
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1.5	O
mg	O
/	O
kg	O
DOX	I-Entity
,	O
i.v	O
.	O

By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	I-Entity
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	I-Entity
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	I-Entity
dose	O
and	O
in	O
all	O
controls	O
.	O

Eighteen	O
of	O
the	O
DOX	I-Entity
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	I-Entity
during	O
the	O
9-week	O
period	O
.	O

/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	I-Entity
group	O
(	O
p<0.001	O
)	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	I-Entity
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	I-Entity
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	I-Entity
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	I-Entity
rats	O
after	O
cumulative	O
doses	O
of	O
7.5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p<0.05	O
)	O
.	O

/	O
kg	O
DOX	I-Entity
.	O

and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	I-Entity
rats	O
compared	O
with	O
controls	O
(	O
p=0.006	O
,	O
0.007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	I-Entity
rats	O
compared	O
with	O
controls	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B-Entity
injury	I-Entity
after	O
DOX	I-Entity
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B-Entity
damage	I-Entity
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	I-Entity
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	I-Entity
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	I-Entity
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O



Calcineurin	O
-	O
inhibitor	O
induced	O
pain	I-Entity
syndrome	O
(	O
CIPS	I-Entity
)	O
:	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	I-Entity
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	I-Entity
.	O

Nine	O
patients	O
with	O
severe	O
pain	I-Entity
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O

Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	B-Entity
marrow	I-Entity
oedema	I-Entity
in	O
the	O
painful	O
bones	O
.	O

Pain	I-Entity
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	I-Entity
,	O
like	O
reflex	B-Entity
sympathetic	I-Entity
dystrophy	I-Entity
,	O
polyneuropathy	I-Entity
,	O
Morton	B-Entity
's	I-Entity
neuralgia	I-Entity
,	O
gout	I-Entity
,	O
osteoporosis	I-Entity
,	O
avascular	B-Entity
necrosis	I-Entity
,	O
intermittent	B-Entity
claudication	I-Entity
,	O
orthopaedic	O
foot	B-Entity
deformities	I-Entity
,	O
stress	B-Entity
fractures	I-Entity
,	O
and	O
hyperparathyroidism	I-Entity
.	O

The	O
reduction	O
of	O
cyclosporine-	I-Entity
or	O
tacrolimus	I-Entity
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	I-Entity
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	I-Entity
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	I-Entity
Syndrome	O
(	O
CIPS	I-Entity
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	I-Entity
or	O
tacrolimus	I-Entity
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	I-Entity
.	O



The	O
haemodynamic	O
effects	O
of	O
propofol	I-Entity
in	O
combination	O
with	O
ephedrine	I-Entity
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	I-Entity
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	I-Entity
to	O
propofol	I-Entity
in	O
order	O
to	O
obtund	O
the	O
hypotensive	I-Entity
response	O
.	O

The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	I-Entity
to	O
200	O
mg	O
of	O
propofol	I-Entity
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3/4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
addition	O
of	O
ephedrine	I-Entity
to	O
propofol	I-Entity
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	I-Entity
response	O
to	O
propofol	I-Entity
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

However	O
,	O
marked	O
tachycardia	I-Entity
associated	O
with	O
the	O
use	O
of	O
ephedrine	I-Entity
in	O
combination	O
with	O
propofol	I-Entity
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	I-Entity
inducing	O
myocardial	B-Entity
ischemia	I-Entity
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	I-Entity
/	O
propofol	I-Entity
/	O
mixtures	O
studied	O
.	O



Neurotoxicity	I-Entity
of	O
halogenated	B-Entity
hydroxyquinolines	I-Entity
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O

An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	I-Entity
reactions	O
to	O
halogenated	B-Entity
hydroxyquinolines	I-Entity
reported	O
from	O
outside	O
Japan	O
.	O

In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	I-Entity
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	I-Entity
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O

In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	B-Entity
disturbance	I-Entity
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	I-Entity
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	I-Entity
over	O
a	O
short	O
period	O
.	O

The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B-Entity
atrophy	I-Entity
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	I-Entity
as	O
treatment	O
for	O
acrodermatitis	B-Entity
enteropathica	I-Entity
.	O

In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	I-Entity
,	O
visual	B-Entity
disturbance	I-Entity
,	O
and	O
peripheral	B-Entity
neuropathy	I-Entity
was	O
the	O
most	O
common	O
manifestation	O
.	O

Isolated	O
myelopathy	I-Entity
or	O
peripheral	B-Entity
neuropathy	I-Entity
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O

The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	I-Entity
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O

The	O
full	O
syndrome	O
of	O
subacute	O
myelo	B-Entity
-	I-Entity
optic	I-Entity
neuropathy	I-Entity
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	O
.	O



Epileptic	B-Entity
seizures	I-Entity
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	B-Entity
acid	I-Entity
in	O
rats	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	B-Entity
acid	I-Entity
(	O
tAMCA	I-Entity
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O

However	O
,	O
tAMCA	I-Entity
has	O
been	O
shown	O
to	O
cause	O
epileptic	B-Entity
seizures	I-Entity
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	I-Entity
retains	O
its	O
convulsive	I-Entity
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	I-Entity
(	O
0.5	O
-	O
47.5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

FS	O
containing	O
tAMCA	I-Entity
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	I-Entity
behaviours	O
.	O

The	O
degree	O
of	O
these	O
seizures	I-Entity
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	I-Entity
.	O

Thus	O
,	O
FS	O
containing	O
47.5	O
mg	O
/	O
ml	O
tAMCA	I-Entity
evoked	O
generalized	B-Entity
seizures	I-Entity
in	O
all	O
tested	O
rats	O
(	O
n=6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	I-Entity
(	O
0.5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	I-Entity
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

INTERPRETATION	O
:	O
Tranexamic	B-Entity
acid	I-Entity
retains	O
its	O
convulsive	I-Entity
action	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	I-Entity
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O



A	O
diet	O
promoting	O
sugar	B-Entity
dependency	I-Entity
causes	O
behavioral	B-Entity
cross	I-Entity
-	I-Entity
sensitization	I-Entity
to	O
a	O
low	O
dose	O
of	O
amphetamine	I-Entity
.	O

Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	B-Entity
dependency	I-Entity
.	O

The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	B-Entity
cross	I-Entity
-	I-Entity
sensitization	I-Entity
to	O
a	O
low	O
dose	O
of	O
amphetamine	I-Entity
.	O

After	O
a	O
30-min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12-h	O
deprivation	O
followed	O
by	O
12-h	O
access	O
to	O
10%	O
sucrose	I-Entity
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O

Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	I-Entity
(	O
0.5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	I-Entity
and	O
chow	O
were	O
hyperactive	I-Entity
in	O
response	O
to	O
amphetamine	I-Entity
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10%	O
sucrose	I-Entity
and	O
chow	O
followed	O
by	O
amphetamine	I-Entity
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	I-Entity
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	I-Entity
,	O
or	O
cyclic	O
10%	O
sucrose	I-Entity
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O

These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	I-Entity
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	I-Entity
system	O
.	O



D	B-Entity
-	I-Entity
penicillamine	I-Entity
-	O
induced	O
angiopathy	I-Entity
in	O
rats	O
.	O

The	O
effect	O
of	O
high	O
dose	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
(	O
D	B-Entity
-	I-Entity
pen	I-Entity
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
days	O
.	O

TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D	B-Entity
-	I-Entity
pen	I-Entity
-	O
treated	O
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O

The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	B-Entity
-	I-Entity
pen	I-Entity
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	I-Entity
.	O

The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D	B-Entity
-	I-Entity
pen	I-Entity
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	O
/	O
serum	O
-	O
ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D	B-Entity
-	I-Entity
pen	I-Entity
treatment	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D	B-Entity
-	I-Entity
pen	I-Entity
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross	O
-	O
linking	O
of	O
collagen	O
and	O
elastin	O
.	O



Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Anthracyclines	I-Entity
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	I-Entity
.	O

The	O
cardiotoxicity	I-Entity
of	O
conventional	O
anthracycline	I-Entity
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B-Entity
dysfunction	I-Entity
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
in	O
patients	O
with	O
acute	B-Entity
leukemia	I-Entity
treated	O
with	O
a	O
daunorubicin	I-Entity
(	O
DNR)-containing	I-Entity
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	B-Entity
leukemia	I-Entity
were	O
treated	O
with	O
a	O
DNR	I-Entity
-	O
containing	O
regimen	O
.	O

Three	O
patients	O
developed	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-Entity
failure	I-Entity
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Entity
failure	I-Entity
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B-Entity
failure	I-Entity
by	O
radionuclide	O
angiography	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B-Entity
failure	I-Entity
given	O
DNR	I-Entity
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m(2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Entity
failure	I-Entity
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O



Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B-Entity
defects	I-Entity
:	O
National	O
Birth	B-Entity
Defects	I-Entity
Prevention	O
Study	O
.	O

OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B-Entity
defects	I-Entity
.	O

Population	O
-	O
based	O
,	O
multisite	O
,	O
case	O
-	O
control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B-Entity
defects	I-Entity
identified	O
via	O
birth	B-Entity
defect	I-Entity
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O

Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-Entity
defects	I-Entity
adjusted	O
for	O
potential	O
confounders	O
.	O

Sulfonamides	I-Entity
were	O
associated	O
with	O
anencephaly	I-Entity
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3.4	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.3	O
-	O
8.8	O
)	O
,	O
hypoplastic	B-Entity
left	I-Entity
heart	I-Entity
syndrome	I-Entity
(	O
AOR	O
=	O
3.2	O
;	O
95%	O
CI	O
,	O
1.3	O
-	O
7.6	O
)	O
,	O
coarctation	B-Entity
of	I-Entity
the	I-Entity
aorta	I-Entity
(	O
AOR	O
=	O
2.7	O
;	O
95%	O
CI	O
,	O
1.3	O
-	O
5.6	O
)	O
,	O
choanal	B-Entity
atresia	I-Entity

(	O
AOR	O
=	O
8.0	O
;	O
95%	O
CI	O
,	O
2.7	O
-	O
23.5	O
)	O
,	O
transverse	B-Entity
limb	I-Entity
deficiency	I-Entity
(	O
AOR	O
=	O
2.5	O
;	O
95%	O
CI	O
,	O
1.0	O
-	O
5.9	O
)	O
,	O
and	O
diaphragmatic	B-Entity
hernia	I-Entity
(	O
AOR	O
=	O
2.4	O
;	O
95%	O
CI	O
,	O
1.1	O
-	O
5.4	O
)	O
.	O

Nitrofurantoins	I-Entity
were	O
associated	O
with	O
anophthalmia	I-Entity
or	O
microphthalmos	I-Entity
(	O
AOR	O
=	O
3.7	O
;	O
95%	O
CI	O
,	O
1.1	O
-	O
12.2	O
)	O
,	O
hypoplastic	B-Entity
left	I-Entity
heart	I-Entity
syndrome	I-Entity
(	O
AOR	O
=	O
4.2	O
;	O
95%	O
CI	O
,	O
1.9	O
-	O
9.1	O
)	O

,	O
atrial	B-Entity
septal	I-Entity
defects	I-Entity
(	O
AOR	O
=	O
1.9	O
;	O
95%	O
CI	O
,	O
1.1	O
-	O
3.4	O
)	O
,	O
and	O
cleft	B-Entity
lip	I-Entity
with	O
cleft	B-Entity
palate	I-Entity
(	O
AOR	O
=	O
2.1	O
;	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	I-Entity
(	O
2	O
defects	O
)	O
,	O
penicillins	I-Entity
(	O
1	O
defect	O
)	O
,	O
cephalosporins	I-Entity
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	I-Entity
(	O
1	O
defect	O
)	O
.	O

CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	I-Entity
,	O
erythromycins	I-Entity
,	O
and	O
cephalosporins	I-Entity
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-Entity
defects	I-Entity
.	O

Sulfonamides	I-Entity
and	O
nitrofurantoins	I-Entity
were	O
associated	O
with	O
several	O
birth	B-Entity
defects	I-Entity
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O



Incidence	O
of	O
neoplasms	I-Entity
in	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O

Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	I-Entity
and	O
chlorambucil	I-Entity
(	O
alkylating	B-Entity
agents	I-Entity
)	O
,	O
azathioprine	I-Entity
(	O
purine	I-Entity
analogue	O
)	O
,	O
and	O
methotrexate	I-Entity
(	O
folic	B-Entity
acid	I-Entity
analogue	O
)	O
.	O

There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	I-Entity
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O

Patients	O
treated	O
with	O
alkylating	B-Entity
agents	I-Entity
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B-Entity
nonlymphocytic	I-Entity
leukemia	I-Entity
,	O
and	O
both	O
alkylating	B-Entity
agents	I-Entity
and	O
azathioprine	I-Entity
are	O
associated	O
with	O
the	O
development	O
of	O
non	B-Entity
-	I-Entity
Hodgkin	I-Entity
's	I-Entity
lymphoma	I-Entity
.	O

Cyclophosphamide	I-Entity
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
bladder	I-Entity
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
studies	O
of	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
treated	O
with	O
azathioprine	I-Entity
and	O
cyclophosphamide	I-Entity
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	I-Entity
is	O
not	O
increased	O
.	O

Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	I-Entity
in	O
rheumatoid	B-Entity
arthritis	I-Entity
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	O
,	O
particularly	O
alkylating	B-Entity
agents	I-Entity
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	B-Entity
arthritis	I-Entity
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	O
or	O
life	O
-	O
threatening	O
complications	O
.	O



Patterns	O
of	O
hepatic	B-Entity
injury	I-Entity
induced	O
by	O
methyldopa	I-Entity
.	O

Twelve	O
patients	O
with	O
liver	B-Entity
disease	I-Entity
related	O
to	O
methyldopa	I-Entity
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Jaundice	I-Entity
with	O
tender	O
hepatomegaly	I-Entity
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	I-Entity
,	O
nausea	I-Entity
and	O
vomiting	I-Entity
,	O
and	O
associated	O
with	O
upper	O
abdominal	B-Entity
pain	I-Entity
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O

Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	I-Entity
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	B-Entity
injury	I-Entity
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B-Entity
change	I-Entity
and	O
focal	O
hepatocellular	O
necrosis	I-Entity
to	O
massive	B-Entity
hepatic	I-Entity
necrosis	I-Entity
.	O

Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B-Entity
hepatitis	I-Entity
or	O
chronic	B-Entity
active	I-Entity
hepatitis	I-Entity
with	O
associated	O
cholestasis	I-Entity
.	O

One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	B-Entity
failure	I-Entity
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	I-Entity
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	B-Entity
hepatitis	I-Entity
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	I-Entity
-	O
induced	O
hepatitis	I-Entity
.	O

In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	I-Entity
and	O
hepatic	B-Entity
dysfunction	I-Entity
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	I-Entity
within	O
2	O
weeks	O
of	O
re	O
-	O
exposure	O
to	O
the	O
drug	O
.	O



A	O
phase	O
I	O
/	O
II	O
study	O
of	O
paclitaxel	I-Entity
plus	O
cisplatin	I-Entity
as	O
first	O
-	O
line	O
therapy	O
for	O
head	B-Entity
and	I-Entity
neck	I-Entity
cancers	I-Entity
:	O
preliminary	O
results	O
.	O

Improved	O
outcomes	O
among	O
patients	O
with	O
head	B-Entity
and	I-Entity
neck	I-Entity
carcinomas	I-Entity
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy	O
.	O

Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single	O
-	O
agent	O
paclitaxel	I-Entity
(	O
Taxol	I-Entity
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37%	O
response	O
rate	O
in	O
patients	O
with	O
head	B-Entity
and	I-Entity
neck	I-Entity
cancer	I-Entity
,	O
and	O
the	O
paclitaxel	I-Entity
/	O
cisplatin	I-Entity
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	B-Entity
cancer	I-Entity
patients	O
.	O

We	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	I-Entity
of	O
escalating	O
paclitaxel	I-Entity
doses	O
combined	O
with	O
fixed	O
-	O
dose	O
cisplatin	I-Entity
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	B-Entity
and	I-Entity
neck	I-Entity
carcinoma	I-Entity
.	O

Primary	O
tumor	I-Entity
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O

Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	I-Entity
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	O
.	O

Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	I-Entity
by	O
3-hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	I-Entity
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	I-Entity
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	I-Entity
permits	O
.	O

With	O
paclitaxel	I-Entity
doses	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higher	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
5	O
micrograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O

Alopecia	I-Entity
,	O
paresthesias	I-Entity
,	O
and	O
arthralgias	I-Entity

/	O
myalgias	I-Entity
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	I-Entity
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O

No	O
dose	O
-	O
limiting	O
hematologic	O
toxicity	I-Entity
has	O
been	O
seen	O
.	O

Paclitaxel	I-Entity
/	O
cisplatin	I-Entity
is	O
an	O
effective	O
first	O
-	O
line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	B-Entity
and	I-Entity
neck	I-Entity
cancer	I-Entity
and	O
continued	O
study	O
is	O
warranted	O
.	O

Results	O
thus	O
far	O
suggest	O
no	O
dose	O
-	O
response	O
effect	O
for	O
paclitaxel	I-Entity
doses	O
above	O
200	O
mg	O
/	O
m2	O
.	O



A	O
phase	O
I	O
study	O
of	O
4'-0-tetrahydropyranyladriamycin	I-Entity
.	O

A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4'-0-tetrahydropyranyladriamycin	I-Entity
(	O
Pirarubicin	I-Entity
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	I-Entity
.	O

Twenty	O
-	O
six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	B-Entity
and/or	I-Entity
hepatic	I-Entity
dysfunction	I-Entity
.	O

The	O
dose	O
-	O
limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	I-Entity
.	O

Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	I-Entity
,	O
anemia	I-Entity
,	O
nausea	I-Entity
,	O
mild	O
alopecia	I-Entity
,	O
phlebitis	I-Entity
,	O
and	O
mucositis	I-Entity
.	O

Myelosuppression	I-Entity
was	O
more	O
in	O
patients	O
with	O
hepatic	B-Entity
dysfunction	I-Entity
.	O

Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	I-Entity
plasma	O
T	O
1/2	O
alpha	O
(	O
+	O
/-	O

Adriamycinol	I-Entity
,	O
doxorubicin	I-Entity
,	O
adriamycinone	I-Entity
,	O
and	O
tetrahydropyranyladriamycinol	I-Entity
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	I-Entity
was	O
less	O
than	O
or	O
equal	O
to	O
10%	O
of	O
the	O
total	O
metabolites	O
.	O

Urinary	O
excretion	O
of	O
Pirarubicin	I-Entity
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10%	O
.	O

Activity	O
was	O
noted	O
in	O
mesothelioma	I-Entity
,	O
leiomyosarcoma	I-Entity
,	O
and	O
basal	B-Entity
cell	I-Entity
carcinoma	I-Entity
.	O



Differential	O
effects	O
of	O
gamma	B-Entity
-	I-Entity
hexachlorocyclohexane	I-Entity
(	O
lindane	I-Entity
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	I-Entity
.	O

Gamma	B-Entity
-	I-Entity
hexachlorocyclohexane	I-Entity
(	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	I-Entity
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	I-Entity
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	I-Entity
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	I-Entity
-	O
induced	O
seizures	I-Entity
24	O
h	O
after	O
exposure	O
to	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
(	O
Vohland	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	I-Entity
-	O
inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg	O

/	O
kg	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
.	O

One	O
hour	O
after	O
the	O
administration	O
of	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
,	O
the	O
activity	O
of	O
seizure	I-Entity
-	O
inducing	O
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
a	O
differential	O
response	O
was	O
observed	O
.	O

Seizure	I-Entity
activity	O
due	O
to	O
PTZ	I-Entity
and	O
picrotoxin	I-Entity
(	O
PTX	I-Entity
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	I-Entity
activity	O
due	O
to	O
3-mercaptopropionic	B-Entity
acid	I-Entity
(	O
MPA	I-Entity
)	O
,	O
bicuculline	I-Entity
(	O
BCC	I-Entity
)	O
,	O
methyl	B-Entity
6,7-dimethoxy-4-ethyl	I-Entity
-	I-Entity
B	I-Entity
-	I-Entity
carboline-3-carboxylate	I-Entity
(	O
DMCM	I-Entity
)	O
,	O
or	O
strychnine	I-Entity
(	O
STR	I-Entity
)	O
was	O
not	O
different	O
from	O
control	O
.	O

In	O
vitro	O
,	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
,	O
pentylenetetrazol	I-Entity
and	O
picrotoxin	I-Entity
were	O
shown	O
to	O
inhibit	O
3H	B-Entity
-	I-Entity
TBOB	I-Entity
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4.6	O
,	O
404	O
and	O
9.4	O
microM	O
,	O
respectively	O
.	O

MPA	I-Entity
,	O
BCC	I-Entity
,	O
DMCM	I-Entity
,	O
and	O
STR	I-Entity
showed	O
no	O
inhibition	O
of	O
3H	B-Entity
-	I-Entity
TBOB	I-Entity
(	O
t	B-Entity
-	I-Entity
butyl	I-Entity
bicyclo	I-Entity
-	I-Entity
orthobenzoate	I-Entity
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	I-Entity
activity	O
induced	O
by	O
PTZ	I-Entity
and	O
PTX	I-Entity
24	O
h	O
after	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	I-Entity
-	O
inducing	O
agents	O
is	O
decreased	O
.	O

The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	I-Entity
activity	O
24	O
h	O
after	O
gamma	B-Entity
-	I-Entity
HCH	I-Entity
may	O
be	O
the	O
GABA	I-Entity
-	O
A	O
receptor	O
-	O
linked	O
chloride	O
channel	O
.	O



Severe	O
ocular	B-Entity
and	I-Entity
orbital	I-Entity
toxicity	I-Entity
after	O
intracarotid	O
injection	O
of	O
carboplatin	I-Entity
for	O
recurrent	O
glioblastomas	I-Entity
.	O

Glioblastoma	I-Entity
is	O
a	O
malignant	B-Entity
tumor	I-Entity
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	I-Entity
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	O
,	O
carboplatin	I-Entity
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	I-Entity
,	O
whose	O
ocular	B-Entity
and	I-Entity
orbital	I-Entity
toxicity	I-Entity
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	B-Entity
and	I-Entity
orbital	I-Entity
toxicity	I-Entity
after	O
intracarotid	O
injection	O
of	O
carboplatin	I-Entity
,	O
which	O
is	O
infrequently	O
reported	O
.	O

A	O
58-year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	I-Entity
for	O
recurrent	O
glioblastomas	I-Entity
in	O
his	O
left	O
temporal	O
lobe	O
.	O

He	O
complained	O
of	O
pain	B-Entity
and	I-Entity
visual	I-Entity
disturbance	I-Entity
in	I-Entity
the	I-Entity
ipsilateral	I-Entity
eye	I-Entity
30	O
h	O
after	O
the	O
injection	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	I-Entity
toxicity	I-Entity
were	O
seen	O
.	O

He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	I-Entity
for	O
6	O
days	O
after	O
the	O
injection	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	I-Entity
decreased	O
and	O
ocular	B-Entity
pain	I-Entity
diminished	O
,	O
inexorable	O
papilledema	I-Entity
and	O
exudative	O
retinal	B-Entity
detachment	I-Entity
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B-Entity
atrophy	I-Entity
with	O
optic	B-Entity
atrophy	I-Entity
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	I-Entity
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	B-Entity
toxicity	I-Entity
.	O



Phase	O
II	O
study	O
of	O
the	O
amsacrine	I-Entity
analogue	O
CI-921	I-Entity
(	O
NSC	B-Entity
343499	I-Entity
)	O
in	O
non	B-Entity
-	I-Entity
small	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
.	O

CI-921	I-Entity
(	O
NSC	B-Entity
343499	I-Entity
;	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	B-Entity
]	I-Entity
-N,5-dimethyl-	I-Entity
4-acridinecarboxamide	I-Entity
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O

It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non	B-Entity
-	I-Entity
small	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
(	O
NSCLC	I-Entity
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery	O
/	O
radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O

The	O
histology	O
comprised	O
squamous	B-Entity
carcinoma	I-Entity
(	O
11	O
)	O
,	O
adenocarcinoma	I-Entity
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio	B-Entity
-	I-Entity
alveolar	I-Entity
carcinoma	I-Entity
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	B-Entity
carcinoma	I-Entity
(	O
1	O
)	O
.	O

Neutropenia	I-Entity
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	I-Entity
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	I-Entity
in	O
1	O
patient	O
.	O

Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	I-Entity
and	O
vomiting	I-Entity
occurred	O
in	O
66%	O
courses	O
and	O
phlebitis	I-Entity
in	O
the	O
infusion	O
arm	O
in	O
37%	O
.	O

1	O
patient	O
with	O
squamous	B-Entity
cell	I-Entity
carcinoma	I-Entity
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O

Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	I-Entity
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O



Alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
prevents	O
mitochondrial	B-Entity
damage	I-Entity
and	O
neurotoxicity	I-Entity
in	O
experimental	O
chemotherapy	O
neuropathy	I-Entity
.	O

The	O
study	O
investigates	O
if	O
alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	I-Entity
,	O
if	O
mitochondrial	B-Entity
damage	I-Entity
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Entity
neurodegenerative	I-Entity
cascade	I-Entity
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
depend	O
on	O
mitochondria	O
protection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Entity
neuropathy	I-Entity
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	I-Entity
and	O
cisplatin	I-Entity
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O

This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
in	O
preventing	O
axonal	B-Entity
damage	I-Entity
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
.	O

Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	I-Entity
and	O
paclitaxel	I-Entity
cause	O
early	O
mitochondrial	B-Entity
impairment	I-Entity
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O

Alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	I-Entity
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Entity
toxicity	I-Entity
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O

In	O
conclusion	O
mitochondrial	B-Entity
toxicity	I-Entity
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	I-Entity
and	O
cisplatin	I-Entity
induced	O
neurotoxicity	I-Entity
.	O

Alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O

These	O
findings	O
suggest	O
that	O
alpha	B-Entity
-	I-Entity
lipoic	I-Entity
acid	I-Entity
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Entity
nerve	I-Entity
toxicity	I-Entity
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O



Optimising	O
stroke	I-Entity
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B-Entity
fibrillation	I-Entity
.	O

Atrial	B-Entity
fibrillation	I-Entity
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	I-Entity
reduces	O
the	O
risk	O
of	O
stroke	I-Entity
by	O
62%	O
,	O
and	O
that	O
aspirin	I-Entity
alone	O
reduces	O
the	O
risk	O
by	O
22%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	I-Entity
is	O
superior	O
to	O
aspirin	I-Entity
in	O
preventing	O
strokes	I-Entity
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36%	O
.	O

Ximelagatran	I-Entity
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	B-Entity
K	I-Entity
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	B-Entity
events	I-Entity
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B-Entity
liver	I-Entity
function	I-Entity
tests	O
.	O

The	O
ACTIVE	O
-	O
W	O
(	O
Atrial	B-Entity
Fibrillation	I-Entity
Clopidogrel	I-Entity
Trial	O
with	O
Irbesartan	I-Entity
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	I-Entity
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	I-Entity
plus	O
aspirin	I-Entity
)	O
in	O
the	O
prevention	O
af	O
embolic	B-Entity
events	I-Entity
.	O

Idraparinux	I-Entity
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-Entity
fibrillation	I-Entity
.	O

Angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	B-Entity
II	I-Entity
receptor	O
-	O
blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	B-Entity
fibrillation	I-Entity
through	O
cardiac	B-Entity
remodelling	I-Entity
.	O

Preliminary	O
studies	O
suggest	O
that	O
statins	I-Entity
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O



Interaction	O
of	O
cyclosporin	B-Entity
A	I-Entity
with	O
antineoplastic	O
agents	O
.	O

A	O
synergistic	O
effect	O
of	O
etoposide	I-Entity
and	O
cyclosporin	B-Entity
A	I-Entity
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B-Entity
T	I-Entity
-	I-Entity
lymphocytic	I-Entity
leukemia	I-Entity
in	O
relapse	O
.	O

The	O
concomitant	O
administration	O
of	O
etoposide	I-Entity
and	O
cyclosporin	B-Entity
A	I-Entity
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B-Entity
infiltration	I-Entity
of	O
bone	O
marrow	O
.	O

Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	I-Entity
and	O
progressive	O
hyperbilirubinemia	I-Entity
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	I-Entity
in	O
normal	O
tissues	O
.	O

This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	B-Entity
A	I-Entity
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T	O
-	O
cell	O
functions	O
.	O



The	O
hematologic	O
effects	O
of	O
cefonicid	I-Entity
and	O
cefazedone	I-Entity
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	I-Entity
hematotoxicity	I-Entity
in	O
man	O
.	O

Cephalosporin	I-Entity
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	B-Entity
disturbances	I-Entity
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B-Entity
dyscrasias	I-Entity
can	O
be	O
studied	O
.	O

In	O
four	O
subacute	O
toxicity	I-Entity
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	I-Entity
or	O
cefazedone	I-Entity
to	O
beagle	O
dogs	O
caused	O
a	O
dose	O
-	O
dependent	O
incidence	O
of	O
anemia	I-Entity
,	O
neutropenia	I-Entity
,	O
and	O
thrombocytopenia	I-Entity
after	O
1	O
-	O
3	O
months	O
of	O
treatment	O
.	O

A	O
nonregenerative	O
anemia	I-Entity
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	I-Entity
and	O
occurred	O
in	O
approximately	O
50%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	I-Entity
or	O
540	O
-	O
840	O
mg	O

/	O
kg	O
cefazedone	I-Entity
.	O

All	O
three	O
cytopenias	I-Entity
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O

Upon	O
rechallenge	O
with	O
either	O
cephalosporin	I-Entity
,	O
the	O
hematologic	B-Entity
syndrome	I-Entity
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	I-Entity
(	O
but	O
not	O
cefazedone)-treated	I-Entity
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+	O
/-	O

This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	I-Entity
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	I-Entity
.	O

We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	I-Entity
or	O
cefazedone	I-Entity
to	O
dogs	O
can	O
induce	O
hematotoxicity	I-Entity
similar	O
to	O
the	O
cephalosporin	I-Entity
-	O
induced	O
blood	B-Entity
dyscrasias	I-Entity
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O



A	O
pyridoxine	I-Entity
-	O
dependent	O
behavioral	B-Entity
disorder	I-Entity
unmasked	O
by	O
isoniazid	I-Entity
.	O

A	O
3-year	O
-	O
old	O
girl	O
had	O
behavioral	B-Entity
deterioration	I-Entity
,	O
with	O
hyperkinesis	I-Entity
,	O
irritability	I-Entity
,	O
and	O
sleeping	B-Entity
difficulties	I-Entity
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	I-Entity
.	O

The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Entity
hydrochloride	I-Entity
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O

After	O
discontinuing	O
isoniazid	I-Entity
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	I-Entity
.	O

A	O
placebo	O
had	O
no	O
effect	O
,	O
but	O
niacinamide	I-Entity
was	O
as	O
effective	O
as	O
pyridoxine	I-Entity
.	O

Periodic	O
withdrawal	O
of	O
pyridoxine	I-Entity
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	I-Entity
.	O

The	O
level	O
of	O
pyridoxal	I-Entity
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	O
.	O

Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	I-Entity
pathway	O
of	O
tryptophan	I-Entity
metabolism	O
.	O

The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	I-Entity
to	O
control	O
her	O
behavior	O
.	O



A	O
selective	O
dopamine	I-Entity
D4	O
receptor	O
antagonist	O
,	O
NRA0160	I-Entity
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

NRA0160	I-Entity
,	O
5	B-Entity
-	I-Entity
[	I-Entity
2-	I-Entity
(	I-Entity
4-	I-Entity
(	I-Entity
3	I-Entity
-	I-Entity
fluorobenzylidene	I-Entity
)	I-Entity
piperidin-1-yl	I-Entity
)	I-Entity
ethyl	I-Entity
]	I-Entity
-	I-Entity
4	I-Entity
-(4-fluorophenyl	I-Entity
)	I-Entity
thiazole-2-carboxamide	I-Entity
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	I-Entity
D4.2	O
,	O
D4.4	O
and	O
D4.7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0.5	O
,	O
0.9	O
and	O
2.7	O
nM	O
,	O
respectively	O
.	O

NRA0160	I-Entity
is	O
over	O
20,000fold	O
more	O
potent	O
at	O
the	O
dopamine	I-Entity
D4.2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	I-Entity
D2L	O
receptor	O
.	O

NRA0160	I-Entity
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	I-Entity
D3	O
receptor	O
(	O
Ki=39	O
nM	O
)	O
,	O
rat	O
serotonin	I-Entity
(	O
5-HT)2A	I-Entity
receptors	O
(	O
Ki=180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki=237	O
nM	O
)	O
.	O

NRA0160	I-Entity
and	O
clozapine	I-Entity
antagonized	O
locomotor	O
hyperactivity	I-Entity
induced	O
by	O
methamphetamine	I-Entity
(	O
MAP	I-Entity
)	O
in	O
mice	O
.	O

NRA0160	I-Entity
and	O
clozapine	I-Entity
antagonized	O
MAP	I-Entity
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	I-Entity
and	O
clozapine	I-Entity
significantly	O
induced	O
catalepsy	I-Entity
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	I-Entity
and	O
clozapine	I-Entity
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	I-Entity
.	O

NRA0160	I-Entity
and	O

clozapine	I-Entity
significantly	O
shortened	O
the	O
phencyclidine	I-Entity
(	O
PCP)-induced	I-Entity
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	O
suggest	O
that	O
NRA0160	I-Entity
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O



Prolonged	O
cholestasis	I-Entity
after	O
troleandomycin	I-Entity
-	O
induced	O
acute	O
hepatitis	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	I-Entity
-	O
induced	O
hepatitis	I-Entity
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	I-Entity
.	O

Jaundice	I-Entity
occurred	O
after	O
administration	O
of	O
troleandomycin	I-Entity
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	I-Entity
.	O

Jaundice	I-Entity
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	I-Entity
marked	O
by	O
pruritus	I-Entity
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities	O
.	O

Finally	O
,	O
pruritus	I-Entity
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	I-Entity
.	O

This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	I-Entity
can	O
follow	O
troleandomycin	I-Entity
-	O
induced	O
acute	O
hepatitis	I-Entity
.	O



Lovastatin	I-Entity
and	O
simvastatin	I-Entity
are	O
the	O
2	O
best	O
-	O
known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Clinical	O
experience	O
with	O
lovastatin	I-Entity
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	I-Entity
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O

Lovastatin	I-Entity
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O

Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	I-Entity
of	O
over	O
30%	O
and	O
in	O
LDL	O
-	O
cholesterol	I-Entity
of	O
40%	O
in	O
clinical	O
studies	O
.	O

Modest	O
increases	O
in	O
HDL	O
-	O
cholesterol	I-Entity
levels	O
of	O
about	O
10%	O
are	O
also	O
reported	O
.	O

Minor	O
elevations	O
of	O
creatine	I-Entity
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5%	O
of	O
patients	O
.	O

Myopathy	I-Entity
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	I-Entity
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B-Entity
failure	I-Entity
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	I-Entity
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	I-Entity
,	O
gemfibrozil	I-Entity
or	O
niacin	I-Entity
.	O

Lovastatin	I-Entity
and	O
simvastatin	I-Entity
are	O
both	O
effective	O
and	O
well	O
-	O
tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	I-Entity
.	O

As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	I-Entity
and	O
its	O
consequences	O
.	O



Sulfasalazine	I-Entity
-	O
induced	O
lupus	B-Entity
erythematosus	I-Entity
.	O

Pneumonitis	I-Entity
,	O
bilateral	O
pleural	B-Entity
effusions	I-Entity
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-Entity
tamponade	I-Entity
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43-year	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazine	I-Entity
therapy	O
for	O
chronic	O
ulcerative	B-Entity
colitis	I-Entity
.	O

After	O
cessation	O
of	O
the	O
sulfasalazine	I-Entity
and	O
completion	O
of	O
a	O
six	O
-	O
week	O
course	O
of	O
corticosteroids	O
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O

It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	I-Entity
-	O
induced	O
lupus	I-Entity
,	O
which	O
manifested	O
with	O
serositis	I-Entity
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O

Physicians	O
who	O
use	O
sulfasalazine	I-Entity
to	O
treat	O
patients	O
with	O
inflammatory	B-Entity
bowel	I-Entity
disease	I-Entity
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	I-Entity
-	O
induced	O
lupus	B-Entity
syndrome	I-Entity
.	O



Optimization	O
of	O
levodopa	I-Entity
therapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	I-Entity
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25/100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	I-Entity
-	O
levodopa	I-Entity
to	O
the	O
point	O
of	O
""""	O
normality	O
,	O
""""	O
which	O
can	O
lead	O
to	O
toxicity	I-Entity
.	O

Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	I-Entity
agonist	O
.	O

Other	O
possible	O
adverse	O
effects	O
--	O
such	O
as	O
gastrointestinal	B-Entity
disorders	I-Entity
,	O
orthostatic	B-Entity
hypotension	I-Entity
,	O
levodopa	I-Entity
-	O
induced	O
psychosis	I-Entity
,	O
sleep	B-Entity
disturbances	I-Entity
or	O
parasomnias	I-Entity
,	O
or	O
drug	O
interactions	O
--	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
patient	O
achieve	O
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O



Alpha	O
and	O
beta	O
coma	I-Entity
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	B-Entity
hypoxia	I-Entity
.	O

Four	O
patients	O
who	O
were	O
rendered	O
comatose	I-Entity
or	O
stuporous	I-Entity
by	O
drug	O
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O

Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	I-Entity
for	O
alcohol	I-Entity
withdrawal	B-Entity
symptoms	I-Entity
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	I-Entity
of	O
nitrazepam	I-Entity
.	O

The	O
patient	O
with	O
nitrazepam	I-Entity
overdose	I-Entity
and	O
two	O
of	O
those	O
with	O
chlormethiazole	I-Entity
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'	O
alpha	O
coma	I-Entity
'	O
,	O
showing	O
non	O
-	O
reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	I-Entity
administration	O
exhibite	O
generalized	O
non	O
-	O
reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O

All	O
four	O
recovered	O
completely	O
without	O
neurological	B-Entity
sequelae	I-Entity
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O

The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	I-Entity
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	I-Entity
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	I-Entity
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O



Omitting	O
fentanyl	I-Entity
reduces	O
nausea	I-Entity
and	O
vomiting	I-Entity
,	O
without	O
increasing	O
pain	I-Entity
,	O
after	O
sevoflurane	I-Entity
for	O
day	O
surgery	O
.	O

Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	I-Entity
,	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
occurs	O
frequently	O
.	O

Fentanyl	I-Entity
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
and	O
pain	I-Entity
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	I-Entity
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	I-Entity
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	I-Entity
in	O
addition	O
to	O
fentanyl	I-Entity
.	O

Omission	O
of	O
fentanyl	I-Entity
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	I-Entity
and/or	O
moderate	O
to	O
severe	O
nausea	I-Entity
prior	O
to	O
discharge	O
from	O
20%	O
and	O
17%	O
with	O
fentanyl	I-Entity
and	O
fentanyl	I-Entity
-	O
dexamethasone	I-Entity
,	O
respectively	O
,	O
to	O
5%	O
(	O
P	O
=	O
0.013	O
)	O
.	O

Dexamethasone	I-Entity
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
.	O

Combining	O
the	O
two	O
fentanyl	I-Entity
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
and	O
nausea	I-Entity
prior	O
to	O
discharge	O
from	O
35%	O
and	O
33%	O
to	O
22%	O
and	O
19%	O
(	O
P	O
=	O
0.049	O
and	O
P	O
=	O
0.035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	I-Entity
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42%	O
to	O
27%	O
(	O
P	O
=	O
0.034	O
)	O
.	O

Pain	I-Entity
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	I-Entity
.	O

Fentanyl	I-Entity
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	I-Entity
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-Entity
depression	I-Entity
,	O
hypotension	I-Entity
and	O
bradycardia	I-Entity
.	O

As	O
fentanyl	I-Entity
exacerbated	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
without	O
an	O
improvement	O
in	O
postoperative	B-Entity
pain	I-Entity
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	I-Entity
in	O
day	O
surgery	O
.	O



Renal	B-Entity
Fanconi	I-Entity
syndrome	I-Entity
and	O
myopathy	I-Entity
after	O
liver	O
transplantation	O
:	O

drug	O
-	O
related	O
mitochondrial	B-Entity
cytopathy	I-Entity
?	O

We	O
describe	O
a	O
15-yr	O
-	O
old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Tacrolimus	I-Entity
,	O
MMF	I-Entity
,	O
and	O
steroids	I-Entity
were	O
given	O
as	O
immunosuppressant	O
.	O

Lamivudine	I-Entity
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B-Entity
B	I-Entity
infection	I-Entity
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B-Entity
Fanconi	I-Entity
syndrome	I-Entity
with	O
severe	O
metabolic	B-Entity
acidosis	I-Entity
,	O
hypophosphatemia	I-Entity
,	O
glycosuria	I-Entity
,	O
and	O
aminoaciduria	I-Entity
.	O

Although	O
tacrolimus	I-Entity
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post	O
-	O
transplant	O
renal	O
acidosis	I-Entity
and	O
was	O
replaced	O
by	O
sirolimus	I-Entity
,	O
acidosis	I-Entity
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O

Proximal	O
muscle	B-Entity
weakness	I-Entity
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fanconi	B-Entity
syndrome	I-Entity
,	O
as	O
well	O
as	O
myopathy	I-Entity
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	B-Entity
disorders	I-Entity
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O

We	O
suggest	O
that	O
our	O
patient	O
's	O
tubular	B-Entity
dysfunction	I-Entity
and	O
myopathy	I-Entity
may	O
have	O
resulted	O
from	O
mitochondrial	B-Entity
dysfunction	I-Entity
which	O
is	O
triggered	O
by	O
tacrolimus	I-Entity
and	O
augmented	O
by	O
lamivudine	I-Entity
.	O



Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	I-Entity
,	O
a	O
selective	O
H3-receptor	O
antagonist	O
in	O
mice	O
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	I-Entity
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	I-Entity
H(3)-receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	I-Entity
,	O
apomorphine	I-Entity
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	I-Entity
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O

Catalepsy	I-Entity
was	O
induced	O
by	O
haloperidol	I-Entity
(	O
2	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
,	O
while	O
apomorphine	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
and	O
amphetamine	I-Entity
(	O
2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O

(	B-Entity
R)-alpha	I-Entity
-	I-Entity
methylhistamine	I-Entity
(	O
RAMH	I-Entity
)	O
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
and	O
thioperamide	I-Entity
(	O
THP	I-Entity
)	O
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	I-Entity
.	O

Administration	O
of	O
THP	I-Entity
(	O
3.75	O
,	O
7.5	O
and	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
1	O

h	O
prior	O
to	O
haloperidol	I-Entity
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	I-Entity
times	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
pretreatment	O
with	O
RAMH	I-Entity
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	I-Entity
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

RAMH	I-Entity
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	I-Entity
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

On	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
,	O
THP	I-Entity
(	O
3.75	O
and	O
7.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

Pretreatment	O
with	O
RAMH	I-Entity
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	I-Entity
(	O
3.75	O
mg	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	I-Entity
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	I-Entity
.	O

Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	I-Entity
.	O

THP	I-Entity
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
,	O
reducing	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
and	O
reducing	O
apomorphine	I-Entity
-	O
induced	O
climbing	O
in	O
mice	O
.	O

Such	O
effects	O
of	O
THP	I-Entity
were	O
reversed	O
by	O
RAMH	I-Entity
indicating	O
the	O
involvement	O
of	O
histamine	I-Entity
H(3)-receptors	O
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H(3)-receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	I-Entity
.	O



Transient	O
platypnea	B-Entity
-	I-Entity
orthodeoxia	I-Entity
-	I-Entity
like	I-Entity
syndrome	I-Entity
induced	O
by	O
propafenone	I-Entity
overdose	I-Entity
in	O
a	O
young	O
woman	O
with	O
Ebstein	B-Entity
's	I-Entity
anomaly	I-Entity
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37-year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	B-Entity
's	I-Entity
anomaly	I-Entity
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea	B-Entity
-	I-Entity
orthodeoxia	I-Entity
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	I-Entity
and	O
cyanosis	I-Entity
.	O

This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	B-Entity
foramen	I-Entity
ovale	I-Entity
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	I-Entity
overdose	I-Entity
.	O

This	O
drug	O
caused	O
biventricular	B-Entity
dysfunction	I-Entity
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	O
,	O
and	O
hypotension	I-Entity
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O



A	O
Phase	O
II	O
trial	O
of	O
cisplatin	I-Entity
plus	O
WR-2721	I-Entity
(	O
amifostine	I-Entity
)	O
for	O
metastatic	O
breast	B-Entity
carcinoma	I-Entity
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

Cisplatin	I-Entity
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-Entity
carcinoma	I-Entity
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	I-Entity
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	I-Entity
,	O
the	O
dose	O
-	O
limiting	O
toxicities	I-Entity
associated	O
with	O
cisplatin	I-Entity
(	O
e.g.	O
,	O
nephrotoxicity	I-Entity
,	O
ototoxicity	I-Entity
,	O
and	O
neurotoxicity	I-Entity
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Entity
carcinoma	I-Entity
.	O

WR-2721	I-Entity

or	O
amifostine	I-Entity
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	I-Entity
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-Entity
agents	I-Entity
and	O
cisplatin	I-Entity
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Early	O
trials	O
of	O
cisplatin	I-Entity
and	O
amifostine	I-Entity
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
,	O
ototoxicity	I-Entity
,	O
and	O
neuropathy	I-Entity
were	O
reduced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	I-Entity
plus	O
amifostine	I-Entity
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B-Entity
carcinoma	I-Entity
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	O
received	O
amifostine	I-Entity
,	O
910	O
mg	O
/	O
m2	O
intravenously	O
over	O
15	O
minutes	O
.	O

After	O
completion	O
of	O
the	O
amifostine	I-Entity
infusion	O
,	O
cisplatin	I-Entity
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

Intravenous	O
hydration	O
and	O
mannitol	I-Entity
was	O
administered	O
before	O
and	O
after	O
cisplatin	I-Entity
.	O

Neurologic	B-Entity
toxicity	I-Entity
was	O
reported	O
in	O
52%	O
of	O
patients	O
.	O

Seven	O
different	O
life	O
-	O
threatening	O
toxicities	I-Entity
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O

The	O
combination	O
of	O
cisplatin	I-Entity
and	O
amifostine	I-Entity
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16%	O
.	O

Neither	O
a	O
tumor	I-Entity
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	I-Entity
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	I-Entity
to	O
cisplatin	I-Entity
in	O
this	O
trial	O
.	O



Warfarin	I-Entity
-	O
induced	O
iliopsoas	O
hemorrhage	I-Entity
with	O
subsequent	O
femoral	B-Entity
nerve	I-Entity
palsy	I-Entity
.	O

We	O
present	O
the	O
case	O
of	O
a	O
28-year	O
-	O
old	O
man	O
on	O
chronic	O
warfarin	I-Entity
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	B-Entity
tear	I-Entity
and	O
developed	O
increasing	O
pain	I-Entity
and	O
a	O
flexure	O
contracture	I-Entity
of	O
the	O
right	O
hip	O
.	O

Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	I-Entity
and	O
femoral	O
nerve	B-Entity
entrapment	I-Entity
,	O
resulting	O
in	O
a	O
femoral	B-Entity
nerve	I-Entity
palsy	I-Entity
and	O
partial	B-Entity
loss	I-Entity
of	I-Entity
quadriceps	I-Entity
functions	I-Entity
.	O

Anticoagulant	O
-	O
induced	O
femoral	B-Entity
nerve	I-Entity
palsy	I-Entity
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	I-Entity
-	O
induced	O
peripheral	B-Entity
neuropathy	I-Entity
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	I-Entity
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	B-Entity
and	I-Entity
sensory	I-Entity
impairment	I-Entity
,	O
and	O
flexure	O
contracture	I-Entity
of	O
the	O
involved	O
extremity	O
.	O



Myasthenia	B-Entity
gravis	I-Entity
caused	O
by	O
penicillamine	I-Entity
and	O
chloroquine	I-Entity
therapy	O
for	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose	O
-	O
related	O
myasthenia	B-Entity
gravis	I-Entity
after	O
penicillamine	I-Entity
and	O
chloroquine	I-Entity
therapy	O
for	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

Although	O
acetylcholine	I-Entity
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O



Nephrotoxicity	I-Entity
of	O
combined	O
cephalothin	I-Entity
-	O
gentamicin	I-Entity
regimen	O
.	O

Two	O
patients	O
developed	O
acute	B-Entity
tubular	I-Entity
necrosis	I-Entity
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	B-Entity
renal	I-Entity
failure	I-Entity
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	B-Entity
sodium	I-Entity
and	O
gentamicin	B-Entity
sulfate	I-Entity
therapy	O
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	I-Entity
.	O

Patients	O
with	O
renal	B-Entity
insufficiency	I-Entity
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O



Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	I-Entity
induced	O
by	O
scopolamine	I-Entity
.	O

The	O
anti	O
-	O
dementia	I-Entity
effects	O
of	O
s	B-Entity
-	I-Entity
limonene	I-Entity
and	O
s	B-Entity
-	I-Entity
perillyl	I-Entity
alcohol	I-Entity
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O

These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	B-Entity
impaired	I-Entity
by	O
scopolamine	I-Entity
;	O
however	O
,	O
s	B-Entity
-	I-Entity
perillyl	I-Entity
alcohol	I-Entity
relieved	O
the	O
deficit	B-Entity
of	I-Entity
associative	I-Entity
memory	I-Entity
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non	O
-	O
associative	O
memory	O
significantly	O
in	O
OFH	O
.	O

Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	I-Entity
concentration	O
of	O
the	O
vehicle	O
/	O
scopolamine	I-Entity
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle	O
/	O
vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s	B-Entity
-	I-Entity
limonene	I-Entity
or	O
s	B-Entity
-	I-Entity
perillyl	I-Entity
alcohol	I-Entity
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	I-Entity
.	O



The	O
selective	O
5-HT6	O
receptor	O
antagonist	O
Ro4368554	I-Entity
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	B-Entity
deficiency	I-Entity
in	O
the	O
rat	O
.	O

Antagonists	O
at	O
serotonin	I-Entity
type	O
6	O
(	O
5-HT(6	I-Entity
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O

Although	O
the	O
underlying	O
mechanism(s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	I-Entity
(	O
ACh	I-Entity
)	O
levels	O
.	O

The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5-HT(6	I-Entity
)	O
antagonist	O
Ro4368554	I-Entity
(	O
3-benzenesulfonyl-7-(4-methyl	B-Entity
-	I-Entity
piperazin-1-yl)1H	I-Entity
-	I-Entity
indole	I-Entity
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	I-Entity
pretreatment	O
)	O
and	O
a	O
serotonergic-	O
(	O
tryptophan	I-Entity
(	O
TRP	I-Entity
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	I-Entity
.	O

Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24-h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	I-Entity
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
whereas	O
Ro4368554	I-Entity
was	O
inactive	O
.	O

Both	O
,	O
Ro4368554	I-Entity
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
)	O
and	O
metrifonate	I-Entity
(	O
10	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O

,	O
respectively	O
)	O
reversed	O
memory	B-Entity
deficits	I-Entity
induced	O
by	O
scopolamine	I-Entity
and	O
TRP	I-Entity
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4368554	I-Entity
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	B-Entity
deficit	I-Entity
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	I-Entity
and	O
,	O
possibly	O
,	O
other	O
5-HT(6	I-Entity
)	O
receptor	O
antagonists	O
.	O



Lone	O
atrial	B-Entity
fibrillation	I-Entity
associated	O
with	O
creatine	I-Entity
monohydrate	O
supplementation	O
.	O

Atrial	B-Entity
fibrillation	I-Entity
in	O
young	O
patients	O
without	O
structural	O
heart	B-Entity
disease	I-Entity
is	O
rare	O
.	O

Therefore	O
,	O
when	O
the	O
arrhythmia	I-Entity
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O

Thyroid	B-Entity
disorders	I-Entity
,	O
illicit	O
drug	O
or	O
stimulant	O
use	O
,	O
and	O
acute	B-Entity
alcohol	I-Entity
intoxication	I-Entity
are	O
among	O
these	O
causes	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
30-year	O
-	O
old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	B-Entity
fibrillation	I-Entity
with	O
rapid	O
ventricular	O
response	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	I-Entity
of	O
the	O
fingers	O
and	O
foot	O
.	O

Thyroid	O
-	O
stimulating	O
hormone	O
,	O
magnesium	I-Entity
,	O
and	O
potassium	I-Entity
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	O
screen	O
was	O
negative	O
,	O
and	O
alcohol	I-Entity
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	I-Entity
monohydrate	O
was	O
revealed	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	I-Entity
,	O
and	O
given	O
intravenous	O
diltiazem	I-Entity
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	I-Entity
for	O
rate	O
and	O
rhythm	O
control	O
.	O

When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	I-Entity
and	O
aspirin	I-Entity
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O

Exogenous	O
creatine	I-Entity
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O

Vegetarians	O
may	O
also	O
take	O
creatine	I-Entity
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O

Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	I-Entity
to	O
the	O
development	O
of	O
arrhythmia	I-Entity
.	O



Comparison	O
of	O
developmental	O
toxicity	I-Entity
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygenase-2	O
inhibitors	O
in	O
CRL:(WI)WUBR	O
Wistar	O
rats	O
--	O
DFU	I-Entity
and	O
piroxicam	I-Entity
study	O
.	O

Unlike	O
general	O
toxicity	I-Entity
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	I-Entity
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	I-Entity
)	O
and	O
selective	O
(	O
DFU	I-Entity
;	O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl	B-Entity
)	I-Entity
phenyl-2(5H)-furanon	I-Entity
)	O
COX-2	O
inhibitors	O
.	O

Doses	O
were	O
set	O
at	O
0.3	O
,	O
3.0	O
and	O
30.0mg	O
/	O
kg	O
for	O
piroxicam	I-Entity
and	O
0.2	O
,	O
2.0	O
and	O
20.0mg	O
/	O
kg	O
for	O
DFU	I-Entity
.	O

The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	B-Entity
septal	I-Entity
(	I-Entity
VSD	I-Entity
)	I-Entity
and	I-Entity
midline	I-Entity
(	I-Entity
MD	I-Entity
)	I-Entity
defects	I-Entity
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	I-Entity
,	O
selective	O
and	O
non	O
-	O
selective	O
COX-2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O

RESULTS	O
:	O
Maternal	O
toxicity	I-Entity
,	O
intrauterine	B-Entity
growth	I-Entity
retardation	I-Entity
,	O
and	O
increase	B-Entity
of	I-Entity
external	I-Entity
and	I-Entity
skeletal	I-Entity
variations	I-Entity
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	I-Entity
.	O

Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	I-Entity
developmental	O
toxicity	I-Entity
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O

Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	I-Entity
and	O
DFU	I-Entity
-	O
exposed	O
groups	O
.	O

Unlike	O
DFU	I-Entity
,	O
piroxicam	I-Entity
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O

Prenatal	O
exposure	O
to	O
selective	O
COX-2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	B-Entity
septal	I-Entity
and	I-Entity
midline	I-Entity
defects	I-Entity
in	O
rat	O
when	O
compared	O
to	O
non	O
-	O
selective	O
drugs	O
and	O
historic	O
control	O
.	O



Protective	O
efficacy	O
of	O
neuroactive	O
steroids	I-Entity
against	O
cocaine	I-Entity
kindled	O
-	O
seizures	I-Entity
in	O
mice	O
.	O

Neuroactive	O
steroids	I-Entity
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-Entity
and	I-Entity
psychiatric	I-Entity
disorders	I-Entity
.	O

They	O
offer	O
protection	O
against	O
seizures	I-Entity
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B-Entity
dependence	I-Entity
in	O
preclinical	O
assessments	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	I-Entity
that	O
positively	O
modulate	O
the	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA(A	I-Entity
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	I-Entity
engendered	O
by	O
repeated	O
cocaine	I-Entity
administration	O
(	O
seizure	I-Entity
kindling	O
)	O
.	O

Allopregnanolone	I-Entity
(	O
3alpha	B-Entity
-	I-Entity
hydroxy-5alpha	I-Entity
-	I-Entity
pregnan-20-one	I-Entity
)	O
,	O
pregnanolone	I-Entity
(	O
3alpha	B-Entity
-	I-Entity
hydroxy-5beta	I-Entity
-	I-Entity
pregnan-20-one	I-Entity
)	O
and	O
ganaxolone	I-Entity
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	I-Entity
3alpha	B-Entity
-	I-Entity
hydroxy-3beta	I-Entity
-	I-Entity
methyl-5alpha	I-Entity
-	I-Entity
pregnan-20-one	I-Entity
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	I-Entity
-	O
kindled	O
seizures	I-Entity
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Kindled	O
seizures	I-Entity
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	I-Entity
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	O
GABA(A	I-Entity
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	I-Entity
,	O
whereas	O
only	O
allopregnanolone	I-Entity
and	O
ganaxolone	I-Entity
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

Allopregnanolone	I-Entity
and	O
pregnanolone	I-Entity
,	O
but	O
not	O
ganaxolone	I-Entity
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	I-Entity
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	I-Entity
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O



Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	O
cyclosporine	B-Entity
A	I-Entity
,	O
tacrolimus	I-Entity
and	O
sirolimus	I-Entity
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	I-Entity
(	O
SRL	I-Entity
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	I-Entity
,	O
but	O
SRL	I-Entity
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	I-Entity
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	I-Entity
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	I-Entity
effect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-Entity
A	I-Entity
(	O
CsA	I-Entity
)	O
,	O
tacrolimus	I-Entity
(	O
FK506	I-Entity
)	O
or	O
SRL	I-Entity
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	I-Entity
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	I-Entity
3.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	I-Entity
0.4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	I-Entity
,	O
subcapsular	O
fibrosis	I-Entity
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	I-Entity
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

CsA	I-Entity
,	O
FK506	I-Entity
and	O
SRL	I-Entity
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	I-Entity
was	O
combined	O
with	O
either	O
FK506	I-Entity
or	O
SRL	I-Entity
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	I-Entity
plus	O
SRL	I-Entity
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	I-Entity
plus	O
SRL	I-Entity
(	O
P<0.001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	I-Entity
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P<0.02	O
)	O
.	O

The	O
FK506	I-Entity
plus	O
SRL	I-Entity
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	I-Entity
as	O
compared	O
with	O
controls	O
(	O
P=0.05	O
)	O
.	O

This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	I-Entity
effect	O
of	O
CsA	I-Entity
plus	O
SRL	I-Entity
,	O
whereas	O
FK506	I-Entity
plus	O
SRL	I-Entity
was	O
better	O
tolerated	O
.	O



Effect	O
of	O
fucoidan	I-Entity
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	B-Entity
hemorrhage	I-Entity
in	O
rats	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B-Entity
damage	I-Entity
following	O
ischemic	B-Entity
stroke	I-Entity
.	O

Intracerebral	B-Entity
hemorrhage	I-Entity
is	O
associated	O
with	O
more	O
inflammation	I-Entity
than	O
ischemic	B-Entity
stroke	I-Entity
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	I-Entity
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B-Entity
damage	I-Entity
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	B-Entity
hemorrhage	I-Entity
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	I-Entity
(	O
30	O
micrograms	O
h-1	O
)	O
or	O
vehicle	O
.	O

The	O
hematoma	I-Entity
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

Fucoidan	I-Entity
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	B-Entity
blood	I-Entity
clotting	I-Entity
and	O
hemodilution	I-Entity
,	O
had	O
larger	O
hematomas	I-Entity
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	I-Entity
in	O
the	O
vicinity	O
of	O
the	O
hematoma	I-Entity
after	O
three	O
days	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	I-Entity
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Acute	O
white	B-Entity
matter	I-Entity
edema	I-Entity
and	O
eventual	O
neuronal	B-Entity
loss	I-Entity
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	I-Entity
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	B-Entity
hemorrhage	I-Entity
.	O



Paracetamol	I-Entity
-	O
associated	O
coma	I-Entity
,	O
metabolic	B-Entity
acidosis	I-Entity
,	O
renal	B-Entity
and	I-Entity
hepatic	I-Entity
failure	I-Entity
.	O

A	O
case	O
of	O
metabolic	B-Entity
acidosis	I-Entity
,	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
and	I-Entity
hepatic	I-Entity
failure	I-Entity
following	O
paracetamol	I-Entity
ingestion	O
is	O
presented	O
.	O



Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	I-Entity
in	O
the	O
United	O
Kingdom	O
.	O

Ketoconazole	I-Entity
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O

By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	I-Entity
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	I-Entity
.	O

An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	I-Entity
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	O
.	O

The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57.9	O
,	O
with	O
hepatotoxicity	I-Entity
being	O
more	O
common	O
in	O
women	O
.	O

The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	I-Entity
was	O
61	O
days	O
.	O

The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	B-Entity
injury	I-Entity
in	O
10	O
(	O
63%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O

In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	I-Entity
.	O

Allergic	O
manifestations	O
such	O
as	O
rash	I-Entity
and	O
eosinophilia	I-Entity
were	O
rare	O
.	O

Hepatitis	I-Entity
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3.1	O
months	O
.	O

In	O
two	O
of	O
the	O
three	O
deaths	I-Entity
probably	O
associated	O
with	O
ketoconazole	I-Entity
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	I-Entity
and	O
other	O
symptoms	O
of	O
hepatitis	I-Entity
.	O

Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	I-Entity
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	I-Entity
to	O
prevent	O
possible	O
serious	O
hepatic	B-Entity
injury	I-Entity
.	O



Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Entity
E1-induced	I-Entity
hypotension	I-Entity
and	O
haemodilution	I-Entity
on	O
human	O
hepatic	O
function	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Entity
E1	I-Entity

(	O
PGE1)-induced	I-Entity
hypotension	I-Entity
and	O
haemodilution	I-Entity
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	I-Entity
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	I-Entity
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	I-Entity
and	O
haemodilution	I-Entity
.	O

Haemodilution	I-Entity
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	I-Entity
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22%	O
.	O

Controlled	O
hypotension	I-Entity
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	I-Entity
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto	B-Entity
-	I-Entity
acetate/3-hydroxybutyrate	I-Entity
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O

In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-40%	O
)	O
and	O
at	O
180	O
min	O
(	O
-49%	O
)	O
after	O
the	O
start	O
of	O
hypotension	I-Entity
and	O
at	O
60	O
min	O
(	O
-32%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	I-Entity
showed	O
significant	O
increases	O
after	O
operation	O
.	O

The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1-induced	I-Entity
hypotension	I-Entity
and	O
moderate	O
haemodilution	I-Entity
would	O
cause	O
impairment	B-Entity
of	I-Entity
hepatic	I-Entity
function	I-Entity
.	O



Levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O

Levodopa	I-Entity
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamine	I-Entity
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	I-Entity
.	O

Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post	O
-	O
receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B-Entity
movements	I-Entity
.	O

Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	I-Entity
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	I-Entity
receptors	O
,	O
and	O
non	O
-	O
dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O



Prevention	O
of	O
seizures	I-Entity
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	I-Entity
induced	O
by	O
pilocarpine	I-Entity
in	O
rats	O
.	O

BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B-Entity
epilepticus	I-Entity
(	O
SE	I-Entity
)	O
.	O

Spontaneous	B-Entity
recurrent	I-Entity
seizures	I-Entity
(	O
SRS	I-Entity
)	O
were	O
monitored	O
using	O
Racine	O
's	O
seizure	I-Entity
severity	O
scale	O
.	O

All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	I-Entity
control	O
group	O
developed	O
SRS	I-Entity
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	I-Entity
animals	O
had	O
seizures	I-Entity
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25%	O
of	O
BMC	O
-	O
treated	O
epileptic	I-Entity
animals	O
had	O
seizures	I-Entity
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	I-Entity
control	O
group	O
.	O

At	O
hippocampal	O
Schaeffer	O
collateral	O
-	O
CA1	O
synapses	O
,	O
long	O
-	O
term	O
potentiation	O
was	O
preserved	O
in	O
BMC	O
-	O
transplanted	O
rats	O
compared	O
to	O
epileptic	I-Entity
controls	O
.	O

cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	I-Entity
rats	O
.	O

In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	I-Entity
,	O
reduce	O
neuronal	B-Entity
loss	I-Entity
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O



Cardioprotective	O
effect	O
of	O
salvianolic	B-Entity
acid	I-Entity
A	I-Entity
on	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Entity
acid	I-Entity
A	I-Entity
on	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

Isoproterenol	I-Entity
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	I-Entity
dehydrogenase	O
,	O
aspartate	I-Entity
transaminase	O
,	O
creatine	I-Entity
kinase	O
and	O
malondialdehyde	I-Entity
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	I-Entity
dismutase	O
,	O
catalase	O
and	O
glutathione	I-Entity
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O

In	O
addition	O
,	O
mitochondrial	O
respiratory	B-Entity
dysfunction	I-Entity
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	I-Entity
/	O
O	O
was	O
observed	O
in	O
isoproterenol	I-Entity
-	O
treated	O
rats	O
.	O

Administration	O
of	O
salvianolic	B-Entity
acid	I-Entity
A	I-Entity
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	I-Entity
-	O
induced	O
cardiac	B-Entity
dysfunction	I-Entity
and	O
myocardial	B-Entity
injury	I-Entity
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O

The	O
protective	O
role	O
of	O
salvianolic	B-Entity
acid	I-Entity
A	I-Entity
against	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
damage	I-Entity
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Entity
acid	I-Entity
A	I-Entity
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
.	O



Acute	O
effects	O
of	O
N-(2-propylpentanoyl)urea	I-Entity
on	O
hippocampal	O
amino	B-Entity
acid	I-Entity
neurotransmitters	O
in	O
pilocarpine	I-Entity
-	O
induced	O
seizure	I-Entity
in	O
rats	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	B-Entity
acid	I-Entity
neurotransmitters	O
(	O
glutamate	I-Entity
,	O
aspartate	I-Entity
,	O
glycine	I-Entity
and	O
GABA	I-Entity
)	O
of	O
N-(2-propylpentanoyl)urea	I-Entity
(	O
VPU	I-Entity
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	B-Entity
acid	I-Entity
(	O
VPA	I-Entity
)	O
.	O

VPU	I-Entity
was	O
more	O
potent	O
than	O
VPA	I-Entity
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED(50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	I-Entity
-	O
induced	O
seizure	I-Entity
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	I-Entity
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	I-Entity
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	I-Entity
and	O
aspartate	I-Entity
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	I-Entity
and	O
GABA	I-Entity
.	O

Pretreatment	O
with	O
either	O
VPU	I-Entity
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	I-Entity
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	I-Entity
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	I-Entity
and	O
aspartate	I-Entity
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	I-Entity
and	O
glycine	I-Entity
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	I-Entity
and	O
aspartate	I-Entity
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	I-Entity
and	O
VPA	I-Entity
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	I-Entity
-	O
induced	O
seizure	I-Entity
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	B-Entity
acid	I-Entity
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	I-Entity
and	O
aspartate	I-Entity
.	O

Therefore	O
,	O
like	O
VPA	I-Entity
,	O
the	O
finding	O
that	O
VPU	I-Entity
could	O
drastically	O
reduce	O
pilocarpine	I-Entity
-	O
induced	O
increases	O
in	O
glutamate	I-Entity
and	O
aspartate	I-Entity
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	I-Entity
-	O
induced	O
seizure	I-Entity
in	O
experimental	O
animals	O
.	O



Acute	O
hepatitis	I-Entity
attack	O
after	O
exposure	O
to	O
telithromycin	I-Entity
.	O

INTRODUCTION	O
:	O
Antibiotic	O
-	O
associated	O
hepatotoxicity	I-Entity
is	O
rare	O
.	O

With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	B-Entity
injury	I-Entity
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B-Entity
drug	I-Entity
reactions	I-Entity
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O

Hospital	O
Emergency	O
Department	O
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	I-Entity
,	O
malaise	O
,	O
nausea	I-Entity
,	O
and	O
vomiting	I-Entity
.	O

He	O
had	O
been	O
prescribed	O
telithromycin	I-Entity
400	O
mg	O
/	O

d	O
PO	O
to	O
treat	O
an	O
upper	B-Entity
respiratory	I-Entity
tract	I-Entity
infection	I-Entity
7	O
days	O
prior	O
.	O

Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	I-Entity
aminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reference	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	I-Entity
aminotransferase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	O
phosphatase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bilirubin	I-Entity
,	O
20.1	O
mg	O
/	O
dL	O
(	O
0.2	O
-	O
1.0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirubin	I-Entity
,	O
14.8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0.3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albumin	O
,	O
4.7	O
mg	O
/	O
dL	O
(	O
3.5	O
-	O
5.4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toxin	O
,	O
alcohol	I-Entity
,	O
or	O
other	O
drugs	O
were	O
reported	O
.	O

The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
""""	O
acute	O
hepatitis	I-Entity
of	O
unknown	O
origin	O
,	O
""""	O
that	O
occurred	O
after	O
telithromycin	I-Entity
usage	O
.	O

Telithromycin	I-Entity
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	B-Entity
dysfunction	I-Entity
.	O

Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-Entity
drug	I-Entity
reaction	I-Entity
probability	O
scale	O
,	O
telithromycin	I-Entity
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	I-Entity
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug	O
-	O
induced	O
toxic	B-Entity
hepatitis	I-Entity
.	O

Recurrence	O
of	O
hepatitis	I-Entity
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	I-Entity
the	O
second	O
time	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	I-Entity
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	I-Entity
.	O



Spironolactone	I-Entity
-	O
induced	O
renal	B-Entity
insufficiency	I-Entity
and	O
hyperkalemia	I-Entity
in	O
patients	O
with	O
heart	B-Entity
failure	I-Entity
.	O

A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	I-Entity
in	O
heart	B-Entity
failure	I-Entity
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	I-Entity
(	O
2%	O
)	O
and	O
renal	B-Entity
insufficiency	I-Entity
(	O
0%	O
)	O
.	O

Because	O
treatments	O
for	O
heart	B-Entity
failure	I-Entity
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	I-Entity
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	I-Entity
and	O
renal	B-Entity
insufficiency	I-Entity
in	O
heart	B-Entity
failure	I-Entity
patients	O
treated	O
with	O
spironolactone	I-Entity
.	O

:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B-Entity
failure	I-Entity
patients	O
treated	O
with	O
spironolactone	I-Entity
in	O
our	O
clinical	O
practice	O
.	O

Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	I-Entity
(	O
K(+	I-Entity
)	O

>	O
5.0	O
mEq	O
/	O
L	O
)	O
or	O
renal	B-Entity
insufficiency	I-Entity

(	O
Cr	I-Entity
>	O
or=2.5	O
mg	O
/	O
dL	O
)	O
,	O
and	O

Sixty	O
-	O
seven	O
of	O
926	O
patients	O
(	O
7.2%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	I-Entity
due	O
to	O
hyperkalemia	I-Entity
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-Entity
failure	I-Entity
(	O
n	O
=	O
34	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	I-Entity
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	I-Entity
,	O
had	O
higher	O
baseline	O
serum	O
potassium	I-Entity
levels	O
and	O
lower	O
baseline	O
potassium	I-Entity
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
renal	B-Entity
insufficiency	I-Entity
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	I-Entity
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	I-Entity
diuretics	O
than	O
controls	O
.	O

CONCLUSIONS	O
:	O
Spironolactone	I-Entity
-	O
induced	O
hyperkalemia	I-Entity
and	O
renal	B-Entity
insufficiency	I-Entity
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O



End	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
(	O
ESRD	I-Entity
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O

The	O
calcineurin	O
inhibitors	O
cyclosporine	I-Entity
and	O
tacrolimus	I-Entity
are	O
both	O
known	O
to	O
be	O
nephrotoxic	I-Entity
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
(	O
ESRD	I-Entity
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	I-Entity
and	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
(	O
CRF	I-Entity
)	O
in	O
OLTX	O
patients	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	I-Entity
or	O
ESRD	I-Entity
,	O
n=748	O
;	O
CRF	I-Entity
,	O
sustained	O
serum	O
creatinine	I-Entity
>	O
2.5	O
mg	O
/	O
dl	O
,	O
n=41	O
;	O
and	O
ESRD	I-Entity
,	O
n=45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	I-Entity
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	I-Entity
.	O

At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Entity
dysfunction	I-Entity
was	O
18.1%	O
(	O
CRF	I-Entity
8.6%	O
and	O
ESRD	I-Entity
9.5%	O
)	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	I-Entity
and	O
ESRD	I-Entity
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	I-Entity
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-Entity
syndrome	I-Entity
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1-year	O
serum	O
creatinine	I-Entity
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	I-Entity
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	I-Entity
or	O
ESRD	I-Entity
with	O
odds	O
ratios	O
of	O
2.6	O
,	O
2.2	O
,	O
and	O
1.6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	I-Entity
was	O
only	O
28.2%	O
compared	O
with	O
54.6%	O
in	O
the	O
control	O
group	O
.	O

Patients	O
developing	O
ESRD	I-Entity
had	O
a	O
6-year	O
survival	O
after	O
onset	O
of	O
ESRD	I-Entity
of	O
27%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71.4%	O
for	O
the	O
patients	O
developing	O
ESRD	I-Entity
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	I-Entity
and	O
ESRD	I-Entity
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	I-Entity
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	O
who	O
develop	O
ESRD	I-Entity
have	O
a	O
higher	O
preoperative	O
and	O
1-year	O
serum	O
creatinine	I-Entity
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Entity
syndrome	I-Entity
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	I-Entity
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	I-Entity
or	O
ESRD	I-Entity
.	O



Effect	O
of	O
intravenous	O
nimodipine	I-Entity
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B-Entity
stroke	I-Entity
.	O

The	O
Intravenous	O
Nimodipine	I-Entity
West	O
European	O
Stroke	I-Entity
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	I-Entity
-	O
induced	O
reduction	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B-Entity
stroke	I-Entity
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	B-Entity
reduction	I-Entity
.	O

Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B-Entity
stroke	I-Entity
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n=100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O

nimodipine	I-Entity
(	O
n=101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	I-Entity
(	O
n=94	O
)	O
.	O

Nimodipine	I-Entity
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	B-Entity
in	I-Entity
systolic	I-Entity
BP	I-Entity
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B-Entity
reduction	I-Entity
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta=0.49	O
,	O
P=0	O
.	O

Patients	O
with	O
a	O
DBP	B-Entity
reduction	I-Entity
of	O
>	O
or	O
=	O
20%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	I-Entity
or	O
dependency	O

(	O
n	O
/	O
N=25/26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95%	O
CI	O
1.02	O
to	O
101.74	O
)	O
and	O
death	I-Entity
alone	O
(	O
n	O
/	O
N=9/26	O
,	O
OR	O
4.336	O
,	O
95%	O
CI	O
1.131	O
16.619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N=62/92	O
and	O
14/92	O
,	O
respectively	O
)	O
.	O

DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	I-Entity
after	O
acute	B-Entity
stroke	I-Entity
.	O

For	O
low	O
-	O
dose	O
nimodipine	I-Entity
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	I-Entity
.	O



Transient	B-Entity
neurologic	I-Entity
symptoms	I-Entity
after	O
spinal	O
anesthesia	O
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	I-Entity
and	O
bupivacaine	I-Entity
than	O
with	O
lidocaine	I-Entity
.	O

Recent	O
evidence	O
suggests	O
that	O
transient	B-Entity
neurologic	I-Entity
symptoms	I-Entity
(	O
TNSs	I-Entity
)	O
frequently	O
follow	O
lidocaine	I-Entity
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	I-Entity
.	O

However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	I-Entity
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O

Prilocaine	I-Entity
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	I-Entity
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double	O
-	O
blind	O
study	O
compares	O
prilocaine	I-Entity
with	O
lidocaine	I-Entity
and	O
bupivacaine	I-Entity
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	I-Entity
.	O

2%	O
lidocaine	I-Entity
in	O
7.5%	O
glucose	I-Entity
,	O
2%	O
prilocaine	I-Entity
in	O
7.5%	O
glucose	I-Entity
,	O
or	O
0.5%	O
bupivacaine	I-Entity
in	O
7.5%	O
glucose	I-Entity
.	O

In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	I-Entity
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure	O
.	O

Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	I-Entity
experienced	O
TNSs	I-Entity
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	I-Entity
(	O
P	O
=	O
0.03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	I-Entity
had	O
TNSs	I-Entity
.	O

Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	I-Entity
and	O
prilocaine	I-Entity
(	O
150	O
vs.	O
165	O
min	O
and	O
238	O
vs.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	I-Entity
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O

Prilocaine	I-Entity
may	O
be	O
preferable	O
to	O
lidocaine	I-Entity
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	I-Entity
.	O



The	O
role	O
of	O
nicotine	I-Entity
in	O
smoking	O
-	O
related	O
cardiovascular	B-Entity
disease	I-Entity
.	O

Nicotine	I-Entity
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B-Entity
disease	I-Entity
.	O

Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	I-Entity
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	I-Entity
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O

Almost	O
certainly	O
,	O
nicotine	I-Entity
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	I-Entity
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	B-Entity
monoxide	I-Entity
.	O

Nicotine	I-Entity
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	I-Entity
among	O
humans	O
.	O

Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	I-Entity
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	I-Entity
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O

Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	I-Entity
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	I-Entity
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
level	O
cigarette	O
exposures	O
.	O



Seizure	I-Entity
resulting	O
from	O
a	O
venlafaxine	I-Entity
overdose	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	I-Entity
overdose	I-Entity
.	O

A	O
40-year	O
-	O
old	O
woman	O
with	O
major	B-Entity
depression	I-Entity
took	O
an	O
overdose	I-Entity
of	O
venlafaxine	I-Entity
in	O
an	O
apparent	O
suicide	O
attempt	O
.	O

After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	I-Entity
50-mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	I-Entity
.	O

She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	I-Entity
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	I-Entity
overdose	I-Entity
that	O
resulted	O
in	O
a	O
generalized	O
seizure	I-Entity
.	O

Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	I-Entity
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O

The	O
venlafaxine	I-Entity
overdose	I-Entity
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	I-Entity
but	O
elicited	O
no	O
further	O
sequelae	O
.	O



Effect	O
of	O
nifedipine	I-Entity
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	I-Entity
.	O

The	O
effect	O
of	O
nifedipine	I-Entity
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	I-Entity
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O

Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	I-Entity
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	I-Entity
patients	O
who	O
were	O
receiving	O
nifedipine	I-Entity
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	I-Entity
.	O

Nifedipine	I-Entity
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	I-Entity
levels	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
observed	O
positive	O
impact	O
of	O
nifedipine	I-Entity
on	O
reducing	O
the	O
nephrotoxicity	I-Entity
associated	O
with	O
tacrolimus	I-Entity
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	I-Entity
in	O
this	O
population	O
.	O



Sinus	B-Entity
arrest	I-Entity
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	I-Entity
.	O

The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	I-Entity
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	I-Entity
.	O

A	O
40-year	O
-	O
old	O
man	O
with	O
leukemia	I-Entity
and	O
no	O
history	O
of	O
cardiac	B-Entity
disease	I-Entity
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-Entity
arrest	I-Entity
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	I-Entity
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhythmias	I-Entity
were	O
temporally	O
related	O
to	O
cimetidine	I-Entity
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	I-Entity
treatment	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B-Entity
arrest	I-Entity
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	I-Entity
.	O



Composition	O
of	O
gall	B-Entity
bladder	I-Entity
stones	I-Entity
associated	O
with	O
octreotide	I-Entity
:	O
response	O
to	O
oral	O
ursodeoxycholic	B-Entity
acid	I-Entity
.	O

Octreotide	I-Entity
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	I-Entity
,	O
induces	O
gall	B-Entity
bladder	I-Entity
stones	I-Entity
in	O
13	O
-	O
60%	O
of	O
patients	O
.	O

Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	I-Entity
treated	O
acromegalic	I-Entity
patients	O
with	O
gall	B-Entity
stones	I-Entity
.	O

Chemical	O
analysis	O
of	O
gall	B-Entity
stones	I-Entity
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71%	O
and	O
87%	O
cholesterol	I-Entity
by	O
weight	O
.	O

In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	I-Entity
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O

All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	I-Entity
saturation	O
index	O
of	O
1.19	O
(	O
0.08	O
)	O
(	O
range	O
1.01	O
-	O
1.53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	I-Entity
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O

,	O
the	O
bile	O
contained	O
cholesterol	I-Entity
microcrystals	O
immediately	O
after	O
sampling	O
.	O

Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	B-Entity
acid	I-Entity
(	O
UDCA	I-Entity
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	I-Entity
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O

n	O
=	O
2	O
)	O
gall	B-Entity
stone	I-Entity
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	I-Entity
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	B-Entity
stone	I-Entity
dissolution	O
rate	O
of	O
58.3	O
(	O
15.9%	O
)	O
.	O

In	O
conclusion	O
,	O
octreotide	I-Entity
induced	O
gall	B-Entity
stones	I-Entity
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	I-Entity
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	B-Entity
stone	I-Entity
disease	I-Entity
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	B-Entity
stones	I-Entity
containing	O
calcium	I-Entity
.	O



Cardiovascular	B-Entity
complications	I-Entity
associated	O
with	O
terbutaline	I-Entity
treatment	O
for	O
preterm	B-Entity
labor	I-Entity
.	O

Severe	O
cardiovascular	B-Entity
complications	I-Entity
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	I-Entity
for	O
preterm	B-Entity
labor	I-Entity
.	O



Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2-chloroprocaine	B-Entity
-	I-Entity
CE	I-Entity
,	O
bupivacaine	I-Entity
,	O
and	O
low	O
pH	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2-chloroprocaine	B-Entity
-	I-Entity
CE	I-Entity
in	O
experimental	O
animals	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	I-Entity
was	O
evaluated	O
.	O

The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	I-Entity
(	O

N	O
=	O
15	O
)	O
,	O
2-chloroprocaine	B-Entity
-	I-Entity
CE	I-Entity
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2-chloroprocaine	B-Entity
-	I-Entity
CE	I-Entity
seven	O
(	O
35%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	I-Entity
.	O

None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	I-Entity
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3.0	O
developed	O
hind	O
-	O
limb	O
paralysis	I-Entity
.	O

Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2-chloroprocaine	B-Entity
-	I-Entity
CE	I-Entity
,	O
13	O
showed	O
subpial	B-Entity
necrosis	I-Entity
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O

The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	I-Entity
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O



Early	O
adjuvant	O
adriamycin	I-Entity
in	O
superficial	O
bladder	B-Entity
carcinoma	I-Entity
.	O

A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
bladder	I-Entity
.	O

Adriamycin	I-Entity
(	O
50	O
mg/50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B-Entity
tumors	I-Entity
.	O

In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	I-Entity
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O

Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	I-Entity
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O

In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year	O
,	O
80%	O
remained	O
tumor	I-Entity
-	O
free	O
during	O
the	O
2-	O
to	O
3-year	O
follow	O
-	O
up	O
period	O
.	O

The	O
beneficial	O
effect	O
of	O
Adriamycin	I-Entity
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	O
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O



Hyperkalemia	I-Entity
associated	O
with	O
sulindac	I-Entity
therapy	O
.	O

Hyperkalemia	I-Entity
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	I-Entity
.	O

Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	I-Entity
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	I-Entity
synthesis	O
.	O

We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	I-Entity
ranging	O
from	O
6.1	O
to	O
6.9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	I-Entity
administration	O
.	O

In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	I-Entity
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	I-Entity
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	I-Entity
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	I-Entity
and	O
hyperkalemia	I-Entity
.	O

These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	I-Entity
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O



Ventricular	B-Entity
tachyarrhythmias	I-Entity
during	O
cesarean	O
section	O
after	O
ritodrine	I-Entity
therapy	O
:	O

This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	I-Entity
for	O
preterm	B-Entity
labor	I-Entity
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	I-Entity
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section	O
.	O

Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B-Entity
complications	I-Entity
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	I-Entity
.	O

Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	I-Entity
level	O
.	O

Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	I-Entity
are	O
advised	O
.	O

After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	O
-	O
adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	I-Entity
to	O
treat	O
hypotensive	I-Entity
patients	O
with	O
tachycardia	I-Entity
.	O



Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	I-Entity
-	O
induced	O
rat	O
prolactinomas	I-Entity
after	O
bromocriptine	I-Entity
treatment	O
.	O

To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	I-Entity
on	O
prolactinoma	I-Entity
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	I-Entity
-	O
induced	O
rat	O
prolactinoma	I-Entity
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	I-Entity
(	O
3	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O

Golgi	O
cisternae	O
in	O
the	O
prolactinoma	I-Entity
cells	O
.	O

These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	I-Entity
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O

The	O
prolactinoma	I-Entity
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O

Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	I-Entity
cells	O
.	O

However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	I-Entity
treatment	O
of	O
the	O
adenoma	I-Entity
cells	O
.	O

An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	I-Entity
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O



On	O
two	O
paradoxical	O
side	O
-	O
effects	O
of	O
prednisolone	I-Entity
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O

Liver	B-Entity
enlargement	I-Entity
and	O
muscle	B-Entity
wastage	I-Entity
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	I-Entity
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	I-Entity
action	O
.	O



Possible	O
intramuscular	O
midazolam	I-Entity
-	O
associated	O
cardiorespiratory	B-Entity
arrest	I-Entity
and	O
death	I-Entity
.	O

Midazolam	B-Entity
hydrochloride	I-Entity
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	B-Entity
and	I-Entity
cardiovascular	I-Entity
depression	I-Entity
.	O

This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B-Entity
arrest	I-Entity
and	O
death	I-Entity
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	I-Entity
.	O

Information	O
regarding	O
midazolam	I-Entity
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O



Serial	O
epilepsy	I-Entity
caused	O
by	O
levodopa	B-Entity
/	I-Entity
carbidopa	I-Entity
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O

Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa	B-Entity
/	I-Entity
levodopa	I-Entity
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	I-Entity
and	O
recurrent	O
seizures	I-Entity
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O

The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	B-Entity
B6	I-Entity
.	O



Effect	O
of	O
L	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
glyceryl	I-Entity
-	I-Entity
phosphorylcholine	I-Entity
on	O
amnesia	I-Entity
caused	O
by	O
scopolamine	I-Entity
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
glycerylphosphorylcholine	I-Entity
(	O
L	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
GFC	I-Entity
)	O
on	O
memory	B-Entity
impairment	I-Entity
induced	O
by	O
scopolamine	I-Entity
in	O
man	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
GFC	I-Entity
or	O
placebo	O
,	O
p.o	O
.	O

,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	I-Entity
or	O
placebo	O
,	O
i.m	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	B-Entity
of	I-Entity
attention	I-Entity
and	I-Entity
memory	I-Entity
induced	O
by	O
scopolamine	I-Entity
.	O



Seizures	I-Entity
induced	O
by	O
the	O
cocaine	I-Entity
metabolite	O
benzoylecgonine	I-Entity
in	O
rats	O
.	O

The	O
half	O
-	O
life	O
(	O
t1/2	O
)	O
of	O
cocaine	I-Entity
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	I-Entity
and	O
strokes	I-Entity
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	I-Entity
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O

We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	I-Entity
,	O
benzoylecgonine	I-Entity
(	O
BE	I-Entity
)	O
,	O
to	O
cause	O
seizures	I-Entity
.	O

Two	O
separate	O
equimolar	O
doses	O
(	O
0.2	O
and	O
0.4	O
mumol	O
)	O
of	O
either	O
cocaine	I-Entity
or	O
BE	I-Entity
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O

Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	I-Entity
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	I-Entity
.	O

BE	I-Entity
-	O
Induced	O
seizures	I-Entity
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	I-Entity
.	O

Whereas	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	I-Entity
,	O
those	O
induced	O
by	O
BE	I-Entity
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	I-Entity
.	O

Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	I-Entity
expression	O
.	O

BE	I-Entity
-	O
Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	I-Entity
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	I-Entity
-	O
injected	O
animals	O
without	O
seizures	I-Entity
.	O

The	O
finding	O
that	O
cocaine-	I-Entity
and	O
BE	I-Entity
-	O
induced	O
seizures	I-Entity
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	I-Entity
metabolite	O
,	O
BE	I-Entity
.	O



Protection	O
against	O
amphetamine	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
toward	O
striatal	O
dopamine	I-Entity
neurons	O
in	O
rodents	O
by	O
LY274614	I-Entity
,	O
an	O
excitatory	O
amino	B-Entity
acid	I-Entity
antagonist	O
.	O

LY274614	I-Entity
,	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	B-Entity
oisoquinoline-3-	I-Entity
carboxylic	I-Entity
acid	I-Entity
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O

subtype	O
of	O
glutamate	I-Entity
receptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
by	O
amphetamine	I-Entity
in	O
iprindole	I-Entity
-	O
treated	O
rats	O
is	O
reported	O
.	O

dose	O
of	O
(	O
+	O
/-)-amphetamine	I-Entity
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	I-Entity
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	I-Entity
(	O
MK-801	I-Entity
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	I-Entity
receptors	O
)	O
or	O
by	O
LY274614	I-Entity
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	I-Entity
receptors	O
)	O
.	O

The	O
protective	O
effect	O
of	O
LY274614	I-Entity
was	O
dose	O
-	O
dependent	O
,	O
being	O
maximum	O
at	O
10	O
-	O
40	O
mgkg	O
(	O
i.p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	I-Entity
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	I-Entity
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	I-Entity
.	O

Depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	I-Entity
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	I-Entity
;	O
LY274614	I-Entity
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	I-Entity
.	O

The	O
prolonged	O
depletion	O
of	O
dopamine	I-Entity
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	I-Entity
,	O
was	O
also	O
antagonized	O
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	I-Entity
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	I-Entity
effect	O
of	O
amphetamine	I-Entity
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	I-Entity
neurons	O
involves	O
NMDA	I-Entity
receptors	O
and	O
that	O
LY274614	I-Entity
is	O
an	O
NMDA	I-Entity
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O



Neonatal	O
pyridoxine	I-Entity
responsive	O
convulsions	I-Entity
due	O
to	O
isoniazid	I-Entity
therapy	O
.	O

A	O
17-day	O
-	O
old	O
infant	O
on	O
isoniazid	I-Entity
therapy	O

13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	I-Entity
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B-Entity
fits	I-Entity
.	O

The	O
fits	I-Entity
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	I-Entity
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	I-Entity
deficiency	O
secondary	O
to	O
isoniazid	I-Entity
medication	O
.	O



Reversal	O
by	O
phenylephrine	I-Entity
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	I-Entity
in	O
patients	O
with	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
.	O

Nitroglycerin	I-Entity
has	O
been	O
shown	O
to	O
reduce	O
ST	O
-	O
segment	O
elevation	O
during	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	I-Entity
-	O
induced	O
hypotension	I-Entity
.	O

Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	I-Entity
and	O
phenylephrine	I-Entity
therapy	O
.	O

Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	B-Entity
infarctions	I-Entity
received	O
intravenous	O
nitroglycerin	I-Entity
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+	O
/-	O

SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0.02	O
)	O
with	O
intravenous	O
nitroglycerin	I-Entity
.	O

Subsequent	O
addition	O
of	O
phenylephrine	I-Entity
infusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+	O
/-	O

Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	I-Entity
to	O
nitroglycerin	I-Entity
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
.	O



Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP-2	O
and	O
MMP-9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2-induced	I-Entity
thoracic	B-Entity
aortic	I-Entity
aneurysm	I-Entity
in	O
a	O
rat	O
model	O
.	O

This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-Entity
aortic	I-Entity
aneurysm	I-Entity
(	O
TAA	I-Entity
)	O
by	O
calcium	B-Entity
chloride	I-Entity
(	O
CaCl(2))-induced	I-Entity
arterial	B-Entity
injury	I-Entity
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	I-Entity
formation	O
.	O

Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0.5	O
M	O
CaCl(2	B-Entity
)	I-Entity
or	O
normal	O
saline	O
(	O
NaCl	I-Entity
)	O
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl(2)-treated	I-Entity
,	O
CaCl(2)-untreated	I-Entity
(	O
n=12	O
)	O
and	O

NaCl	I-Entity
-	O
treated	O
aortic	O
segments	O
(	O
n=12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

Despite	O
similar	O
external	O
diameters	O
among	O
CaCl(2)-treated	I-Entity
,	O
non	O
-	O
CaCl(2)-treated	I-Entity
and	O
NaCl	I-Entity
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n=6	O
,	O
50%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n=12	O
,	O
100%	O
)	O
were	O
demonstrated	O
in	O
CaCl(2)-treated	I-Entity
segments	O
.	O

MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl(2)-treated	I-Entity
segments	O
(	O
all	O
p<0.01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl(2)-untreated	I-Entity
segments	O
,	O
as	O
compared	O
with	O
NaCl	I-Entity
-	O
treated	O
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
(	O
all	O
p<0.01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl(2)-treated	I-Entity
segments	O
.	O

This	O
study	O
establishes	O
a	O
TAA	I-Entity
model	O
by	O
periarterial	O
CaCl(2	B-Entity
)	I-Entity
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O



Twenty	O
-	O
three	O
hours	O
after	O
heart	O
transplantation	O
,	O
life	O
-	O
threatening	O
acute	O
right	B-Entity
heart	I-Entity
failure	I-Entity
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O

Increasing	O
doses	O
of	O
catecholamines	I-Entity
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O

However	O
,	O
a	O
bolus	O
of	O
epinephrine	I-Entity
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	I-Entity
crisis	O
.	O

The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	I-Entity
doses	O
.	O



Long	O
-	O
term	O
glutamate	I-Entity
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B-Entity
neurotoxicity	I-Entity
of	O
paclitaxel	I-Entity
.	O

Toxic	O
peripheral	B-Entity
neuropathy	I-Entity
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	I-Entity
(	O
PAC	I-Entity
)	O
,	O
although	O
glutamate	I-Entity
and	O
its	O
closely	O
related	O
amino	B-Entity
acid	I-Entity
glutamine	I-Entity
were	O
claimed	O
to	O
ameliorate	O
PAC	I-Entity
neurotoxicity	I-Entity
.	O

This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	I-Entity
supplementation	O
for	O
preventing	O
PAC	I-Entity
-	O
induced	O
peripheral	B-Entity
neuropathy	I-Entity
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O

Forty	O
-	O
three	O
ovarian	B-Entity
cancer	I-Entity
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	I-Entity
-	O
containing	O
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	I-Entity
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	I-Entity
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G.	O

However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	I-Entity
sensation	O
(	O
P	O
=	O
0.011	O
)	O
.	O

This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	I-Entity
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	B-Entity
neurotoxicity	I-Entity
of	O
PAC	I-Entity
.	O



Attentional	O
modulation	O
of	O
perceived	O
pain	I-Entity
intensity	O
in	O
capsaicin	I-Entity
-	O
induced	O
secondary	O
hyperalgesia	I-Entity
.	O

Perceived	O
pain	I-Entity
intensity	O
is	O
modulated	O
by	O
attention	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	I-Entity
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	I-Entity
-	O
induced	O
secondary	O
hyperalgesia	I-Entity
.	O

Here	O
we	O
show	O
that	O
perceived	O
pain	I-Entity
intensity	O
in	O
secondary	O
hyperalgesia	I-Entity
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	I-Entity
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	I-Entity
-	O
untreated	O
,	O
control	O
condition	O
.	O

Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	I-Entity
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	I-Entity
-	O
induced	O
secondary	O
hyperalgesia	I-Entity
and	O
attention	O
might	O
affect	O
mechanical	O
pain	I-Entity
through	O
independent	O
mechanisms	O
.	O



Testosterone	I-Entity
-	O
dependent	O
hypertension	I-Entity
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	I-Entity
-	O
sensitive	O
rats	O
.	O

Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	I-Entity
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O

In	O
Dahl	O
salt	I-Entity
-	O
sensitive	O
rats	O
(	O
DS	O
)	O
,	O
high	O
-	O
salt	I-Entity
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O

In	O
contrast	O
to	O
the	O
systemic	O
renin	O
-	O
angiotensin	I-Entity
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	I-Entity
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-Entity
injury	I-Entity
.	O

On	O
a	O
low	O
-	O
salt	I-Entity
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	B-Entity
sclerosis	I-Entity
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O

Testosterone	I-Entity
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B-Entity
injury	I-Entity
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O

Testosterone	I-Entity
contributes	O
to	O
the	O
development	O
of	O
hypertension	I-Entity
and	O
renal	B-Entity
injury	I-Entity
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	I-Entity
system	O
.	O



Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	I-Entity
-	O
mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding	O
.	O

Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	I-Entity
.	O

The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	I-Entity
.	O

We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	I-Entity
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	I-Entity
in	O
adulthood	O
.	O

No	O
changes	O
in	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
or	O
MK-801-induced	I-Entity
locomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3)H	I-Entity
-	O
MK-801	I-Entity
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3)H	I-Entity
-	O
haloperidol	I-Entity
binding	O
and	O
decreased	O
dopamine	I-Entity
transporter	O
binding	O
in	O
striatum	O
.	O

No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3)H	I-Entity
-	O
MK-801	I-Entity
binding	O
in	O
cortex	O
.	O

This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	B-Entity
deficiency	I-Entity
enhances	O
risk	O
for	O
schizophrenia	I-Entity
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	O
of	O
abuse	O
.	O



inhibitors	O
-	O
induced	O
proteinuria	I-Entity
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O

Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	I-Entity
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	I-Entity
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Entity
allograft	I-Entity
nephropathy	I-Entity
.	O

Because	O
proteinuria	I-Entity
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O

Whether	O
proteinuria	I-Entity
was	O
due	O
to	O
sirolimus	I-Entity
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	I-Entity
has	O
been	O
observed	O
during	O
sirolimus	I-Entity
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	I-Entity
de	O
novo	O
.	O

Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	I-Entity
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	I-Entity
.	O



Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	B-Entity
acid	I-Entity
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	I-Entity
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	I-Entity
.	O

Hyperprolactinemia	I-Entity
can	O
reduce	O
fertility	O
and	O
libido	O
.	O

We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	I-Entity
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	I-Entity
-	O
induced	O
LH	O
surge	O
.	O

Chronic	O
hyperprolactinemia	I-Entity
induced	O
by	O
the	O
dopamine	I-Entity
antagonist	O
sulpiride	I-Entity
caused	O
a	O
40%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	I-Entity
.	O

Sulpiride	I-Entity
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	I-Entity
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O

Estradiol	I-Entity
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
's	O
signaling	O
pathway	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
estrogen	I-Entity
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	I-Entity
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O

Lastly	O
,	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS-1	O
and	O
-3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	I-Entity
and	O
estradiol	I-Entity
.	O

Sulpiride	I-Entity
induced	O
only	O
SOCS-1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O

Estradiol	I-Entity
enhanced	O
these	O
effects	O
on	O
SOCS-3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradiol	I-Entity
also	O
induced	O
PRL	O
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O

These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	I-Entity
in	O
a	O
steroid	I-Entity
-	O
dependent	O
manner	O
.	O

They	O
also	O
provide	O
evidence	O
for	O
estradiol	I-Entity
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O



Estrogen	O
prevents	O
cholesteryl	B-Entity
ester	I-Entity
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	I-Entity
.	O

Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	I-Entity
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Entity
atherosclerosis	I-Entity
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	I-Entity
treatment	O
increases	O
atherosclerotic	B-Entity
lesion	I-Entity
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	I-Entity
-	O
treated	O
females	O
had	O
less	O
cholesteryl	B-Entity
ester	I-Entity
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	I-Entity
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	I-Entity
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-Entity
-	I-Entity
estradiol	I-Entity
(	O
E2	I-Entity
)	O
,	O
100	O
nM	O
progesterone	I-Entity
or	O
vehicle	O
(	O
0.01%	O
ethanol	I-Entity
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	I-Entity
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h.	O
Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	I-Entity
decreased	O
the	O
accumulation	O
of	O
cholesteryl	B-Entity
esters	I-Entity
in	O
macrophages	O
following	O
ritonavir	I-Entity
treatment	O
.	O

Ritonavir	I-Entity
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	I-Entity
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	I-Entity
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	I-Entity
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	I-Entity
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	B-Entity
ester	I-Entity
accumulation	O
following	O
ritonavir	I-Entity
treatment	O
.	O



Upregulation	O
of	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2-deficient	O
TR(-	O
)	O
rats	O
resembles	O
seizure	I-Entity
-	O
induced	O
up	O
-	O
regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O

By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	I-Entity
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O

Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	I-Entity
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	I-Entity
in	O
TR(-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	B-Entity
to	I-Entity
the	I-Entity
brain	I-Entity
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR(-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	I-Entity
or	O
other	O
Pgp	O
-	O
enhancing	O
events	O
for	O
this	O
purpose	O
.	O



Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	I-Entity
susceptibility	O
loci	O
in	O
mice	O
.	O

Seizure	I-Entity
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O

Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	I-Entity
susceptibility	O
.	O

QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
,	O
a	O
model	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	I-Entity
susceptibility	O
genes	O
.	O

CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

A	O
/	O
J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

B6	O
mice	O
were	O
resistant	O
to	O
seizures	I-Entity
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O

CSS	O
mapping	O
suggests	O
seizure	I-Entity
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O



Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	I-Entity
induced	O
by	O
pilocarpine	I-Entity
.	O

Mitochondrial	B-Entity
abnormalities	I-Entity
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	I-Entity
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B-Entity
epilepticus	I-Entity
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	I-Entity
model	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O

Although	O
evidences	O
of	O
mitochondrial	B-Entity
abnormalities	I-Entity
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O



Causes	O
of	O
acute	O
thrombotic	B-Entity
microangiopathy	I-Entity
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O

Thrombotic	B-Entity
microangiopathy	I-Entity
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O

In	O
postrenal	O
transplantation	O
,	O
thrombotic	B-Entity
microangiopathy	I-Entity
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O

:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
during	O
a	O
1-year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O

Five	O
cases	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
were	O
found	O
.	O

Three	O
cases	O
were	O
related	O
to	O
cyclosporine	I-Entity
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	I-Entity
and	O
tacrolimus	I-Entity
.	O

The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
related	O
to	O
an	O
antiphospholipid	B-Entity
syndrome	I-Entity
in	O
a	O
patient	O
with	O
systemic	B-Entity
lupus	I-Entity
erythematosus	I-Entity
.	O

In	O
the	O
literature	O
,	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
.	O

cyclosporine	I-Entity
,	O
tacrolimus	I-Entity
)	O

toxicity	I-Entity
,	O
procoagulant	O
status	O
,	O
and	O
antibody	O
-	O
mediated	O
rejection	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
was	O
drug	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	I-Entity
.	O

In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20%	O
)	O
.	O



Severe	O
reversible	O
left	B-Entity
ventricular	I-Entity
systolic	I-Entity
and	I-Entity
diastolic	I-Entity
dysfunction	I-Entity
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	I-Entity
overdose	I-Entity
.	O

Catecholamine	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	I-Entity
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O

In	O
contrast	O
,	O
reports	O
of	O
myocardial	B-Entity
dysfunction	I-Entity
due	O
to	O
acute	O
iatrogenic	O
overdose	I-Entity
are	O
rare	O
.	O

A	O
35-year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	I-Entity
developed	O
myocardial	B-Entity
stunning	I-Entity
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	B-Entity
ventricular	I-Entity
systolic	I-Entity
and	I-Entity
diastolic	I-Entity
dysfunction	I-Entity
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B-Entity
necrosis	I-Entity
.	O



Urinary	B-Entity
bladder	I-Entity
cancer	I-Entity
in	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
:	O

risks	O
and	O
relation	O
to	O
cyclophosphamide	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-Entity
cancer	I-Entity
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	I-Entity
,	O
in	O
patients	O
with	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	I-Entity
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-Entity
cancer	I-Entity
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	I-Entity
and	O
bladder	B-Entity
cancer	I-Entity
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-Entity
cancer	I-Entity
after	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-Entity
cancer	I-Entity
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
,	O
were	O
also	O
estimated	O
.	O

The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	I-Entity
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	B-Entity
cancer	I-Entity
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	I-Entity
(	O
OR	O
=	O
2.0	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.8	O
to	O
4.9	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	B-Entity
cancer	I-Entity
in	O
the	O
cohort	O
reached	O
10%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
,	O
and	O
a	O
history	O
of	O
bladder	B-Entity
cancer	I-Entity
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	I-Entity
and	O
the	O
risk	O
of	O
bladder	B-Entity
cancer	I-Entity
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
.	O



L	B-Entity
-	I-Entity
arginine	I-Entity
transport	O
in	O
humans	O
with	O
cortisol	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

A	O
deficient	O
L	B-Entity
-	I-Entity
arginine	I-Entity
-	O
nitric	B-Entity
oxide	I-Entity
system	O
is	O
implicated	O
in	O
cortisol	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L	B-Entity
-	I-Entity
arginine	I-Entity
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

Hydrocortisone	B-Entity
acetate	I-Entity
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5-day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

L	B-Entity
-	I-Entity
arginine	I-Entity
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	B-Entity
-	I-Entity
arginine	I-Entity
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O

L	O
[	B-Entity
3H]-l	I-Entity
-	I-Entity
arginine	I-Entity
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C.	O
Forearm	O
[	B-Entity
3H]-L	I-Entity
-	I-Entity
arginine	I-Entity
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	B-Entity
3H]-L	I-Entity
-	I-Entity
arginine	I-Entity
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	B-Entity
-	I-Entity
arginine	I-Entity
extraction	O
.	O

Plasma	O
cortisol	I-Entity
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323+/-43	O
to	O
1082+/-245	O
mmol	O
/	O

Neither	O
L	B-Entity
-	I-Entity
arginine	I-Entity
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26.3+/-3.6	O
vs	O
29.0+/-2.1	O

pmol/10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Entity
-	I-Entity
arginine	I-Entity
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Entity
-	I-Entity
arginine	I-Entity
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904+/-434	O
962	O
vs	O
2	O
013	O
910+/-770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	I-Entity
treatment	O
;	O

ie	O
,	O
that	O
L	B-Entity
-	I-Entity
arginine	I-Entity
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	I-Entity
treatment	O
.	O

We	O
conclude	O
that	O
cortisol	I-Entity
-	O
induced	O
increases	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	B-Entity
-	I-Entity
arginine	I-Entity
transport	O
system	O
.	O



MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
in	O
organ	O
transplant	O
patients	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	I-Entity
therapy	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	I-Entity
who	O
developed	O
neurologic	B-Entity
complications	I-Entity
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35.7%	O
)	O
had	O
white	B-Entity
matter	I-Entity
abnormalities	I-Entity
,	O

1	O
(	O
7.1%	O
)	O
had	O
putaminal	B-Entity
hemorrhage	I-Entity
,	O
and	O
8	O
(	O
57.1%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	O
the	O
5	O
patients	O
with	O
white	B-Entity
matter	I-Entity
abnormalities	I-Entity
,	O
4	O
patients	O
(	O
80.0%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O

The	O
remaining	O
1	O
patient	O
(	O
20.0%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-Entity
laminar	I-Entity
necrosis	I-Entity
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
.	O



Octreotide	I-Entity
-	O
induced	O
hypoxemia	I-Entity
and	O
pulmonary	B-Entity
hypertension	I-Entity
in	O
premature	O
neonates	O
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	I-Entity
complicating	O
necrotizing	B-Entity
enterocolitis	I-Entity
.	O

Pulmonary	B-Entity
hypertension	I-Entity
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	I-Entity
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	I-Entity
.	O



Sequential	O
observations	O
of	O
exencephaly	I-Entity
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	I-Entity
to	O
anencephaly	I-Entity
.	O

Anencephaly	I-Entity
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	I-Entity
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	O
observed	O
the	O
exencephaly	I-Entity
induced	O
by	O
5-azacytidine	I-Entity
at	O
embryonic	O
day	O
13.5	O
(	O
E13.5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18.5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18.5	O
.	O

We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	I-Entity
to	O
anencephaly	I-Entity
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	I-Entity
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	I-Entity
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	I-Entity
tissue	O
into	O
several	O
types	O
at	O
E13.5	O
and	O
E18.5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	I-Entity
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	I-Entity
at	O
E18.5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	I-Entity
tissue	O
at	O
E13.5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	I-Entity
at	O
E13.5	O
,	O
frequent	O
hemorrhaging	I-Entity
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	I-Entity
head	O
at	O
E15.5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	I-Entity
tissue	O
at	O
E18.5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	I-Entity
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	I-Entity
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B-Entity
failure	I-Entity
and/or	O
hemorrhaging	I-Entity
in	O
various	O
parts	O
of	O
the	O
exencephalic	I-Entity
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	I-Entity
to	O
anencephaly	I-Entity
.	O



Acute	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	I-Entity
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	I-Entity
.	O

Cocaine	I-Entity
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O

Seizure	I-Entity
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	I-Entity
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	I-Entity
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	I-Entity
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O



Microangiopathic	B-Entity
hemolytic	I-Entity
anemia	I-Entity
complicating	O
FK506	I-Entity
(	O
tacrolimus	I-Entity
)	O
therapy	O
.	O

We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B-Entity
hemolytic	I-Entity
anemia	I-Entity
(	O
MAHA	I-Entity
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	I-Entity
(	O
tacrolimus	I-Entity
)	O
therapy	O
.	O

In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	I-Entity
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	I-Entity
,	O
aspirin	I-Entity
,	O
and	O
dipyridamole	I-Entity
led	O
to	O
resolution	O
of	O
MAHA	I-Entity
.	O

In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	I-Entity
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	I-Entity
.	O

FK506-associated	I-Entity
MAHA	I-Entity
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O

In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	I-Entity
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	B-Entity
A	I-Entity
(	O
CyA	I-Entity
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	I-Entity
.	O



Variant	O
ventricular	B-Entity
tachycardia	I-Entity
in	O
desipramine	I-Entity
toxicity	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B-Entity
tachycardia	I-Entity
induced	O
by	O
desipramine	I-Entity
toxicity	I-Entity
.	O

Unusual	O
features	O
of	O
the	O
arrhythmia	I-Entity
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R	O
-	O
R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O

Recognition	O
of	O
variant	O
ventricular	B-Entity
tachycardia	I-Entity
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B-Entity
tachycardia	I-Entity
.	O



Desipramine	I-Entity
-	O
induced	O
delirium	I-Entity
at	O
""""	O
subtherapeutic	O
""""	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	I-Entity
developed	O
a	O
delirium	I-Entity
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
""""	O
subtherapeutic	O
""""	O
range	O
.	O

Delirium	I-Entity
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency	O
.	O

Therapeutic	O
ranges	O
for	O
antidepressants	I-Entity
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O



Mouse	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	I-Entity
on	O
motility	O
and	O
brain	O
biogenic	O
amines	I-Entity
.	O

The	O
effect	O
of	O
amantadine	B-Entity
hydrochloride	I-Entity
,	O
injected	O
i.p	O
.	O

in	O
6	O
increments	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	I-Entity
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O

Amantadine	I-Entity
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O

The	O
initial	O
dose	O
of	O
amantadine	I-Entity
depressed	I-Entity
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O

Subsequent	O
amantadine	I-Entity
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O

The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug	O
-	O
free	O
period	O
following	O
the	O
fourth	O
amantadine	I-Entity
treatment	O
.	O

Readministration	O
of	O
amantadine	I-Entity
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	B-Entity
of	I-Entity
motility	I-Entity
occurred	O
.	O

Treatment	O
with	O
amantadine	I-Entity
did	O
not	O
alter	O
whole	O
brain	O
dopamine	I-Entity
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3,4-dihydroxyphenylacetic	B-Entity
acid	I-Entity
in	O
the	O
BALB	O
/	O
C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O

Conversely	O
,	O
brain	O
normetanephrine	I-Entity
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	I-Entity
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

The	O
results	O
suggest	O
a	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	I-Entity
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O

The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	I-Entity
.	O

The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	I-Entity
of	O
BALB	O
/	O
C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	I-Entity
turnover	O
rate	O
and/or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	I-Entity
which	O
may	O
account	O
for	O
a	O
behavioral	B-Entity
depression	I-Entity
caused	O
by	O
amantadine	I-Entity
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O



No	O
enhancement	O
by	O
phenobarbital	I-Entity
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	I-Entity
-	O
devoid	O
diet	O
in	O
the	O
rat	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	I-Entity
in	O
a	O
choline	I-Entity
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

semipurified	O
choline	I-Entity
-	O
devoid	O
or	O
choline	I-Entity
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0.06%	O
phenobarbital	I-Entity
.	O

No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	B-Entity
carcinomas	I-Entity
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	I-Entity
-	O
supplemented	O
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B-Entity
carcinoma	I-Entity
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	I-Entity
.	O

The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B-Entity
carcinomas	I-Entity
was	O
10%	O
and	O
37%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	I-Entity
-	O
devoid	O
diet	O
,	O
and	O
17%	O
and	O
30%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital	I-Entity
-	O
containing	O
choline	I-Entity
-	O
devoid	O
diet	O
.	O

The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	I-Entity
-	O
devoid	O
diet	O
by	O
phenobarbital	I-Entity
.	O



Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	I-Entity
in	O
patients	O
with	O
and	O
without	O
variant	B-Entity
angina	I-Entity
.	O

The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	I-Entity
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B-Entity
angina	I-Entity
and	O
22	O
patients	O
with	O
atypical	O
chest	B-Entity
pain	I-Entity
and	O
in	O
others	O
without	O
angina	B-Entity
pectoris	I-Entity
(	O
control	O
group	O
)	O
.	O

Methylergonovine	I-Entity
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O

In	O
all	O
patients	O
with	O
variant	B-Entity
angina	I-Entity
,	O
coronary	B-Entity
spasm	I-Entity
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+	O
/-	O

In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	I-Entity
occurred	O
.	O

These	O
results	O
suggest	O
that	O
spasm	I-Entity
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	I-Entity
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B-Entity
angina	I-Entity
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O



Dobutamine	I-Entity
stress	O
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	I-Entity
-	O
treated	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	I-Entity
.	O

Doxorubicin	I-Entity
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	I-Entity
.	O

To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B-Entity
damage	I-Entity
due	O
to	O
doxorubicin	I-Entity
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	I-Entity
infusion	O
to	O
differentiate	O
asymptomatic	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	I-Entity
treated	O
with	O
doxorubicin	I-Entity
from	O
healthy	O
control	O
subjects	O
.	O

5	O
years	O
)	O
treated	O
from	O
1.6	O
to	O
14.3	O
years	O
(	O
median	O
5.3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicin	I-Entity
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

Graded	O
dobutamine	I-Entity
infusions	O
of	O
0.5	O
,	O
2.5	O
,	O
5	O
and	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
were	O
administered	O
.	O

Dobutamine	I-Entity
infusion	O
at	O
10	O
micrograms	O

The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	I-Entity
-	O
treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	I-Entity
stimulation	O
.	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	I-Entity
-	O
treated	O
group	O
was	O
11	O
+	O
/-	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5-micrograms	O
/	O
kg	O
per	O
min	O
dobutamine	I-Entity
infusion	O
for	O
the	O
doxorubicin	I-Entity
-	O
treated	O
group	O
was	O
14.1	O
+	O
/-	O



Effects	O
of	O
aminophylline	I-Entity
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-Entity
fibrillation	I-Entity
during	O
respiratory	B-Entity
failure	I-Entity
.	O

Cardiac	B-Entity
arrhythmias	I-Entity
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B-Entity
failure	I-Entity
.	O

The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B-Entity
disturbances	I-Entity
in	O
patients	O
with	O
respiratory	B-Entity
failure	I-Entity
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effects	O
of	O
aminophylline	I-Entity
on	O
the	O
ventricular	B-Entity
fibrillation	I-Entity
threshold	O
during	O
normal	O
acid	O
-	O
base	O
conditions	O
and	O
during	O
respiratory	B-Entity
failure	I-Entity
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O

The	O
ventricular	B-Entity
fibrillation	I-Entity
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O

During	O
the	O
infusion	O
of	O
aminophylline	I-Entity
,	O
the	O
ventricular	B-Entity
fibrillation	I-Entity
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	I-Entity
(	O
PO2	I-Entity
)	O
and	O
carbon	B-Entity
dioxide	I-Entity
(	O
CO2	I-Entity
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O

When	O
respiratory	B-Entity
failure	I-Entity
was	O
produced	O
by	O
hypoventilation	I-Entity
(	O
pH	O
7.05	O
to	O
7.25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O

P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	I-Entity
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B-Entity
fibrillation	I-Entity
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O

These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B-Entity
arrhythmias	I-Entity
in	O
respiratory	B-Entity
failure	I-Entity
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	I-Entity
,	O
may	O
play	O
a	O
significant	O
role	O
.	O



Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	I-Entity
intoxication	O
.	O

INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	I-Entity
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O

We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	I-Entity
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84-year	O
-	O
old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O

The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	I-Entity
'	O
;	O
that	O
is	O
,	O
carbachol	I-Entity
.	O

He	O
bought	O
25	O
g	O
of	O
carbachol	I-Entity
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O

Carbachol	I-Entity
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O

RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	I-Entity
,	O
sweating	O
and	O
hypotension	I-Entity
,	O
and	O
finally	O
collapsed	O
.	O

Bradycardia	I-Entity
,	O
cholinergic	O
symptoms	O
and	O
asystole	I-Entity
occurred	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	I-Entity
(	O
epinephrine	I-Entity
)	O
,	O
atropine	I-Entity
and	O
furosemide	I-Entity
was	O
successful	O
.	O

Further	O
signs	O
were	O
hyperhidrosis	I-Entity
,	O
hypersalivation	I-Entity
,	O
bronchorrhoea	I-Entity
,	O
and	O
severe	O
miosis	I-Entity
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio	B-Entity
-	I-Entity
ventricular	I-Entity
dissociation	I-Entity
.	O

High	O
doses	O
of	O
atropine	I-Entity
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	I-Entity
and	O
dopamine	I-Entity
were	O
necessary	O
.	O

However	O
,	O
increased	O
dyspnoea	I-Entity
and	O
bronchospasm	I-Entity
necessitated	O
reintubation	O
.	O

Respiratory	B-Entity
insufficiency	I-Entity
was	O
further	O
worsened	O
by	O
Proteus	B-Entity
mirabilis	I-Entity
infection	I-Entity
and	O
severe	O
bronchoconstriction	O
.	O

On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B-Entity
failure	I-Entity
.	O

Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3.6	O
and	O
1.9	O
mg	O
/	O
l	O
carbachol	I-Entity
,	O
respectively	O
.	O

For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	I-Entity
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O

The	O
analysed	O
carbachol	I-Entity
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	O
)	O
as	O
a	O
cause	O
of	O
acute	B-Entity
cardiovascular	I-Entity
failure	I-Entity
.	O



Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	I-Entity
10	O
mg	O
versus	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
in	O
migraine	I-Entity
.	O

Rizatriptan	I-Entity
is	O
a	O
selective	O
5-HT(1B/1D	I-Entity
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	I-Entity
.	O

This	O
randomized	O
double-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	I-Entity
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	I-Entity
1	O
mg	O
/	O
caffeine	I-Entity
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	I-Entity
attack	O
with	O
each	O
therapy	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89.1%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	I-Entity
to	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
(	O
69.9	O
vs.	O
30.1%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Faster	O
relief	O
of	O
headache	I-Entity
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67.3%	O
of	O
patients	O
preferring	O
rizatriptan	I-Entity
and	O
54.2%	O
of	O
patients	O
who	O
preferred	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
.	O

The	O
co	O
-	O
primary	O
endpoint	O
of	O
being	O
pain	I-Entity
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	I-Entity
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	I-Entity
free	O
2	O
h	O
after	O
rizatriptan	I-Entity
,	O
compared	O
with	O
24.3%	O
treated	O
with	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
rizatriptan	I-Entity
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	I-Entity
relief	O
at	O
2	O
h	O
was	O
75.9%	O
for	O
rizatriptan	I-Entity
and	O
47.3%	O
for	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
(	O

p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
with	O
rizatriptan	I-Entity
being	O
superior	O
to	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
within	O
30	O
min	O
of	O
dosing	O
.	O

Almost	O
36%	O
of	O
patients	O
taking	O
rizatriptan	I-Entity
were	O
pain	I-Entity
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20%	O
of	O
patients	O
on	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Rizatriptan	I-Entity
was	O
also	O
superior	O
to	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	I-Entity
,	O
vomiting	I-Entity
,	O
phonophobia	I-Entity
or	O
photophobia	I-Entity
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	I-Entity
(	O
69.8%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
(	O
38.6%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Recurrence	O
rates	O
were	O
31.4%	O
with	O
rizatriptan	I-Entity
and	O
15.3%	O
with	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	I-Entity
and	O
ergotamine	I-Entity
/	O
caffeine	I-Entity
,	O
respectively	O
,	O
were	O
dizziness	I-Entity
(	O
6.7	O
and	O
5.3%	O
)	O
,	O
nausea	I-Entity
(	O
4.2	O
and	O
8.5%	O
)	O
and	O
somnolence	I-Entity
(	O
5.5	O
and	O
2.3%	O
)	O
.	O



Thrombotic	B-Entity
microangiopathy	I-Entity
and	O
renal	B-Entity
failure	I-Entity
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O

Five	O
patients	O
with	O
carcinoma	I-Entity
developed	O
thrombotic	B-Entity
microangiopathy	I-Entity
(	O
characterized	O
by	O
renal	B-Entity
insufficiency	I-Entity
,	O
microangiopathic	B-Entity
hemolytic	I-Entity
anemia	I-Entity
,	O
and	O
usually	O
thrombocytopenia	I-Entity
)	O
after	O
treatment	O
with	O
cisplatin	I-Entity
,	O
bleomycin	I-Entity
,	O
and	O
a	O
vinca	B-Entity
alkaloid	I-Entity
.	O

One	O
patient	O
had	O
thrombotic	B-Entity
thrombocytopenic	I-Entity
purpura	I-Entity
,	O
three	O
the	O
hemolytic	B-Entity
-	I-Entity
uremic	I-Entity
syndrome	I-Entity
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O

Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	B-Entity
coagulation	I-Entity
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O

Because	O
each	O
patient	O
was	O
tumor	I-Entity
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tumor	I-Entity
at	O
the	O
onset	O
of	O
this	O
syndrome	O
,	O
the	O
thrombotic	B-Entity
microangiopathy	I-Entity
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O

Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B-Entity
failure	I-Entity
may	O
be	O
ascribed	O
to	O
cisplatin	I-Entity
nephrotoxicity	I-Entity
and	O
the	O
anemia	I-Entity
and	O
thrombocytopenia	I-Entity
to	O
drug	O
-	O
induced	O
bone	B-Entity
marrow	I-Entity
suppression	I-Entity
.	O



Salvage	O
therapy	O
with	O
nelarabine	I-Entity
,	O
etoposide	I-Entity
,	O
and	O
cyclophosphamide	I-Entity
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B-Entity
-	I-Entity
cell	I-Entity
lymphoblastic	I-Entity
leukaemia	I-Entity
and	I-Entity
lymphoma	I-Entity
.	O

A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	I-Entity
(	O
AraG	I-Entity
)	O
with	O
5	O
d	O
of	O
etoposide	I-Entity
(	O
VP	I-Entity
)	O
and	O
cyclophosphamide	I-Entity
(	O
CPM	I-Entity
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B-Entity
-	I-Entity
cell	I-Entity
leukaemia	I-Entity
or	I-Entity
lymphoma	I-Entity
.	O

The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	I-Entity
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	I-Entity
and	O
musculoskeletal	B-Entity
pain	I-Entity
.	O

Haematological	B-Entity
toxicity	I-Entity
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	I-Entity
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O

All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	I-Entity
/	O
VP	I-Entity
/	O
CPM	I-Entity
.	O

Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	I-Entity
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	I-Entity
and	O
cyclophosphamide	I-Entity
,	O
although	O
neurological	B-Entity
toxicity	I-Entity
must	O
be	O
closely	O
monitored	O
.	O



The	O
3-week	O
sulphasalazine	I-Entity
syndrome	O
strikes	O
again	O
.	O

A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	I-Entity
,	O
fever	I-Entity
,	O
lymphadenopathy	I-Entity
and	O
hepatitis	I-Entity
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	I-Entity
for	O
sero	O
-	O
negative	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	I-Entity
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Entity
drug	I-Entity
reaction	I-Entity
.	O

A	O
week	O
later	O
,	O
fulminant	O
drug	B-Entity
-	I-Entity
induced	I-Entity
hepatitis	I-Entity
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	I-Entity
)	O
,	O
and	O
accompanied	O
by	O
multi	B-Entity
-	I-Entity
organ	I-Entity
failure	I-Entity
and	O
sepsis	I-Entity
,	O
supervened	O
.	O

Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	B-Entity
hepatocellular	I-Entity
necrosis	I-Entity
,	O
acute	O
hypersensitivity	O
myocarditis	I-Entity
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	I-Entity
and	O
extensive	O
bone	B-Entity
marrow	I-Entity
necrosis	I-Entity
,	O
with	O
no	O
evidence	O
of	O
malignancy	I-Entity
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	I-Entity
syndrome	O
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	I-Entity
.	O



Bupropion	I-Entity
(	O
Zyban	I-Entity
)	O
toxicity	I-Entity
.	O

Bupropion	I-Entity
is	O
a	O
monocyclic	O
antidepressant	I-Entity
structurally	O
related	O
to	O
amphetamine	I-Entity
.	O

Zyban	I-Entity
,	O
a	O
sustained	O
-	O
release	O
formulation	O
of	O
bupropion	B-Entity
hydrochloride	I-Entity
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
's	O
introduction	O
,	O
12	O
overdose	I-Entity
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	I-Entity
.	O

Common	O
features	O
included	O
tachycardia	I-Entity
,	O
drowsiness	O
,	O
hallucinations	I-Entity
and	O
convulsions	I-Entity
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	B-Entity
arrhythmias	I-Entity
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-Entity
arrest	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13.5	O
g	O
bupropion	I-Entity
.	O

Recurrent	O
seizures	I-Entity
were	O
treated	O
with	O
diazepam	I-Entity
and	O
broad	O
complex	O
tachycardia	I-Entity
was	O
successfully	O
treated	O
with	O
adenosine	I-Entity
.	O

Zyban	I-Entity
caused	O
significant	O
neurological	B-Entity
and	I-Entity
cardiovascular	I-Entity
toxicity	I-Entity
in	O
overdose	I-Entity
.	O



Survey	O
of	O
complications	O
of	O
indocyanine	B-Entity
green	I-Entity
angiography	O
in	O
Japan	O
.	O

We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	B-Entity
green	I-Entity
for	O
use	O
in	O
fundus	O
angiography	O
.	O

:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	B-Entity
green	I-Entity
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	B-Entity
green	I-Entity
fundus	O
camera	O
.	O

Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3,774	O
indocyanine	B-Entity
green	I-Entity
angiograms	O
performed	O
on	O
2,820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O

Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	B-Entity
green	I-Entity
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O

The	O
dosage	O
of	O
indocyanine	B-Entity
green	I-Entity
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O

There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0.34%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	I-Entity
,	O
exanthema	I-Entity
,	O
urtication	I-Entity
,	O
itchiness	I-Entity
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O

Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	I-Entity
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	I-Entity
.	O

The	O
two	O
hypotensive	I-Entity
patients	O
required	O
treatment	O
for	O
shock	I-Entity
.	O

A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Entity
green	I-Entity
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Entity
sodium	I-Entity
indicated	O
that	O
indocyanine	B-Entity
green	I-Entity
is	O
a	O
safe	O
as	O
fluorescein	I-Entity
for	O
use	O
in	O
angiography	O
.	O



Bradykinin	I-Entity
receptors	O
antagonists	O
and	O
nitric	B-Entity
oxide	I-Entity
synthase	O
inhibitors	O
in	O
vincristine	I-Entity
and	O
streptozotocin	I-Entity
induced	O
hyperalgesia	I-Entity
in	O
chemotherapy	O
and	O
diabetic	B-Entity
neuropathy	I-Entity
rat	O
model	O
.	O

NO	I-Entity
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	I-Entity
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	I-Entity
synthase	O
(	O
7-NI	O
;	O
0.1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg-[Hyp3,Thi5,D	O
-	O
Tic7,Oic8	O
]	O
bradykinin	I-Entity
(	O
HOE	B-Entity
140	I-Entity
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	B-Entity
Arg10	I-Entity
HOE	I-Entity
140	I-Entity
(	O
70	O
nmol	O
/	O
kg	O

ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-Entity
(	I-Entity
streptozotocin	I-Entity
-	I-Entity
induced	I-Entity
)	I-Entity
and	I-Entity
toxic	I-Entity
(	I-Entity
vincristine	I-Entity
-	I-Entity
induced	I-Entity
)	I-Entity
neuropathy	I-Entity
was	O
investigated	O
.	O

The	O
changes	O
in	O
pain	I-Entity
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
--	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O

The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	I-Entity
receptors	O
and	O
inducible	O

NO	I-Entity
synthase	O
but	O
not	O
neuronal	O

NO	I-Entity
synthase	O
activity	O
reduces	O
diabetic	B-Entity
hyperalgesia	I-Entity
.	O

both	O
HOE	B-Entity
140	I-Entity
and	O
des	B-Entity
Arg10	I-Entity
HOE	I-Entity
140	I-Entity
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	I-Entity
synthase	O
and	O
neuronal	O
NO	I-Entity
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	I-Entity
are	O
involved	O
in	O
hyperalgesia	I-Entity
produced	O
by	O
vincristine	I-Entity
.	O

Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7-NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	B-Entity
140	I-Entity
or	O
des	B-Entity
-	I-Entity
Arg10HOE	I-Entity
140	I-Entity
in	O
toxic	B-Entity
neuropathy	I-Entity
.	O

Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Entity
and	I-Entity
toxic	I-Entity
neuropathy	I-Entity
.	O

In	O
streptozotocin	I-Entity
-	O
induced	O
hyperalgesia	I-Entity
,	O
inducible	O

NO	I-Entity
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	I-Entity
,	O
whereas	O
in	O
vincristine	I-Entity
-	O
induced	O
hyperalgesia	I-Entity
bradykinin	I-Entity
seemed	O
to	O
activate	O
neuronal	O
NO	I-Entity
synthase	O
pathway	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	I-Entity
receptor	O
antagonists	O
and	O
NO	I-Entity
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Entity
pain	I-Entity
,	O
even	O
in	O
hospital	O
care	O
.	O



Cardiac	B-Entity
toxicity	I-Entity
observed	O
in	O
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	I-Entity
-	O
based	O
chemotherapy	O
for	O
metastatic	O
breast	B-Entity
cancer	I-Entity
.	O

Cyclophosphamide	I-Entity
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O

In	O
high	O
doses	O
,	O
its	O
nonhematological	O
dose	O
-	O
limiting	O
toxicity	I-Entity
is	O
cardiomyopathy	I-Entity
.	O

We	O
combined	O
paclitaxel	I-Entity
,	O
melphalan	I-Entity
and	O
high	O
-	O
dose	O
cyclophosphamide	I-Entity
,	O
thiotepa	I-Entity
,	O
and	O
carboplatin	I-Entity
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	B-Entity
cancer	I-Entity
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	B-Entity
cancer	I-Entity
receiving	O
96-h	O
infusional	O
cyclophosphamide	I-Entity
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
(	O
CHF	I-Entity
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	I-Entity
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	B-Entity
mellitus	I-Entity
,	O
prior	O
use	O
of	O
anthracyclines	I-Entity
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Six	O
of	O
61	O
women	O
(	O
10%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	I-Entity
following	O
infusional	O
cyclophosphamide	I-Entity
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31%	O
.	O

Incidence	O
of	O
transient	O
cyclophosphamide	I-Entity
-	O
related	O
cardiac	B-Entity
toxicity	I-Entity
(	O
10%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O

Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	I-Entity
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	I-Entity
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	I-Entity
did	O
not	O
predict	O
CHF	I-Entity
development	O
.	O



Inappropriate	O
use	O
of	O
carbamazepine	I-Entity
and	O
vigabatrin	I-Entity
in	O
typical	O
absence	B-Entity
seizures	I-Entity
.	O

Carbamazepine	I-Entity
and	O
vigabatrin	I-Entity
are	O
contraindicated	O
in	O
typical	O
absence	B-Entity
seizures	I-Entity
.	O

Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	I-Entity
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatrin	I-Entity
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	I-Entity
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Entity
jerks	I-Entity
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	I-Entity
.	O

Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	I-Entity
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O

Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Entity
valproate	I-Entity
,	O
lamotrigine	I-Entity
,	O
or	O
ethosuximide	I-Entity
alone	O
or	O
in	O
combination	O
.	O



Hemolytic	B-Entity
anemia	I-Entity
associated	O
with	O
the	O
use	O
of	O
omeprazole	I-Entity
.	O

Omeprazole	I-Entity
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B-Entity
ulcer	I-Entity
disease	I-Entity
,	O
reflux	B-Entity
esophagitis	I-Entity
,	O
and	O
the	O
Zollinger	B-Entity
-	I-Entity
Ellison	I-Entity
syndrome	I-Entity
.	O

Although	O
clinical	O
experience	O
with	O
omeprazole	I-Entity
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short	O
-	O
term	O
safety	O
of	O
this	O
drug	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short	O
-	O
term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	I-Entity
:	O
hemolytic	B-Entity
anemia	I-Entity
.	O

The	O
patient	O
developed	O
weakness	O
,	O
lethargy	I-Entity
,	O
and	O
shortness	B-Entity
of	I-Entity
breath	I-Entity
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	I-Entity
.	O

Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44.1%	O
to	O
20.4%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	I-Entity
.	O

After	O
she	O
discontinued	O
the	O
omeprazole	I-Entity
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O

The	O
mechanism	O
by	O
which	O
omeprazole	I-Entity
caused	O
the	O
patient	O
's	O
hemolytic	B-Entity
anemia	I-Entity
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O



The	O
use	O
and	O
toxicity	I-Entity
of	O
didanosine	I-Entity
(	O
ddI	I-Entity
)	O
in	O
HIV	B-Entity
antibody	I-Entity
-	I-Entity
positive	I-Entity
individuals	O
intolerant	O
to	O
zidovudine	I-Entity
(	O
AZT	I-Entity
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
patients	O
intolerant	O
to	O
zidovudine	I-Entity
(	O
AZT	I-Entity
)	O
received	O
didanosine	I-Entity
(	O
ddI	I-Entity
)	O
to	O
a	O
maximum	O
dose	O
of	O
12.5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Seventy	O
patients	O
developed	O
major	O
opportunistic	B-Entity
infections	I-Entity
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	I-Entity
diagnosis	O
in	O
17	O
.	O

+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	I-Entity
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	I-Entity
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrhoea	I-Entity
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O

Peripheral	B-Entity
neuropathy	I-Entity
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	I-Entity
in	O
six	O
.	O

Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	B-Entity
pain	I-Entity
.	O

Seven	O
patients	O
developed	O
glucose	B-Entity
tolerance	I-Entity
curves	I-Entity
characteristic	O
of	O
diabetes	I-Entity
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	I-Entity
.	O



Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	I-Entity
associated	O
hemolytic	B-Entity
anemia	I-Entity
?	O

Recently	O
ribavirin	I-Entity
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	I-Entity
and	O
sorafenib	I-Entity
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	I-Entity
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	I-Entity
.	O

METHODS	O
:	O
Fourteen	O
patients	O
chronically	B-Entity
infected	I-Entity
with	I-Entity
hepatitis	I-Entity
C	I-Entity
virus	I-Entity
were	O
treated	O
by	O
pegylated	B-Entity
interferon	I-Entity
alpha	I-Entity
2a	I-Entity
and	O
ribavirin	I-Entity
.	O

In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	B-Entity
interferon	I-Entity
and	O
ribavirin	I-Entity
therapy	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	I-Entity
induced	O
anemia	I-Entity
in	O
patients	O
with	O
hepatitis	B-Entity
C	I-Entity
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	I-Entity
therapy	O
.	O



Cocaine	I-Entity
causes	O
memory	B-Entity
and	I-Entity
learning	I-Entity
impairments	I-Entity
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	I-Entity
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	I-Entity
toxicity	I-Entity
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	I-Entity
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	I-Entity
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	O
nitric	B-Entity
oxide	I-Entity
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	I-Entity
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Entity
addiction	I-Entity
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	I-Entity
administration	O
in	O
rats	O
.	O

NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	I-Entity
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	I-Entity
concentration	O
and	O
glutathione	I-Entity
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	I-Entity
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	I-Entity
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	I-Entity
.	O

Topiramate	I-Entity
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O



Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG-9	I-Entity
.	O

The	O
antinociceptive	O
effect	O
of	O
3	B-Entity
alpha	I-Entity
-	I-Entity
tropyl	I-Entity
2-(p	I-Entity
-	I-Entity
bromophenyl)propionate	I-Entity
[	O
(	O
+	O
/-)-PG-9	I-Entity
]	O
(	O
10	O
-	O
40	O
mg	O
kg-1	O
s.c	O
.	O

(	O
+	O
/-)-PG-9	I-Entity
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinociception	O
produced	O
by	O
(	O
+	O
/-)-PG-9	I-Entity
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	I-Entity
,	O
the	O
M1-selective	O
antagonists	O
pirenzepine	I-Entity
and	O
dicyclomine	I-Entity
and	O
the	O
acetylcholine	I-Entity
depletor	O
hemicholinium-3	I-Entity
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	I-Entity
,	O
the	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acidB	I-Entity
antagonist	O
3-aminopropyl	B-Entity
-	I-Entity
diethoxy	I-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
phosphinic	I-Entity
acid	I-Entity
,	O
the	O
H3	O
agonist	O
R-(alpha)-methylhistamine	I-Entity
,	O
the	O
D2	O
antagonist	O
quinpirole	I-Entity
,	O
the	O
5-hydroxytryptamine4	I-Entity
antagonist	O
2-methoxy-4-amino-5-chlorobenzoic	B-Entity
acid	I-Entity
2-(diethylamino)ethyl	I-Entity
ester	I-Entity
hydrochloride	O
,	O
the	O
5-hydroxytryptamin1A	I-Entity
antagonist	O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	I-Entity
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	I-Entity
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/-)-PG-9	I-Entity
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O

(	O
+	O
/-)-PG-9	I-Entity
(	O
10	O
-	O
40	O
mg	O
kg-1	O
i.p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	I-Entity
induced	O
by	O
scopolamine	I-Entity
(	O
1	O
mg	O
kg-1	O
i.p	O
.	O
)	O
and	O
dicyclomine	I-Entity
(	O
2	O
mg	O
kg-1	O
i.p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O

Affinity	O
profiles	O
of	O
(	O
+	O
/-)-PG-9	I-Entity
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O

,	O
have	O
shown	O
an	O
M4/M1	O
selectivity	O
ratio	O
of	O
10.2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti	O
-	O
amnesic	I-Entity
effect	O
induced	O
by	O
(	O
+	O
/-)-PG-9	I-Entity
through	O
an	O
increase	O
in	O
acetylcholine	I-Entity
extracellular	O
levels	O
.	O

In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/-)-PG-9	I-Entity
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O



Hyperbaric	O
oxygen	I-Entity
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	I-Entity
-	O
induced	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	B-Entity
cystitis	I-Entity
due	O
to	O
cyclophosphamide	I-Entity
therapy	O
for	O
Wegener	B-Entity
's	I-Entity
granulomatosis	I-Entity
.	O

Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	B-Entity
F2	I-Entity
alpha	I-Entity
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	I-Entity
.	O

We	O
then	O
used	O
hyperbaric	O
oxygen	I-Entity
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O

The	O
bleeding	I-Entity
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	I-Entity
thereafter	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	I-Entity
-	O
induced	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O



The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	B-Entity
-	I-Entity
choloroaniline	I-Entity
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	B-Entity
-	I-Entity
digluconate	I-Entity
associated	O
erosive	O
cystitis	I-Entity
.	O

A	O
high	O
percentage	O
of	O
kanamycin	I-Entity
-	O
colistin	I-Entity
and	O
povidone	B-Entity
-	I-Entity
iodine	I-Entity
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	I-Entity
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	I-Entity
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	I-Entity
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O



A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	I-Entity
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	I-Entity
as	O
the	O
reference	O
substance	O
.	O

Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B-Entity
concomitant	I-Entity
symptoms	I-Entity
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	I-Entity
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	B-Entity
syndromes	I-Entity
belonging	I-Entity
predominantly	I-Entity
to	I-Entity
the	I-Entity
schizophrenia	I-Entity
group	I-Entity
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	I-Entity
.	O



Curcumin	I-Entity
ameliorates	O
cognitive	B-Entity
dysfunction	I-Entity
and	O
oxidative	O
damage	O
in	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
administered	O
rats	O
.	O

The	O
antiepileptic	O
drugs	O
,	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Entity
impairment	I-Entity
on	O
chronic	O
use	O
.	O

The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Entity
impairment	I-Entity
by	O
antiepileptic	O
drugs	O
.	O

Curcumin	I-Entity
has	O
shown	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
neuro	O
-	O
protective	O
properties	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	I-Entity
administration	O
on	O
phenobarbitone-	I-Entity
and	O
carbamazepine	I-Entity
-	O
induced	O
cognitive	B-Entity
impairment	I-Entity
and	O
oxidative	O
stress	O
in	O
rats	O
.	O

Pharmacokinetic	O
interactions	O
of	O
curcumin	I-Entity
with	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
were	O
also	O
studied	O
.	O

At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
,	O
whole	O
brain	O
malondialdehyde	I-Entity
and	O
reduced	O
glutathione	I-Entity
levels	O
were	O
estimated	O
.	O

The	O
administration	O
of	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Entity
of	I-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O

Concomitant	O
curcumin	I-Entity
administration	O
prevented	O
the	O
cognitive	B-Entity
impairment	I-Entity
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O

Curcumin	I-Entity
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	I-Entity
as	O
well	O
as	O
carbamazepine	I-Entity
.	O

These	O
results	O
show	O
that	O
curcumin	I-Entity
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Entity
of	I-Entity
cognitive	I-Entity
functions	I-Entity
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O

The	O
findings	O
suggest	O
that	O
curcumin	I-Entity
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	I-Entity
and	O
carbamazepine	I-Entity
therapy	O
in	O
preventing	O
cognitive	B-Entity
impairment	I-Entity
associated	O
with	O
these	O
drugs	O
.	O



Pyrrolidine	B-Entity
dithiocarbamate	I-Entity
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	I-Entity
status	B-Entity
epilepticus	I-Entity
model	O
.	O

Pyrrolidine	B-Entity
dithiocarbamate	I-Entity
(	O
PDTC	I-Entity
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa	O
-	O
beta	O
.	O

Both	O
,	O
production	O
of	O
reactive	O
oxygen	I-Entity
species	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B-Entity
damage	I-Entity
in	O
different	O
sub	O
-	O
regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O

The	O
effect	O
of	O
PDTC	I-Entity
on	O
status	B-Entity
epilepticus	I-Entity
-	O
associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O

piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	I-Entity
model	O
.	O

PDTC	I-Entity
before	O
and	O
following	O
status	B-Entity
epilepticus	I-Entity
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100%	O
.	O

Administration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	I-Entity
(	O
low	O
-	O
dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	B-Entity
epilepticus	I-Entity
or	O
the	O
mortality	O
rate	O
.	O

In	O
vehicle	O
-	O
treated	O
rats	O
,	O
status	B-Entity
epilepticus	I-Entity
caused	O
pronounced	O
neuronal	B-Entity
damage	I-Entity
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O

Low	O
-	O
dose	O
PDTC	I-Entity
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O

A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle-	O
and	O
PDTC	I-Entity
-	O
treated	O
rats	O
following	O
status	B-Entity
epilepticus	I-Entity
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	I-Entity
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	B-Entity
loss	I-Entity
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	I-Entity
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	I-Entity
-	O
associated	O
neuronal	B-Entity
damage	I-Entity
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	I-Entity
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O



Safety	O
profile	O
of	O
a	O
nicotine	I-Entity
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	I-Entity
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12-week	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
.	O

Nicotine	I-Entity
polacrilex	O
lozenges	O
deliver	O
25%	O
to	O
27%	O
more	O
nicotine	I-Entity
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	I-Entity
polacrilex	O
gum	O
.	O

The	O
increased	O
nicotine	I-Entity
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4-mg	O
nicotine	I-Entity
lozenge	O
and	O
4-mg	O
nicotine	I-Entity
gum	O
in	O
smokers	O
with	O
selected	O
label	O
-	O
restricted	O
diseases	O
.	O

This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B-Entity
disease	I-Entity
,	O
hypertension	I-Entity
not	O
controlled	O
by	O
medication	O
,	O
and/or	O
diabetes	B-Entity
mellitus	I-Entity
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
the	O
4-mg	O
nicotine	I-Entity
lozenge	O
or	O
4-mg	O
nicotine	I-Entity
gum	O
.	O

The	O
nicotine	I-Entity
lozenge	O
and	O
nicotine	I-Entity
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	I-Entity
exposure	O
from	O
the	O
lozenge	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	I-Entity
(	O
17.2%	O
and	O
16.1%	O
;	O
95%	O
CI	O
,	O
-3.7	O
to	O
6.0	O
)	O
,	O
hiccups	I-Entity
(	O
10.7%	O
and	O
6.6%	O
;	O
95%	O
CI	O
,	O
0.5	O
to	O
7.8	O
)	O
,	O
and	O
headache	I-Entity
(	O
8.7%	O
and	O
9.9%	O
;	O
95%	O
Cl	O
,	O
-5.0	O
to	O
2.6	O
)	O
.	O

The	O
4-mg	O
nicotine	I-Entity
lozenge	O
and	O
4-mg	O
nicotine	I-Entity
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label	O
-	O
restricted	O
medical	O
conditions	O
.	O



Development	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
parkinsonian	I-Entity
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and/or	O
duration	O
of	O
symptoms	O
.	O

Levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
(	O
LIDs	I-Entity
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
patients	O
.	O

Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	I-Entity
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	I-Entity
-	O
induced	O
parkinsonism	I-Entity
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	I-Entity
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	I-Entity
.	O

MPTP	I-Entity
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	I-Entity
therapy	O
developed	O
dyskinesia	I-Entity
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	I-Entity
administration	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	I-Entity
exposure	O
,	O
slow	O
symptom	O
progression	O
and/or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	I-Entity
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	I-Entity
(	O
e.g.	O
,	O
dyskinesia	I-Entity
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	I-Entity
administration	O
)	O
.	O

All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	I-Entity
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	O
.	O

These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	I-Entity
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	I-Entity
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	I-Entity
.	O



Propylthiouracil	I-Entity
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	I-Entity
in	O
conjunction	O
with	O
pericarditis	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	I-Entity
-	O
induced	O
vasculitis	I-Entity
manifesting	O
with	O
pericarditis	I-Entity
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	I-Entity
treated	O
with	O
propylthiouracil	I-Entity
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	I-Entity
,	O
fever	I-Entity
,	O
and	O
glomerulonephritis	I-Entity
developed	O
.	O

A	O
25-year	O
-	O
old	O
woman	O
with	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
had	O
a	O
febrile	B-Entity
illness	I-Entity
and	O
evidence	O
of	O
pericarditis	I-Entity
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

Propylthiouracil	I-Entity
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1-month	O
course	O
of	O
prednisone	I-Entity
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	I-Entity
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	I-Entity
associated	O
with	O
propylthio-	B-Entity
uracil	I-Entity
therapy	O
.	O

Pericarditis	I-Entity
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	I-Entity
attributable	O
to	O
propylthio-	B-Entity
uracil	I-Entity
therapy	O
.	O



Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	B-Entity
-	I-Entity
carboline	I-Entity
-	O
induced	O
seizures	I-Entity
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA(A	I-Entity
)	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	I-Entity
induced	O
by	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
methyl	B-Entity
beta	I-Entity
-	I-Entity
carboline-3-carboxylate	I-Entity
(	O
beta	B-Entity
-	I-Entity
CCM	I-Entity
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA(A	I-Entity
)	O
receptor	O
benzodiazepine	I-Entity
site	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA(A	I-Entity
)	O
receptor	O
.	O

We	O
measured	O
diazepam	I-Entity
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	I-Entity
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin-	I-Entity
and	O
pentylenetetrazol	I-Entity
-	O
induced	O
seizures	I-Entity
after	O
i.p	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	B-Entity
-	I-Entity
CCM	I-Entity
can	O
be	O
extended	O
to	O
diazepam	I-Entity
,	O
picrotoxin	I-Entity
,	O
and	O
pentylenetetrazol	I-Entity
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA(A	I-Entity
)	O
receptor	O
.	O



Analgesic	O
effect	O
of	O
intravenous	O
ketamine	I-Entity
in	O
cancer	I-Entity
patients	O
on	O
morphine	I-Entity
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	I-Entity
not	O
responsive	O
to	O
morphine	I-Entity
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
antagonists	O
,	O
such	O
as	O
ketamine	I-Entity
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	I-Entity
syndromes	O
,	O
such	O
as	O
neuropathic	B-Entity
pain	I-Entity
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	I-Entity
(	O
0.25	O
mg	O
/	O
kg	O
or	O
0.50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	I-Entity
patients	O
whose	O
pain	I-Entity
was	O
unrelieved	O
by	O
morphine	I-Entity
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	I-Entity
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O

nausea	I-Entity
and	O
vomiting	I-Entity
,	O
drowsiness	O
,	O
confusion	I-Entity
,	O
and	O
dry	B-Entity
mouth	I-Entity
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Ketamine	I-Entity
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	I-Entity
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

Hallucinations	I-Entity
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
""""	O
empty	O
head	O
""""	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	I-Entity
1	O
mg	O
intravenously	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	I-Entity
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	I-Entity
0.50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0.50	O
mg	O
/	O
kg	O
of	O
ketamine	I-Entity
.	O

Ketamine	I-Entity
can	O
improve	O
morphine	I-Entity
analgesia	O
in	O
difficult	O
pain	I-Entity
syndromes	O
,	O
such	O
as	O
neuropathic	B-Entity
pain	I-Entity
.	O

This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	I-Entity
administration	O
.	O



Endocrine	O
screening	O
in	O
1,022	O
men	O
with	O
erectile	B-Entity
dysfunction	I-Entity
:	O
clinical	O
significance	O
and	O
cost	O
-	O
effective	O
strategy	O
.	O

We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	I-Entity
and	O
prolactin	O
determination	O
in	O
1,022	O
patients	O
referred	O
because	O
of	O
erectile	B-Entity
dysfunction	I-Entity
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	I-Entity
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Every	O
patient	O
was	O
screened	O
for	O
testosterone	I-Entity
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B-Entity
sexual	I-Entity
desire	I-Entity
,	O
gynecomastia	I-Entity
or	O
testosterone	I-Entity
less	O
than	O
4	O
ng./ml	O
.	O

Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1,340	O
patients	O
with	O
erectile	B-Entity
dysfunction	I-Entity
and	O
systematic	O
prolactin	O
determination	O
.	O

Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B-Entity
sexual	I-Entity
desire	I-Entity
,	O
small	O
testes	O
and	O
gynecomastia	I-Entity
.	O

Endocrine	O
therapy	O
consisted	O
of	O
testosterone	B-Entity
heptylate	I-Entity
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	I-Entity
and	O
bromocriptine	I-Entity
for	O
hyperprolactinemia	I-Entity
.	O

Testosterone	I-Entity
was	O
less	O
than	O
3	O
ng./ml	O
.	O

The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	I-Entity
increased	O
with	O
age	O
(	O
4%	O
before	O
age	O
50	O
years	O
and	O
9%	O
50	O
years	O
or	O
older	O
)	O
.	O

Two	O
pituitary	B-Entity
tumors	I-Entity
were	O
discovered	O
after	O
testosterone	I-Entity
determination	O
.	O

Most	O
of	O
the	O
other	O
low	O
testosterone	I-Entity
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	B-Entity
dysfunction	I-Entity
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B-Entity
dysfunction	I-Entity
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42%	O
)	O
.	O

Determining	O
testosterone	I-Entity
only	O
in	O
cases	O
of	O
low	B-Entity
sexual	I-Entity
desire	I-Entity
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	I-Entity
,	O
including	O
37%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O

Only	O
1	O
prolactinoma	I-Entity
was	O
discovered	O
.	O

in	O
1.86%	O
of	O
1,821	O
patients	O
,	O
prolactinomas	I-Entity
in	O
7	O
,	O
0.38%	O
)	O
.	O

Bromocriptine	I-Entity
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O

Testosterone	I-Entity
was	O
low	O
in	O
less	O
than	O
50%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O

Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	I-Entity
and	O
high	O
prolactin	O
in	O
erectile	B-Entity
dysfunction	I-Entity
can	O
not	O
justify	O
their	O
routine	O
determination	O
.	O

However	O
,	O
cost	O
-	O
effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-Entity
tumors	I-Entity
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	I-Entity
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Entity
sexual	I-Entity
desire	I-Entity
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O

Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Entity
sexual	I-Entity
desire	I-Entity
,	O
gynecomastia	I-Entity
and/or	O
testosterone	I-Entity
less	O
than	O
4	O
ng./ml	O
.	O



Thiopentone	I-Entity
pretreatment	O
for	O
propofol	I-Entity
injection	O
pain	I-Entity
in	O
ambulatory	O
patients	O
.	O

This	O
study	O
investigated	O
propofol	I-Entity
injection	O
pain	I-Entity
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	I-Entity
.	O

Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	I-Entity
2%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O

thiopentone	I-Entity
2.5%	O
(	O
50	O
mg	O
)	O
.	O

Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	I-Entity
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms.kg-1.min-1	O
)	O
.	O

Loss	B-Entity
of	I-Entity
consciousness	I-Entity
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	I-Entity
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0.7045	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Assessing	O
their	O
overall	O
satisfaction	O
,	O
89.7%	O
would	O
choose	O
propofol	I-Entity
anaesthesia	O
again	O
.	O

We	O
conclude	O
that	O
lidocaine	I-Entity
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	I-Entity
injection	O
pain	I-Entity
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	I-Entity
only	O
reduces	O
its	O
severity	O
.	O



glycopyrrolate	I-Entity
and	O
atropine	I-Entity
in	O
the	O
prevention	O
of	O
bradycardia	I-Entity
and	O
arrhythmias	I-Entity
following	O
repeated	O
doses	O
of	O
suxamethonium	I-Entity
in	O
children	O
.	O

The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	I-Entity
5	O
and	O
10	O
micrograms	O
kg-1	O
and	O
atropine	I-Entity
10	O
and	O
20	O
micrograms	O
kg-1	O

immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	I-Entity
and	O
bradycardia	I-Entity
following	O
repeated	O
doses	O
of	O
suxamethonium	I-Entity
in	O
children	O
,	O
was	O
studied	O
.	O

A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	I-Entity
and	O
atropine	I-Entity
.	O

A	O
frequency	O
of	O
bradycardia	I-Entity
of	O
50%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O

Bradycardia	I-Entity
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min-1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used	O
.	O

It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	I-Entity
10	O
micrograms	O
kg-1	O
or	O
atropine	I-Entity
20	O
micrograms	O
kg-1	O
i.v	O
.	O

should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	I-Entity
is	O
anticipated	O
.	O



Reduction	O
in	O
caffeine	I-Entity
toxicity	I-Entity
by	O
acetaminophen	I-Entity
.	O

A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	B-Entity
acetylsalicylate	I-Entity
,	O
caffeine	I-Entity
,	O
and	O
acetaminophen	I-Entity
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	I-Entity
per	O
mL	O
of	O
serum	O
.	O

Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	I-Entity
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	I-Entity
(	O
52	O
micrograms	O
/	O
mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	I-Entity
of	O
caffeine	I-Entity
.	O

Studies	O
in	O
DBA/2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	I-Entity
(	O
100	O
mg	O
/	O
kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	I-Entity
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	I-Entity
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	I-Entity
(	O
75	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	I-Entity
produced	O
in	O
the	O
presence	O
of	O
caffeine	I-Entity
(	O
12.5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
frequency	O
of	O
sound	O
-	O
induced	O
seizures	I-Entity
after	O
12.5	O
or	O
25	O
mg	O
/	O
kg	O
caffeine	I-Entity
was	O
reduced	O
from	O
50	O
to	O
5%	O
by	O
acetaminophen	I-Entity
.	O

In	O
the	O
absence	O
of	O
caffeine	I-Entity
,	O
acetaminophen	I-Entity
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	I-Entity
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	I-Entity
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O

Acetaminophen	I-Entity
(	O
up	O
to	O
150	O
micrograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	I-Entity
into	O
ATP	I-Entity
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O

Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	I-Entity
antagonizes	O
the	O
actions	O
of	O
caffeine	I-Entity
in	O
the	O
CNS	O
remains	O
unknown	O
.	O



Flestolol	I-Entity
:	O

Flestolol	I-Entity
(	O
ACC-9089	I-Entity
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	O
.	O

Flestolol	I-Entity
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half	O
-	O
life	O
of	O
approximately	O
6.5	O
minutes	O
.	O

In	O
long	O
-	O
term	O
infusion	O
studies	O
,	O
flestolol	I-Entity
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta	O
-	O
blocking	O
dose	O
(	O
5	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O

Flestolol	I-Entity
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	I-Entity
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O

Flestolol	I-Entity
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	I-Entity
-	O
induced	O
tachycardia	I-Entity
.	O

Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	I-Entity
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O

In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol	I-Entity
-	O
induced	O
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half	O
-	O
life	O
.	O

Flestolol	I-Entity
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	B-Entity
tachyarrhythmia	I-Entity
.	O

In	O
patients	O
with	O
unstable	B-Entity
angina	I-Entity
,	O
flestolol	I-Entity
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B-Entity
pain	I-Entity
.	O

It	O
is	O
concluded	O
that	O
flestolol	I-Entity
is	O
a	O
potent	O
,	O
well	O
-	O
tolerated	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Use	O
of	O
flestolol	I-Entity
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O



Adverse	O
effect	O
of	O
the	O
calcium	I-Entity
channel	O
blocker	O
nitrendipine	I-Entity
on	O
nephrosclerosis	I-Entity
in	O
rats	O
with	O
renovascular	B-Entity
hypertension	I-Entity
.	O

The	O
effect	O
of	O
a	O
6-week	O
treatment	O
with	O
the	O
calcium	I-Entity
channel	O
blocker	O
nitrendipine	I-Entity
or	O
the	O
angiotensin	I-Entity
converting	O
enzyme	O
inhibitor	O
enalapril	I-Entity
on	O
blood	O
pressure	O
,	O
albuminuria	I-Entity
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two	O
-	O
kidney	O
,	O
one	O
clip	O
renovascular	B-Entity
hypertension	I-Entity
.	O

Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	I-Entity
rats	O
(	O
178	O
+	O
/-	O

4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	I-Entity
controls	O
(	O
n	O
=	O
8)	O
,	O
enalapril	I-Entity
-	O
treated	O
(	O
n	O
=	O
8)	O
,	O
or	O
nitrendipine	I-Entity
-	O
treated	O
(	O

Enalapril	I-Entity
but	O
not	O
nitrendipine	I-Entity
reduced	O
blood	O
pressure	O
significantly	O
.	O

Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	I-Entity
did	O
not	O
change	O
after	O
enalapril	I-Entity
treatment	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipine	I-Entity
-	O
treated	O
group	O
albuminuria	I-Entity
increased	O
from	O
12.8	O
+	O
/-	O

9	O
mg/24	O
hr	O
in	O
the	O
hypertensive	I-Entity
controls	O
.	O

Furthermore	O
,	O
glomerulosclerosis	I-Entity
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	I-Entity
-	O
treated	O
group	O
compared	O
with	O
the	O
hypertensive	I-Entity
controls	O
(	O
0.38	O
+	O
/-	O

In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	I-Entity
-	O
treated	O
group	O
(	O
14.9	O
+	O
/-	O

0.17	O
10(-3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	I-Entity
-	O
treated	O
group	O
(	O
11.5	O
+	O
/-	O

mm2	O
)	O
compared	O
with	O
the	O
hypertensive	I-Entity
controls	O
(	O
12.1	O
+	O
/-	O



Treatment	O
of	O
tinnitus	I-Entity
by	O
intratympanic	O
instillation	O
of	O
lignocaine	I-Entity
(	O
lidocaine	I-Entity
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	O
.	O

Idiopathic	B-Entity
subjective	I-Entity
tinnitus	I-Entity
(	O
IST	I-Entity
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O

This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	I-Entity
by	O
intratympanic	O
instillation	O
of	O
lignocaine	I-Entity
(	O
lidocaine	I-Entity
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O

Fifty	O
-	O
two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	I-Entity
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O

In	O
one	O
patient	O
,	O
the	O
tinnitus	I-Entity
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	I-Entity
changed	O
to	O
a	O
compensated	O
one	O
.	O

Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	I-Entity
and	O
vomiting	I-Entity
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	I-Entity
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O



Perhexiline	B-Entity
maleate	I-Entity
and	O
peripheral	B-Entity
neuropathy	I-Entity
.	O

Peripheral	B-Entity
neuropathy	I-Entity
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	B-Entity
maleate	I-Entity
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B-Entity
pectoris	I-Entity
.	O

In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-Entity
disorder	I-Entity
.	O

The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	I-Entity
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O



Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	I-Entity
-	O
induced	O
increase	B-Entity
in	I-Entity
locomotor	I-Entity
activity	I-Entity
of	O
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	I-Entity
-	O
induced	O
increase	B-Entity
in	I-Entity
locomotor	I-Entity
activity	I-Entity
of	O
mice	O
was	O
studied	O
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	I-Entity
-	O
HC1	O
produced	O
a	O
marked	O
increase	B-Entity
in	I-Entity
locomotor	I-Entity
activity	I-Entity
in	O
mice	O
.	O

The	O
morphine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
was	O
potentiated	O
by	O
scopolamine	I-Entity
and	O
attenuated	O
by	O
physostigmine	I-Entity
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	I-Entity
and	O
neostigmine	I-Entity
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	I-Entity
produced	O
by	O
morphine	I-Entity
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	B-Entity
-	I-Entity
methyltyrosine	I-Entity
(	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O

,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	I-Entity
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	I-Entity
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	B-Entity
-	I-Entity
chlorophenylalamine	I-Entity
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i.p	O
.	O

,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	I-Entity
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	I-Entity
.	O

The	O
study	O
suggests	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	I-Entity
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	I-Entity
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	I-Entity
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	I-Entity
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	I-Entity
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	I-Entity
in	O
rats	O
.	O



Mechanisms	O
of	O
FK	B-Entity
506-induced	I-Entity
hypertension	I-Entity
in	O
the	O
rat	O
.	O

-Tacrolimus	I-Entity
(	O
FK	B-Entity
506	I-Entity
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O

The	O
clinical	O
utility	O
of	O
FK	B-Entity
506	I-Entity
is	O
complicated	O
by	O
substantial	O
hypertension	I-Entity
and	O
nephrotoxicity	I-Entity
.	O

To	O
clarify	O
the	O
mechanisms	O
of	O
FK	B-Entity
506-induced	I-Entity
hypertension	I-Entity
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	B-Entity
506	I-Entity
on	O
the	O
synthesis	O
of	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET-1	O
and	O
endothelin	O
-	O
converting	O
enzyme-1	O
(	O
ECE-1	O
)	O
,	O
the	O
endothelial	O
nitric	B-Entity
oxide	I-Entity
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	B-Entity
139317	I-Entity
on	O
FK	B-Entity
506-induced	I-Entity
hypertension	I-Entity
in	O
rats	O
was	O
studied	O
.	O

FK	B-Entity
506	I-Entity
,	O
5	O
mg	O
.	O

FK	B-Entity
506	I-Entity
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48%	O
and	O
55%	O
,	O
respectively	O
)	O
.	O

The	O
administration	O
of	O
FR	B-Entity
139317	I-Entity
(	O
10	O
mg	O
.	O

d-1	O
)	O
prevented	O
FK	B-Entity
506-induced	I-Entity
hypertension	I-Entity
in	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
FK	B-Entity
506	I-Entity
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET-1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	I-Entity
synthesis	O
in	O
the	O
vasculature	O
.	O



Suxamethonium	I-Entity
induced	O
prolonged	O
apnea	I-Entity
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O

Suxamethonium	I-Entity
causes	O
prolonged	O
apnea	I-Entity
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	B-Entity
(	I-Entity
OP	I-Entity
)	I-Entity
poisons	I-Entity
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	I-Entity
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Prolonged	O
apnea	I-Entity
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	B-Entity
compound	I-Entity
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O



The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	I-Entity
on	O
male	O
sexual	B-Entity
dysfunction	I-Entity
induced	O
by	O
a	O
selective	B-Entity
serotonin	I-Entity
reuptake	I-Entity
inhibitor	I-Entity
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
and	O
randomized	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	I-Entity
sustained	O
-	O
release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B-Entity
dysfunction	I-Entity
(	O
SD	I-Entity
)	O
induced	O
by	O
a	O
selective	B-Entity
serotonin	I-Entity
reuptake	I-Entity
inhibitor	I-Entity
(	O
SSRI	I-Entity
)	O
,	O
as	O
SD	I-Entity
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
SSRIs	I-Entity
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	I-Entity
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	I-Entity
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Sexual	O
Function	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-Entity
Dysfunction	I-Entity
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O

After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i.e.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	I-Entity
SR	O
,	O
at	O
2.4	O
(	O
1.2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3.9	O
(	O
1.1	O
)	O

Men	O
who	O
received	O
bupropion	I-Entity
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54.4%	O
vs	O
1.2%	O
;	O
P=	O
0.003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i.e.	O
better	O
,	O
among	O
men	O
who	O
received	O
bupropion	I-Entity
than	O
placebo	O
,	O
at	O
15.5	O
(	O
4.3	O
)	O
vs	O
21.5	O
(	O
4.7	O
)	O
(	O
P=	O
0.002	O
)	O
.	O

The	O
EDITS	O
scores	O
were	O
67.4	O
(	O
10.2	O
)	O
for	O
the	O
bupropion	I-Entity
and	O
36.3	O
(	O
11.7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P=	O
0.001	O
)	O
.	O

In	O
linear	O
regression	O
analyses	O
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	I-Entity
,	O
type	O
of	O
SSRI	I-Entity
used	O
and	O
age	O
.	O

Bupropion	I-Entity
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	I-Entity
induced	O
by	O
SSRIs	I-Entity
.	O

These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	I-Entity
.	O



Lamivudine	I-Entity
for	O
the	O
prevention	O
of	O
hepatitis	B-Entity
B	I-Entity
virus	O
reactivation	O
in	O
hepatitis	B-Entity
-	I-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
(	O
HBSAG	I-Entity
)	O
seropositive	O
cancer	I-Entity
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	B-Entity
disease	I-Entity
worldwide	O
.	O

Cancer	I-Entity
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	B-Entity
complication	I-Entity
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O

In	O
this	O
study	O
,	O
cancer	I-Entity
patients	O
who	O
have	O
solid	O
and	O
hematological	B-Entity
malignancies	I-Entity
with	O
chronic	O
HBV	B-Entity
infection	I-Entity
received	O
the	O
antiviral	O
agent	O
lamivudine	I-Entity
prior	O

and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	I-Entity
.	O

The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	I-Entity
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT	O
.	O

The	O
prophylactic	O
lamivudin	I-Entity
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	I-Entity
treatment	O
.	O

The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	I-Entity
.	O

Of	O
our	O
control	O
group	O
(	O
n=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42%	O
)	O
were	O
established	O
hepatitis	I-Entity
.	O

Twelve	O
(	O
24%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	I-Entity
.	O

In	O
the	O
prophylactic	O
lamivudine	I-Entity
group	O
severe	O
hepatitis	I-Entity
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2.7%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0.006	O
)	O
.	O

Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	I-Entity
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	I-Entity
group	O
;	O
154:64	O
(	O
p	O
<	O
0.32	O
)	O
.	O

Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	I-Entity
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	I-Entity
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	I-Entity
or	O
nucleotide	I-Entity
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O



Ginsenoside	B-Entity
Rg1	I-Entity
restores	O
the	O
impairment	B-Entity
of	I-Entity
learning	I-Entity
induced	O
by	O
chronic	O
morphine	I-Entity
administration	O
in	O
rats	O
.	O

Rg1	I-Entity
,	O
as	O
a	O
ginsenoside	I-Entity
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	B-Entity
impairment	I-Entity
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	I-Entity
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	I-Entity
on	O
learning	B-Entity
impairment	I-Entity
by	O
chronic	O
morphine	I-Entity
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O

Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	I-Entity
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	I-Entity
once	O
a	O
day	O
for	O
10	O
days	O
.	O

The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	I-Entity
/	O
Rg1	I-Entity
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O

By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	I-Entity
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	I-Entity
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O

The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	I-Entity
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	I-Entity
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline-	O
or	O
morphine	I-Entity
/	O
Rg1-treated	I-Entity
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptor	O
antagonist	O
MK801	I-Entity
.	O

We	O
conclude	O
that	O
Rg1	I-Entity
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	I-Entity
administration	O
and	O
restore	O
the	O
morphine	I-Entity
-	O
inhibited	O
LTP	O
.	O

This	O
effect	O
is	O
NMDA	I-Entity
receptor	O
dependent	O
.	O



A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	I-Entity
injection	O
on	O
bruising	I-Entity
and	O
pain	I-Entity
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	I-Entity
and	O
pain	I-Entity
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	I-Entity
.	O

Although	O
different	O
methods	O
to	O
prevent	O
bruising	I-Entity
and	O
pain	I-Entity
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	I-Entity
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	I-Entity
and	O
pain	I-Entity
is	O
little	O
documented	O
.	O

The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	I-Entity
was	O
administered	O
.	O

Heparin	I-Entity
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O

Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	I-Entity
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O

Dimensions	O
of	O
the	O
bruising	I-Entity
on	O
the	O
heparin	I-Entity
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	I-Entity
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	I-Entity
period	O
.	O

The	O
percentage	O
of	O
bruising	I-Entity
occurrence	O
was	O
64%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42%	O
in	O
the	O
30-second	O
injection	O
.	O

It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	I-Entity
was	O
smaller	O
in	O
the	O
30-second	O
injection	O
.	O

Pain	I-Entity
intensity	O
and	O
pain	I-Entity
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30-second	O
injection	O
than	O
for	O
the	O
10-second	O
injection	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	I-Entity
and	O
pain	I-Entity
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	I-Entity
.	O

PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	I-Entity
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O



Acute	O
reserpine	I-Entity
and	O
subchronic	O
haloperidol	I-Entity
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	I-Entity
uptake	O
and	O
elicit	O
orofacial	B-Entity
dyskinesia	I-Entity
in	O
rats	O
.	O

Reserpine-	I-Entity
and	O
haloperidol	I-Entity
-	O
induced	O
orofacial	B-Entity
dyskinesia	I-Entity
are	O
putative	O
animal	O
models	O
of	O
tardive	B-Entity
dyskinesia	I-Entity
(	O
TD	I-Entity
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	B-Entity
dyskinesia	I-Entity
by	O
acute	O
reserpine	I-Entity
and	O
subchronic	O
haloperidol	I-Entity
administration	O
to	O
rats	O
.	O

Reserpine	I-Entity
injection	O
(	O
one	O
dose	O
of	O
1	O
mg	O

Haloperidol	I-Entity
administration	O
(	O
one	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s.c	O
.	O
)	O

After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	I-Entity
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed	O
.	O

A	O
decreased	O
glutamate	I-Entity
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	I-Entity
and	O
haloperidol	I-Entity
,	O
compared	O
to	O
the	O
control	O
.	O

Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	I-Entity
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	B-Entity
diskinesia	I-Entity
.	O

These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	I-Entity
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O



Acute	B-Entity
psychosis	I-Entity
due	O
to	O
treatment	O
with	O
phenytoin	I-Entity
in	O
a	O
nonepileptic	O
patient	O
.	O

The	O
development	O
of	O
psychosis	I-Entity
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	I-Entity
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	O
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	I-Entity
following	O
phenytoin	I-Entity
treatment	O
for	O
trigeminal	B-Entity
neuralgia	I-Entity
is	O
described	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	B-Entity
symptoms	I-Entity
that	O
occur	O
following	O
phenytoin	I-Entity
treatment	O
in	O
some	O
epileptic	I-Entity
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	I-Entity
.	O



The	O
effect	O
of	O
treatment	O
with	O
gum	B-Entity
Arabic	I-Entity
on	O
gentamicin	I-Entity
nephrotoxicity	I-Entity
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	B-Entity
Arabic	I-Entity
on	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
induced	O
by	O
gentamicin	I-Entity
(	O
GM	I-Entity
)	O
nephrotoxicity	I-Entity
.	O

kg	O
of	O
distilled	O
water	O
and	O
5%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Entity
Arabic	I-Entity
(	O
2	O
mL	O
/	O

kg	O
of	O
a	O
10%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-Entity
Arabic	I-Entity
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Entity
Arabic	I-Entity
concomitantly	O
with	O
GM	I-Entity
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Nephrotoxicity	I-Entity
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	I-Entity
and	O
urea	I-Entity
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	I-Entity
(	O
GSH	I-Entity
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Entity
Arabic	I-Entity
and	O
GM	I-Entity
significantly	O
increased	O
creatinine	I-Entity
and	O
urea	I-Entity
by	O
about	O
183	O
and	O
239%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	I-Entity
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	I-Entity
by	O
21%	O
(	O
compared	O
to	O
27%	O
in	O
the	O
cellulose	O
plus	O
GM	I-Entity
group	O
)	O

The	O
GM	I-Entity
-	O
induced	O
proximal	O
tubular	B-Entity
necrosis	I-Entity
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	I-Entity
together	O
with	O
gum	B-Entity
Arabic	I-Entity
than	O
in	O
those	O
given	O
GM	I-Entity
and	O
cellulose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	B-Entity
Arabic	I-Entity
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	I-Entity
nephrotoxicity	I-Entity
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
,	O
and	O
on	O
the	O
mechanism(s	O
)	O
involved	O
.	O



Visual	B-Entity
hallucinations	I-Entity
associated	O
with	O
zonisamide	I-Entity
.	O

Zonisamide	I-Entity
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	I-Entity
.	O

Although	O
visual	B-Entity
hallucinations	I-Entity
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B-Entity
hallucinations	I-Entity
and	O
altered	O
mental	O
status	O
after	O
zonisamide	I-Entity
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	I-Entity
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O

During	O
monitoring	O
,	O
visual	B-Entity
hallucinations	I-Entity
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-Entity
hallucinations	I-Entity
before	O
this	O
event	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	I-Entity
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	I-Entity
.	O



GLEPP1	O
receptor	O
tyrosine	I-Entity
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	I-Entity
nephrosis	I-Entity
.	O

Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	I-Entity
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Entity
injury	I-Entity
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	B-Entity
aminonucleoside	I-Entity
nephrosis	I-Entity
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
,	O
20	O
mg/100	O
g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	I-Entity
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	I-Entity
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	I-Entity
associated	O
with	O
glomerulosclerosis	I-Entity
(	O
days	O
45	O
-	O
126	O
)	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	I-Entity
.	O



Ticlopidine	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
:	O

In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O

Agranulocytosis	I-Entity
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	I-Entity
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B-Entity
marrow	I-Entity
suppression	I-Entity
.	O

Treatment	O
for	O
ticlopidine	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	I-Entity
channel	O
blockers	O
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	O
simultaneously	O
.	O



Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	I-Entity
and	O
its	O
state	O
dependency	O
in	O
the	O
step	O
-	O
through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O

Amnesia	I-Entity
produced	O
by	O
scopolamine	I-Entity
and	O
cycloheximide	I-Entity
were	O
reversed	O
by	O
morphine	I-Entity
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre	O
-	O
test	O
)	O
,	O
and	O
pre	O
-	O
test	O
morphine	I-Entity
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	I-Entity
during	O
the	O
training	O
trial	O
.	O

Similarly	O
,	O
pre	O
-	O
test	O
scopolamine	I-Entity
partially	O
reversed	O
the	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
test	O
cycloheximide	I-Entity
failed	O
to	O
reverse	O
the	O
cycloheximide	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	I-Entity
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	I-Entity
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O



Apomorphine	I-Entity
,	O
a	O
nonselective	O
dopamine	B-Entity
agonist	I-Entity
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	I-Entity
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	I-Entity
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	I-Entity
-	O
induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	I-Entity
such	O
as	O
drug	O
-	O
induced	O
hypothermia	I-Entity
.	O

In	O
mice	O
,	O
apomorphine	I-Entity
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

By	O
contrast	O
,	O
apomorphine	I-Entity
-	O
induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	I-Entity
turnover	O
ratios	O
(	O
DOPAC	I-Entity
:	O
DA	I-Entity
and	O
HVA	I-Entity
:	O

DA	I-Entity
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine	I-Entity
-	O
induced	O
reductions	O
in	O
striatal	O
dopamine	I-Entity
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O


